

1 John Fiske (CA SBN 249256)
2 **BARON & BUDD, P.C.**
3 603 North Coast Highway, Suite G
4 Solana Beach, CA 92075
5 Tel.: 858-633-8337
6 jfiske@baronbudd.com

7 Charles J. McKee (CA SBN 152458)
8 **MONTEREY COUNTY COUNSEL**
9 William Litt (CA SBN 166614)
10 Deputy County Counsel
11 168 West Alisal Street, 3rd Floor
12 Salinas, CA 93901
13 Tel: 831-755-5045
14 mckeecj@co.monterey.ca.us
15 LittWM@co.monterey.ca.us

(Additional Counsel Listed on Signature Page)

Attorneys for Plaintiffs COUNTY OF MONTEREY, a political subdivision of the
State of California; THE PEOPLE OF THE STATE OF CALIFORNIA, acting by
and through the COUNTY OF MONTEREY

13 **UNITED STATES DISTRICT COURT**
14 **NORTHERN DISTRICT OF CALIFORNIA**

16 COUNTY OF MONTEREY,
17 a political subdivision of the
18 State of California; THE PEOPLE
19 OF THE STATE OF CALIFORNIA,
20 acting by and through the COUNTY
21 OF MONTEREY,

Plaintiffs,

vs.

22 AMERISOURCEBERGEN DRUG
23 CORPORATION; CARDINAL
24 HEALTH, INC.; McKESSON
25 CORPORATION; PURDUE PHARMA
26 L.P.; PURDUE PHARMA, INC.; THE
27 PURDUE FREDERICK COMPANY,
28 INC.; TEVA PHARMACEUTICAL
INDUSTRIES, LTD.; TEVA
PHARMACEUTICALS USA, INC.;
CEPHALON, INC.; JOHNSON &
JOHNSON; JANSSEN
PHARMACEUTICALS, INC.;
ORTHO-MCNEIL-JANSSEN
PHARMACEUTICALS, INC. n/k/a
JANSSEN PHARMACEUTICALS,

Case No.: _____

**COMPLAINT FOR DAMAGES
AND DEMAND FOR JURY
TRIAL**

- (1) Public Nuisance;
- (2) Violations of Racketeer
Influenced and Corrupt
Organizations Act (RICO), 18
U.S.C. § 1961 et seq.;
- (3) Violations of 18 U.S.C. § 1962
et seq.;
- (4) Violations of the California
False Advertising Act, Cal. Bus.
& Prof. Code § 17500 et seq.;
- (5) Negligent Misrepresentation;
- (6) Fraud and Fraudulent
Misrepresentation; and
- (7) Unjust Enrichment.

1 INC.; JANSSEN PHARMACEUTICA)
2 INC. n/k/a JANSSEN)
3 PHARMACEUTICALS, INC.;)
4 NORAMCO, INC.; ENDO HEALTH)
5 SOLUTIONS INC.; ENDO)
6 PHARMACEUTICALS, INC.;)
7 ALLERGAN PLC f/k/a ACTAVIS)
8 PLS; WATSON)
9 PHARMACEUTICALS, INC. n/k/a)
10 ACTAVIS, INC.; WATSON)
11 LABORATORIES, INC.; ACTAVIS)
12 LLC; ACTAVIS PHARMA, INC. f/k/a)
13 WATSON PHARMA, INC.;)
14 MALLINCKRODT PLC;)
15 MALLINCKRODT LLC; INSYS)
16 THERAPEUTICS, INC; CVS)
17 HEALTH CORP.; THE KROGER CO.;)
18 RITE AID OF MARYLAND, INC.;)
19 THRIFTY PAYLESS, INC.;)
20 WALGREENS BOOTS ALLIANCE,)
21 INC.; and WAL-MART, INC.)

22 Defendants.)
23
24
25
26
27
28

TABLE OF CONTENTS

I.	INTRODUCTION.....	1
II.	PARTIES.....	2
	A. PLAINTIFFS.....	2
	B. DEFENDANTS.....	4
	1. Manufacturer Defendants.	4
	2. Distributor Defendants.	10
III.	JURISDICTION & VENUE	14
IV.	FACTUAL BACKGROUND	15
	A. THE OPIOID EPIDEMIC.	15
	1. The National Opioid Epidemic.....	15
	2. The California Opioid Epidemic.	19
	3. The Opioid Epidemic in Plaintiffs’ Community.	22
	B. THE MANUFACTURER DEFENDANTS’ FALSE, DECEPTIVE, AND UNFAIR MARKETING OF OPIOIDS.	24
	1. Each Manufacturer Defendant Used Multiple Avenues to Disseminate Their False and Deceptive Statements about Opioids.....	26
	a) Direct Marketing.	27
	b) Indirect Marketing.	29
	2. The Manufacturer Defendants’ Marketing Scheme Misrepresented the Risks and Benefits of Opioids.	40
	i. The Manufacturer Defendants embarked upon a campaign of false, deceptive, and unfair assurances grossly understating and misstating the dangerous addiction risks of the opioid drugs.	40
	ii. The Manufacturer Defendants embarked upon a campaign of false, deceptive, and unfair assurances grossly overstating the benefits of the opioid drugs.....	51

1	3. The Manufacturer Defendants Targeted Susceptible Prescribers and Vulnerable Patient Populations.....	58
2		
3	4. Insys Employed Fraudulent, Illegal, and Misleading Marketing Schemes to Promote Subsys.	59
4		
5	5. The Manufacturer Defendants made Materially Deceptive Statements and Concealed Material Facts.....	63
6		
7	6. The Manufacturer Defendants Fraudulently Concealed Their Misconduct.....	69
8	C. THE DISTRIBUTOR DEFENDANTS’ UNLAWFUL DISTRIBUTION OF OPIOIDS.....	71
9	1. Wholesale Drug Distributors Have a Duty under State and Federal Law to Guard Against, and Report, Unlawful Diversion and to Report and Prevent Suspicious Orders.	72
10		
11	2. The Distributor Defendants Breached Their Duties.....	81
12		
13	3. The Distributor Defendants Have Sought to Avoid and Have Misrepresented their Compliance with Their Legal Duties.	83
14		
15	4. The National Retail Pharmacies Were on Notice of and Contributed to Illegal Diversion of Prescription Opioids	91
16		
17	D. THE MANUFACTURER DEFENDANTS’ UNLAWFUL FAILURE TO PREVENT DIVERSION AND MONITOR, REPORT, AND PREVENT SUSPICIOUS ORDERS.....	103
18		
19	E. DEFENDANTS’ UNLAWFUL CONDUCT AND BREACHES OF LEGAL DUTIES CAUSED THE HARM ALLEGED HEREIN AND SUBSTANTIAL DAMAGES.	109
20		
21	F. DEFENDANTS’ FRAUDULENT AND DECEPTIVE MARKETING OF OPIOIDS DIRECTLY CAUSED HARM TO THE COUNTY.	112
22	1. Increase in Opioid Prescribing Nationally	112
23		
24	2. The County’s Increased Spending on Opioids through Self-Insured Worker’s Compensation Program.	114
25		
26	i. Workers’ Compensation Programs	114
27	ii. The County’s Increased Costs Correlate with the Defendants’ Promotion.....	116
28		

1	G. STATUTES OF LIMITATIONS ARE TOLLED AND	
2	DEFENDANTS ARE ESTOPPED FROM ASSERTED	
3	STATUTES OF LIMITATIONS AS DEFENSES.....	117
4	1. Enforcement of a Public Right.	117
5	2. Continuing Conduct.....	117
6	3. Equitable Estoppel.....	118
7	4. Fraudulent Concealment.....	120
8	V. LEGAL CAUSES OF ACTION	121
9	COUNT I – PUBLIC NUISANCE (Brought by The People Against all	
10	Defendants).....	121
11	COUNT II – PUBLIC NUISANCE (Brought by The County Against all	
12	Defendants).....	131
13	COUNT III - RACKETEER INFLUENCED AND CORRUPT	
14	ORGANIZATIONS ACT 18 U.S.C. § 1961, et seq.	136
15	(Against Defendants Purdue, Cephalon, Janssen, and Endo).....	136
16	A. THE OPIOID MARKETING ENTERPRISE	139
17	1. The RICO Defendants.....	141
18	2. The Front Groups	145
19	3. The KOLs.....	156
20	4. Members of the Opioid Marketing Enterprise Furthered the	
21	Common Purpose by Making Misrepresentations.....	171
22	B. CONDUCT OF THE OPIOID MARKETING ENTERPRISE....	233
23	C. PATTERN OF RACKETEERING ACTIVITY.....	237
24	D. DAMAGES.....	244
25	1. Impact of the Opioid Marketing Enterprise.....	244
26	2. Relief Sought.....	249
27	COUNT IV - RACKETEER INFLUENCED AND CORRUPT	
28	ORGANIZATIONS ACT.....	252
	18 U.S.C. 1961, et seq.	252
	(Against Defendants Purdue, Cephalon, Endo, Mallinckrodt, Actavis,	
	McKesson, Cardinal, and AmerisourceBergen).....	252

1	(The “Opioid Diversion Enterprise”)	252
2	A. THE OPIOID DIVERSION ENTERPRISE.....	257
3	B. CONDUCT OF THE OPIOID DIVERSION ENTERPRISE.	270
4	C. PATTERN OF RACKETEERING ACTIVITY.....	278
5	1. The RICO Defendants Manufactured, Sold and/or Dealt in	
6	Controlled Substances and Their Actions Constitute Crimes Punishable	
	as Felonies.	278
7	2. The RICO Diversion Defendants Engaged in Mail and Wire Fraud.	285
8	D. DAMAGES.	293
9	1. Impact of the Opioid Diversion Enterprise.	293
10	2. The Relief Sought.	297
11	COUNT V – FALSE ADVERTISING	300
12	Violations of California Business and Professions Code section 17500, et	
13	seq.	300
14	COUNT VI – NEGLIGENT MISREPRESENTATION	304
15	COUNT VII – FRUAD AND FRAUDULENT MISREPRESENTATION.....	308
16	COUNT VIII – UNJUST ENRICHMENT	310
17	PUNITIVE DAMAGES	312
18	RELIEF	313
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		

1 Plaintiffs, COUNTY OF MONTEREY, and THE PEOPLE OF THE
 2 STATE OF CALIFORNIA, acting by and through Monterey County Counsel,
 3 (collectively “Plaintiffs”) bring this Complaint against Defendants Purdue Pharma
 4 L.P.; Purdue Pharma, Inc.; The Purdue Frederick Company, Inc.; Teva
 5 Pharmaceutical Industries, LTD.; Teva Pharmaceuticals USA, Inc.; Cephalon,
 6 Inc.; Johnson & Johnson; Janssen Pharmaceuticals, Inc.; Ortho-McNeil-Janssen
 7 Pharmaceuticals, Inc. n/k/a Janssen Pharmaceuticals, Inc.; Janssen Pharmaceutica
 8 Inc. n/k/a Janssen Pharmaceuticals, Inc.; Noramco, Inc.; Endo Health Solutions,
 9 Inc.; Endo Pharmaceuticals, Inc.; Allergan PLC f/k/a Actavis PLS; Watson
 10 Pharmaceuticals, Inc. n/k/a Actavis, Inc.; Watson Laboratories, Inc.; Actavis,
 11 LLC; Actavis Pharma, Inc. f/k/a Watson Pharma, Inc.; Mallinckrodt PLC;
 12 Mallinckrodt LLC; Insys Therapeutics, Inc., McKesson Corporation; Cardinal
 13 Health, Inc.; AmerisourceBergen Drug Corporation, CVS Health Corporation;
 14 The Kroger Co.; Rite Aid of Maryland, Inc. d/b/a Rite Aid Mid-Atlantic Customer
 15 Support Center, Inc.; Thrifty Payless, Inc.; Walgreens Boots Alliance, Inc. a/k/a
 16 Walgreen Co., and Wal-Mart Inc., f/k/a Wal-Mart Stores, Inc., (collectively
 17 “Defendants”) and allege as follows:

18 **I. INTRODUCTION**

19 1. Plaintiffs bring this civil action to eliminate the hazard to public
 20 health and safety caused by the opioid epidemic, to abate the nuisance caused
 21 thereby, and to recoup monies that have been spent and will be spent because of
 22 Defendants’ false, deceptive and unfair marketing and/or unlawful diversion of
 23 prescription opioids.¹ Such economic damages were foreseeable to Defendants
 24 and were sustained because of Defendants’ intentional and/or unlawful actions
 25 and omissions.

26
 27
 28 ¹ As used herein, the term “opioid” refers to the entire family of opiate drugs including natural, synthetic and semi-synthetic opiates.

1 the State of California. Cal. Gov't Code § 23003. The County is authorized to
2 bring this action. Cal. Gov't Code § 23004(a).

3 7. The County is responsible for the public health, safety and welfare of
4 its citizens.

5 8. The County has declared, *inter alia*, that opioid abuse, addiction,
6 morbidity and mortality have created a serious public health and safety crisis, and
7 is a public nuisance, and that the diversion of legally produced controlled
8 substances into the illicit market causes or contributes to this public nuisance.

9 9. The distribution and diversion of opioids into California (“the
10 State”), and into Monterey County and surrounding areas (collectively,
11 “Plaintiffs’ Community”), created the foreseeable opioid crisis and opioid public
12 nuisance for which Plaintiffs here seek relief.

13 10. Plaintiffs directly and foreseeably sustained all economic damages
14 alleged herein. Defendants’ conduct has exacted a financial burden for which the
15 Plaintiffs seek relief. Categories of past and continuing sustained damages
16 include, *inter alia*,: (1) costs for providing medical care, additional therapeutic,
17 and prescription drug purchases, and other treatments for patients suffering from
18 opioid-related addiction or disease, including overdoses and deaths; (2) costs for
19 providing treatment, counseling, and rehabilitation services; (3) costs for
20 providing treatment of infants born with opioid-related medical conditions; (4)
21 costs associated with law enforcement and public safety relating to the opioid
22 epidemic; (5) costs associated with providing care for children whose parents
23 suffer from opioid-related disability or incapacitation and (6) costs associated with
24 The County having to repair and remake its infrastructure, property and systems
25 that have been damaged by Defendants’ actions, including, *inter alia*, its property
26 and systems to treat addiction and abuse, to respond to and manage an elevated
27 level of crime, to treat injuries, and to investigate and process deaths in Plaintiffs’
28

1 Community. These damages have been suffered, and continue to be suffered,
2 directly by the Plaintiffs.

3 11. Plaintiffs also seek the means to abate the epidemic created by
4 Defendants' wrongful and/or unlawful conduct.

5 12. The People have standing to bring an action for the opioid epidemic
6 nuisance created by Defendants. Cal. Civ. Proc. Code § 731 ("A civil action may
7 be brought in the name of the people of the State of California to abate a public
8 nuisance, as defined in Section 3480 of the Civil Code, by the . . . county counsel
9 of any county in which the nuisance exists.").

10 13. The County has standing to bring an action for damages incurred to
11 its property by the public nuisance created by Defendants. Cal. Civ. Proc. Code §
12 731 ("An action may be brought by any person whose property is injuriously
13 affected, . . . and by the judgment in that action the nuisance may be enjoined or
14 abated as well as damages recovered therefor.").

15 14. The People have standing to bring this claim for injunctive relief and
16 civil penalties under the California False Advertising Act. Cal. Bus. & Prof. Code
17 §§ 17535, 17536.

18 15. The County has standing to recover damages incurred as a result of
19 Defendants' actions and omissions. Cal. Gov't Code § 23004(a). The County has
20 standing to bring claims under the federal RICO statute, pursuant to 18 U.S.C. §
21 1961(3) ("persons" include entities which can hold legal title to property) and 18
22 U.S.C. § 1964 ("persons" have standing).

23 **B. DEFENDANTS.**

24 **1. Manufacturer Defendants.**

25 16. The Manufacturer Defendants are defined below. At all relevant
26 times, the Manufacturer Defendants have packaged, distributed, supplied, sold,
27 placed into the stream of commerce, labeled, described, marketed, advertised,
28 promoted and purported to warn or purported to inform prescribers and users

1 regarding the benefits and risks associated with the use of the prescription opioid
2 drugs. The Manufacturer Defendants, at all times, have manufactured and sold
3 prescription opioids without fulfilling their legal duty to prevent diversion and
4 report suspicious orders.

5 17. PURDUE PHARMA L.P. is a limited partnership organized under
6 the laws of Delaware. PURDUE PHARMA INC. is a New York corporation with
7 its principal place of business in Stamford, Connecticut, and THE PURDUE
8 FREDERICK COMPANY, INC. is a Delaware corporation with its principal
9 place of business in Stamford, Connecticut (collectively, “Purdue”).

10 18. Purdue manufactures, promotes, sells, and distributes opioids such as
11 OxyContin, MS Contin, Dilaudid/Dilaudid HP, Butrans, Hysingla ER, and
12 Targiniq ER in the United States. OxyContin is Purdue’s best-selling opioid.
13 Since 2009, Purdue’s annual nationwide sales of OxyContin have fluctuated
14 between \$2.47 billion and \$2.99 billion, up four-fold from its 2006 sales of \$800
15 million. OxyContin constitutes roughly 30% of the entire market for analgesic
16 drugs (painkillers).

17 19. CEPHALON, INC. is a Delaware corporation with its principal place
18 of business in Frazer, Pennsylvania. TEVA PHARMACEUTICAL
19 INDUSTRIES, LTD. (“Teva Ltd.”) is an Israeli corporation with its principal
20 place of business in Petah Tikva, Israel. In 2011, Teva Ltd. acquired Cephalon,
21 Inc. TEVA PHARMACEUTICALS USA, INC. (“Teva USA”) is a Delaware
22 corporation and is a wholly owned subsidiary of Teva Ltd. in Pennsylvania. Teva
23 USA acquired Cephalon in October 2011.

24 20. Cephalon, Inc. manufactures, promotes, sells, and distributes opioids
25 such as Actiq and Fentora in the United States. Actiq has been approved by the
26 FDA only for the “management of breakthrough cancer pain in patients 16 years
27 and older with malignancies who are already receiving and who are tolerant to
28

1 around-the-clock opioid therapy for the underlying persistent cancer pain.”⁴
 2 Fentora has been approved by the FDA only for the “management of breakthrough
 3 pain in cancer patients 18 years of age and older who are already receiving and
 4 who are tolerant to around-the-clock opioid therapy for their underlying persistent
 5 cancer pain.”⁵ In 2008, Cephalon pled guilty to a criminal violation of the Federal
 6 Food, Drug and Cosmetic Act for its misleading promotion of Actiq and two other
 7 drugs, and agreed to pay \$425 million.⁶

8 21. Teva Ltd., Teva USA, and Cephalon, Inc. work together closely to
 9 market and sell Cephalon products in the United States. Teva Ltd. conducts all
 10 sales and marketing activities for Cephalon in the United States through Teva
 11 USA and has done so since its October 2011 acquisition of Cephalon. Teva Ltd.
 12 and Teva USA hold out Actiq and Fentora as Teva products to the public. Teva
 13 USA sells all former Cephalon branded products through its “specialty medicines”
 14 division. The FDA-approved prescribing information and medication guide, which
 15 is distributed with Cephalon opioids, discloses that the guide was submitted by
 16 Teva USA, and directs physicians to contact Teva USA to report adverse events.

17 22. All of Cephalon’s promotional websites, including those for Actiq
 18 and Fentora, display Teva Ltd.’s logo.⁷ Teva Ltd.’s financial reports list
 19 Cephalon’s and Teva USA’s sales as its own, and its year-end report for 2012 –
 20 the year immediately following the Cephalon acquisition – attributed a 22%
 21

22 ⁴ *Highlights of Prescribing Information, ACTIQ® (fentanyl citrate) oral*
 23 *transmucosal lozenge, CII* (2009),
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020747s030lbl.pdf.

24 ⁵ *Highlights of Prescribing Information, FENTORA® (fentanyl citrate) buccal*
 25 *tablet, CII* (2011),
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021947s015lbl.pdf.

26 ⁶ Press Release, U.S. Dep’t of Justice, Biopharmaceutical Company, Cephalon, to
 27 Pay \$425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing
 (Sept. 29, 2008), <https://www.justice.gov/archive/opa/pr/2008/September/08-civ-860.html>.

28 ⁷ *E.g.*, ACTIQ, <http://www.actiq.com/> (displaying logo at bottom-left) (last visited Jan. 16, 2018).

1 increase in its specialty medicine sales to “the inclusion of a full year of
 2 Cephalon’s specialty sales,” including *inter alia* sales of Fentora®.⁸ Through
 3 interrelated operations like these, Teva Ltd. operates in the United States through
 4 its subsidiaries Cephalon and Teva USA. The United States is the largest of Teva
 5 Ltd.’s global markets, representing 53% of its global revenue in 2015, and, were it
 6 not for the existence of Teva USA and Cephalon, Inc., Teva Ltd. would conduct
 7 those companies’ business in the United States itself. Upon information and
 8 belief, Teva Ltd. directs the business practices of Cephalon and Teva USA, and
 9 their profits inure to the benefit of Teva Ltd. as controlling shareholder. Teva
 10 Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., and Cephalon,
 11 Inc. are referred to as “Cephalon.”

12 23. JANSSEN PHARMACEUTICALS, INC. is a Pennsylvania
 13 corporation with its principal place of business in Titusville, New Jersey, and is a
 14 wholly owned subsidiary of JOHNSON & JOHNSON (J&J), a New Jersey
 15 corporation with its principal place of business in New Brunswick, New Jersey.
 16 NORAMCO, INC. (“Noramco”) is a Delaware company headquartered in
 17 Wilmington, Delaware and was a wholly owned subsidiary of J&J until July 2016.
 18 ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC., now known as
 19 JANSSEN PHARMACEUTICALS, INC., is a Pennsylvania corporation with its
 20 principal place of business in Titusville, New Jersey. JANSSEN
 21 PHARMACEUTICA INC., now known as JANSSEN PHARMACEUTICALS,
 22 INC., is a Pennsylvania corporation with its principal place of business in
 23 Titusville, New Jersey. J&J is the only company that owns more than 10% of
 24 Janssen Pharmaceuticals’ stock, and corresponds with the FDA regarding
 25 Janssen’s products. Upon information and belief, J&J controls the sale and
 26

27 ⁸ Teva Ltd., Annual Report (Form 20-F) 62 (Feb. 12, 2013),
 28 http://annualreports.com/HostedData/AnnualReportArchive/t/NASDAQ_TEVA_2012.pdf.

1 development of Janssen Pharmaceuticals' drugs and Janssen's profits inure to
2 J&J's benefit. Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen
3 Pharmaceuticals, Inc., Janssen Pharmaceutica, Inc., Noramco, and J&J are
4 referred to as "Janssen."

5 24. Janssen manufactures, promotes, sells, and distributes drugs in the
6 United States, including the opioid Duragesic (fentanyl). Before 2009, Duragesic
7 accounted for at least \$1 billion in annual sales. Until January 2015, Janssen
8 developed, marketed, and sold the opioids Nucynta (tapentadol) and Nucynta ER.
9 Together, Nucynta and Nucynta ER accounted for \$172 million in sales in 2014.

10 25. ENDO HEALTH SOLUTIONS INC. is a Delaware corporation with
11 its principal place of business in Malvern, Pennsylvania. ENDO
12 PHARMACEUTICALS INC. is a wholly owned subsidiary of Endo Health
13 Solutions Inc. and is a Delaware corporation with its principal place of business in
14 Malvern, Pennsylvania. Endo Health Solutions Inc. and Endo Pharmaceuticals
15 Inc. are referred to as "Endo."

16 26. Endo develops, markets, and sells prescription drugs, including the
17 opioids Opana/Opana ER, Percodan, Percocet, and Zydone, in the United States.
18 Opioids made up roughly \$403 million of Endo's overall revenues of \$3 billion in
19 2012. Opana ER yielded \$1.15 billion in revenue from 2010 and 2013, and it
20 accounted for 10% of Endo's total revenue in 2012. Endo also manufactures and
21 sells generic opioids such as oxycodone, oxymorphone, hydromorphone, and
22 hydrocodone products in the United States, by itself and through its subsidiary,
23 Qualitest Pharmaceuticals, Inc.

24 27. ALLERGAN PLC is a public limited company incorporated in
25 Ireland with its principal place of business in Dublin, Ireland. ACTAVIS PLC
26 acquired ALLERGAN PLC in March 2015, and the combined company changed
27 its name to ALLERGAN PLC in January 2013. Before that, WATSON
28 PHARMACEUTICALS, INC. acquired ACTAVIS, INC. in October 2012, and

1 the combined company changed its name to Actavis, Inc. as of January 2013 and
2 then ACTAVIS PLC in October 2013. WATSON LABORATORIES, INC. is a
3 Nevada corporation with its principal place of business in Corona, California, and
4 is a wholly-owned subsidiary of ALLERGAN PLC (f/k/a Actavis, Inc., f/k/a
5 Watson Pharmaceuticals, Inc.). ACTAVIS PHARMA, INC. (f/k/a Actavis, Inc.) is
6 a Delaware corporation with its principal place of business in New Jersey and was
7 formerly known as WATSON PHARMA, INC. ACTAVIS LLC is a Delaware
8 limited liability company with its principal place of business in Parsippany, New
9 Jersey. Each of these defendants is owned by ALLERGAN PLC, which uses them
10 to market and sell its drugs in the United States. Upon information and belief,
11 ALLERGAN PLC exercises control over these marketing and sales efforts and
12 profits from the sale of Allergan/Actavis products ultimately inure to its benefit.
13 ALLERGAN PLC, ACTAVIS PLC, ACTAVIS, Inc., Actavis LLC, Actavis
14 Pharma, Inc., Watson Pharmaceuticals, Inc., Watson Pharma, Inc., and Watson
15 Laboratories, Inc. are referred to as “Actavis.”

16 28. Actavis manufactures, promotes, sells, and distributes opioids,
17 including the branded drugs Kadian and Norco, a generic version of Kadian, and
18 generic versions of Duragesic and Opana, in the United States. Actavis acquired
19 the rights to Kadian from King Pharmaceuticals, Inc. on December 30, 2008, and
20 began marketing Kadian in 2009.

21 29. MALLINCKRODT, PLC is an Irish public limited company
22 headquartered in Staines-upon-Thames, United Kingdom, with its U.S.
23 headquarters in St. Louis, Missouri. MALLINCKRODT, LLC is a limited liability
24 company organized and existing under the laws of the State of Delaware.
25 Mallinckrodt, LLC is a wholly owned subsidiary of Mallinckrodt, PLC.
26 Mallinckrodt, PLC and Mallinckrodt, LLC are referred to as “Mallinckrodt.”

27 30. Mallinckrodt manufactures, markets, and sells drugs in the United
28 States including generic oxycodone, of which it is one of the largest

1 manufacturers. In July 2017 Mallinckrodt agreed to pay \$35 million to settle
2 allegations brought by the Department of Justice that it failed to detect and notify
3 the DEA of suspicious orders of controlled substances.

4 31. INSYS THERAPEUTICS, INC. is a Delaware corporation with its
5 principal place of business in Chandler, Arizona. Insys's principal product and
6 source of revenue is Subsys.

7 32. Insys made thousands of payments to physicians nationwide,
8 including in the State, ostensibly for activities including participating on speakers'
9 bureaus, providing consulting services, assisting in post-marketing safety
10 surveillance and other services, but in fact to deceptively promote and maximize
11 the use of opioids.

12 33. Subsys is a transmucosal immediate-release formulation (TIRF) of
13 fentanyl, contained in a single-dose spray device intended for oral, under the
14 tongue administration. Subsys was approved by the FDA solely for the treatment
15 of breakthrough cancer pain.

16 34. In 2016, Insys made approximately \$330 million in net revenue from
17 Subsys. Insys promotes, sells, and distributes Subsys throughout the United
18 States, the County, and Plaintiffs' Community.

19 35. Insys's founder and owner was recently arrested and charged, along
20 with other Insys executives, with multiple felonies in connection with an alleged
21 conspiracy to bribe practitioners to prescribe Subsys and defraud insurance
22 companies. Other Insys executives and managers were previously indicted.

23 **2. Distributor Defendants.**

24 36. The Distributor Defendants also are defined below. At all relevant
25 times, the Distributor Defendants have distributed, supplied, sold, and placed into
26 the stream of commerce the prescription opioids, without fulfilling the
27 fundamental duty of wholesale drug distributors to detect and warn of diversion of
28 dangerous drugs for non-medical purposes. The Distributor Defendants

1 universally failed to comply with federal and/or state law. The Distributor
2 Defendants are engaged in “wholesale distribution,” as defined under state and
3 federal law. Plaintiffs allege the unlawful conduct by the Distributor Defendants is
4 responsible for the volume of prescription opioids plaguing Plaintiffs’
5 Community.

6 37. McKESSON CORPORATION (“McKesson”) at all relevant times,
7 operated as a licensed distributor in California, licensed by the California State
8 Board of Pharmacy and holding both wholesaler and out of state wholesaler
9 distributor licenses. McKesson is a Delaware corporation. McKesson has its
10 principal place of business located in San Francisco, California. McKesson
11 operates distribution centers in Chino, Fullerton, Sacramento and Visalia,
12 California.

13 38. CARDINAL HEALTH, INC. (“Cardinal”) at all relevant times,
14 operated as a licensed distributor in California, licensed by the California State
15 Board of Pharmacy and holding both wholesaler and out of state wholesaler
16 distributor licenses. Cardinal’s principal office is located in Dublin, Ohio.
17 Cardinal operates a distribution center in Sacramento, California.

18 39. AMERISOURCEBERGEN DRUG CORPORATION
19 (“AmerisourceBergen”) at all relevant times, operated as a licensed distributor in
20 California, licensed by the California State Board of Pharmacy and holding both
21 wholesaler and out of state wholesaler distributor licenses. AmerisourceBergen is
22 a Delaware corporation and its principal place of business is located in
23 Chesterbrook, Pennsylvania.

24 40. Defendant CVS HEALTH CORPORATION is a Delaware
25 corporation with its principal place of business in Rhode Island. CVS Health
26 Corporation conducts business as a licensed wholesale distributor under the
27 following named business entities: CVS Indiana, L.L.C.; CVS Orlando FL
28 Distribution; CVS Pharmacy, Inc.; CVS RX Services, Inc, d/b/a CVS Pharmacy

1 Distribution Center; CVS TN Distribution, LLC ; and CVS VERO FL
 2 Distribution, L.L.C (collectively “CVS”). At all times relevant to this Complaint,
 3 CVS distributed prescription opioids throughout the United States, including in
 4 the State and the County and Plaintiffs’ Community specifically. At all relevant
 5 times, this Defendant operated as a licensed distributor in California, licensed by
 6 the California State Board of Pharmacy.

7 41. Defendant THE KROGER CO. is an Ohio corporation with
 8 headquarters in Cincinnati, OH. Kroger operates 2,268 pharmacies in the United
 9 States, including in California. The Kroger Co. conducts business as a licensed
 10 wholesale distributor under the following named business entities: Kroger Limited
 11 Partnership I and Kroger Limited Partnership II (collectively “Kroger”). At all
 12 times relevant to this Complaint, Kroger distributed and dispensed prescription
 13 opioids throughout the United States, including in California and Plaintiffs’
 14 Community specifically. At all relevant times, this Defendant operated licensed
 15 pharmacies in California, licensed by the California State Board of Pharmacy.

16 42. Defendant RITE AID OF MARYLAND, INC., d/b/a Rite Aid Mid-
 17 Atlantic Customer Support Center, Inc. is a Maryland corporation with its
 18 principal office located in Camp Hill, Pennsylvania and is a subsidiary of Rite Aid
 19 Corporation. Defendant THRIFTY PAYLESS, INC. is a California corporation
 20 with its principal office in located in Camp Hill, Pennsylvania and is a subsidiary
 21 of Rite Aid Corporation. Rite Aid of Maryland, Inc., d/b/a as Rite Aid Mid-
 22 Atlantic Customer Support Center, Inc. and Thrifty Payless, Inc. are referred to as
 23 “Rite Aid.” At all times relevant to this Complaint, Rite Aid distributed
 24 prescription opioids throughout the United States, including in the State, the
 25 County and Plaintiffs’ Community specifically. Rite Aid of Maryland, Inc., d/b/a
 26 Rite Aid Mid-Atlantic Customer Support Center, Inc. conducts business as a
 27 licensed wholesale distributor under the name Rite Aid Mid-Atlantic Customer
 28 Support Center and at all relevant times, operated as a licensed distributor in

1 California, licensed by the California State of Pharmacy. Thrifty Payless, Inc.
2 conducts business as a licensed wholesale distributor and at all relevant times,
3 operated as a licensed distributor in California, licensed by the California State of
4 Pharmacy.

5 43. Defendant WALGREENS BOOTS ALLIANCE, INC., also known
6 as Walgreen Co. ("Walgreens") is a Delaware corporation with its principal place
7 of business in Illinois. Walgreens Boots Alliance Inc. conducts business as a
8 licensed wholesale distributor under the following named business entities:
9 Walgreen Co.; Walgreen Eastern Co., Inc.; Walgreen Arizona Drug Co.
10 (collectively "Walgreens"). At all times relevant to this Complaint, Walgreens
11 distributed prescription opioids throughout the United States, including in the
12 State, the County and Plaintiffs' Community specifically. At all relevant times,
13 this Defendant operated as a licensed distributor in California, licensed by the
14 California State Board of Pharmacy.

15 44. Defendant WAL-MART INC., formerly known as Wal-Mart Stores,
16 Inc. ("Wal-Mart"), is a Delaware corporation with its principal place of business
17 in Arkansas. At all times relevant to this Complaint, Wal-Mart distributed
18 prescription opioids throughout the United States, including in the State, the
19 County and Plaintiffs' Community specifically. Wal-Mart Stores, Inc. conducts
20 business as a licensed wholesale distributor under the following named business
21 entities: Wal-Mart Warehouse #28; Wal-Mart Warehouse #6045 aka Wal-Mart
22 Warehouse #45; Wal-Mart Warehouse # 6046 aka Wal-Mart Warehouse #46
23 ("collectively "Wal-Mart"). At all relevant times, this Defendant operated as a
24 licensed distributor in California, licensed by the California State Board of
25 Pharmacy.

26 45. Collectively, Defendants CVS, Kroger, Rite Aid, Walgreens, Wal-
27 Mart are referred to as "National Retail Pharmacies." Cardinal, McKesson,
28

1 AmerisourceBergen, and the National Retail Pharmacies are collectively referred
2 to as the “Distributor Defendants.”

3 46. Defendants include the above referenced entities as well as their
4 predecessors, successors, affiliates, subsidiaries, partnerships and divisions to the
5 extent that they are engaged in the manufacture, promotion, distribution, sale
6 and/or dispensing of opioids.

7 **III. JURISDICTION & VENUE**

8 47. This Court has subject matter jurisdiction under 28 U.S.C. § 1331
9 based upon the federal claims asserted under the Racketeer Influenced and
10 Corrupt Organizations Act, 18 U.S.C. § 1961, *et seq.* (“RICO”). This Court has
11 supplemental jurisdiction over Plaintiffs’ state law claims pursuant to 28 U.S.C. §
12 1367 because those claims are so related to Plaintiffs’ federal claims that they
13 form part of the same case or controversy.

14 48. This Court has personal jurisdiction over Defendants because they
15 conduct business in the State, purposefully direct or directed their actions toward
16 the State, some or all consented to be sued in the State by registering an agent for
17 service of process, they consensually submitted to the jurisdiction of the State
18 when obtaining a manufacturer or distributor license, and because they have the
19 requisite minimum contacts with the State necessary to constitutionally permit the
20 Court to exercise jurisdiction.

21 49. This Court also has personal jurisdiction over all of the defendants
22 under 18 U.S.C. § 1965(b). This Court may exercise nation-wide jurisdiction over
23 the named Defendants where the “ends of justice” require national service and
24 Plaintiffs demonstrate national contacts. Here, the interests of justice require that
25 Plaintiffs be allowed to bring all members of the nationwide RICO enterprise
26 before the court in a single trial. *See, e.g., Iron Workers Local Union No. 17*
27 *Insurance Fund v. Philip Morris Inc.*, 23 F. Supp. 2d 796, 803 (N.D. Ohio 1998)
28 (citing *LaSalle National Bank v. Arroyo Office Plaza, Ltd.*, 1988 WL 23824, *2

(N.D. Ill. Mar 10, 1988); *Butcher's Union Local No. 498 v. SDC Invest., Inc.*, 788 F.2d 535, 539 (9th Cir. 1986)).

50. Venue is proper in this District pursuant to 28 U.S.C. § 1391 and 18 U.S.C. §1965 because a substantial part of the events or omissions giving rise to the claim occurred in this District and each Defendant transacted affairs and conducted activity that gave rise to the claim of relief in this District. 28 U.S.C. § 1391(b); 18 U.S.C. §1965(a).

IV. FACTUAL BACKGROUND

A. THE OPIOID EPIDEMIC.

1. The National Opioid Epidemic.

51. The past two decades have been characterized by increasing abuse and diversion of prescription drugs, including opioid medications, in the United States.⁹

52. Prescription opioids have become widely prescribed. By 2010, enough prescription opioids were sold to medicate every adult in the United States with a dose of 5 milligrams of hydrocodone every 4 hours for 1 month.¹⁰

53. By 2011, the U.S. Department of Health and Human Resources, Centers for Disease Control and Prevention, declared prescription painkiller overdoses at epidemic levels. The News Release noted:

- a. The death toll from overdoses of prescription painkillers has more than tripled in the past decade.
- b. More than 40 people die every day from overdoses involving narcotic pain relievers like hydrocodone (Vicodin), methadone, oxycodone (OxyContin), and oxymorphone (Opana).
- c. Overdoses involving prescription painkillers are at epidemic levels and now kill more Americans than heroin and cocaine combined.

⁹ See Richard C. Dart et al., Trends in Opioid Analgesic Abuse and Mortality in the United States, 372 N. Eng. J. Med. 241 (2015).

¹⁰ Katherine M. Keyes et al., Understanding the Rural-Urban Differences in Nonmedical Prescription Opioid Use and Abuse in the United States, 104 Am. J. Pub. Health e52 (2014).

d. The increased use of prescription painkillers for nonmedical reasons, along with growing sales, has contributed to a large number of overdoses and deaths. In 2010, 1 in every 20 people in the United States age 12 and older—a total of 12 million people—reported using prescription painkillers non-medically according to the National Survey on Drug Use and Health. Based on the data from the Drug Enforcement Administration, sales of these drugs to pharmacies and health care providers have increased by more than 300 percent since 1999.

e. Prescription drug abuse is a silent epidemic that is stealing thousands of lives and tearing apart communities and families across America.

f. Almost 5,500 people start to misuse prescription painkillers every day.¹¹

54. The number of annual opioid prescriptions written in the United States is now roughly equal to the number of adults in the population.¹²

55. Many Americans are now addicted to prescription opioids, and the number of deaths due to prescription opioid overdose is unacceptable. In 2016, drug overdoses killed roughly 64,000 people in the United States, an increase of more than 22 percent over the 52,404 drug deaths recorded the previous year.¹³

56. Moreover, the CDC has identified addiction to prescription pain medication as the strongest risk factor for heroin addiction. People who are addicted to prescription opioid painkillers are forty times more likely to be addicted to heroin.¹⁴

57. Heroin is pharmacologically similar to prescription opioids. The majority of current heroin users report having used prescription opioids non-

¹¹ See Press Release, Ctrs. for Disease Control and Prevention, U.S. Dep't of Health and Human Servs., Prescription Painkiller Overdoses at Epidemic Levels (Nov. 1, 2011), https://www.cdc.gov/media/releases/2011/p1101_flu_pain_killer_overdose.html.

¹² See Robert M. Califf et al., *A Proactive Response to Prescription Opioid Abuse*, 374 N. Eng. J. Med. 1480 (2016).

¹³ See Ctrs. for Disease Control and Prevention, U.S. Dep't of Health and Human Servs., Provisional Counts of Drug Overdose Deaths, (August 8, 2016), https://www.cdc.gov/nchs/data/health_policy/monthly-drug-overdose-death-estimates.pdf.

¹⁴ See Ctrs. for Disease Control and Prevention, U.S. Dep't of Health and Human Servs., *Today's Heroin Epidemic*, <https://www.cdc.gov/vitalsigns/heroin/index.html> (last updated July 7, 2015).

1 medically before they initiated heroin use. Available data indicates that the
2 nonmedical use of prescription opioids is a strong risk factor for heroin use.¹⁵

3 58. The CDC reports that drug overdose deaths involving heroin
4 continued to climb sharply, with heroin overdoses more than tripling in 4 years.
5 This increase mirrors large increases in heroin use across the country and has been
6 shown to be closely tied to opioid pain reliever misuse and dependence. ***Past***
7 ***misuse of prescription opioids is the strongest risk factor for heroin initiation***
8 ***and use***, specifically among persons who report past-year dependence or abuse.
9 The increased availability of heroin, combined with its relatively low price
10 (compared with diverted prescription opioids) and high purity appear to be major
11 drivers of the upward trend in heroin use and overdose.¹⁶

12 59. The societal costs of prescription drug abuse are “huge.”¹⁷

13 60. Across the nation, local governments are struggling with a
14 pernicious, ever-expanding epidemic of opioid addiction and abuse. Every day,
15 more than 90 Americans lose their lives after overdosing on opioids.¹⁸

16 61. The National Institute on Drug Abuse identifies misuse and addiction
17 to opioids as “a serious national crisis that affects public health as well as social
18 and economic welfare.”¹⁹ The economic burden of prescription opioid misuse
19

20 ¹⁵ See Wilson M. Compton, Relationship Between Nonmedical Prescription-
21 Opioid Use and Heroin, 374 N. Eng. J. Med. 154 (2016).

22 ¹⁶ See Rose A. Rudd et al., *Increases in Drug and Opioid Overdose Deaths—*
United States, 2000–2014, 64 Morbidity & Mortality Wkly. Rep. 1378 (2016).

23 ¹⁷ See Amicus Curiae Brief of Healthcare Distribution Management Association in
24 Support of Appellant Cardinal Health, Inc., *Cardinal Health, Inc. v. United States*
Dept. Justice, No. 12-5061 (D.C. Cir. May 9, 2012), 2012 WL 1637016, at *10
[hereinafter Brief of HDMA].

25 ¹⁸ Opioid Crisis, NIH, National Institute on Drug Abuse (available at
26 <https://www.drugabuse.gov/drugs-abuse/opioids/opioid-crisis>, last visited Sept. 19,
2017) (“Opioid Crisis, NIH”) (citing at note 1 Rudd RA, Seth P, David F, Scholl L,
27 *Increases in Drug and Opioid-Involved Overdose Deaths — United States, 2010–*
2015, MMWR MORB MORTAL WKLY REP. 2016;65,
28 doi:10.15585/mmwr.mm65051e1).

¹⁹ Opioid Crisis, NIH.

1 alone is \$78.5 billion a year, including the costs of healthcare, lost productivity,
2 addiction treatment, and criminal justice expenditures.²⁰

3 62. The U.S. opioid epidemic is continuing, and drug overdose deaths
4 nearly tripled during 1999–2014. Among 47,055 drug overdose deaths that
5 occurred in 2014 in the United States, 28,647 (60.9%) involved an opioid.²¹

6 63. The rate of death from opioid overdose has quadrupled during the
7 past 15 years in the United States. Nonfatal opioid overdoses that require medical
8 care in a hospital or emergency department have increased by a factor of six in the
9 past 15 years.²²

10 64. Every day brings a new revelation regarding the depth of the opioid
11 plague: just to name one example, the New York Times reported in September
12 2017 that the epidemic, which now claims 60,000 lives a year, is now killing
13 babies and toddlers because ubiquitous, deadly opioids are “everywhere” and
14 mistaken as candy.²³

15 65. In 2016, the President of the United States declared an opioid and
16 heroin epidemic.²⁴

17 66. The epidemic of prescription pain medication and heroin deaths is
18 devastating families and communities across the country.²⁵ Meanwhile, the
19
20

21 ²⁰ *Id.* (citing at note 2 Florence CS, Zhou C, Luo F, Xu L, *The Economic Burden*
22 *of Prescription Opioid Overdose, Abuse, and Dependence in the United States*,
2013, *MED CARE* 2016;54(10):901-906, doi:10.1097/MLR.0000000000000625).

23 ²¹ See Rose A. Rudd et al., Increases in Drug and Opioid-Involved Overdose
24 Deaths—United States, 2010–2015, 65 *Morbidity & Mortality Wkly. Rep.* 1445
(2016).

25 ²² See Nora D. Volkow & A. Thomas McLellan, *Opioid Abuse in Chronic Pain—*
Misconceptions and Mitigation Strategies, 374 *N. Eng. J. Med.* 1253 (2016).

26 ²³ Julie Turkewitz, ‘*The Pills are Everywhere*’: *How the Opioid Crisis Claims Its*
27 *Youngest Victims*, *N.Y. Times*, Sept. 20, 2017 (“‘It’s a cancer,’ said [grandmother
of dead one-year old], of the nation’s opioid problem, ‘with tendrils that are going
everywhere.’”).

28 ²⁴ See Proclamation No. 9499, 81 *Fed. Reg.* 65,173 (Sept. 16, 2016) (proclaiming
“Prescription Opioid and Heroin Epidemic Awareness Week”).

1 manufacturers and distributors of prescription opioids extract billions of dollars of
 2 revenue from the addicted American public while public entities experience
 3 hundreds of millions of dollars of injury – if not more – caused by the reasonably
 4 foreseeable consequences of the prescription opioid addiction epidemic.

5 67. The prescription opioid manufacturers and distributors, including the
 6 Defendants, have continued their wrongful, intentional, and unlawful conduct,
 7 despite their knowledge that such conduct is causing and/or contributing to the
 8 national, state, and local opioid epidemic.

9 **2. The California Opioid Epidemic.**

10 68. California has been especially ravaged by the national opioid crisis.

11 69. More people die each year from drug overdoses in California than in
 12 any other state.²⁶ The State's death rate has continued to climb, increasing by 30
 13 percent from 1999 to 2015, according to the Center for Disease Control (CDC).²⁷

14 70. In 2016, 1,925 Californians died due to prescription opioids.²⁸ This
 15 number is on par with other recent years: in 2015, 1,966 deaths in California were
 16 due just to prescription opioids (not including heroin); in 2014 that number was
 17 even higher at 2,024 prescription opioid deaths; and in 2013, 1,934 Californians
 18 died from a prescription opioid overdose.²⁹

20 ²⁵ See Presidential Memorandum – Addressing Prescription Drug Abuse and
 21 Heroin Use, 2015 Daily Comp. Pres. Doc. 743 (Oct. 21, 2015),
<https://www.gpo.gov/fdsys/pkg/DCPD-201500743/pdf/DCPD-201500743.pdf>.

22 ²⁶ Kristina Davis, “How California ranks in the nation’s opioid epidemic,” *The San*
 23 *Diego Union-Tribune* (Nov. 8, 2017) available at
[http://www.sandiegouniontribune.com/news/health/sd-me-opioid-conference-](http://www.sandiegouniontribune.com/news/health/sd-me-opioid-conference-20171108-story.html)
 24 [20171108-story.html](http://www.sandiegouniontribune.com/news/health/sd-me-opioid-conference-20171108-story.html) (last visited March 2, 2018).

25 ²⁷ Soumya Karlamangla, “California’s opioid death rate is among the national’s
 26 lowest. Experts aren’t sure why,” *The Los Angeles Times* (Oct. 27, 2017) available
 at [http://www.latimes.com/health/la-me-ln-california-opioids-20171026-](http://www.latimes.com/health/la-me-ln-california-opioids-20171026-htmlstory.html)
[htmlstory.html](http://www.latimes.com/health/la-me-ln-california-opioids-20171026-htmlstory.html) (last visited March 2, 2018).

27 ²⁸ Davis, *supra*.

28 ²⁹ California Department of Public Health, *California Opioid Overdose*
Surveillance Dashboard, available at https://pdop.shinyapps.io/ODdash_v1/ (last
 visited March 2, 2018).

1 71. Of the 1,925 opioid-related deaths in California in 2016, fentanyl was
2 a factor in at least 234 of them.³⁰ This is an increase of 47 percent for 2016.³¹
3 Heroin-related deaths have risen by 67 percent in California since 2006.³²

4 72. The high number of deaths are due in part to the extraordinary
5 number of opioids prescribed in the State. Over 23.6 million prescriptions for
6 opioids were written in California in just 2016.³³

7 73. The California Department of Public Health tracks the number of
8 reported hospitalizations and emergency department visits due to prescription
9 opioids.³⁴ In 2015, the last year for which information is currently available,
10 California had 3,935 emergency department visits and 4,095 hospitalizations
11 related to prescription opioid overdoses (excluding heroin).³⁵ The numbers were
12 even higher in 2014, when 4,106 people visited the emergency department and
13 4,482 people were hospitalized due to prescription opioid abuse.³⁶ In 2013, there
14 were 3,964 emergency department visits and 4,344 hospitalizations for
15 prescription opioid overdoses.³⁷ When emergency visits and hospitalizations
16 include heroin, the numbers are even higher.³⁸

19 ³⁰ Davis, *supra*.

20 ³¹ Karlamangla, *supra*.

21 ³² California Department of Public Health, *State of California Strategies to Address*
22 *Prescription Drug (Opioid) Misuse, Abuse, and Overdose Epidemic in California*
at 3 (June 2016), available at
23 <https://www.cdph.ca.gov/Programs/CCDPHP/DCDIC/SACB/CDPH%20Document%20Library/Prescription%20Drug%20Overdose%20Program/CAOpioidPreventionStrategies4.17.pdf> (last visited March 2, 2018).

24 ³³ California Department of Public Health, *California Opioid Overdose*
25 *Surveillance Dashboard*, *supra*.

26 ³⁴ *Id.*


27 ³⁵ *Id.*

28 ³⁶ *Id.*

³⁷ *Id.*

³⁸ *Id.*

74. Neonatal Abstinence Syndrome (NAS), a collection of symptoms newborn babies experience withdrawing from opioid medications taken by the mother, has increased dramatically in California, with the rate of infants born with NAS more than tripling from 2008 to 2013.³⁹ While the number of affected newborns rose from 1,862 in 2008 to 3,007 in 2014, that number jumped by



*Includes cocaine, hallucinogenic agents, other narcotics, other drugs of addiction, or noxious substances, or those that displayed withdrawal symptoms of the same.
Source: Inpatient Discharge Data, 2006 – 2015; Office of Statewide Health Planning and Development

another 21 percent in 2015.⁴⁰ This is despite a steady decline in the overall number of birth in California during that same time.⁴¹

³⁹ California Child Welfare Co-Investment Partnership, *A Matter of Substance, Challenges and Responses to Parental Substance Use in Child Welfare*, at 5 (Summer 2017), available at http://www.chhs.ca.gov/Child%20Welfare/CCW_Co-Invest_Insights_DIGITAL_FINAL_053017.pdf (last visited March 2, 2018).

⁴⁰ Cheryl Clark, "Report Shows Spike in San Diego County Babies Born with Drugs in their Systems," *KPBS* (April 17, 2017), available at <http://www.kpbs.org/news/2017/apr/17/report-shows-spike-san-diego-county-babies-born-dr/> (last visited March 2, 2018).

⁴¹ *Id.*

1 75. Reports from California's Office of Statewide Health Planning,
2 which collects data from licensed health care facilities, have shown a 95 percent
3 increase between 2008 and 2015 of newborns affected by drugs transmitted via
4 placenta or breast milk.⁴²

5 76. The opioid epidemic has also had an impact on crime in California.
6 Pharmacy robberies have gone up by 163 percent in California over the last two
7 years, according to the DEA. The DEA recorded 90 incidents in 2015, 154 in
8 2016 and, through mid-November of 2017, that number had climbed to 237.⁴³
9 Most perpetrators were after prescription opioids.⁴⁴ In addition, fentanyl seizures
10 at California ports increased 266 percent in fiscal year 2017.⁴⁵

11 **3. The Opioid Epidemic in Plaintiffs' Community.**

12 77. The opioid epidemic is particularly devastating in Plaintiffs'
13 Community.

14 78. In 2016, 12 people died from opioid overdoses in the County.⁴⁶ The
15 County also had 13 deaths from opioid overdoses in 2015 and 14 in 2014.⁴⁷ These
16 numbers are down from prior years. In 2013, the County suffered 26 fatalities due
17 to opioids.⁴⁸ There were 25 deaths in 2012 and 31 in 2011.⁴⁹ Monterey County has
18 a higher rate of opioid overdose deaths than Los Angeles County.⁵⁰

19
20 ⁴² California Child Welfare Co-Investment Partnership, *supra*, at 3.

21 ⁴³ Ed Fletcher, "What's behind the spike in drug store robberies?" *The Sacramento*
22 *Bee*, Dec. 8, 2017 (available at <http://www.sacbee.com/news/local/crime/article188636384.html> (last visited
March 2, 2018)).

23 ⁴⁴ *Id.*

24 ⁴⁵ United State Department of Justice, The United States Attorney's Office,
25 Southern District of California, *U.S. Attorney Appoints Opioid Coordinators* (Feb.
8, 2018) available at [https://www.justice.gov/usao-sdca/pr/us-attorney-appoints-](https://www.justice.gov/usao-sdca/pr/us-attorney-appoints-opioid-coordinators)
opioid-coordinators (last visited March 2, 2018).

26 ⁴⁶ California Department of Public Health, *California Opioid Overdose*
27 *Surveillance Dashboard*, available at https://pdop.shinyapps.io/ODdash_v1/ (last
visited May 1, 2018) (Monterey County specific page).

28 ⁴⁷ *Id.* at Table on California Deaths by County for 2015, 2014.

⁴⁸ *Id.* at Table on California Deaths by County for 2013.

1 79. From 2012 to 2014, the County suffered 146 deaths due to drug
2 overdoses, which is a drug overdose mortality rate of 11 deaths per 100,000
3 people.⁵¹

4 80. Prescription opioids have also been responsible for increased
5 emergency department visits and hospitalizations in the County. In 2016,
6 Monterey County had 40 emergency department visits due to opioid overdoses
7 (excluding heroin) for a rate of 8.9, and 30 opioid overdose hospitalizations for a
8 rate of 6.7 per 100,000 residents.⁵²

9 81. In 2016, an estimated 5.8 percent of the population aged 12 and up in
10 Monterey County misused opioids (almost 4,000 people) and about one percent
11 had an opioid use disorder.⁵³

12 82. Law enforcement in the County has been equipped with naloxone – a
13 drug that can reverse opioid overdoses – and all of the ambulances in Monterey
14 County are carrying it.⁵⁴

15 83. One reason for these high numbers is the high number of
16 prescriptions being written for opioids in Monterey County. According to the
17
18

19 ⁴⁹ *Id.* at Table on California Deaths by County for 2012, 2011.

20 ⁵⁰ Brynne Whittaker, “Opioid overdoses rising in Santa Cruz, Monterey counties,”
21 *KSBW8*, Jan. 23, 2017, available at <http://www.ksbw.com/article/california-sees-increase-in-opioid-overdose-deaths/3311493> (last visited May 1, 2018).

22 ⁵¹ County Health Rankings & Roadmaps, Drug overdose deaths, available at
23 <http://www.countyhealthrankings.org/app/california/2016/measure/factors/138/data>
24 a (last visited April 20, 2018).

25 ⁵² California Department of Public Health, *California Opioid Overdose*
26 *Surveillance Dashboard*, *supra*, (Monterey County specific page).

27 ⁵³ Lisa Clemans-Cope, Marni Epstein, and Doug Wissoker, “County-Level
28 Estimates of Opioid Use Disorder and Treatment Needs in California,” *The Urban*
Institute, March 19, 2018, available at
<https://www.urban.org/sites/default/files/monterey.pdf> (last visited May 1, 2018).

⁵⁴ Tom Wright, “Pacific Grove, Carmel police equip officers with opioid overdose
antidote,” *Monterey Herald*, (September 1, 2017), available at
<http://www.montereyherald.com/article/NF/20170901/NEWS/170909972> (last
visited May 1, 2018).

1 California Department of Public Health, over 237,300 prescriptions were written
2 in 2016 in Monterey County alone.⁵⁵

3 84. The sheer volume of these dangerously addictive drugs was destined
4 to create the present crisis of addiction, abuse, and overdose deaths.

5 **B. THE MANUFACTURER DEFENDANTS' FALSE, DECEPTIVE,**
6 **AND UNFAIR MARKETING OF OPIOIDS.**

7 85. The opioid epidemic did not happen by accident.

8 86. Before the 1990s, generally accepted standards of medical practice
9 dictated that opioids should only be used short-term for acute pain, pain relating to
10 recovery from surgery, or for cancer or palliative (end-of-life) care. Due to the
11 lack of evidence that opioids improved patients' ability to overcome pain and
12 function, coupled with evidence of greater pain complaints as patients developed
13 tolerance to opioids over time and the serious risk of addiction and other side
14 effects, the use of opioids for chronic pain was discouraged or prohibited. As a
15 result, doctors generally did not prescribe opioids for chronic pain.

16 87. Each Manufacturer Defendant has conducted, and has continued to
17 conduct, a marketing scheme designed to persuade doctors and patients that
18 opioids can and should be used for chronic pain, resulting in opioid treatment for a
19 far broader group of patients who are much more likely to become addicted and
20 suffer other adverse effects from the long-term use of opioids. In connection with
21 this scheme, each Manufacturer Defendant spent, and continues to spend, millions
22 of dollars on promotional activities and materials that falsely deny or trivialize the
23 risks of opioids while overstating the benefits of using them for chronic pain.

24 88. The Manufacturer Defendants have made false and misleading
25 claims, contrary to the language on their drugs' labels, regarding the risks of using
26 their drugs that: (1) downplayed the serious risk of addiction; (2) created and
27

28 ⁵⁵ California Department of Public Health, *California Opioid Overdose
Surveillance Dashboard*, *supra*, (Monterey County specific page).

1 promoted the concept of “pseudoaddiction” when signs of actual addiction began
 2 appearing and advocated that the signs of addiction should be treated with more
 3 opioids; (3) exaggerated the effectiveness of screening tools to prevent addiction;
 4 (4) claimed that opioid dependence and withdrawal are easily managed; (5) denied
 5 the risks of higher opioid dosages; and (6) exaggerated the effectiveness of
 6 “abuse-deterrent” opioid formulations to prevent abuse and addiction. The
 7 Manufacturer Defendants have also falsely touted the benefits of long-term opioid
 8 use, including the supposed ability of opioids to improve function and quality of
 9 life, even though there was no scientifically reliable evidence to support the
 10 Manufacturer Defendants’ claims.

11 89. The Manufacturer Defendants have disseminated these common
 12 messages to reverse the popular and medical understanding of opioids and risks of
 13 opioid use. They disseminated these messages directly, through their sales
 14 representatives, in speaker groups led by physicians the Manufacturer Defendants
 15 recruited for their support of their marketing messages, and through unbranded
 16 marketing and industry-funded front groups.

17 90. The Manufacturer Defendants’ efforts have been wildly successful.
 18 Opioids are now the most prescribed class of drugs. Globally, opioid sales
 19 generated \$11 billion in revenue for drug companies in 2010 alone; sales in the
 20 United States have exceeded \$8 billion in revenue annually since 2009.⁵⁶ In an
 21 open letter to the nation’s physicians in August 2016, the then-U.S. Surgeon
 22 General expressly connected this “urgent health crisis” to “heavy marketing of
 23 opioids to doctors . . . [m]any of [whom] were even taught – incorrectly – that
 24
 25

26 ⁵⁶ See Katherine Eban, *Oxycontin: Purdue Pharma’s Painful Medicine*, Fortune,
 27 Nov. 9, 2011, [http://fortune.com/2011/11/09/oxycontin-purdue-pharmas-painful-](http://fortune.com/2011/11/09/oxycontin-purdue-pharmas-painful-medicine/)
 28 [medicine/](http://fortune.com/2011/11/09/oxycontin-purdue-pharmas-painful-medicine/); David Crow, *Drugmakers Hooked on \$10bn Opioid Habit*, Fin. Times,
 Aug. 10, 2016, [https://www.ft.com/content/f6e989a8-5dac-11e6-bb77-](https://www.ft.com/content/f6e989a8-5dac-11e6-bb77-a121aa8abd95)
[a121aa8abd95](https://www.ft.com/content/f6e989a8-5dac-11e6-bb77-a121aa8abd95).

1 opioids are not addictive when prescribed for legitimate pain.”⁵⁷ This epidemic
 2 has resulted in a flood of prescription opioids available for illicit use or sale (the
 3 supply), and a population of patients physically and psychologically dependent on
 4 them (the demand). And when those patients can no longer afford or obtain
 5 opioids from licensed dispensaries, they often turn to the street to buy prescription
 6 opioids or even non-prescription opioids, like heroin.

7 91. The Manufacturer Defendants intentionally continued their conduct,
 8 as alleged herein, with knowledge that such conduct was creating the opioid
 9 nuisance and causing the harms and damages alleged herein.

10 **1. Each Manufacturer Defendant Used Multiple Avenues to**
 11 **Disseminate Their False and Deceptive Statements about Opioids.**

12 92. The Manufacturer Defendants spread their false and deceptive
 13 statements by marketing their branded opioids directly to doctors and patients in
 14 and around the State, including in Plaintiffs’ Community. Defendants also
 15 deployed seemingly unbiased and independent third parties that they controlled to
 16 spread their false and deceptive statements about the risks and benefits of opioids
 17 for the treatment of chronic pain throughout the State and Plaintiffs’ Community.

18 93. The Manufacturer Defendants employed the same marketing plans
 19 and strategies and deployed the same messages in and around the State, including
 20 in Plaintiffs’ Community, as they did nationwide. Across the pharmaceutical
 21 industry, “core message” development is funded and overseen on a national basis
 22 by corporate headquarters. This comprehensive approach ensures that the
 23 Manufacturer Defendants’ messages are accurately and consistently delivered
 24 across marketing channels – including detailing visits, speaker events, and
 25 advertising – and in each sales territory. The Manufacturer Defendants consider
 26

27
 28 ⁵⁷ Letter from Vivek H. Murthy, U.S. Surgeon General (Aug. 2016),
<http://turnthetidex.org/>.

1 this high level of coordination and uniformity crucial to successfully marketing
2 their drugs.

3 94. The Manufacturer Defendants ensure marketing consistency
4 nationwide through national and regional sales representative training; national
5 training of local medical liaisons, the company employees who respond to
6 physician inquiries; centralized speaker training; single sets of visual aids, speaker
7 slide decks and sales training materials; and nationally coordinated advertising.
8 The Manufacturer Defendants' sales representatives and physician speakers were
9 required to stick to prescribed talking points, sales messages, and slide decks, and
10 supervisors rode along with them periodically to both check on their performance
11 and compliance.

12 **a) Direct Marketing.**

13 95. The Manufacturer Defendants' direct marketing of opioids generally
14 proceeded on two tracks. First, each Manufacturer Defendant conducted and
15 continues to conduct advertising campaigns touting the purported benefits of their
16 branded drugs. For example, upon information and belief, the Manufacturer
17 Defendants spent more than \$14 million on medical journal advertising of opioids
18 in 2011, nearly triple what they spent in 2001.

19 96. Many of the Manufacturer Defendants' branded ads deceptively
20 portrayed the benefits of opioids for chronic pain. For example, Endo distributed
21 and made available on its website opana.com a pamphlet promoting Opana ER
22 with photographs depicting patients with physically demanding jobs like
23 construction worker, chef, and teacher, misleadingly implying that the drug would
24 provide long-term pain-relief and functional improvement. Upon information and
25 belief, Purdue also ran a series of ads, called "Pain vignettes," for OxyContin in
26 2012 in medical journals. These ads featured chronic pain patients and
27 recommended OxyContin for each. One ad described a "54-year-old writer with
28

1 osteoarthritis of the hands” and implied that OxyContin would help the writer
2 work more effectively.

3 97. Second, each Manufacturer Defendant promoted the use of opioids
4 for chronic pain through “detailers” – sales representatives who visited individual
5 doctors and medical staff in their offices – and small-group speaker programs. The
6 Manufacturer Defendants have not corrected this misinformation. Instead, each
7 Defendant devoted massive resources to direct sales contacts with doctors. Upon
8 information and belief, in 2014 alone, the Manufacturer Defendants spent in
9 excess of \$168 million on detailing branded opioids to doctors, more than twice
10 what they spent on detailing in 2000.

11 98. The Manufacturer Defendants’ detailing to doctors is effective.
12 Numerous studies indicate that marketing impacts prescribing habits, with face-to-
13 face detailing having the greatest influence. Even without such studies, the
14 Manufacturer Defendants purchase, manipulate and analyze some of the most
15 sophisticated data available in any industry, data available from IMS Health
16 Holdings, Inc., to track, precisely, the rates of initial prescribing and renewal by
17 individual doctor, which in turn allows them to target, tailor, and monitor the
18 impact of their core messages. Thus, the Manufacturer Defendants know their
19 detailing to doctors is effective.

20 99. The Manufacturer Defendants’ detailers have been reprimanded for
21 their deceptive promotions. In March 2010, for example, the FDA found that
22 Actavis had been distributing promotional materials that “minimize[] the risks
23 associated with Kadian and misleadingly suggest[] that Kadian is safer than has
24 been demonstrated.” Those materials in particular “fail to reveal warnings
25 regarding potentially fatal abuse of opioids, use by individuals other than the
26 patient for whom the drug was prescribed.”⁵⁸

27
28 ⁵⁸ Letter from Thomas Abrams, Dir., Div. of Drug Mktg., Advert., & Commc’ns,
U.S. Food & Drug Admin., to Doug Boothe, CEO, Actavis Elizabeth LLC (Feb.18,

b) Indirect Marketing.

100. The Manufacturer Defendants indirectly marketed their opioids using unbranded advertising, paid speakers and “key opinion leaders” (“KOLs”), and industry-funded organizations posing as neutral and credible professional societies and patient advocacy groups (referred to hereinafter as “Front Groups”).

101. The Manufacturer Defendants deceptively marketed opioids in the State and Plaintiffs’ Community through unbranded advertising – e.g., advertising that promotes opioid use generally but does not name a specific opioid. This advertising was ostensibly created and disseminated by independent third parties. But by funding, directing, reviewing, editing, and distributing this unbranded advertising, the Manufacturer Defendants controlled the deceptive messages disseminated by these third parties and acted in concert with them to falsely and misleadingly promote opioids for the treatment of chronic pain. Much as Defendants controlled the distribution of their “core messages” via their own detailers and speaker programs, the Manufacturer Defendants similarly controlled the distribution of these messages in scientific publications, treatment guidelines, Continuing Medical Education (“CME”) programs, and medical conferences and seminars. To this end, the Manufacturer Defendants used third-party public relations firms to help control those messages when they originated from third-parties.

102. The Manufacturer Defendants marketed through third-party, unbranded advertising to avoid regulatory scrutiny because that advertising is not submitted to and typically is not reviewed by the FDA. The Manufacturer Defendants also used third-party, unbranded advertising to give the false appearance that the deceptive messages came from an independent and objective source. Like the tobacco companies, the Manufacturer Defendants used third

2010),
<http://www.fdanews.com/ext/resources/files/archives/a/ActavisElizabethLLC.pdf>.

1 parties that they funded, directed, and controlled to carry out and conceal their
2 scheme to deceive doctors and patients about the risks and benefits of long term
3 opioid use for chronic pain.

4 103. Defendants also identified doctors to serve, for payment, on their
5 speakers' bureaus and to attend programs with speakers and meals paid for by
6 Defendants. These speaker programs provided: (1) an incentive for doctors to
7 prescribe a particular opioid (so they might be selected to promote the drug); (2)
8 recognition and compensation for the doctors selected as speakers; and (3) an
9 opportunity to promote the drug through the speaker to his or her peers. These
10 speakers give the false impression that they are providing unbiased and medically
11 accurate presentations when they are, in fact, presenting a script prepared by
12 Defendants. On information and belief, these presentations conveyed misleading
13 information, omitted material information, and failed to correct Defendants' prior
14 misrepresentations about the risks and benefits of opioids.

15 104. Borrowing a page from Big Tobacco's playbook, the Manufacturer
16 Defendants worked through third parties they controlled by: (a) funding, assisting,
17 encouraging, and directing doctors who served as KOLS, and (b) funding,
18 assisting, directing, and encouraging seemingly neutral and credible Front Groups.
19 The Manufacturer Defendants then worked together with those KOLs and Front
20 Groups to taint the sources that doctors and patients relied on for ostensibly
21 "neutral" guidance, such as treatment guidelines, CME programs, medical
22 conferences and seminars, and scientific articles. Thus, working individually and
23 collectively, and through these Front Groups and KOLs, the Manufacturer
24 Defendants persuaded doctors and patients that what they have long known – that
25 opioids are addictive drugs, unsafe in most circumstances for long-term use – was
26 untrue, and that the compassionate treatment of pain required opioids.

27 105. In 2007, multiple States sued Purdue for engaging in unfair and
28 deceptive practices in its marketing, promotion, and sale of OxyContin. Certain

1 states settled their claims in a series of Consent Judgments that prohibited Purdue
2 from making misrepresentations in the promotion and marketing of OxyContin in
3 the future. By using indirect marketing strategies, however, Purdue intentionally
4 circumvented these restrictions. Such actions include contributing to the creation
5 of misleading publications and prescribing guidelines which lack reliable
6 scientific basis, and promoting prescribing practices which have worsened the
7 opioid crisis.

8 106. Pro-opioid doctors are one of the most important avenues that the
9 Manufacturer Defendants use to spread their false and deceptive statements about
10 the risks and benefits of long-term opioid use. The Manufacturer Defendants
11 know that doctors rely heavily and less critically on their peers for guidance, and
12 KOLs provide the false appearance of unbiased and reliable support for chronic
13 opioid therapy. For example, the State of New York found in its settlement with
14 Purdue that the Purdue website “In the Face of Pain” failed to disclose that doctors
15 who provided testimonials on the site were paid by Purdue and concluded that
16 Purdue’s failure to disclose these financial connections potentially misled
17 consumers regarding the objectivity of the testimonials.

18 107. Defendants utilized many KOLs, including many of the same ones.

19 108. Dr. Russell Portenoy, former Chairman of the Department of Pain
20 Medicine and Palliative Care at Beth Israel Medical Center in New York, is one
21 example of a KOL whom the Manufacturer Defendants identified and promoted to
22 further their marketing campaign. Dr. Portenoy received research support,
23 consulting fees, and honoraria from Cephalon, Endo, Janssen, and Purdue (among
24 others), and was a paid consultant to Cephalon and Purdue. Dr. Portenoy was
25 instrumental in opening the door for the regular use of opioids to treat chronic
26 pain. He served on the American Pain Society (“APS”) / American Academy of
27 Pain Medicine (“AAPM”) Guidelines Committees, which endorsed the use of
28 opioids to treat chronic pain, first in 1996 and again in 2009. He was also a

1 member of the board of the American Pain Foundation (“APF”), an advocacy
2 organization almost entirely funded by the Manufacturer Defendants.

3 109. Dr. Portenoy also made frequent media appearances promoting
4 opioids and spreading misrepresentations, such as his claim that “the likelihood
5 that the treatment of pain using an opioid drug which is prescribed by a doctor
6 will lead to addiction is extremely low.” He appeared on Good Morning America
7 in 2010 to discuss the use of opioids long-term to treat chronic pain. On this
8 widely-watched program, broadcast across the country, Dr. Portenoy claimed:
9 “Addiction, when treating pain, is distinctly uncommon. If a person does not have
10 a history, a personal history, of substance abuse, and does not have a history in the
11 family of substance abuse, and does not have a very major psychiatric disorder,
12 most doctors can feel very assured that that person is not going to become
13 addicted.”⁵⁹

14 110. Dr. Portenoy later admitted that he “gave innumerable lectures in the
15 late 1980s and ‘90s about addiction that weren’t true.” These lectures falsely
16 claimed that fewer than 1% of patients would become addicted to opioids.
17 According to Dr. Portenoy, because the primary goal was to “destigmatize”
18 opioids, he and other doctors promoting them overstated their benefits and glossed
19 over their risks. Dr. Portenoy also conceded that “[d]ata about the effectiveness of
20 opioids does not exist.”⁶⁰ Portenoy candidly stated: “Did I teach about pain
21 management, specifically about opioid therapy, in a way that reflects
22 misinformation? Well, . . . I guess I did.”⁶¹

23
24
25 ⁵⁹ Good Morning America (ABC television broadcast Aug. 30, 2010).

26 ⁶⁰ Thomas Catan & Evan Perez, *A Pain-Drug Champion Has Second Thoughts*,
27 Wall St. J., Dec. 17, 2012,
28 [https://www.wsj.com/articles/SB1000142412788732447830457817334265704460](https://www.wsj.com/articles/SB10001424127887324478304578173342657044604)
4.

⁶¹ *Id.*

1 111. Another KOL, Dr. Lynn Webster, was the co-founder and Chief
2 Medical Director of Lifetree Clinical Research, an otherwise unknown pain clinic
3 in Salt Lake City, Utah. Dr. Webster was President of the AAPM in 2013. He is a
4 Senior Editor of Pain Medicine, the same journal that published Endo special
5 advertising supplements touting Opana ER. Dr. Webster was the author of
6 numerous CMEs sponsored by Cephalon, Endo, and Purdue. At the same time,
7 Dr. Webster was receiving significant funding from the Manufacturer Defendants
8 (including nearly \$2 million from Cephalon).

9 112. During a portion of his time as a KOL, Dr. Webster was under
10 investigation for overprescribing by the U.S. Department of Justice's Drug
11 Enforcement Agency, which raided his clinic in 2010. Although the investigation
12 was closed without charges in 2014, more than 20 of Dr. Webster's former
13 patients at the Lifetree Clinic have died of opioid overdoses.

14 113. Ironically, Dr. Webster created and promoted the Opioid Risk Tool, a
15 five question, one-minute screening tool relying on patient self-reports that
16 purportedly allows doctors to manage the risk that their patients will become
17 addicted to or abuse opioids. The claimed ability to pre-sort patients likely to
18 become addicted is an important tool in giving doctors confidence to prescribe
19 opioids long-term, and for this reason, references to screening appear in various
20 industry-supported guidelines. Versions of Dr. Webster's Opioid Risk Tool appear
21 on, or are linked to, websites run by Endo, Janssen, and Purdue. Unaware of the
22 flawed science and industry bias underlying this tool, certain states and public
23 entities have incorporated the Opioid Risk Tool into their own guidelines,
24 indicating, also, their reliance on the Manufacturer Defendants and those under
25 their influence and control.

26 114. In 2011, Dr. Webster presented, via webinar, a program sponsored by
27 Purdue entitled "Managing Patient's Opioid Use: Balancing the Need and the
28 Risk." Dr. Webster recommended use of risk screening tools, urine testing, and

1 patient agreements as a way to prevent “overuse of prescriptions” and “overdose
2 deaths.” This webinar was available to and was intended to reach doctors in the
3 State and doctors treating members of Plaintiffs’ Community.⁶²

4 115. Dr. Webster also was a leading proponent of the concept of
5 “pseudoaddiction,” the notion that addictive behaviors should be seen not as
6 warnings, but as indications of undertreated pain. In Dr. Webster’s description, the
7 only way to differentiate the two was to increase a patient’s dose of opioids. As he
8 and co-author Beth Dove wrote in their 2007 book *Avoiding Opioid Abuse While*
9 *Managing Pain*—a book that is still available online—when faced with signs of
10 aberrant behavior, increasing the dose “in most cases . . . should be the clinician’s
11 first response.”⁶³ Upon information and belief, Endo distributed this book to
12 doctors. Years later, Dr. Webster reversed himself, acknowledging that
13 “[pseudoaddiction] obviously became too much of an excuse to give patients more
14 medication.”⁶⁴

15 116. The Manufacturer Defendants also entered into arrangements with
16 seemingly unbiased and independent patient and professional organizations to
17 promote opioids for the treatment of chronic pain. Under the direction and control
18 of the Manufacturer Defendants, these “Front Groups” generated treatment
19 guidelines, unbranded materials, and programs that favored chronic opioid
20 therapy. They also assisted the Manufacturer Defendants by responding to
21 negative articles, by advocating against regulatory changes that would limit opioid
22

23 ⁶² See Emerging Solutions in Pain, *Managing Patient’s Opioid Use: Balancing the*
24 *Need and the Risk*, [http://www.emergingsolutionsinpain.com/ce-education/opioid-](http://www.emergingsolutionsinpain.com/ce-education/opioid-management?option=com_continued&view=frontmatter&Itemid=303&course=209)
25 [management?option=com_continued&view=frontmatter&Itemid=303&course=20](http://www.emergingsolutionsinpain.com/ce-education/opioid-management?option=com_continued&view=frontmatter&Itemid=303&course=209)
26 9 (last visited Aug. 22, 2017).

26 ⁶³ Lynn Webster & Beth Dove, *Avoiding Opioid Abuse While Managing Pain*
(2007).

27 ⁶⁴ John Fauber, *Painkiller Boom Fueled by Networking*, Milwaukee Wisc. J.
28 Sentinel, Feb. 18, 2012,
[http://archive.jsonline.com/watchdog/watchdogreports/painkiller-boom-fueled-by-](http://archive.jsonline.com/watchdog/watchdogreports/painkiller-boom-fueled-by-networking-dp3p2rn-139609053.html)
[networking-dp3p2rn-139609053.html](http://archive.jsonline.com/watchdog/watchdogreports/painkiller-boom-fueled-by-networking-dp3p2rn-139609053.html).

1 prescribing in accordance with the scientific evidence, and by conducting outreach
2 to vulnerable patient populations targeted by the Manufacturer Defendants.

3 117. These Front Groups depended on the Manufacturer Defendants for
4 funding and, in some cases, for survival. The Manufacturer Defendants also
5 exercised control over programs and materials created by these groups by
6 collaborating on, editing, and approving their content, and by funding their
7 dissemination. In doing so, the Manufacturer Defendants made sure that the Front
8 Groups would generate only the messages that the Manufacturer Defendants
9 wanted to distribute. Despite this, the Front Groups held themselves out as
10 independent and serving the needs of their members – whether patients suffering
11 from pain or doctors treating those patients.

12 118. Defendants Cephalon, Endo, Janssen, and Purdue, in particular,
13 utilized many Front Groups, including many of the same ones. Several of the most
14 prominent are described below, but there are many others, including the American
15 Pain Society (“APS”), American Geriatrics Society (“AGS”), the Federation of
16 State Medical Boards (“FSMB”), American Chronic Pain Association (“ACPA”),
17 the Center for Practical Bioethics (“CPB”), the U.S. Pain Foundation (“USPF”) and
18 Pain & Policy Studies Group (“PPSG”).⁶⁵

19 119. The most prominent of the Manufacturer Defendants’ Front Groups
20 was the American Pain Foundation (“APF”), which, upon information and belief,
21 received more than \$10 million in funding from opioid manufacturers from 2007
22 until it closed its doors in May 2012, primarily from Endo and Purdue. APF
23 issued education guides for patients, reporters, and policymakers that touted the
24 benefits of opioids for chronic pain and trivialized their risks, particularly the risk
25

26 ⁶⁵ See generally, e.g., Letter from Sen. Ron Wyden, U.S. Senate Comm. on Fin., to
27 Sec. Thomas E. Price, U.S. Dep’t of Health and Human Servs., (May 5, 2015),
28 <https://www.finance.senate.gov/imo/media/doc/050517%20Senator%20Wyden%20to%20Secretary%20Price%20re%20FDA%20Opioid%20Prescriber%20Working%20Group.pdf>.

1 of addiction. APF also launched a campaign to promote opioids for returning
2 veterans, which has contributed to high rates of addiction and other adverse
3 outcomes – including death – among returning soldiers. APF also engaged in a
4 significant multimedia campaign – through radio, television and the internet – to
5 educate patients about their “right” to pain treatment, namely opioids. All of the
6 programs and materials were available nationally and were intended to reach
7 citizens of the State and Plaintiffs’ Community.

8 120. In 2009 and 2010, more than 80% of APF’s operating budget came
9 from pharmaceutical industry sources. Including industry grants for specific
10 projects, APF received about \$2.3 million from industry sources out of total
11 income of about \$2.85 million in 2009; its budget for 2010 projected receipts of
12 roughly \$2.9 million from drug companies, out of total income of about \$3.5
13 million. By 2011, upon information and belief, APF was entirely dependent on
14 incoming grants from defendants Purdue, Cephalon, Endo, and others to avoid
15 using its line of credit.

16 121. APF held itself out as an independent patient advocacy organization.
17 It often engaged in grassroots lobbying against various legislative initiatives that
18 might limit opioid prescribing, and thus the profitability of its sponsors. Upon
19 information and belief, it was often called upon to provide “patient
20 representatives” for the Manufacturer Defendants’ promotional activities,
21 including for Purdue’s Partners Against Pain and Janssen’s Let’s Talk Pain. APF
22 functioned largely as an advocate for the interests of the Manufacturer
23 Defendants, not patients. Indeed, upon information and belief, as early as 2001,
24 Purdue told APF that the basis of a grant was Purdue’s desire to “strategically
25 align its investments in nonprofit organizations that share [its] business interests.”

26 122. Plaintiffs are informed and believe that on several occasions,
27 representatives of the Manufacturer Defendants, often at informal meetings at
28 conferences, suggested activities and publications for APF to pursue. APF then

1 submitted grant proposals seeking to fund these activities and publications,
2 knowing that drug companies would support projects conceived as a result of
3 these communications.

4 123. The U.S. Senate Finance Committee began looking into APF in May
5 2012 to determine the links, financial and otherwise, between the organization and
6 the manufacturers of opioid painkillers. The investigation caused considerable
7 damage to APF's credibility as an objective and neutral third party, and the
8 Manufacturer Defendants stopped funding it. Within days of being targeted by
9 Senate investigation, APF's board voted to dissolve the organization "due to
10 irreparable economic circumstances." APF "cease[d] to exist, effective
11 immediately."⁶⁶

12 124. Another front group for the Manufacturer Defendants was the
13 American Academy of Pain Medicine ("AAPM"). With the assistance, prompting,
14 involvement, and funding of the Manufacturer Defendants, the AAPM issued
15 purported treatment guidelines and sponsored and hosted medical education
16 programs essential to the Manufacturer Defendants' deceptive marketing of
17 chronic opioid therapy.

18 125. AAPM received substantial funding from opioid manufacturers. For
19 example, AAPM maintained a corporate relations council, whose members paid
20 \$25,000 per year (on top of other funding) to participate. The benefits included
21 allowing members to present educational programs at off-site dinner symposia in
22 connection with AAPM's marquee event – its annual meeting held in Palm
23 Springs, California, or other resort locations. AAPM describes the annual event as
24 an "exclusive venue" for offering education programs to doctors. Membership in
25

26 ⁶⁶ Charles Ornstein & Tracy Weber, *Senate Panel Investigates Drug Companies'*
27 *Ties to Pain Groups*, Wash. Post, May 8, 2012,
28 https://www.washingtonpost.com/national/health-science/senate-panel-investigates-drug-companies-ties-to-pain-groups/2012/05/08/gIQA2X4qBU_story.html.

1 the corporate relations council also allows drug company executives and
 2 marketing staff to meet with AAPM executive committee members in small
 3 settings. Defendants Endo, Purdue, and Cephalon were members of the council
 4 and presented deceptive programs to doctors who attended this annual event.

5 126. Upon information and belief, AAPM is viewed internally by Endo as
 6 “industry friendly,” with Endo advisors and speakers among its active members.
 7 Endo attended AAPM conferences, funded its CMEs, and distributed its
 8 publications. The conferences sponsored by AAPM heavily emphasized sessions
 9 on opioids – 37 out of roughly 40 at one conference alone. AAPM’s presidents
 10 have included top industry-supported KOLs Perry Fine and Lynn Webster. Dr.
 11 Webster was even elected president of AAPM while under a DEA investigation.

12 127. The Manufacturer Defendants were able to influence AAPM through
 13 both their significant and regular funding and the leadership of pro-opioid KOLs
 14 within the organization.

15 128. In 1996, AAPM and APS jointly issued a consensus statement, “The
 16 Use of Opioids for the Treatment of Chronic Pain,” which endorsed opioids to
 17 treat chronic pain and claimed that the risk of a patients’ addiction to opioids was
 18 low. Dr. Haddox, who co-authored the AAPM/APS statement, was a paid speaker
 19 for Purdue at the time. Dr. Portenoy was the sole consultant. The consensus
 20 statement remained on AAPM’s website until 2011, and, upon information and
 21 belief, was taken down from AAPM’s website only after a doctor complained.⁶⁷

22 129. AAPM and APS issued their own guidelines in 2009 (“AAPM/APS
 23 Guidelines”) and continued to recommend the use of opioids to treat chronic
 24 pain.⁶⁸ Treatment guidelines have been relied upon by doctors, especially the
 25

26 ⁶⁷ The Use of Opioids for the Treatment of Chronic Pain: A Consensus Statement
 27 From the American Academy of Pain Medicine and the American Pain Society, 13
 Clinical J. Pain 6 (1997).

28 ⁶⁸ Roger Chou et al., Clinical Guidelines for the Use of Chronic Opioid Therapy in
 Chronic Non-Cancer Pain, 10 J. Pain 113 (2009).

1 general practitioners and family doctors targeted by the Manufacturer Defendants.
2 Treatment guidelines not only directly inform doctors' prescribing practices, but
3 are cited throughout the scientific literature and referenced by third-party payors
4 in determining whether they should cover treatments for specific indications.
5 Pharmaceutical sales representatives employed by Endo, Actavis, and Purdue
6 discussed treatment guidelines with doctors during individual sales visits.

7 130. At least fourteen of the 21 panel members who drafted the
8 AAPM/APS Guidelines, including KOLs Dr. Portenoy and Dr. Perry Fine of the
9 University of Utah, received support from Janssen, Cephalon, Endo, and Purdue.
10 The 2009 Guidelines promote opioids as "safe and effective" for treating chronic
11 pain, despite acknowledging limited evidence, and conclude that the risk of
12 addiction is manageable for patients regardless of past abuse histories.⁶⁹ One panel
13 member, Dr. Joel Saper, Clinical Professor of Neurology at Michigan State
14 University and founder of the Michigan Headache & Neurological Institute,
15 resigned from the panel because of his concerns that the 2009 Guidelines were
16 influenced by contributions that drug companies, including Manufacturer
17 Defendants, made to the sponsoring organizations and committee members. These
18 AAPM/APS Guidelines have been a particularly effective channel of deception
19 and have influenced not only treating physicians, but also the body of scientific
20 evidence on opioids; the Guidelines have been cited hundreds of times in
21 academic literature, were disseminated in the State and/or Plaintiffs' Community
22 during the relevant time period, are still available online, and were reprinted in the
23 Journal of Pain. The Manufacturer Defendants widely referenced and promoted
24 the 2009 Guidelines without disclosing the lack of evidence to support them or the
25 Manufacturer Defendants' financial support to members of the panel.

26
27
28

⁶⁹ *Id.*

131. The Manufacturer Defendants worked together, through Front Groups, to spread their deceptive messages about the risks and benefits of long-term opioid therapy. For example, Defendants combined their efforts through the Pain Care Forum (“PCF”), which began in 2004 as an APF project. PCF is comprised of representatives from opioid manufacturers (including Cephalon, Endo, Janssen, and Purdue) and various Front Groups, almost all of which received substantial funding from the Manufacturer Defendants. Among other projects, PCF worked to ensure that an FDA-mandated education project on opioids was not unacceptably negative and did not require mandatory participation by prescribers, which the Manufacturer Defendants determined would reduce prescribing.

2. The Manufacturer Defendants’ Marketing Scheme Misrepresented the Risks and Benefits of Opioids.

i. The Manufacturer Defendants embarked upon a campaign of false, deceptive, and unfair assurances grossly understating and misstating the dangerous addiction risks of the opioid drugs.

132. To falsely assure physicians and patients that opioids are safe, the Manufacturer Defendants deceptively trivialized and failed to disclose the risks of long-term opioid use, particularly the risk of addiction, through a series of misrepresentations that have been conclusively debunked by the FDA and CDC. These misrepresentations – which are described below – reinforced each other and created the dangerously misleading impression that: (1) starting patients on opioids was low risk because most patients would not become addicted, and because those at greatest risk for addiction could be identified and managed; (2) patients who displayed signs of addiction probably were not addicted and, in any event, could easily be weaned from the drugs; (3) the use of higher opioid doses, which many patients need to sustain pain relief as they develop tolerance to the drugs, do not pose special risks; and (4) abuse-deterrent opioids both prevent abuse and overdose and are inherently less addictive. The Manufacturer

1 Defendants have not only failed to correct these misrepresentations, they continue
2 to make them today.

3 133. Opioid manufacturers, including Defendants Endo Pharmaceuticals,
4 Inc. and Purdue Pharma L.P., have entered into settlement agreements with public
5 entities that prohibit them from making many of the misrepresentations identified
6 in this Complaint. Yet even afterward, each Manufacturer Defendant continued to
7 misrepresent the risks and benefits of long-term opioid use in the State and
8 Plaintiffs' Community and each continues to fail to correct its past
9 misrepresentations.

10 134. Some illustrative examples of the Manufacturer Defendants' false,
11 deceptive, and unfair claims about the purportedly low risk of addiction include:

- 12 a. Actavis's predecessor caused a patient education brochure, *Managing*
13 *Chronic Back Pain*, to be distributed beginning in 2003 that admitted
14 that opioid addiction is possible, but falsely claimed that it is "less
15 likely if you have never had an addiction problem." Based on
16 Actavis's acquisition of its predecessor's marketing materials along
17 with the rights to Kadian, it appears that Actavis continued to use this
18 brochure in 2009 and beyond.
- 19 b. Cephalon and Purdue sponsored APF's *Treatment Options: A Guide*
20 *for People Living with Pain* (2007), which suggested that addiction is
21 rare and limited to extreme cases of unauthorized dose escalations,
22 obtaining duplicative opioid prescriptions from multiple sources, or
23 theft. This publication is still available online.⁷⁰
- 24 c. Endo sponsored a website, "PainKnowledge," which, upon
25 information and belief, claimed in 2009 that "[p]eople who take
26 opioids as prescribed usually do not become addicted." Upon
27 information and belief, another Endo website, PainAction.com, stated
28 "Did you know? Most chronic pain patients do not become addicted
to the opioid medications that are prescribed for them." Endo also
distributed an "Informed Consent" document on PainAction.com that
misleadingly suggested that only people who "have problems with
substance abuse and addiction" are likely to become addicted to
opioid medications.
- d. Upon information and belief, Endo distributed a pamphlet with the
Endo logo entitled *Living with Someone with Chronic Pain*, which

⁷⁰ Am. Pain Found., *Treatment Options: A Guide for People Living in Pain* (2007)
[hereinafter APF, *Treatment Options*],
<https://assets.documentcloud.org/documents/277605/apf-treatmentoptions.pdf>.

1 stated that: "Most health care providers who treat people with pain
2 agree that most people do not develop an addiction problem."

- 3 e. Janssen reviewed, edited, approved, and distributed a patient
4 education guide entitled *Finding Relief: Pain Management for Older*
5 *Adults* (2009), which described as "myth" the claim that opioids are
6 addictive, and asserted as fact that "[m]any studies show that opioids
7 are rarely addictive when used properly for the management of
8 chronic pain."
9 f. Janssen currently runs a website, Prescriberresponsibly.com (last
10 updated July 2, 2015), which claims that concerns about opioid
11 addiction are "overestimated."
12 g. Purdue sponsored APF's *A Policymaker's Guide to Understanding*
13 *Pain & Its Management*, which claims that less than 1% of children
14 prescribed opioids will become addicted and that pain is undertreated
15 due to "[m]isconceptions about opioid addiction."⁷¹
16 h. In 2010, Mallinckrodt sponsored an initiative "Collaborating and
17 Acting Responsibly to Ensure Safety (C.A.R.E.S.), through which it
18 published and promoted the book "Defeat Chronic Pain Now!" aimed
19 at chronic pain patients. The book, which is still available for sale in
20 New Mexico and elsewhere, and is promoted online at
21 www.defeatchronicpainnow.com, advises laypeople who are
22 considering taking opioid drugs that "[o]nly rarely does opioid
23 medication cause a true addiction."⁷² Further, the book advises that
24 even the issue of tolerance is "overblown," because "[o]nly a
25 minority of chronic pain patients who are taking long-term opioids
26 develop tolerance." In response to a hypothetical question from a
27 chronic back pain patient who expresses a fear of becoming addicted,
28 the book advises that "[i]t is very uncommon for a person with
chronic pain to become 'addicted' to narcotics IF (1) he doesn't have
a prior history of any addiction and (2) he only takes the medication
to treat pain."
i. Consistent with the Manufacturer Defendants' published marketing
materials, upon information and belief, detailers for Purdue, Endo,
Janssen, and Cephalon in the State and Plaintiffs' Community
minimized or omitted any discussion with doctors of the risk of
addiction; misrepresented the potential for abuse of opioids with
purportedly abuse-deterrent formulations; and routinely did not
correct the misrepresentations noted above.
j. Seeking to overturn the criminal conviction of a doctor for illegally
prescribing opioids, the Manufacturer Defendants' Front Groups APF
and NFP argued in an *amicus* brief to the United States Fourth

⁷¹ Am. Pain Found., *A Policymaker's Guide to Understanding Pain and Its Management* 6 (2011) [hereinafter APF, *Policymaker's Guide*], <http://s3.documentcloud.org/documents/277603/apf-policymakers-guide.pdf>.

⁷² Charles E. Argoff & Bradley S. Galer, *Defeat Chronic Pain Now!* (2010).

Circuit Court of Appeals that “patients rarely become addicted to prescribed opioids,” citing research by their KOL, Dr. Portenoy.⁷³

135. These claims are contrary to longstanding scientific evidence. A 2016 opioid-prescription guideline issued by the CDC (the “2016 CDC Guideline”) explains that there is “[e]xtensive evidence” of the “possible harms of opioids (including opioid use disorder [an alternative term for opioid addiction], [and] overdose . . .).”⁷⁴ The 2016 CDC Guideline further explains that “[o]pioid pain medication use presents serious risks, including overdose and opioid use disorder” and that “continuing opioid therapy for 3 months substantially increases risk for opioid use disorder.”⁷⁵

136. The FDA further exposed the falsity of Defendants’ claims about the low risk of addiction when it announced changes to the labels for extended-release and long-acting (“ER/LA”) opioids in 2013 and for immediate release (“IR”) opioids in 2016. In its announcements, the FDA found that “most opioid drugs have ‘high potential for abuse’” and that opioids “are associated with a substantial risk of misuse, abuse, NOWS [neonatal opioid withdrawal syndrome], addiction, overdose, and death.” According to the FDA, because of the “known serious risks” associated with long-term opioid use, including “risks of addiction, abuse, and misuse, even at recommended doses, and because of the greater risks of overdose and death,” opioids should be used only “in patients for whom alternative treatment options” like non-opioid drugs have failed.⁷⁶

⁷³ Brief of the American Pain Foundation, the National Pain Foundation, and the National Foundation for the Treatment of Pain in Support of Appellant and Reversal of the Conviction, *United States v. Hurowitz*, No. 05-4474 (4th Cir. Sept. 8, 2005) [hereinafter Brief of APF] at 9.

⁷⁴ Deborah Dowell et al., *CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016*, Morbidity & Mortality Wkly. Rep., Mar. 18, 2016, at 15 [hereinafter 2016 CDC Guideline], <https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm>.

⁷⁵ *Id.* at 2, 25.

⁷⁶ Letter from Janet Woodcock, M.D., Dir., Ctr. For Drug Evaluation and Research, U.S. Food and Drug Admin., U.S. Dep’t of Health and Human Servs., to Andrew Koldny, M.D., President, Physicians for Responsible Opioid Prescribing (Sept. 10, 2013), <https://www.regulations.gov/contentStreamer?documentId=FDA->

1 137. The State of New York, in a 2016 settlement agreement with Endo,
 2 found that opioid “use disorders appear to be highly prevalent in chronic pain
 3 patients treated with opioids, with up to 40% of chronic pain patients treated in
 4 specialty and primary care outpatient centers meeting the clinical criteria for an
 5 opioid use disorder.”⁷⁷ Endo had claimed on its www.opana.com website that
 6 “[m]ost healthcare providers who treat patients with pain agree that patients
 7 treated with prolonged opioid medicines usually do not become addicted,” but the
 8 State of New York found that Endo had no evidence for that statement. Consistent
 9 with this, Endo agreed not to “make statements that . . . opioids generally are non-
 10 addictive” or “that most patients who take opioids do not become addicted” in
 11 New York. Endo remains free, however, to make those statements in this State.

12 138. In addition to mischaracterizing the highly addictive nature of the
 13 drugs they were pushing, the Manufacturer Defendants also fostered a
 14 fundamental misunderstanding of the signs of addiction. Specifically, the
 15 Manufacturer Defendants misrepresented, to doctors and patients, that warning
 16 signs and/or symptoms of addiction were, instead, signs of undertreated pain (i.e.
 17 pseudoaddiction) – and instructed doctors to increase the opioid prescription dose
 18 for patients who were already in danger.

19 139. To this end, one of Purdue’s employees, Dr. David Haddox, invented
 20 a phenomenon called “pseudoaddiction.” KOL Dr. Portenoy popularized the term.
 21 Examples of the false, misleading, deceptive, and unfair statements regarding
 22 pseudoaddiction include:

23
 24 2012-P-0818-0793&attachmentNumber=1&contentType=pdf.; Letter from Janet
 25 Woodcock, M.D., Dir., Ctr. For Drug Evaluation and Research, U.S. Food and
 26 Drug Admin., U.S. Dep’t of Health and Human Servs., to Peter R. Mathers &
 27 Jennifer A. Davidson, Kleinfeld, Kaplan and Becker, LLP (Mar. 22, 2016),
<https://www.regulations.gov/contentStreamer?documentId=FDA-2014-P-0205-0006&attachmentNumber=1&contentType=pdf>.

28 ⁷⁷ Assurance of Discontinuance, *In re Endo Health Solutions Inc. and Endo Pharm. Inc.* (Assurance No. 15-228), at 16,
https://ag.ny.gov/pdfs/Endo_AOD_030116-Fully_Executed.pdf.

- a. Cephalon and Purdue sponsored *Responsible Opioid Prescribing* (2007), which taught that behaviors such as “requesting drugs by name,” “demanding or manipulative behavior,” seeing more than one doctor to obtain opioids, and hoarding, are all signs of pseudoaddiction, rather than true addiction.⁷⁸ The 2012 edition, which remains available for sale online, continues to teach that pseudoaddiction is real.⁷⁹
- b. Janssen sponsored, funded, and edited the Let’s Talk Pain website, which in 2009 stated: “pseudoaddiction . . . refers to patient behaviors that may occur when pain is under-treated Pseudoaddiction is different from true addiction because such behaviors can be resolved with effective pain management.”
- c. Endo sponsored a National Initiative on Pain Control (“NIPC”) CME program in 2009 entitled “Chronic Opioid Therapy: Understanding Risk While Maximizing Analgesia,” which, upon information and belief, promoted pseudoaddiction by teaching that a patient’s aberrant behavior was the result of untreated pain. Endo appears to have substantially controlled NIPC by funding NIPC projects; developing, specifying, and reviewing content; and distributing NIPC materials.
- d. Purdue published a pamphlet in 2011 entitled *Providing Relief, Preventing Abuse*, which, upon information and belief, described pseudoaddiction as a concept that “emerged in the literature” to describe the inaccurate interpretation of [drug-seeking behaviors] in patients who have pain that has not been effectively treated.”
- e. Upon information and belief, Purdue sponsored a CME program titled “Path of the Patient, Managing Chronic Pain in Younger Adults at Risk for Abuse”. In a role play, a chronic pain patient with a history of drug abuse tells his doctor that he is taking twice as many hydrocodone pills as directed. The narrator notes that because of pseudoaddiction, the doctor should not assume the patient is addicted even if he persistently asks for a specific drug, seems desperate, hoards medicine, or “overindulges in unapproved escalating doses.” The doctor treats this patient by prescribing a high-dose, long-acting opioid.
- f. In 2010, Mallinckrodt sponsored an initiative “Collaborating and Acting Responsibly to Ensure Safety (C.A.R.E.S.), through which it published and promoted the book “Defeat Chronic Pain Now!” aimed at chronic pain patients. The book, which is still available for sale, and is promoted online at www.defeatchronicpainnow.com, teaches laypeople that “pseudoaddiction” is “caused by their doctor not appropriately prescribing the opioid medication.” It teaches that “[p]seudoaddiction happens when a patient’s opioid medication is not being prescribed in doses strong enough to provide good pain relief,

⁷⁸ Scott M. Fishman, M.D., *Responsible Opioid Prescribing: A Physician’s Guide* (2007) at 62.

⁷⁹ See Scott M. Fishman, M.D., *Responsible Opioid Prescribing: A Physician’s Guide* (2d ed. 2012).

1 or if the drug is not being prescribed often enough throughout the
 2 day. . . When a pseudoaddicted patient is prescribed the proper
 amount of opioid medication, he or she doesn't take any extra pills
 because his or her pain is relieved."

3 140. In the 2016 CDC Guideline, the CDC rejects the validity of the
 4 pseudoaddiction fallacy invented by a Purdue employee as a reason to push more
 5 opioid drugs onto already addicted patients.

6 141. In addition to misstating the addiction risk and inventing the
 7 pseudoaddiction falsehood, a third category of false, deceptive, and unfair practice
 8 is the Manufacturer Defendants' false instructions that addiction risk screening
 9 tools, patient contracts, urine drug screens, and similar strategies allow them to
 10 reliably identify and safely prescribe opioids to patients predisposed to addiction.
 11 These misrepresentations were especially insidious because the Manufacturer
 12 Defendants aimed them at general practitioners and family doctors who lack the
 13 time and expertise to closely manage higher-risk patients on opioids. The
 14 Manufacturer Defendants' misrepresentations made these doctors feel more
 15 comfortable prescribing opioids to their patients, and patients more comfortable
 16 starting on opioid therapy for chronic pain. Illustrative examples include:

- 17 a. Endo paid for a 2007 supplement in the *Journal of Family Practice*
 18 written by a doctor who became a member of Endo's speakers bureau
 in 2010. The supplement, entitled *Pain Management Dilemmas in*
 19 *Primary Care: Use of Opioids*, emphasized the effectiveness of
 screening tools, claiming that patients at high risk of addiction could
 20 safely receive chronic opioid therapy using a "maximally structured
 approach" involving toxicology screens and pill counts.
- 21 b. Purdue, upon information and belief, sponsored a 2011 webinar,
 22 *Managing Patient's Opioid Use: Balancing the Need and Risk*, which
 claimed that screening tools, urine tests, and patient agreements
 23 prevent "overuse of prescriptions" and "overdose deaths."
- 24 c. As recently as 2015, upon information and belief, Purdue has
 25 represented in scientific conferences that "bad apple" patients – and
 not opioids – are the source of the addiction crisis and that once those
 26 "bad apples" are identified, doctors can safely prescribe opioids
 without causing addiction.

27 142. The 2016 CDC Guideline confirms the falsity of these claims. The
 28 Guideline explains that there are no studies assessing the effectiveness of risk

1 mitigation strategies “for improving outcomes related to overdose, addiction,
2 abuse or misuse.”⁸⁰

3 143. A fourth category of deceptive messaging regarding dangerous
4 opioids is the Manufacturer Defendants’ false assurances regarding the alleged
5 ease of eliminating opioid dependence. The Manufacturer Defendants falsely
6 claimed that opioid dependence can easily be addressed by tapering and that
7 opioid withdrawal is not a problem, but they failed to disclose the increased
8 difficulty of stopping opioids after long-term use. In truth, the 2016 CDC
9 Guideline explains that the symptoms of opioid withdrawal include abdominal
10 pain, vomiting, diarrhea, sweating, tremor, tachycardia, drug cravings, anxiety,
11 insomnia, spontaneous abortion and premature labor in pregnant women.⁸¹

12 144. The Manufacturer Defendants nonetheless downplayed the severity
13 of opioid detoxification. For example, upon information and belief, a CME
14 sponsored by Endo, entitled *Persistent Pain in the Older Adult*, claimed that
15 withdrawal symptoms can be avoided by tapering a patient’s opioid dose by 10%-
16 20% for 10 days. And Purdue sponsored APF’s *A Policymaker’s Guide to*
17 *Understanding Pain & Its Management*, which claimed that “[s]ymptoms of
18 physical dependence can often be ameliorated by gradually decreasing the dose of
19 medication during discontinuation” without mentioning any hardships that might
20 occur.⁸² Similarly, in the 2010 Mallinckrodt/C.A.R.E.S. publication “Defeat
21 Chronic Pain Now!” potential opioid users are advised that tolerance to opioids is
22 “easily remedied,” and that “[a]ll patients can be safely taken off opioid
23 medication if the dose is slowly tapered down by their doctor.”

25 ⁸⁰ *Id.* at 11.

26 ⁸¹ *Id.* at 26.

27 ⁸² Am. Pain Found., *A Policymaker’s Guide to Understanding Pain and Its*
28 *Management* 6 (2011) [hereinafter APF, *Policymaker’s Guide*],
<http://s3.documentcloud.org/documents/277603/apf-policymakers-guide.pdf>, at 32.

1 145. A fifth category of false, deceptive, and unfair statements the
 2 Manufacturer Defendants made to sell more drugs is that opioid dosages could be
 3 increased indefinitely without added risk. The ability to escalate dosages was
 4 critical to Defendants' efforts to market opioids for long-term use to treat chronic
 5 pain because, absent this misrepresentation, doctors would have abandoned
 6 treatment when patients built up tolerance and lower dosages did not provide pain
 7 relief. The Manufacturer Defendants' deceptive claims include:

- 8
- 9 a. Upon information and belief, Actavis's predecessor created a patient
 10 brochure for Kadian in 2007 that stated, "Over time, your body may
 11 become tolerant of your current dose. You may require a dose
 12 adjustment to get the right amount of pain relief. This is not
 13 addiction." Based on Actavis's acquisition of its predecessor's
 14 marketing materials along with the rights to Kadian, Actavis appears
 15 to have continued to use these materials in 2009 and beyond.
- 16 b. Cephalon and Purdue sponsored APF's *Treatment Options: A Guide*
 17 *for People Living with Pain* (2007), which claims that some patients
 18 "need" a larger dose of an opioid, regardless of the dose currently
 19 prescribed. The guide stated that opioids have "no ceiling dose" and
 20 insinuated that they are therefore the most appropriate treatment for
 21 severe pain.⁸³ This publication is still available online.
- 22 c. Endo sponsored a website, "PainKnowledge," which, upon
 23 information and belief, claimed in 2009 that opioid dosages may be
 24 increased until "you are on the right dose of medication for your
 25 pain."
- 26 d. Endo distributed a pamphlet edited by a KOL entitled *Understanding*
 27 *Your Pain: Taking Oral Opioid Analgesics* (2004 Endo
 28 Pharmaceuticals PM-0120). In Q&A format, it asked "If I take the
 opioid now, will it work later when I really need it?" The response is,
 "The dose can be increased. . . . You won't 'run out' of pain relief."⁸⁴
- e. Janssen sponsored a patient education guide entitled *Finding Relief:*
Pain Management for Older Adults (2009), which was distributed by
 its sales force. This guide listed dosage limitations as

⁸³ Am. Pain Found., *Treatment Options: A Guide for People Living in Pain* (2007)
 [hereinafter APF, *Treatment Options*],
<https://assets.documentcloud.org/documents/277605/apf-treatmentoptions.pdf>, at
 12.

⁸⁴ Margo McCaffery & Chris Pasero, Endo Pharm., *Understanding Your Pain:*
Taking Oral Opioid Analgesics (Russell K Portenoy, M.D., ed., 2004).

“disadvantages” of other pain medicines but omitted any discussion of risks of increased opioid dosages.

- f. Upon information and belief, Purdue’s In the Face of Pain website promoted the notion that if a patient’s doctor does not prescribe what, in the patient’s view, is a sufficient dosage of opioids, he or she should find another doctor who will.
- g. Purdue sponsored APF’s *A Policymaker’s Guide to Understanding Pain & Its Management*, which taught that dosage escalations are “sometimes necessary,” and that “the need for higher doses of medication is not necessarily indicative of addiction,” but inaccurately downplayed the risks from high opioid dosages.⁸⁵
- h. In 2007, Purdue sponsored a CME entitled “Overview of Management Options” that was available for CME credit and available until at least 2012. The CME was edited by a KOL and taught that Non-steroidal Anti-inflammatory Drugs (“NSAIDs”) and other drugs, but not opioids, are unsafe at high dosages.
- i. Purdue presented a 2015 paper at the College on the Problems of Drug Dependence, “the oldest and largest organization in the US dedicated to advancing a scientific approach to substance use and addictive disorders,” challenging the correlation between opioid dosage and overdose.⁸⁶
- j. Seeking to overturn the criminal conviction of a doctor for illegally prescribing opioids, the Manufacturer Defendants’ Front Groups APF and NFP argued in an *amicus* brief to the United States Fourth Circuit Court of Appeals that “there is no ‘ceiling dose’” for opioids.⁸⁷
- k. In the 2010 Mallinckrodt/C.A.R.E.S. publication “Defeat Chronic Pain Now!”, potential opioid users are warned about the risk of “[p]seudoaddiction [b]ecause of a [l]ow [d]ose,” and advised that this condition may be corrected through the prescription of a higher dose. Similarly, the book recommends that for chronic pain patients, the opioid dose should be “gradually increased to find the best daily dose, as is done with all the other oral drugs.” The book discusses the risks of NSAIDs and other drugs at higher doses, but not explain this risk for opioids.

⁸⁵ Am. Pain Found., *A Policymaker’s Guide to Understanding Pain and Its Management* 6 (2011) [hereinafter APF, *Policymaker’s Guide*], <http://s3.documentcloud.org/documents/277603/apf-policymakers-guide.pdf>, at 32.

⁸⁶ The College on Problems of Drug Dependence, *About the College*, <http://cpdd.org> (last visited Aug. 21, 2017).

⁸⁷ Brief of APF, at 9.

1 146. Once again, the 2016 CDC Guideline reveals that the Manufacturer
 2 Defendants' representations regarding opioids were lacking in scientific evidence.
 3 The 2016 CDC Guideline clarifies that the "[b]enefits of high-dose opioids for
 4 chronic pain are not established" while the "risks for serious harms related to
 5 opioid therapy increase at higher opioid dosage."⁸⁸ More specifically, the CDC
 6 explains that "there is now an established body of scientific evidence showing that
 7 overdose risk is increased at higher opioid dosages."⁸⁹ The CDC also states that
 8 there is an increased risk "for opioid use disorder, respiratory depression, and
 9 death at higher dosages."⁹⁰ That is why the CDC advises doctors to "avoid
 10 increasing dosage" to above 90 morphine milligram equivalents per day.⁹¹

11 147. Defendants' deceptive marketing of the so-called abuse-deterrent
 12 properties of some of their opioids has created false impressions that these opioids
 13 can cure addiction and abuse.

14 148. The Manufacturer Defendants made misleading claims about the
 15 ability of their so-called abuse-deterrent opioid formulations to deter abuse. For
 16 example, Endo's advertisements for the 2012 reformulation of Opana ER claimed
 17 that it was designed to be crush resistant, in a way that suggested it was more
 18 difficult to abuse. This claim was false. The FDA warned in a 2013 letter that
 19 Opana ER Extended-Release Tablets' "extended-release features can be
 20 compromised, causing the medication to 'dose dump,' when subject to . . . forms
 21 of manipulation such as cutting, grinding, or chewing, followed by swallowing."⁹²
 22 Also troubling, Opana ER can be prepared for snorting using commonly available
 23

24 ⁸⁸ 2016 CDC Guideline at 22–23.

25 ⁸⁹ *Id.* at 23–24.

26 ⁹⁰ *Id.* at 21.

27 ⁹¹ *Id.* at 16.

28 ⁹² Letter from Janet Woodcock, M.D., Dir., Ctr. For Drug Evaluation and Research, U.S. Food and Drug Admin., U.S. Dep't of Health and Human Servs., to Robert Barto, Vice President, Reg. Affairs, Endo Pharm. Inc. (May 10, 2013), at 5.

1 methods and “readily prepared for injection.”⁹³ The letter discussed “the troubling
 2 possibility that a higher (and rising) percentage of [Opana ER Extended-Release
 3 Tablet] abuse is occurring via injection.”⁹⁴ Endo’s own studies, which it failed to
 4 disclose, showed that Opana ER could still be ground and chewed. In June 2017,
 5 the FDA requested that Opana ER be removed from the market.

6 **ii. The Manufacturer Defendants embarked upon a**
 7 **campaign of false, deceptive, and unfair assurances**
 8 **grossly overstating the benefits of the opioid drugs.**

9 149. To convince doctors and patients that opioids should be used to treat
 10 chronic pain, the Manufacturer Defendants also had to persuade them that there
 11 was a significant upside to long-term opioid use. But as the CDC Guideline makes
 12 clear, “[n]o evidence shows a long-term benefit of opioids in pain and function
 13 versus no opioids for chronic pain with outcomes examined at least 1 year later
 14 (with most placebo-controlled randomized trials \leq 6 weeks in duration)” and that
 15 other treatments were more or equally beneficial and less harmful than long-term
 16 opioid use.⁹⁵ The FDA, too, has recognized the lack of evidence to support long-
 17 term opioid use. Despite this, Defendants falsely and misleadingly touted the
 18 benefits of long-term opioid use and falsely and misleadingly suggested that these
 19 benefits were supported by scientific evidence.

20 150. Some illustrative examples of the Manufacturer Defendants’ false
 21 claims are:

- 22 a. Upon information and belief, Actavis distributed an advertisement
 23 claiming that the use of Kadian to treat chronic pain would allow
 24 patients to return to work, relieve “stress on your body and your
 25 mental health,” and help patients enjoy their lives.
- 26 b. Endo distributed advertisements that claimed that the use of Opana
 27 ER for chronic pain would allow patients to perform demanding tasks
 28 like construction work or work as a chef and portrayed seemingly
 healthy, unimpaired subjects.

27 ⁹³ *Id.* at 6.

28 ⁹⁴ *Id.* at 6 n.21.

⁹⁵ *Id.* at 15.

- c. Janssen sponsored and edited a patient education guide entitled *Finding Relief: Pain Management for Older Adults* (2009) – which states as “a fact” that “opioids may make it easier for people to live normally.” The guide lists expected functional improvements from opioid use, including sleeping through the night, returning to work, recreation, sex, walking, and climbing stairs.
- d. Janssen promoted Ultracet for everyday chronic pain and distributed posters, for display in doctors’ offices, of presumed patients in active professions; the caption read, “Pain doesn’t fit into their schedules.”
- e. Upon information and belief, Purdue ran a series of advertisements for OxyContin in 2012 in medical journals entitled “Pain vignettes,” which were case studies featuring patients with pain conditions persisting over several months and recommending OxyContin for them. The ads implied that OxyContin improves patients’ function.
- f. *Responsible Opioid Prescribing* (2007), sponsored and distributed by Cephalon, Endo and Purdue, taught that relief of pain by opioids, by itself, improved patients’ function.
- g. Cephalon and Purdue sponsored APF’s *Treatment Options: A Guide for People Living with Pain* (2007), which counseled patients that opioids “give [pain patients] a quality of life we deserve.”⁹⁶ This publication is still available online.
- h. Endo’s NIPC website “PainKnowledge” claimed in 2009, upon information and belief, that with opioids, “your level of function should improve; you may find you are now able to participate in activities of daily living, such as work and hobbies, that you were not able to enjoy when your pain was worse.” Elsewhere, the website touted improved quality of life (as well as “improved function”) as benefits of opioid therapy. The grant request that Endo approved for this project specifically indicated NIPC’s intent to make misleading claims about function, and Endo closely tracked visits to the site.
- i. Endo was the sole sponsor, through NIPC, of a series of CMEs entitled “Persistent Pain in the Older Patient.”⁹⁷ Upon information and belief, a CME disseminated via webcast claimed that chronic opioid therapy has been “shown to reduce pain and improve depressive symptoms and cognitive functioning.”
- j. Janssen sponsored and funded a multimedia patient education campaign called “Let’s Talk Pain.” One feature of the campaign was to complain that patients were under-treated. In 2009, upon information and belief, a Janssen-sponsored website, part of the

⁹⁶ Am. Pain Found., *Treatment Options: A Guide for People Living in Pain* (2007) [hereinafter APF, *Treatment Options*], <https://assets.documentcloud.org/documents/277605/apf-treatmentoptions.pdf>.

⁹⁷ E.g., NIPC, *Persistent Pain and the Older Patient* (2007), https://www.painedu.org/Downloads/NIPC/Activities/B173_Providence_RI_%20Invite.pdf.

1 “Let’s Talk Pain” campaign, featured an interview edited by Janssen
claiming that opioids allowed a patient to “continue to function.”

2 k. Purdue sponsored the development and distribution of APF’s *A*
3 *Policymaker’s Guide to Understanding Pain & Its Management*,
which claimed that “[m]ultiple clinical studies” have shown that
4 opioids are effective in improving “[d]aily function,”
5 “[p]sychological health,” and “[o]verall health-related quality of life
for chronic pain.”⁹⁸ The Policymaker’s Guide was originally
published in 2011.

6 l. Purdue’s, Cephalon’s, Endo’s, and Janssen’s sales representatives
7 have conveyed and continue to convey the message that opioids will
improve patient function.

8
9 151. As the FDA and other agencies have made clear for years, these
10 claims have no support in the scientific literature.

11 152. In 2010, the FDA warned Actavis, in response to its advertising of
12 Kadian described above, that “we are not aware of substantial evidence or
13 substantial clinical experience demonstrating that the magnitude of the effect of
14 the drug [Kadian] has in alleviating pain, taken together with any drug-related side
15 effects patients may experience . . . results in any overall positive impact on a
16 patient’s work, physical and mental functioning, daily activities, or enjoyment of
17 life.”⁹⁹ And in 2008, upon information and belief, the FDA sent a warning letter to
18 an opioid manufacturer, making it clear “that [the claim that] patients who are
19 treated with the drug experience an improvement in their overall function, social
20 function, and ability to perform daily activities . . . has not been demonstrated by
21 substantial evidence or substantial clinical experience.”

22 153. The Manufacturer Defendants also falsely and misleadingly
23 emphasized or exaggerated the risks of competing medications like NSAIDs, so

24
25 ⁹⁸ Am. Pain Found., *A Policymaker’s Guide to Understanding Pain and Its*
26 *Management* 6 (2011) [hereinafter APF, *Policymaker’s Guide*],
<http://s3.documentcloud.org/documents/277603/apf-policymakers-guide.pdf>, at
29.

27 ⁹⁹ Letter from Thomas Abrams, Dir., Div. of Drug Mktg., Advert., & Commc’ns,
28 U.S. Food & Drug Admin., to Doug Boothe, CEO, Actavis Elizabeth LLC (Feb.
18, 2010),
<http://www.fdanews.com/ext/resources/files/archives/a/ActavisElizabethLLC.pdf>.

1 that doctors and patients would look to opioids first for the treatment of chronic
2 pain. Once again, these misrepresentations by the Manufacturer Defendants
3 contravene pronouncements by and guidance from the FDA and CDC based on
4 the scientific evidence. Indeed, the FDA changed the labels for extended-release
5 and long-acting (“ER/LA”) opioids in 2013 and immediate-release (“IR”) opioids
6 in 2016 to state that opioids should only be used as a last resort “in patients for
7 which alternative treatment options” like non-opioid drugs “are inadequate.” And
8 the 2016 CDC Guideline states that NSAIDs, not opioids, should be the first-line
9 treatment for chronic pain, particularly arthritis and lower back pain.¹⁰⁰ Purdue
10 misleadingly promoted OxyContin as being unique among opioids in providing 12
11 continuous hours of pain relief with one dose. In fact, OxyContin does not last for
12 12 hours – a fact that Purdue has known at all times relevant to this action. Upon
13 information and belief, Purdue’s own research shows that OxyContin wears off in
14 under six hours in one quarter of patients and in under 10 hours in more than half.
15 This is because OxyContin tablets release approximately 40% of their active
16 medicine immediately, after which release tapers. This triggers a powerful initial
17 response, but provides little or no pain relief at the end of the dosing period, when
18 less medicine is released. This phenomenon is known as “end of dose” failure, and
19 the FDA found in 2008 that a “substantial proportion” of chronic pain patients
20 taking OxyContin experience it. This not only renders Purdue’s promise of 12
21 hours of relief false and deceptive, it also makes OxyContin more dangerous
22 because the declining pain relief patients experience toward the end of each
23 dosing period drives them to take more OxyContin before the next dosing period
24 begins, quickly increasing the amount of drug they are taking and spurring
25 growing dependence.

26
27
28 ¹⁰⁰ 2016 CDC Guideline at 12.

154. Purdue's competitors were aware of this problem. For example, upon information and belief, Endo ran advertisements for Opana ER referring to "real" 12-hour dosing. Nevertheless, Purdue falsely promoted OxyContin as if it were effective for a full 12 hours. Upon information and belief, Purdue's sales representatives continue to tell doctors that OxyContin lasts a full 12 hours.

155. Front Groups supported by Purdue likewise echoed these representations. For example, in an amicus brief submitted to the Supreme Court of Ohio by the American Pain Foundation, the National Foundation for the Treatment of Pain and the Ohio Pain Initiative in support of Purdue, those amici represented:

OxyContin is particularly useful for sustained long-term pain because it comes in higher, compact pills with a slow release coating. OxyContin pills can work for 12 hours. This makes it easier for patients to comply with dosing requirements without experiencing a roller-coaster of pain relief followed quickly by pain renewal that can occur with shorter acting medications. It also helps the patient sleep through the night, which is often impossible with short-acting medications. For many of those serviced by Pain Care Amici, OxyContin has been a miracle medication.¹⁰¹

156. Cephalon deceptively marketed its opioids Actiq and Fentora for chronic pain even though the FDA has expressly limited their use to the treatment of cancer pain in opioid tolerant individuals. Both Actiq and Fentora are extremely powerful fentanyl-based IR opioids. Neither is approved for or has been shown to be safe or effective for chronic pain. Indeed, the FDA expressly prohibited Cephalon from marketing Actiq for anything but cancer pain, and refused to approve Fentora for the treatment of chronic pain because of the potential harm, including the high risk of "serious and life-threatening adverse events" and abuse – which are greatest in non-cancer patients. The FDA also

¹⁰¹ Reply Brief of Amicus Curiae of the American Pain Foundation, The National Foundation for the Treatment of Pain and the Ohio Pain Initiative Supporting Appellants, *Howland v. Purdue Pharma L.P.*, No. 2003-1538 (Ohio Apr. 13, 2004), 2004 WL 1637768, at *4 (footnote omitted).

1 issued a Public Health Advisory in 2007 emphasizing that Fentora should only be
 2 used for cancer patients who are opioid-tolerant and should not be used for any
 3 other conditions, such as migraines, post-operative pain, or pain due to injury.¹⁰²
 4 Specifically, the FDA advised that Fentora “is only approved for breakthrough
 5 cancer pain in patients who are *opioid-tolerant*, meaning those patients who take a
 6 regular, daily, around-the-clock narcotic pain medication.”¹⁰³

7 157. Despite this, Cephalon conducted and continues to conduct a well-
 8 funded campaign to promote Actiq and Fentora for chronic pain and other non-
 9 cancer conditions for which it was not approved, appropriate, and for which it is
 10 not safe. As part of this campaign, Cephalon used CMEs, speaker programs,
 11 KOLs, journal supplements, and detailing by its sales representatives to give
 12 doctors the false impression that Actiq and Fentora are safe and effective for
 13 treating non-cancer pain. For example:

- 14 a. Cephalon paid to have a CME it sponsored, *Opioid-Based*
 15 *Management of Persistent and Breakthrough Pain*, published in a
 16 supplement of Pain Medicine News in 2009. The CME instructed
 17 doctors that “[c]linically, broad classification of pain syndromes as
 either cancer- or non-cancer-related has limited utility” and
 recommended Actiq and Fentora for patients with chronic pain.
- 18 b. Upon information and belief, Cephalon’s sales representatives set up
 19 hundreds of speaker programs for doctors, including many non-
 oncologists, which promoted Actiq and Fentora for the treatment of
 non-cancer pain.
- 20 c. In December 2011, Cephalon widely disseminated a journal
 21 supplement entitled “Special Report: An Integrated Risk Evaluation
 22 and Mitigation Strategy for Fentanyl Buccal Tablet (FENTORA) and
 23 Oral Transmucosal Fentanyl Citrate (ACTIQ)” to Anesthesiology
 24 News, Clinical Oncology News, and Pain Medicine News – three
 publications that are sent to thousands of anesthesiologists and other
 medical professionals. The Special Report openly promotes Fentora
 for “multiple causes of pain” – and not just cancer pain.

26 ¹⁰² See U.S. Food & Drug Admin., *Public Health Advisory: Important Information*
 27 *for the Safe Use of Fentora (fentanyl buccal tablets)* (Sept. 26, 2007),
 28 <https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm051273.htm>.

¹⁰³ *Id.*

1 158. Cephalon’s deceptive marketing gave doctors and patients the false
2 impression that Actiq and Fentora were not only safe and effective for treating
3 chronic pain, but were also approved by the FDA for such uses.

4 159. Purdue also unlawfully and unfairly failed to report or address illicit
5 and unlawful prescribing of its drugs, despite knowing about it for years. Purdue’s
6 sales representatives have maintained a database since 2002 of doctors suspected
7 of inappropriately prescribing its drugs. Rather than report these doctors to state
8 medical boards or law enforcement authorities (as Purdue is legally obligated to
9 do) or cease marketing to them, Purdue used the list to demonstrate the high rate
10 of diversion of OxyContin – the same OxyContin that Purdue had promoted as
11 less addictive – in order to persuade the FDA to bar the manufacture and sale of
12 generic copies of the drug because the drug was too likely to be abused. In an
13 interview with the Los Angeles Times, Purdue’s senior compliance officer
14 acknowledged that in five years of investigating suspicious pharmacies, Purdue
15 failed to take action – even where Purdue employees personally witnessed the
16 diversion of its drugs. The same was true of prescribers; despite its knowledge of
17 illegal prescribing, Purdue did not report that a Los Angeles clinic prescribed
18 more than 1.1 million OxyContin tablets and that Purdue’s district manager
19 described it internally as “an organized drug ring” until years after law
20 enforcement shut it down. In doing so, Purdue protected its own profits at the
21 expense of public health and safety.¹⁰⁴

22 160. Like Purdue, Endo has been cited for its failure to set up an effective
23 system for identifying and reporting suspicious prescribing. In its settlement
24 agreement with Endo, the State of New York found that Endo failed to require
25 sales representatives to report signs of abuse, diversion, and inappropriate
26

27
28 ¹⁰⁴ Harriet Ryan et al., *More Than 1 Million Oxycontin Pills Ended Up in the
Hands of Criminals and Addicts. What the Drugmaker Knew*, L.A. Times, July 10,
2016, <http://www.latimes.com/projects/la-me-oxycontin-part2/>.

1 prescribing; paid bonuses to sales representatives for detailing prescribers who
 2 were subsequently arrested or convicted for illegal prescribing; and failed to
 3 prevent sales representatives from visiting prescribers whose suspicious conduct
 4 had caused them to be placed on a no-call list.

5 **3. The Manufacturer Defendants Targeted Susceptible Prescribers**
 6 **and Vulnerable Patient Populations.**

7 161. As a part of their deceptive marketing scheme, the Manufacturer
 8 Defendants identified and targeted susceptible prescribers and vulnerable patient
 9 populations in the U.S., including this State and Plaintiffs' Community. For
 10 example, the Manufacturer Defendants focused their deceptive marketing on
 11 primary care doctors, who were more likely to treat chronic pain patients and
 12 prescribe them drugs, but were less likely to be educated about treating pain and
 13 the risks and benefits of opioids and therefore more likely to accept the
 14 Manufacturer Defendants' misrepresentations.

15 162. The Manufacturer Defendants also targeted vulnerable patient
 16 populations like the elderly and veterans, who tend to suffer from chronic pain.
 17 The Manufacturer Defendants targeted these vulnerable patients even though the
 18 risks of long-term opioid use were significantly greater for them. For example, the
 19 2016 CDC Guideline observes that existing evidence confirms that elderly
 20 patients taking opioids suffer from elevated fall and fracture risks, reduced renal
 21 function and medication clearance, and a smaller window between safe and unsafe
 22 dosages.¹⁰⁵ The 2016 CDC Guideline concludes that there must be "additional
 23 caution and increased monitoring" to minimize the risks of opioid use in elderly
 24 patients. *Id.* at 27. The same is true for veterans, who are more likely to use anti-
 25 anxiety drugs (benzodiazepines) for post-traumatic stress disorder, which interact
 26 dangerously with opioids.

27
 28 ¹⁰⁵ 2016 CDC Guideline at 13.

1 **4. Insys Employed Fraudulent, Illegal, and Misleading Marketing**
 2 **Schemes to Promote Subsys.**

3 163. Insys’s opioid, Subsys, was approved by the FDA in 2012 for
 4 “management of breakthrough pain in adult cancer patients who are already
 5 receiving and who are tolerant to around-the-clock opioid therapy for their
 6 underlying persistent cancer pain.” Under FDA rules, Insys could only market
 7 Subsys for this use. Subsys consists of the highly addictive narcotic, fentanyl,
 8 administered via a sublingual (under the tongue) spray, which provides rapid-
 9 onset pain relief. It is in the class of drugs described as Transmucosal Immediate-
 10 Release Fentanyl (“TIRF”).

11 164. To reduce the risk of abuse, misuse, and diversion, the FDA
 12 instituted a Risk Evaluation and Mitigation Strategy (“REMS”) for Subsys and
 13 other TIRF products, such as Cephalon’s Actiq and Fentora. The purpose of
 14 REMS was to educate “prescribers, pharmacists, and patients on the potential for
 15 misuse, abuse, addiction, and overdose” for this type of drug and to “ensure safe
 16 use and access to these drugs for patients who need them.”¹⁰⁶ Prescribers must
 17 enroll in the TIRF REMS before writing a prescription for Subsys.

18 165. Since its launch, Subsys has been an extremely expensive
 19 medication, and its price continues to rise each year. Depending on a patient’s
 20 dosage and frequency of use, a month’s supply of Subsys could cost in the
 21 thousands of dollars.

22 166. Due to its high cost, in most instances prescribers must submit
 23 Subsys prescriptions to insurance companies or health benefit payors for prior
 24 authorization to determine whether they will pay for the drug prior to the patient
 25 attempting to fill the prescription. According to the U.S. Senate Homeland
 26 Security and Governmental Affairs Committee Minority Staff Report (“Staff
 27

28 ¹⁰⁶ Press Release, FDA, *FDA Approves Shared System REMS for TIRF Products*,
 Dec. 29, 2011.

Report”), the prior authorization process includes “confirmation that the patient had an active cancer diagnosis, was being treated by an opioid (and, thus, was opioid tolerant), and was being prescribed Subsys to treat breakthrough pain that the other opioid could not eliminate. If any one of these factors was not present, the prior authorization would be denied”¹⁰⁷

167. These prior authorization requirements proved to be daunting. Subsys received reimbursement approval in only approximately 30% of submitted claims. In order to increase approvals, Insys created a prior authorization unit, called the Insys Reimbursement Center (“IRC”), to obtain approval for Subsys reimbursements. This unit employed a number of fraudulent and misleading tactics to secure reimbursements, including falsifying medical histories of patients, falsely claiming that patients had cancer, and providing misleading information to insurers and payors regarding patients’ diagnoses and medical conditions.

168. Subsys has proved to be extremely profitable for Insys. Insys made approximately \$330 million in net revenue from Subsys last year. Between 2013 and 2016, the value of Insys stock rose 296%.

169. Since its launch in 2012, Insys aggressively worked to grow its profits through fraudulent, illegal, and misleading tactics, including its reimbursement-related fraud. Through its sales representatives and other marketing efforts, Insys deceptively promoted Subsys as safe and appropriate for uses such as neck and back pain, without disclosing the lack of approval or evidence for such uses, and misrepresented the appropriateness of Subsys for treatment those conditions. It implemented a kickback scheme wherein it paid prescribers for fake speakers programs in exchange for prescribing Subsys. All of

¹⁰⁷ U.S. Senate Homeland Security & Governmental Affairs Committee, *Fueling an Epidemic, Insys Therapeutics and the Systemic Manipulation of Prior Authorization*, <https://www.documentcloud.org/documents/3987564-REPORT-Fueling-an-Epidemic-Insys-Therapeutics.html>.

1 these fraudulent and misleading schemes had the effect of pushing Insys's
2 dangerous opioid onto patients who did not need it.

3 170. Insys incentivized its sales force to engage in illegal and fraudulent
4 conduct. Many of the Insys sales representatives were new to the pharmaceutical
5 industry and their base salaries were low compared to industry standard. The
6 compensation structure was heavily weighted toward commissions and rewarded
7 reps more for selling higher (and more expensive) doses of Subsys, a "highly
8 unusual" practice because most companies consider dosing a patient-specific
9 decision that should be made by a doctor.¹⁰⁸

10 171. The Insys "speakers program" was perhaps its most widespread and
11 damaging scheme. A former Insys salesman, Ray Furchak, alleged in a qui tam
12 action that the sole purpose of the speakers program was "in the words of his then
13 supervisor Alec Burlakoff, 'to get money in the doctor's pocket.'" Furchak went
14 on to explain that "[t]he catch . . . was that doctors who increased the level of
15 Subsys prescriptions, and at higher dosages (such as 400 or 800 micrograms
16 instead of 200 micrograms), would receive the invitations to the program—and
17 the checks."¹⁰⁹ It was a pay-to-prescribe program.

18 172. Insys's sham speaker program and other fraudulent and illegal tactics
19 have been outlined in great detail in indictments and guilty pleas of Insys
20 executives, employees, and prescribers across the country, as well as in a number
21 of lawsuits against the company itself.

22 173. In May of 2015, two Alabama pain specialists were arrested and
23 charged with illegal prescription drug distribution, among other charges. The
24 doctors were the top prescribers of Subsys, though neither were oncologists.
25 According to prosecutors, the doctors received illegal kickbacks from Insys for
26

27 ¹⁰⁸ *Id.*

28 ¹⁰⁹ Roddy Boyd, *Insys Therapeutics and the New 'Killing It'*, Southern
Investigative Reporting Foundation, The Investigator, April 24, 2015.

1 prescribing Subsys. Both doctors had prescribed Subsys to treat neck, back, and
2 joint pain. In February of 2016, a former Insys sales manager pled guilty to
3 conspiracy to commit health care fraud, including engaging in a kickback scheme
4 in order to induce one of these doctors to prescribe Subsys. The plea agreement
5 states that nearly all of the Subsys prescriptions written by the doctor were off-
6 label to non-cancer patients. In May of 2017, one of the doctors was sentenced to
7 20 years in prison.

8 174. In June of 2015, a nurse practitioner in Connecticut described as the
9 state's highest Medicare prescriber of narcotics, pled guilty to receiving \$83,000
10 in kickbacks from Insys for prescribing Subsys. Most of her patients were
11 prescribed the drug for chronic pain. Insys paid the nurse as a speaker for more
12 than 70 dinner programs at approximately \$1,000 per event; however, she did not
13 give any presentations. In her guilty plea, the nurse admitted receiving the
14 speaker fees in exchange for writing prescriptions for Subsys.

15 175. In August of 2015, Insys settled a complaint brought by the Oregon
16 Attorney General. In its complaint, the Oregon Department of Justice cited Insys
17 for, among other things, misrepresenting to doctors that Subsys could be used to
18 treat migraine, neck pain, back pain, and other uses for which Subsys is neither
19 safe nor effective, and using speaking fees as kickbacks to incentivize doctors to
20 prescribe Subsys.

21 176. In August of 2016, the State of Illinois sued Insys for similar
22 deceptive and illegal practices. The Complaint alleged that Insys marketed
23 Subsys to high-volume prescribers of opioid drugs instead of to oncologists whose
24 patients experienced the breakthrough cancer pain for which the drug is indicated.
25 The Illinois Complaint also details how Insys used its speaker program to pay
26 high volume prescribers to prescribe Subsys. The speaker events took place at
27 upscale restaurants in the Chicago area, and Illinois speakers received an
28 "honorarium" ranging from \$700 to \$5,100, and they were allowed to order as

1 much food and alcohol as they wanted. At most of the events, the “speaker” being
 2 paid by Insys did not speak, and, on many occasions, the only attendees at the
 3 events were the speaker and an Insys sales representative.

4 177. In December of 2016, six Insys executives and managers were
 5 indicted and then, in October 2017, Insys’s founder and owner was arrested and
 6 charged with multiple felonies in connection with an alleged conspiracy to bribe
 7 practitioners to prescribe Subsys and defraud insurance companies. A U.S.
 8 Department of Justice press release explained that, among other things: “Insys
 9 executives improperly influenced health care providers to prescribe a powerful
 10 opioid for patients who did not need it, and without complying with FDA
 11 requirements, thus putting patients at risk and contributing to the current opioid
 12 crisis.”¹¹⁰ A Drug Enforcement Administration (“DEA”) Special Agent in Charge
 13 further explained that: “Pharmaceutical companies whose products include
 14 controlled medications that can lead to addiction and overdose have a special
 15 obligation to operate in a trustworthy, transparent manner, because their
 16 customers’ health and safety and, indeed, very lives depend on it.”¹¹¹

17 **5. The Manufacturer Defendants made Materially Deceptive**
 18 **Statements and Concealed Material Facts.**

19 178. As alleged herein, the Manufacturer Defendants made and/or
 20 disseminated deceptive statements regarding material facts and further concealed
 21 material facts, in the course of manufacturing, marketing, and selling prescription
 22 opioids. The Manufacturer Defendants’ actions were intentional and/or unlawful.
 23 Such statements include, but are not limited to, those set out below and alleged
 24 throughout this Complaint.

25
 26 ¹¹⁰ Press Release, DOJ, U.S. Attorney’s Office, Dist. of Mass., *Founder and Owner*
 27 *of Pharmaceutical Company Insys Arrested and Charged with Racketeering* (Oct.
 28 26, 2017), available at <https://www.justice.gov/usao-ma/pr/founder-and-owner-pharmaceutical-company-insys-arrested-and-charged-racketeering>.

¹¹¹ *Id.*

1 179. Defendant Purdue made and/or disseminated deceptive statements,
2 and concealed material facts in such a way to make their statements deceptive,
3 including, but not limited to, the following:

- 4 a. Creating, sponsoring, and assisting in the distribution of patient
5 education materials distributed to consumers that contained deceptive
6 statements;
- 7 b. Creating and disseminating advertisements that contained deceptive
8 statements concerning the ability of opioids to improve function
9 long-term and concerning the evidence supporting the efficacy of
10 opioids long-term for the treatment of chronic non-cancer pain;
- 11 c. Disseminating misleading statements concealing the true risk of
12 addiction and promoting the deceptive concept of pseudoaddiction
13 through Purdue's own unbranded publications and on internet sites
14 Purdue operated that were marketed to and accessible by consumers;
- 15 d. Distributing brochures to doctors, patients, and law enforcement
16 officials that included deceptive statements concerning the indicators
17 of possible opioid abuse;
- 18 e. Sponsoring, directly distributing, and assisting in the distribution of
19 publications that promoted the deceptive concept of pseudoaddiction,
20 even for high-risk patients;
- 21 f. Endorsing, directly distributing, and assisting in the distribution of
22 publications that presented an unbalanced treatment of the long-term
23 and dose-dependent risks of opioids versus NSAIDs;
- 24 g. Providing significant financial support to pro-opioid KOL doctors
25 who made deceptive statements concerning the use of opioids to treat
26 chronic non-cancer pain;
- 27 h. Providing needed financial support to pro-opioid pain organizations
28 that made deceptive statements, including in patient education
materials, concerning the use of opioids to treat chronic non-cancer
pain;
- i. Assisting in the distribution of guidelines that contained deceptive
statements concerning the use of opioids to treat chronic non-cancer
pain and misrepresented the risks of opioid addiction;
- j. Endorsing and assisting in the distribution of CMEs containing
deceptive statements concerning the use of opioids to treat chronic
non-cancer pain;
- k. Developing and disseminating scientific studies that misleadingly
concluded opioids are safe and effective for the long-term treatment
of chronic non-cancer pain and that opioids improve quality of life,
while concealing contrary data;

1. Assisting in the dissemination of literature written by pro-opioid KOLs that contained deceptive statements concerning the use of opioids to treat chronic noncancer pain;
- m. Creating, endorsing, and supporting the distribution of patient and prescriber education materials that misrepresented the data regarding the safety and efficacy of opioids for the long-term treatment of chronic non-cancer pain, including known rates of abuse and addiction and the lack of validation for long-term efficacy;
- n. Targeting veterans by sponsoring and disseminating patient education marketing materials that contained deceptive statements concerning the use of opioids to treat chronic non-cancer pain;
- o. Targeting the elderly by assisting in the distribution of guidelines that contained deceptive statements concerning the use of opioids to treat chronic non-cancer pain and misrepresented the risks of opioid addiction in this population;
- p. Exclusively disseminating misleading statements in education materials to hospital doctors and staff while purportedly educating them on new pain standards;
- q. Making deceptive statements concerning the use of opioids to treat chronic noncancer pain to prescribers through in-person detailing; and
- r. Withholding from law enforcement the names of prescribers Purdue believed to be facilitating the diversion of its opioid, while simultaneously marketing opioids to these doctors by disseminating patient and prescriber education materials and advertisements and CMEs they knew would reach these same prescribers.

180. Defendant Endo made and/or disseminated deceptive statements, and concealed material facts in such a way to make their statements deceptive, including, but not limited to, the following:

- a. Creating, sponsoring, and assisting in the distribution of patient education materials that contained deceptive statements;
- b. Creating and disseminating advertisements that contained deceptive statements concerning the ability of opioids to improve function long-term and concerning the evidence supporting the efficacy of opioids long-term for the treatment of chronic non-cancer pain;
- c. Creating and disseminating paid advertisement supplements in academic journals promoting chronic opioid therapy as safe and effective for long term use for high risk patients;
- d. Creating and disseminating advertisements that falsely and inaccurately conveyed the impression that Endo's opioids would provide a reduction in oral, intranasal, or intravenous abuse;
- e. Disseminating misleading statements concealing the true risk of addiction and promoting the misleading concept of pseudoaddiction

1 through Endo's own unbranded publications and on internet sites
2 Endo sponsored or operated;

- 3 f. Endorsing, directly distributing, and assisting in the distribution of
4 publications that presented an unbalanced treatment of the long-term
5 and dose-dependent risks of opioids versus NSAIDs;
- 6 g. Providing significant financial support to pro-opioid KOLs, who
7 made deceptive statements concerning the use of opioids to treat
8 chronic non-cancer pain;
- 9 h. Providing needed financial support to pro-opioid pain organizations –
10 including over \$5 million to the organization responsible for many of
11 the most egregious misrepresentations – that made deceptive
12 statements, including in patient education materials, concerning the
13 use of opioids to treat chronic non-cancer pain;
- 14 i. Targeting the elderly by assisting in the distribution of guidelines that
15 contained deceptive statements concerning the use of opioids to treat
16 chronic non-cancer pain and misrepresented the risks of opioid
17 addiction in this population;
- 18 j. Endorsing and assisting in the distribution of CMEs containing
19 deceptive statements concerning the use of opioids to treat chronic
20 non-cancer pain;
- 21 k. Developing and disseminating scientific studies that deceptively
22 concluded opioids are safe and effective for the long-term treatment
23 of chronic non-cancer pain and that opioids improve quality of life,
24 while concealing contrary data;
- 25 l. Directly distributing and assisting in the dissemination of literature
26 written by pro-opioid KOLs that contained deceptive statements
27 concerning the use of opioids to treat chronic non-cancer pain,
28 including the concept of pseudoaddiction;
- m. Creating, endorsing, and supporting the distribution of patient and
prescriber education materials that misrepresented the data regarding
the safety and efficacy of opioids for the long-term treatment of
chronic non-cancer pain, including known rates of abuse and
addiction and the lack of validation for long-term efficacy; and
- n. Making deceptive statements concerning the use of opioids to treat
chronic non-cancer pain to prescribers through in-person detailing.

181. Defendant Janssen made and/or disseminated deceptive statements,
and concealed material facts in such a way to make their statements deceptive,
including, but not limited to, the following:

- a. Creating, sponsoring, and assisting in the distribution of patient
education materials that contained deceptive statements;
- b. Directly disseminating deceptive statements through internet sites
over which Janssen exercised final editorial control and approval
stating that opioids are safe and effective for the long-term treatment

1 of chronic non-cancer pain and that opioids improve quality of life,
2 while concealing contrary data;

- 3 c. Disseminating deceptive statements concealing the true risk of
4 addiction and promoting the deceptive concept of pseudoaddiction
5 through internet sites over which Janssen exercised final editorial
6 control and approval;
- 7 d. Promoting opioids for the treatment of conditions for which Janssen
8 knew, due to the scientific studies it conducted, that opioids were not
9 efficacious and concealing this information;
- 10 e. Sponsoring, directly distributing, and assisting in the dissemination
11 of patient education publications over which Janssen exercised final
12 editorial control and approval, which presented an unbalanced
13 treatment of the long-term and dose dependent risks of opioids versus
14 NSAIDs;
- 15 f. Providing significant financial support to pro-opioid KOLs, who
16 made deceptive statements concerning the use of opioids to treat
17 chronic non-cancer pain;
- 18 g. Providing necessary financial support to pro-opioid pain
19 organizations that made deceptive statements, including in patient
20 education materials, concerning the use of opioids to treat chronic
21 non-cancer pain;
- 22 h. Targeting the elderly by assisting in the distribution of guidelines that
23 contained deceptive statements concerning the use of opioids to treat
24 chronic non-cancer pain and misrepresented the risks of opioid
25 addiction in this population;
- 26 i. Targeting the elderly by sponsoring, directly distributing, and
27 assisting in the dissemination of patient education publications
28 targeting this population that contained deceptive statements about
the risks of addiction and the adverse effects of opioids, and made
false statements that opioids are safe and effective for the long-term
treatment of chronic non-cancer pain and improve quality of life,
while concealing contrary data;
- j. Endorsing and assisting in the distribution of CMEs containing
deceptive statements concerning the use of opioids to treat chronic
non-cancer pain;
- k. Directly distributing and assisting in the dissemination of literature
written by pro-opioid KOLs that contained deceptive statements
concerning the use of opioids to treat chronic non-cancer pain,
including the concept of pseudoaddiction;
- l. Creating, endorsing, and supporting the distribution of patient and
prescriber education materials that misrepresented the data regarding
the safety and efficacy of opioids for the long-term treatment of
chronic non-cancer pain, including known rates of abuse and
addiction and the lack of validation for long-term efficacy;

1 m. Targeting veterans by sponsoring and disseminating patient
2 education marketing materials that contained deceptive statements
concerning the use of opioids to treat chronic non-cancer pain; and

3 n. Making deceptive statements concerning the use of opioids to treat
4 chronic non-cancer pain to prescribers through in-person detailing.

5 182. Defendant Cephalon made and/or disseminated untrue, false and
6 deceptive statements, and concealed material facts in such a way to make their
statements deceptive, including, but not limited to, the following:

7 a. Creating, sponsoring, and assisting in the distribution of patient
8 education materials that contained deceptive statements;

9 b. Sponsoring and assisting in the distribution of publications that
10 promoted the deceptive concept of pseudoaddiction, even for high-
risk patients;

11 c. Providing significant financial support to pro-opioid KOL doctors
12 who made deceptive statements concerning the use of opioids to treat
chronic non-cancer pain and breakthrough chronic non-cancer pain;

13 d. Developing and disseminating scientific studies that deceptively
14 concluded opioids are safe and effective for the long-term treatment
of chronic non-cancer pain in conjunction with Cephalon's potent
rapid-onset opioids;

15 e. Providing needed financial support to pro-opioid pain organizations
16 that made deceptive statements, including in patient education
materials, concerning the use of opioids to treat chronic non-cancer
17 pain;

18 f. Endorsing and assisting in the distribution of CMEs containing
19 deceptive statements concerning the use of opioids to treat chronic
non-cancer pain;

20 g. Endorsing and assisting in the distribution of CMEs containing
21 deceptive statements concerning the use of Cephalon's rapid-onset
opioids;

22 h. Directing its marketing of Cephalon's rapid-onset opioids to a wide
23 range of doctors, including general practitioners, neurologists, sports
medicine specialists, and workers' compensation programs, serving
chronic pain patients;

24 i. Making deceptive statements concerning the use of Cephalon's
25 opioids to treat chronic non-cancer pain to prescribers through in-
person detailing and speakers' bureau events, when such uses are
unapproved and unsafe; and

26 j. Making deceptive statements concerning the use of opioids to treat
27 chronic non-cancer pain to prescribers through in-person detailing
and speakers' bureau events.
28

1 183. Defendant Actavis made and/or disseminated deceptive statements,
2 and concealed material facts in such a way to make their statements deceptive,
3 including, but not limited to, the following:

- 4 a. Making deceptive statements concerning the use of opioids to treat
5 chronic non-cancer pain to prescribers through in-person detailing;
6 b. Creating and disseminating advertisements that contained deceptive
7 statements that opioids are safe and effective for the long-term
8 treatment of chronic non-cancer pain and that opioids improve
9 quality of life;
10 c. Creating and disseminating advertisements that concealed the risk of
11 addiction in the long-term treatment of chronic, non-cancer pain; and
12 d. Developing and disseminating scientific studies that deceptively
13 concluded opioids are safe and effective for the long-term treatment
14 of chronic non-cancer pain and that opioids improve quality of life
15 while concealing contrary data.

12 **6. The Manufacturer Defendants Fraudulently Concealed Their**
13 **Misconduct.**

14 184. The Manufacturer Defendants, both individually and collectively,
15 made, promoted, and profited from their misrepresentations about the risks and
16 benefits of opioids for chronic pain even though they knew that their
17 misrepresentations were false and deceptive. The history of opioids, as well as
18 research and clinical experience establish that opioids are highly addictive and are
19 responsible for a long list of very serious adverse outcomes. The FDA warned
20 Defendants of this, and Defendants had access to scientific studies, detailed
21 prescription data, and reports of adverse events, including reports of addiction,
22 hospitalization, and death – all of which clearly described the harm from long-
23 term opioid use and that patients were suffering from addiction, overdose, and
24 death in alarming numbers. More recently, the FDA and CDC have issued
25 pronouncements, based on medical evidence, that conclusively expose the falsity
26 of Defendants' misrepresentations, and Endo and Purdue have recently entered
27 into agreements in New York prohibiting them from making some of the same
28 misrepresentations described in this Complaint.

1 185. At all times relevant to this Complaint, the Manufacturer Defendants
2 took steps to avoid detection of and to fraudulently conceal their deceptive
3 marketing and unlawful, unfair, and fraudulent conduct. For example, the
4 Manufacturer Defendants disguised their role in the deceptive marketing of
5 chronic opioid therapy by funding and working through third parties like Front
6 Groups and KOLs. The Manufacturer Defendants purposefully hid behind the
7 assumed credibility of these individuals and organizations and relied on them to
8 vouch for the accuracy and integrity of the Manufacturer Defendants' false and
9 deceptive statements about the risks and benefits of long-term opioid use for
10 chronic pain. Defendants also never disclosed their role in shaping, editing, and
11 approving the content of information and materials disseminated by these third
12 parties. The Manufacturer Defendants exerted considerable influence on these
13 promotional and "educational" materials in emails, correspondence, and meetings
14 with KOLs, Front Groups, and public relations companies that were not, and have
15 not yet become, public. For example, PainKnowledge.org, which is run by the
16 NIPC, did not disclose Endo's involvement. Other Manufacturer Defendants, such
17 as Purdue and Janssen, ran similar websites that masked their own role.

18 186. Finally, the Manufacturer Defendants manipulated their promotional
19 materials and the scientific literature to make it appear that these documents were
20 accurate, truthful, and supported by objective evidence when they were not. The
21 Manufacturer Defendants distorted the meaning or import of studies they cited
22 and offered them as evidence for propositions the studies did not support. The
23 Manufacturer Defendants invented "pseudoaddiction" and promoted it to an
24 unsuspecting medical community. The Manufacturer Defendants provided the
25 medical community with false and misleading information about ineffectual
26 strategies to avoid or control opioid addiction. The Manufacturer Defendants
27 recommended to the medical community that dosages be increased, without
28 disclosing the risks. The Manufacturer Defendants spent millions of dollars over a

1 period of years on a misinformation campaign aimed at highlighting opioids’
 2 alleged benefits, disguising the risks, and promoting sales. The lack of support for
 3 the Manufacturer Defendants’ deceptive messages was not apparent to medical
 4 professionals who relied upon them in making treatment decisions, nor could it
 5 have been detected by the Plaintiffs or Plaintiffs’ Community. Thus, the
 6 Manufacturer Defendants successfully concealed from the medical community,
 7 patients, and health care payors facts sufficient to arouse suspicion of the claims
 8 that the Plaintiffs now assert. Plaintiffs did not know of the existence or scope of
 9 the Manufacturer Defendants’ industry-wide fraud and could not have acquired
 10 such knowledge earlier through the exercise of reasonable diligence.

11 **C. THE DISTRIBUTOR DEFENDANTS’ UNLAWFUL DISTRIBUTION** 12 **OF OPIOIDS.**

13 187. The Distributor Defendants owe a duty under both federal law (21
 14 U.S.C. § 823, 21 CFR 1301.74) and California law (*see, e.g.*, Cal. Bus. & Prof.
 15 Code § 4169.1) to monitor, detect, investigate, refuse to fill, and report suspicious
 16 orders of prescription opioids originating from Plaintiffs’ Community as well as
 17 those orders which the Distributor Defendants knew or should have known were
 18 likely to be diverted into Plaintiffs’ Community.

19 188. The foreseeable harm from a breach of these duties is the diversion of
 20 prescription opioids for nonmedical purposes.

21 189. Each Distributor Defendant repeatedly and purposefully breached its
 22 duties under state and federal law. Such breaches are a direct and proximate cause
 23 of the widespread diversion of prescription opioids for nonmedical purposes into
 24 Plaintiffs’ Community.

25 190. The unlawful diversion of prescription opioids is a direct and
 26 proximate cause and/or substantial contributing factor to the opioid epidemic,
 27 prescription opioid abuse, addiction, morbidity and mortality in the State and in
 28

1 Plaintiffs' Community. This diversion and the epidemic are direct causes of harms
2 for which Plaintiffs seek to recover here.

3 191. The opioid epidemic in the State, including *inter alia* in Plaintiffs'
4 Community, remains an immediate ***hazard to public health and safety***.

5 192. The opioid epidemic in Plaintiffs' Community is a temporary and
6 continuous ***public nuisance*** and remains unabated.

7 193. The Distributor Defendants intentionally continued their conduct, as
8 alleged herein, with knowledge that such conduct was creating the opioid nuisance
9 and causing the harms and damages alleged herein.

10 **1. Wholesale Drug Distributors Have a Duty under State and**
11 **Federal Law to Guard Against, and Report, Unlawful Diversion**
12 **and to Report and Prevent Suspicious Orders.**

13 194. As under federal law, opioids are a Schedule II controlled substance
14 under California law. *See* Cal. Health & Safety Code § 11055. Opioids are
15 categorized as "Schedule II" drugs because they have a "high potential for abuse"
16 and the potential to cause "severe psychic or physical dependence" and/or "severe
17 psychological . . . dependence." 21 U.S.C. § 812(b)(2)(A)-(C).

18 195. California law required Distributor Defendants to be licensed by the
19 California State Board of Pharmacy. Cal. Bus. & Prof. Code § 4160; Cal. Bus. &
20 Prof. Code § 4161. California law required Manufacturer Defendants to be
21 licensed by the State Department of Health Services. Cal. Health & Safety Code §
22 111615.

23 196. The California State Board of Pharmacy has the authority to "deny,
24 revoke, or suspend any license" issued to out-of-state manufacturers or wholesale
25 distributors who violate the Pharmacy Law or the state's Sherman Food, Drug and
26 Cosmetic Law. Cal. Bus. & Prof. Code § 4304.

1 197. It is unlawful under California law for a distributor or manufacturer
2 to “furnish controlled substances for other than legitimate medical purposes.” Cal.
3 Health & Safety Code § 11153.5.

4 198. The California State Board of Pharmacy has the authority to “take
5 action against any holder of a license who is guilty of unprofessional conduct”
6 which includes “clearly excessive furnishing of controlled substances” for other
7 than legitimate medical purposes. Cal. Bus. & Prof. Code § 4301(e) (citing Cal.
8 Health & Safety Code § 11153.5). “Factors to be considered in determining
9 whether the furnishing of controlled substances is clearly excessive shall include,
10 but not be limited to, the amount of controlled substances furnished, the previous
11 ordering pattern of the customer (including size and frequency of orders), the type
12 and size of the customer, and where and to whom the customer distributes its
13 product.” *Id.*

14 199. Other examples of unprofessional conduct include procuring a
15 license by fraud or misrepresentation, gross negligence, fraud, making or signing
16 documents with false statements, and violating any state or federal statute or rule
17 regulating controlled substances. Cal. Bus. & Prof. Code § 4301.

18 200. California requires manufacturers and distributors of controlled
19 substances to maintain records of the manufacture and sale of dangerous drugs.
20 *See* Cal. Bus. & Prof. Code §§ 4081; 4161(c)(2)(A); 4332; Cal. Code Regs. tit. 16,
21 §§ 1780(f); 1783(e).

22 201. Furthermore, California law incorporates federal requirements set out
23 under the Controlled Substance Act and related controlled substance laws and
24 regulations. *See* Cal. Bus. & Prof. Code §§ 4160(d) (representative-in-charge of
25 wholesaler is responsible for wholesaler’s compliance with applicable state and
26 federal laws); 4301(j) (unprofessional conduct includes violating federal laws
27 related to controlled substances); 4301(o) (unprofessional conduct includes
28 violating, attempting to violate, assisting in or abetting or conspiring to violate any

1 applicable federal law); Cal. Code Regs. tit. 16, § 1780(f)(2) (records required for
2 identifying, recording and reporting losses or thefts shall be in accordance with
3 federal regulations).

4 202. Each Distributor Defendant was further required to register with the
5 DEA, pursuant to the federal Controlled Substance Act. *See* 21 U.S.C. § 823(b),
6 (e); 28 C.F.R. § 0.100. Each Distributor Defendant is a “registrant” as a
7 wholesale distributor in the chain of distribution of Schedule II controlled
8 substances with a duty to comply with all security requirements imposed under
9 that statutory scheme. California law adopts and incorporates those requirements,
10 as set out above. *See, e.g.*, Cal. Code Regs. tit. 16, 1780(f)(2).

11 203. Each Distributor Defendant has an affirmative duty under federal and
12 California law to act as a gatekeeper guarding against the diversion of the highly
13 addictive, dangerous opioid drugs. Federal law requires that Distributors of
14 Schedule II drugs, including opioids, must maintain “effective control against
15 diversion of particular controlled substances into other than legitimate medical,
16 scientific, and industrial channels.” 21 U.S.C. §§ 823(b)(1). California law
17 requires that “[t]he following minimum standards shall apply to all wholesale
18 establishments for which permits have been issued by the Board: . . . (c)(2) All
19 facilities shall be equipped with a security system that will provide suitable
20 protection against theft and diversion.” Cal. Code Regs. Tit. 16 § 1780(c)(2). In
21 addition, drug distributors shall “establish, maintain, and adhere to written policies
22 and procedures, which shall be followed for the receipt, security, storage,
23 inventory, and distribution of prescription drugs, including policies and
24 procedures for identifying, recording, and reporting losses or thefts[.]” Cal. Code
25 Regs. Tit. 16 § 1780(f)(1).

26 204. The California Legislature has found that “Protection of the public
27 shall be the highest priority for the California State Board of Pharmacy in
28 exercising its licensing, regulatory, and disciplinary functions. Whenever the

1 protection of the public is inconsistent with other interests sought to be promoted,
 2 the protection of the public shall be paramount.” Cal. Bus. & Prof. Code § 4001.1.

3 205. Federal regulations and California law impose a non-delegable duty
 4 upon wholesale drug distributors to “design and operate a system to disclose to the
 5 registrant suspicious orders of controlled substances. The registrant [distributor]
 6 shall inform the Field Division Office of the Administration in his area of
 7 suspicious orders when discovered by the registrant. Suspicious orders include
 8 orders of unusual size, orders deviating substantially from a normal pattern, and
 9 orders of unusual frequency.” 21 C.F.R. § 1301.74(b). *See also* Cal. Bus. & Prof.
 10 Code § 4169.1 (“A wholesaler, upon discovery, shall notify the board in writing of
 11 any suspicious orders of controlled substances placed by a California-licensed
 12 pharmacy or wholesaler by providing the board a copy of the information that the
 13 wholesaler provides to the United States Drug Enforcement Administration.”);
 14 Cal. Health & Safety Code § 11153.5(c) (factors considered in determining if
 15 distributor or manufacturer furnished controlled substances with a conscious
 16 disregard that they were being used for other than legitimate medical purposes
 17 include the amount of controlled substances furnished, the size and frequency of
 18 previous orders, the type and size of customer and where the customer distributes
 19 the product).

20 206. “Suspicious orders” include orders of an unusual size, orders of
 21 unusual frequency or orders deviating substantially from a normal pattern. *See* 21
 22 CFR 1301.74(b); *see also* Cal. Bus. & Prof. Code § 4169.1. These criteria are
 23 disjunctive and are not all inclusive. For example, if an order deviates
 24 substantially from a normal pattern, the size of the order does not matter and the
 25 order should be reported as suspicious. Likewise, a wholesale distributor need not
 26 wait for a normal pattern to develop over time before determining whether a
 27 particular order is suspicious. The size of an order alone, regardless of whether it
 28 deviates from a normal pattern, is enough to trigger the wholesale distributor’s

responsibility to report the order as suspicious. The determination of whether an order is suspicious depends not only on the ordering patterns of the particular customer but also on the patterns of the entirety of the wholesale distributor's customer base and the patterns throughout the relevant segment of the wholesale distributor industry.

207. In addition to reporting all suspicious orders, distributors must also stop shipment on any order which is flagged as suspicious and only ship orders which were flagged as potentially suspicious if, after conducting due diligence, the distributor can determine that the order is not likely to be diverted into illegal channels. *See Southwood Pharm., Inc.*, 72 Fed. Reg. 36,487, 36,501 (Drug Enf't Admin. July 3, 2007); *Masters Pharmaceutical, Inc. v. Drug Enforcement Administration*, No. 15-11355 (D.C. Cir. June 30, 2017). Regardless, all flagged orders must be reported. *Id.*

208. These prescription drugs are regulated for the purpose of providing a "closed" system **intended to reduce the widespread diversion of these drugs out of legitimate channels into the illicit market**, while at the same time providing the legitimate drug industry with a unified approach to narcotic and dangerous drug control.¹¹²

209. Different entities supervise the discrete links in the chain that separate a consumer from a controlled substance. Statutes and regulations define each participant's role and responsibilities.¹¹³

¹¹² See 1970 U.S.C.C.A.N. 4566, 4571-72.

¹¹³ Brief for Healthcare Distribution Management Association and National Association of Chain Drug Stores as Amici Curiae in Support of Neither Party, *Masters Pharm., Inc. v. U.S. Drug Enf't Admin.* (No. 15-1335) (D.C. Cir. Apr. 4, 2016), 2016 WL 1321983, at *22 [hereinafter Brief for HDMA and NACDS]. The Healthcare Distribution Management Association (HDMA or HMA)—now known as the Healthcare Distribution Alliance (HDA)—is a national, not-for-profit trade association that represents the nation's primary, full-service healthcare distributors whose membership includes, among others: AmerisourceBergen Drug Corporation, Cardinal Health, Inc., and McKesson Corporation. *See generally* HDA, *About*, <https://www.healthcaredistribution.org/about> (last visited Aug. 21, 2017). The National Association of Chain Drug Stores (NACDS) is a national,

210. As the DEA advised the Distributor Defendants in a letter to them dated September 27, 2006, wholesale distributors are “one of the key components of the distribution chain. If the closed system is to function properly ... distributors must be vigilant in deciding whether a prospective customer can be trusted to deliver controlled substances only for lawful purposes. This responsibility is critical, as ... the illegal distribution of controlled substances has a substantial and detrimental effect on the health and general welfare of the American people.”¹¹⁴

211. The Distributor Defendants have admitted that they are responsible for reporting suspicious orders.¹¹⁵

212. The DEA sent a letter to each of the Distributor Defendants on September 27, 2006, warning that it would use its authority to revoke and suspend registrations when appropriate. The letter expressly states that a distributor, *in addition* to reporting suspicious orders, has a “statutory responsibility to exercise due diligence to avoid filling suspicious orders that might be diverted into other than legitimate medical, scientific, and industrial channels.”¹¹⁶ The letter also

not-for-profit trade association that represents traditional drug stores and supermarkets and mass merchants with pharmacies whose membership includes, among others: Walgreen Company, CVS Health, Rite Aid Corporation and Walmart. *See generally* NACDS, *Mission*, <https://www.nacds.org/about/mission/> (last visited Aug. 21, 2017).

¹¹⁴ *See* Letter from Joseph T. Rannazzisi, Deputy Assistant Adm’r, Office of Diversion Control, Drug. Enf’t Admin., U.S. Dep’t of Justice, to Cardinal Health (Sept. 27, 2006) [hereinafter Rannazzisi Letter] (“This letter is being sent to every commercial entity in the United States registered with the Drug Enforcement Agency (DEA) to distribute controlled substances. The purpose of this letter is to reiterate the responsibilities of controlled substance distributors in view of the prescription drug abuse problem our nation currently faces.”), filed in *Cardinal Health, Inc. v. Holder*, No. 1:12-cv-00185-RBW (D.D.C. Feb. 10, 2012), ECF No. 14-51.

¹¹⁵ *See* Brief for HDMA and NACDS, 2016 WL 1321983, at *4 (“[R]egulations . . . in place for more than 40 years require distributors to report suspicious orders of controlled substances to DEA based on information readily available to them (e.g., a pharmacy’s placement of unusually frequent or large orders).”).

¹¹⁶ Rannazzisi Letter, at 2.

1 instructs that “distributors must be vigilant in deciding whether a prospective
2 customer can be trusted to deliver controlled substances only for lawful
3 purposes.”¹¹⁷ The DEA warns that “even just one distributor that uses its DEA
4 registration to facilitate diversion can cause enormous harm.”¹¹⁸

5 213. The DEA sent a second letter to each of the Distributor Defendants
6 on December 27, 2007.¹¹⁹ This letter reminds the Defendants of their statutory and
7 regulatory duties to “maintain effective controls against diversion” and “design
8 and operate a system to disclose to the registrant suspicious orders of controlled
9 substances.”¹²⁰ The letter further explains:

10 The regulation also requires that the registrant inform the local DEA
11 Division Office of suspicious orders when discovered by the
12 registrant. Filing a monthly report of completed transactions (e.g.,
13 “excessive purchase report” or “high unity purchases”) does not meet
14 the regulatory requirement to report suspicious orders. Registrants are
15 reminded that their responsibility does not end merely with the filing
16 of a suspicious order report. Registrants must conduct an independent
analysis of suspicious orders prior to completing a sale to determine
whether the controlled substances are likely to be diverted from
legitimate channels. Reporting an order as suspicious will not absolve
the registrant of responsibility if the registrant knew, or should have
known, that the controlled substances were being diverted.

17 The regulation specifically states that suspicious orders include orders
18 of unusual size, orders deviating substantially from a normal pattern,
19 and orders of an unusual frequency. These criteria are disjunctive and
20 are not all inclusive. For example, if an order deviates substantially
21 from a normal pattern, the size of the order does not matter and the
22 order should be reported as suspicious. Likewise, a registrant need
23 not wait for a “normal pattern” to develop over time before
24 determining whether a particular order is suspicious. The size of an
order alone, whether or not it deviates from a normal pattern, is
enough to trigger the registrant’s responsibility to report the order as
suspicious. The determination of whether an order is suspicious
depends not only on the ordering patterns of the particular customer,

25 ¹¹⁷ *Id.* at 1.

26 ¹¹⁸ *Id.* at 2.

27 ¹¹⁹ See Letter from Joseph T. Rannazzisi, Deputy Assistant Adm’r, Office of
Diversion Control, Drug. Enf’t Admin., U.S. Dep’t of Justice, to Cardinal Health
(Dec. 27, 2007), filed in *Cardinal Health, Inc. v. Holder*, No. 1:12-cv-00185-RBW
(D.D.C. Feb. 10, 2012), ECF No. 14-8.

28 ¹²⁰ *Id.*

1 but also on the patterns of the registrant's customer base and the
2 patterns throughout the segment of the regulated industry.

3 Registrants that rely on rigid formulas to define whether an order is
4 suspicious may be failing to detect suspicious orders. For example, a
5 system that identifies orders as suspicious only if the total amount of a
6 controlled substance ordered during one month exceeds the amount
7 ordered the previous month by a certain percentage or more is
8 insufficient. This system fails to identify orders placed by a pharmacy
9 if the pharmacy placed unusually large orders from the beginning of
10 its relationship with the distributor. Also, this system would not
11 identify orders as suspicious if the order were solely for one highly
12 abused controlled substance if the orders never grew substantially.
13 Nevertheless, ordering one highly abused controlled substance and
14 little or nothing else deviates from the normal pattern of what
15 pharmacies generally order.

16 When reporting an order as suspicious, registrants must be clear in
17 their communication with DEA that the registrant is actually
18 characterizing an order as suspicious. Daily, weekly, or monthly
19 reports submitted by registrant indicating "excessive purchases" do
20 not comply with the requirement to report suspicious orders, even if
21 the registrant calls such reports "suspicious order reports."

22 Lastly, registrants that routinely report suspicious orders, yet fill these
23 orders without first determining that order is not being diverted into
24 other than legitimate medical, scientific, and industrial channels, may
25 be failing to maintain effective controls against diversion. Failure to
26 maintain effective controls against diversion is inconsistent with the
27 public interest as that term is used in 21 USC 823 and 824, and may
28 result in the revocation of the registrant's DEA Certificate of
Registration.¹²¹

29 Finally, the DEA letter references the Revocation of Registration issued in
30 *Southwood Pharmaceuticals, Inc.*, 72 Fed. Reg. 36,487-01 (July 3, 2007), which
31 discusses the obligation to report suspicious orders and "some criteria to use when
32 determining whether an order is suspicious."¹²²

33 214. The Distributor Defendants admit that they "have not only statutory
34 and regulatory responsibilities to detect and prevent diversion of controlled
35 prescription drugs, but undertake such efforts as responsible members of
36 society."¹²³

37 ¹²¹ *Id.*

38 ¹²² *Id.*

¹²³ See Brief of HDMA, 2012 WL 1637016, at *2.

1 215. The Distributor Defendants knew they were required to monitor,
 2 detect, and halt suspicious orders. Industry compliance guidelines established by
 3 the Healthcare Distribution Management Association, the trade association of
 4 pharmaceutical distributors, explain that distributors are “[a]t the center of a
 5 sophisticated supply chain” and therefore “are uniquely situated to perform due
 6 diligence in order to help support the security of the controlled substances they
 7 deliver to their customers.” The guidelines set forth recommended steps in the
 8 “due diligence” process, and note in particular: If an order meets or exceeds a
 9 distributor’s threshold, as defined in the distributor’s monitoring system, or is
 10 otherwise characterized by the distributor as an order of interest, the distributor
 11 should not ship to the customer, in fulfillment of that order, any units of the
 12 specific drug code product as to which the order met or exceeded a threshold or as
 13 to which the order was otherwise characterized as an order of interest.¹²⁴

14 216. Each of the Distributor Defendants sold prescription opioids,
 15 including hydrocodone and/or oxycodone, to retailers in Plaintiffs’ Community
 16 and/or to retailers from which Defendants knew prescription opioids were likely
 17 to be diverted to Plaintiffs’ Community.

18 217. Each Distributor Defendant owes a duty to monitor and detect
 19 suspicious orders of prescription opioids.

20 218. Each Distributor Defendant owes a duty under federal and state law
 21 to investigate and refuse suspicious orders of prescription opioids.

22 219. Each Distributor Defendant owes a duty under federal and state law
 23 to report suspicious orders of prescription opioids.

24
 25
 26
 27 ¹²⁴ Healthcare Distribution Management Association (HDMA) Industry
 28 Compliance Guidelines: Reporting Suspicious Orders and Preventing Diversion of
 Controlled Substances, filed in *Cardinal Health, Inc. v. Holder*, No. 12-5061 (D.C.
 Cir. Mar. 7, 2012), Doc. No. 1362415 (App’x B).

1 220. Each Distributor Defendant owes a duty under federal and state law
2 to prevent the diversion of prescription opioids into illicit markets in the State and
3 Plaintiffs' Community.

4 221. The foreseeable harm resulting from a breach of these duties is the
5 diversion of prescription opioids for nonmedical purposes and subsequent plague
6 of opioid addiction.

7 222. The foreseeable harm resulting from the diversion of prescription
8 opioids for nonmedical purposes is abuse, addiction, morbidity and mortality in
9 Plaintiffs' Community and the damages caused thereby.

10 **2. The Distributor Defendants Breached Their Duties.**

11 223. Because distributors handle such large volumes of controlled
12 substances, and are the first major line of defense in the movement of legal
13 pharmaceutical controlled substances from legitimate channels into the illicit
14 market, it is incumbent on distributors to maintain effective controls to prevent
15 diversion of controlled substances. Should a distributor deviate from these checks
16 and balances, the closed system collapses.¹²⁵

17 224. The sheer volume of prescription opioids distributed to pharmacies in
18 the Plaintiffs' Community, and/or to pharmacies from which the Distributor
19 Defendants knew the opioids were likely to be diverted into Plaintiffs'
20 Community, is excessive for the medical need of the community and facially
21 suspicious. Some red flags are so obvious that no one who engages in the
22 legitimate distribution of controlled substances can reasonably claim ignorance of
23 them.¹²⁶

24
25
26 ¹²⁵ See Rannazzisi Decl. ¶ 10, filed in *Cardinal Health, Inc. v. Holder*, No. 1:12-
27 cv-00185-RBW (D.D.C. Feb. 10, 2012), ECF No. 14-2.

28 ¹²⁶ *Masters Pharmaceuticals, Inc.*, 80 Fed. Reg. 55,418-01, 55,482 (Sept. 15, 2015)
(citing *Holiday CVS, L.L.C., d/b/a CVS/Pharmacy Nos. 219 and 5195*, 77 Fed.
Reg. 62,316, 62,322 (2012)).

227. The Distributor Defendants breached their duty to monitor, detect, investigate, refuse and report suspicious orders of prescription opiates originating from Plaintiffs' Community, and/or in areas from which the Distributor Defendants knew opioids were likely to be diverted to Plaintiffs' Community.

229. The Distributor Defendants breached their duty to “design and operate a system to disclose to the registrant suspicious orders of controlled substances” and failed to inform the authorities including the DEA of suspicious orders when discovered, in violation of their duties under federal and state law.

231. The federal and state laws at issue here are public safety laws.

¹²⁷ See *Cardinal Health, Inc. v. Holder*, 846 F. Supp. 2d 203, 206 (D.D.C. 2012).

1 233. The Distributor Defendants supplied prescription opioids to
2 obviously suspicious physicians and pharmacies, enabled the illegal diversion of
3 opioids, aided criminal activity, and disseminated massive quantities of
4 prescription opioids into the black market.

5 234. The unlawful conduct by the Distributor Defendants is purposeful
6 and intentional. The Distributor Defendants refuse to abide by the duties imposed
7 by federal and state law which are required to legally acquire and maintain a
8 license to distribute prescription opiates.

9 235. The Distributor Defendants acted with actual malice in breaching
10 their duties, *i.e.*, they have acted with a conscious disregard for the rights and
11 safety of other persons, and said actions have a great probability of causing
12 substantial harm.

13 236. The Distributor Defendants' repeated shipments of suspicious orders,
14 over an extended period of time, in violation of public safety statutes, and without
15 reporting the suspicious orders to the relevant authorities demonstrates wanton,
16 willful, or reckless conduct or criminal indifference to civil obligations affecting
17 the rights of others.

18 **3. The Distributor Defendants Have Sought to Avoid and Have**
19 **Misrepresented their Compliance with Their Legal Duties.**

20 237. The Distributor Defendants have repeatedly misrepresented their
21 compliance with their legal duties under state and federal law and have wrongfully
22 and repeatedly disavowed those duties in an effort to mislead regulators and the
23 public regarding the Distributor Defendants' compliance with their legal duties.

24 238. Distributor Defendants have refused to recognize any duty beyond
25 *reporting* suspicious orders. In *Masters Pharmaceuticals*, the HDMA, a trade
26 association run by the Distributor Defendants, and the NACDS submitted amicus
27 briefs regarding the legal duty of wholesale distributors. Inaccurately denying the
28

1 legal duties that the wholesale drug industry has been tragically recalcitrant in
2 performing, they argued as follows:

- 3 a. The Associations complained that the “DEA has required distributors
4 not only to report suspicious orders, but to *investigate* orders (e.g., by
5 interrogating pharmacies and physicians) and take action to *halt*
6 suspicious orders before they are filled.”¹²⁸
- 7 b. The Associations argued that, “DEA now appears to have changed its
8 position to require that distributors not only *report* suspicious orders,
9 but *investigate* and *halt* suspicious orders. Such a change in agency
10 position must be accompanied by an acknowledgment of the change
11 and a reasoned explanation for it. In other words, an agency must
12 display awareness that it *is* changing position and show that there are
13 good reasons for the new policy. This is especially important here,
14 because imposing intrusive obligations on distributors threatens to
15 disrupt patient access to needed prescription medications.”¹²⁹
- 16 c. The Associations alleged (inaccurately) that nothing “requires
17 distributors to investigate the legitimacy of orders, or to halt
18 shipment of any orders deemed to be suspicious.”¹³⁰
- 19 d. The Association complained that the purported “practical infeasibility
20 of requiring distributors to investigate and halt suspicious orders (as
21 well as report them) underscores the importance of ensuring that
22 DEA has complied with the APA before attempting to impose such
23 duties.”¹³¹
- 24 e. The Associations alleged (inaccurately) that “DEA’s regulations []
25 sensibly impose[] a duty on distributors simply to *report* suspicious
26 orders, but left it to DEA and its agents to investigate and halt
27 suspicious orders.”¹³²
- 28 f. Also inaccurately, the Associations argued that, “[i]mposing a duty
on distributors – which lack the patient information and the necessary
medical expertise – to investigate and halt orders may force
distributors to take a shot-in-the-dark approach to complying with
DEA’s demands.”¹³³

¹²⁸ Brief for HDMA and NACDS, 2016 WL 1321983, at *4–5.

¹²⁹ *Id.* at *8 (citations and quotation marks omitted).

¹³⁰ *Id.* at *14.

¹³¹ *Id.* at *22.

¹³² *Id.* at *24–25.

¹³³ *Id.* at *26.

1 239. The positions taken by the trade groups is emblematic of the position
2 taken by the Distributor Defendants in a futile attempt to deny their legal
3 obligations to prevent diversion of the dangerous drugs.¹³⁴

4 240. The Court of Appeals for the District of Columbia recently issued its
5 opinion affirming that a wholesale drug distributor does, in fact, have duties
6 beyond reporting. *Masters Pharm., Inc. v. Drug Enf't Admin.*, 861 F.3d 206 (D.C.
7 Cir. 2017). The D.C. Circuit Court upheld the revocation of Master
8 Pharmaceutical's license and determined that DEA regulations require that in
9 addition to reporting suspicious orders, distributors must "decline to ship the
10 order, or conduct some 'due diligence' and—if it is able to determine that the
11 order is not likely to be diverted into illegal channels—ship the order." *Id.* at 212.
12 Master Pharmaceutical was in violation of legal requirements because it failed to
13 conduct necessary investigations and filled suspicious orders. *Id.* at 218–19, 226.
14 A distributor's investigation must dispel all the red flags giving rise to suspicious
15 circumstances prior to shipping a suspicious order. *Id.* at 226. The Circuit Court
16 also rejected the argument made by the HDMA and NACDS (quoted above), that,
17 allegedly, the DEA had created or imposed new duties. *Id.* at 220.

18 241. Wholesale Distributor McKesson has recently been forced to
19 specifically admit to breach of its duties to monitor, report, and prevent suspicious
20 orders. Pursuant to an Administrative Memorandum of Agreement ("2017
21 Agreement") entered into between McKesson and the DEA in January 2017,
22 McKesson admitted that, at various times during the period from January 1, 2009
23 through the effective date of the Agreement (January 17, 2017) it "did not identify
24 or report to [the] DEA certain orders placed by certain pharmacies which should
25 have been detected by McKesson as suspicious based on the guidance contained
26

27
28 ¹³⁴ See Brief of HDMA, 2012 WL 1637016, at *3 (arguing the wholesale distributor industry "does not know the rules of the road because" they claim (inaccurately) that the "DEA has not adequately explained them").

1 in the DEA Letters.”¹³⁵ Further, the 2017 Agreement specifically finds that
 2 McKesson “distributed controlled substances to pharmacies even though those
 3 McKesson Distribution Centers should have known that the pharmacists
 4 practicing within those pharmacies had failed to fulfill their corresponding
 5 responsibility to ensure that controlled substances were dispensed pursuant to
 6 prescriptions issued for legitimate medical purposes by practitioners acting in the
 7 usual course of their professional practice, as required by 21 C.F.R.
 8 § 1306.04(a).”¹³⁶ McKesson admitted that, during this time period, it “failed to
 9 maintain effective controls against diversion of particular controlled substances
 10 into other than legitimate medical, scientific and industrial channels by sales to
 11 certain of its customers in violation of the CSA and the CSA’s implementing
 12 regulations, 21 C.F.R. Part 1300 *et seq.*, at the McKesson Distribution Centers.”¹³⁷
 13 Due to these violations, McKesson agreed that its authority to distribute controlled
 14 substances from numerous facilities would be partially suspended.¹³⁸

15 242. The 2017 Memorandum of Agreement followed a 2008 Settlement
 16 Agreement in which McKesson also admitted failure to report suspicious orders of
 17 controlled substances to the DEA.¹³⁹ In the 2008 Settlement Agreement,
 18 McKesson “recognized that it had a duty to monitor its sales of all controlled
 19 substances and report suspicious orders to DEA,” but had failed to do so.¹⁴⁰ The
 20 2017 Memorandum of Agreement documents that McKesson continued to breach
 21 its admitted duties by “fail[ing] to properly monitor its sales of controlled
 22

23
 24 ¹³⁵ See Administrative Memorandum of Agreement between the U.S. Dep’t of
 Justice, the Drug Enf’t Admin., and the McKesson Corp. (Jan. 17, 2017),
 25 <https://www.justice.gov/opa/press-release/file/928476/download>.

26 ¹³⁶ *Id.* at 4.

27 ¹³⁷ *Id.*

28 ¹³⁸ *Id.* at 6.

¹³⁹ *Id.* at 4.

¹⁴⁰ *Id.*

1 substances and/or report suspicious orders to DEA, in accordance with
 2 McKesson's obligations."¹⁴¹ As a result of these violations, McKesson was fined
 3 and required to pay to the United States \$150,000,000.¹⁴²

4 243. Even though McKesson had been sanctioned in 2008 for failure to
 5 comply with its legal obligations regarding controlling diversion and reporting
 6 suspicious orders, and even though McKesson had specifically agreed in 2008 that
 7 it would no longer violate those obligations, McKesson continued to violate the
 8 laws in contrast to its written agreement not to do so.

9 244. Because of the Distributor Defendants' refusal to abide by their legal
 10 obligations, the DEA has repeatedly taken administrative action to attempt to
 11 force compliance. For example, in May 2014, the United States Department of
 12 Justice, Office of the Inspector General, Evaluation and Inspections Divisions,
 13 reported that the DEA issued final decisions in 178 registrant actions between
 14 2008 and 2012.¹⁴³ The Office of Administrative Law Judges issued a
 15 recommended decision in a total of 117 registrant actions before the DEA issued
 16 its final decision, including 76 actions involving orders to show cause and 41
 17 actions involving immediate suspension orders.¹⁴⁴ These actions include the
 18 following:

- 19 a. On April 24, 2007, the DEA issued an *Order to Show Cause and*
 20 *Immediate Suspension Order* against the AmerisourceBergen
 21 Orlando, Florida distribution center ("Orlando Facility") alleging

22 ¹⁴¹ *Id.*; see also Settlement Agreement and Release between the U.S. and
 23 McKesson Corp., at 5 (Jan. 17, 2017) [hereinafter 2017 Settlement Agreement and
 24 Release] ("McKesson acknowledges that, at various times during the Covered
 25 Time Period [2009-2017], it did not identify or report to DEA certain orders placed
 by certain pharmacies, which should have been detected by McKesson as
 suspicious, in a manner fully consistent with the requirements set forth in the 2008
 MOA."), <https://www.justice.gov/opa/press-release/file/928471/download>.

26 ¹⁴² See 2017 Settlement Agreement and Release, at 6.

27 ¹⁴³ Evaluation and Inspections Div., Office of the Inspector Gen., U.S. Dep't of
 Justice, *The Drug Enforcement Administration's Adjudication of Registrant*
 28 *Actions* 6 (2014), <https://oig.justice.gov/reports/2014/e1403.pdf>.

¹⁴⁴ *Id.*

1 failure to maintain effective controls against diversion of controlled
2 substances. On June 22, 2007, AmerisourceBergen entered into a
3 settlement that resulted in the suspension of its DEA registration;

4 b. On November 28, 2007, the DEA issued an *Order to Show Cause*
5 *and Immediate Suspension Order* against the Cardinal Health
6 Auburn, Washington Distribution Center ("Auburn Facility") for failure to maintain effective controls against diversion of
7 hydrocodone;

8 c. On December 5, 2007, the DEA issued an *Order to Show Cause and*
9 *Immediate Suspension Order* against the Cardinal Health Lakeland,
10 Florida Distribution Center ("Lakeland Facility") for failure to
11 maintain effective controls against diversion of hydrocodone;

12 d. On December 7, 2007, the DEA issued an *Order to Show Cause and*
13 *Immediate Suspension Order* against the Cardinal Health
14 Swedesboro, New Jersey Distribution Center ("Swedesboro
15 Facility") for failure to maintain effective controls against diversion
16 of hydrocodone;

17 e. On January 30, 2008, the DEA issued an *Order to Show Cause and*
18 *Immediate Suspension Order* against the Cardinal Health Stafford,
19 Texas Distribution Center ("Stafford Facility") for failure to maintain
20 effective controls against diversion of hydrocodone;

21 f. On May 2, 2008, McKesson Corporation entered into an
22 *Administrative Memorandum of Agreement* ("2008 MOA") with the
23 DEA which provided that McKesson would "maintain a compliance
24 program designed to detect and prevent the diversion of controlled
25 substances, inform DEA of suspicious orders required by 21 C.F.R. §
26 1301.74(b), and follow the procedures established by its Controlled
27 Substance Monitoring Program";

28 g. On September 30, 2008, Cardinal Health entered into a *Settlement*
and Release Agreement and Administrative Memorandum of
Agreement with the DEA related to its Auburn Facility, Lakeland
Facility, Swedesboro Facility and Stafford Facility. The document
also referenced allegations by the DEA that Cardinal failed to
maintain effective controls against the diversion of controlled
substances at its distribution facilities located in McDonough,
Georgia ("McDonough Facility"), Valencia, California ("Valencia
Facility") and Denver, Colorado ("Denver Facility");

h. On February 2, 2012, the DEA issued an *Order to Show Cause and*
Immediate Suspension Order against the Cardinal Health Lakeland,
Florida Distribution Center ("Lakeland Facility") for failure to
maintain effective controls against diversion of oxycodone;

i. On December 23, 2016, Cardinal Health agreed to pay a \$44 million
fine to the DEA to resolve the civil penalty portion of the
administrative action taken against its Lakeland, Florida Distribution
Center; and

j. On January 5, 2017, McKesson Corporation entered into an
Administrative Memorandum Agreement with the DEA wherein it
agreed to pay a \$150 million civil penalty for violation of the 2008

1 MOA as well as failure to identify and report suspicious orders at its
 2 facilities in Aurora CO, Aurora IL, Delran NJ, LaCrosse WI,
 3 Lakeland FL, Landover MD, La Vista NE, Livonia MI, Methuen
 MA, Santa Fe Springs CA, Washington Courthouse OH and West
 Sacramento CA.

4 245. Rather than abide by their non-delegable duties under public safety
 5 laws, the Distributor Defendants, individually and collectively through trade
 6 groups in the industry, pressured the U.S. Department of Justice to “halt”
 7 prosecutions and lobbied Congress to strip the DEA of its ability to immediately
 8 suspend distributor registrations. The result was a “sharp drop in enforcement
 9 actions” and the passage of the “Ensuring Patient Access and Effective Drug
 10 Enforcement Act” which, ironically, raised the burden for the DEA to revoke a
 11 distributor’s license from “imminent harm” to “immediate harm” and provided the
 12 industry the right to “cure” any violations of law before a suspension order can be
 13 issued.¹⁴⁵

14 246. In addition to taking actions to limit regulatory prosecutions and
 15 suspensions, the Distributor Defendants undertook to fraudulently convince the
 16 public that they were complying with their legal obligations, including those
 17 imposed by licensing regulations. Through such statements, the Distributor
 18 Defendants attempted to assure the public they were working to curb the opioid
 19 epidemic.

20 247. For example, a Cardinal Health executive claimed that it uses
 21 “advanced analytics” to monitor its supply chain, and represented that it was being

22 ¹⁴⁵ See Lenny Bernstein & Scott Higham, *Investigation: The DEA Slowed*
 23 *Enforcement While the Opioid Epidemic Grew Out of Control*, Wash. Post, Oct.
 24 22, 2016, https://www.washingtonpost.com/investigations/the-dea-slowed-enforcement-while-the-opioid-epidemic-grew-out-of-control/2016/10/22/aea2bf8e-7f71-11e6-8d13-d7c704ef9fd9_story.html; Lenny Bernstein & Scott Higham,
 25 *Investigation: U.S. Senator Calls for Investigation of DEA Enforcement Slowdown*
 26 *Amid Opioid Crisis*, Wash. Post, Mar. 6, 2017, https://www.washingtonpost.com/investigations/us-senator-calls-for-investigation-of-dea-enforcement-slowdown/2017/03/06/5846ee60-028b-11e7-b1e9-a05d3c21f7cf_story.html; Eric Eyre, *DEA Agent: “We Had No Leadership” in WV*
 27 *Amid Flood of Pain Pills*, Charleston Gazette-Mail, Feb. 18, 2017,
 28 <http://www.wvgazettemail.com/news/20170218/dea-agent-we-had-no-leadership-in-wv-amid-flood-of-pain-pills->.

1 “as effective and efficient as possible in constantly monitoring, identifying, and
 2 eliminating any outside criminal activity.”¹⁴⁶ Given the sales volumes and the
 3 company’s history of violations, this executive was either not telling the truth, or,
 4 if Cardinal Health had such a system, it ignored the results.

5 248. Similarly, Defendant McKesson publicly stated that it has a “best-in-
 6 class controlled substance monitoring program to help identify suspicious orders,”
 7 and claimed it is “deeply passionate about curbing the opioid epidemic in our
 8 country.”¹⁴⁷ Again, given McKesson’s historical conduct, this statement is either
 9 false, or the company ignored outputs of the monitoring program.

10 249. By misleading the public about the effectiveness of their controlled
 11 substance monitoring programs, the Distributor Defendants successfully
 12 concealed the facts sufficient to arouse suspicion of the claims that the Plaintiffs
 13 now assert. The Plaintiffs did not know of the existence or scope of Defendants’
 14 industry-wide fraud and could not have acquired such knowledge earlier through
 15 the exercise of reasonable diligence.

16 250. Meanwhile, the opioid epidemic rages unabated in the Nation, the
 17 State, and in Plaintiffs’ Community.

18 251. The epidemic still rages because the fines and suspensions imposed
 19 by the DEA do not change the conduct of the industry. The distributors, including
 20 the Distributor Defendants, pay fines as a cost of doing business in an industry
 21 that generates billions of dollars in annual revenue. They hold multiple DEA
 22

23
 24 ¹⁴⁶ Lenny Bernstein et al., *How Drugs Intended for Patients Ended Up in the*
 25 *Hands of Illegal Users: “No One Was Doing Their Job,”* Wash. Post, Oct. 22,
 26 2016, https://www.washingtonpost.com/investigations/how-drugs-intended-for-patients-ended-up-in-the-hands-of-illegal-users-no-one-was-doing-their-job/2016/10/22/10e79396-30a7-11e6-8ff7-7b6c1998b7a0_story.html.

27 ¹⁴⁷ Scott Higham et al., *Drug Industry Hired Dozens of Officials from the DEA as*
 28 *the Agency Tried to Curb Opioid Abuse*, Wash. Post, Dec. 22, 2016,
https://www.washingtonpost.com/investigations/key-officials-switch-sides-from-dea-to-pharmaceutical-industry/2016/12/22/55d2e938-c07b-11e6-b527-949c5893595e_story.html.

1 registration numbers and when one facility is suspended, they simply ship from
2 another facility.

3 252. The wrongful actions and omissions of the Distributor Defendants
4 which have caused the diversion of opioids and which have been a substantial
5 contributing factor to and/or proximate cause of the opioid crisis are alleged in
6 greater detail in the racketeering allegations below.

7 253. The Distributor Defendants have abandoned their duties imposed
8 under federal and state law, taken advantage of a lack of DEA law enforcement,
9 and abused the privilege of distributing controlled substances in the State and
10 Plaintiffs' Community.

11 **4. The National Retail Pharmacies Were on Notice of and**
12 **Contributed to Illegal Diversion of Prescription Opioids**

13 254. National retail pharmacy chains earned enormous profits by flooding
14 the country with prescription opioids.¹⁴⁸ They were keenly aware of the
15 oversupply of prescription opioids through the extensive data and information
16 they developed and maintained as both distributors and dispensaries. Yet, instead
17 of taking any meaningful action to stem the flow of opioids into communities,
18 they continued to participate in the oversupply and profit from it.

19 255. Each of the National Retail Pharmacies does substantial business
20 throughout the United States. This business includes the distribution and
21 dispensing of prescription opioids.

22 256. On information and belief, the National Retail Pharmacies distributed
23 and dispensed substantial quantities of prescription opioids, including fentanyl,
24 hydrocodone, and oxycodone in California. In addition, they distributed and
25 dispensed substantial quantities of prescription opioids in other states, and these
26

27 ¹⁴⁸ The allegations contained in this Complaint are based, in part, on discovery that
28 is in its infancy. Plaintiffs do not have access to transactional ARCOS data for
California. Accordingly, Plaintiffs reserve their right to further amend this
complaint to add supporting allegations, claims and parties.

1 drugs were diverted from these other states to California. The National Retail
2 Pharmacies failed to take meaningful action to stop this diversion despite their
3 knowledge of it, and contributed substantially to the diversion problem.

4 257. The National Retail Pharmacies developed and maintained extensive
5 data on opioids they distributed and dispensed. Through this data, National Retail
6 Pharmacies had direct knowledge of patterns and instances of improper
7 distribution, prescribing, and use of prescription opioids in communities
8 throughout the country, and in California in particular. They used the data to
9 evaluate their own sales activities and workforce. On information and belief, the
10 National Retail Pharmacies also provided Defendants with data regarding, *inter*
11 *alia*, individual doctors in exchange for rebates or other forms of consideration.
12 The National Retail Pharmacies' data is a valuable resource that they could have
13 used to help stop diversion, but failed to do so.

14 **a. The National Retail Pharmacies Have a Duty to Prevent**
15 **Diversion**

16 258. Each participant in the supply chain of opioid distribution, including
17 the National Retail Pharmacies, is responsible for preventing diversion of
18 prescription opioids into the illegal market by, among other things, monitoring
19 and reporting suspicious activity.

20 259. The National Retail Pharmacies, like manufacturers and other
21 distributors, are registrants under the CSA. 21 C.F.R. § 1301.11. Under the CSA,
22 pharmacy registrants are required to "provide effective controls and procedures to
23 guard against theft and diversion of controlled substances." See 21 C.F.R. §
24 1301.71(a). In addition, 21 C.F.R. § 1306.04(a) states, "[t]he responsibility for the
25 proper prescribing and dispensing of controlled substances is upon the prescribing
26 practitioner, but a corresponding responsibility rests with the pharmacist who fills
27 the prescription." Because pharmacies themselves are registrants under the CSA,
28

1 the duty to prevent diversion lies with the pharmacy entity, not the individual
2 pharmacist alone.

3 260. The DEA, among others, has provided extensive guidance to
4 pharmacies concerning their duties to the public. The guidance advises
5 pharmacies how to identify suspicious orders and other evidence of diversion.

6 261. Suspicious pharmacy orders include orders of unusually large size,
7 orders that are disproportionately large in comparison to the population of a
8 community served by the pharmacy, orders that deviate from a normal pattern
9 and/or orders of unusual frequency and duration, among others.

10 262. Additional types of suspicious orders include: (1) prescriptions
11 written by a doctor who writes significantly more prescriptions (or in larger
12 quantities or higher doses) for controlled substances compared to other
13 practitioners in the area; (2) prescriptions which should last for a month in
14 legitimate use, but are being refilled on a shorter basis; (3) prescriptions for
15 antagonistic drugs, such as depressants and stimulants, at the same time; (4)
16 prescriptions that look “too good” or where the prescriber’s handwriting is too
17 legible; (5) prescriptions with quantities or doses that differ from usual medical
18 usage; (6) prescriptions that do not comply with standard abbreviations and/or
19 contain no abbreviations; (7) photocopied prescriptions; or (8) prescriptions
20 containing different handwriting. Most of the time, these attributes are not
21 difficult to detect and should be easily recognizable by pharmacies.

22 263. Suspicious pharmacy orders are red flags for if not direct evidence of
23 diversion.

24 264. Other signs of diversion can be observed through data gathered,
25 consolidated, and analyzed by the National Retail Pharmacies themselves. That
26 data allows them to observe patterns or instances of dispensing that are potentially
27 suspicious, of oversupply in particular stores or geographic areas, or of prescribers
28 or facilities that seem to engage in improper prescribing.

1 265. According to industry standards, if a pharmacy finds evidence of
2 prescription diversion, the local Board of Pharmacy and DEA must be contacted.

3 266. Despite their legal obligations as registrants under the CSA, the
4 National Retail Pharmacies allowed widespread diversion to occur—and they did
5 so knowingly.

6 267. Performance metrics and prescription quotas adopted by the National
7 Retail Pharmacies for their retail stores contributed to their failure. Under CVS's
8 Metrics System, for example, pharmacists are directed to meet high goals that
9 make it difficult, if not impossible, to comply with applicable laws and
10 regulations. There is no measurement for pharmacy accuracy or customer safety.
11 Moreover, the bonuses for pharmacists are calculated, in part, on how many
12 prescriptions that pharmacist fills within a year. The result is both deeply
13 troubling and entirely predictable: opioids flowed out of National Retail
14 Pharmacies and into communities throughout the country. The policies remained
15 in place even as the epidemic raged.

16 268. Upon information and belief, this problem was compounded by the
17 Pharmacies' failure to adequately train their pharmacists and pharmacy
18 technicians on how to properly and adequately handle prescriptions for opioid
19 painkillers, including what constitutes a proper inquiry into whether a prescription
20 is legitimate, whether a prescription is likely for a condition for which the FDA
21 has approved treatments with opioids, and what measures and/or actions to take
22 when a prescription is identified as phony, false, forged, or otherwise illegal, or
23 when suspicious circumstances are present, including when prescriptions are
24 procured and pills supplied for the purpose of illegal diversion and drug
25 trafficking.

26 269. Upon information and belief, the National Retail Pharmacies also
27 failed to adequately use data available to them to identify doctors who were
28 writing suspicious numbers of prescriptions and/or prescriptions of suspicious

1 amounts of opioids, or to adequately use data available to them to do statistical
2 analysis to prevent the filling of prescriptions that were illegally diverted or
3 otherwise contributed to the opioid crisis.

4 270. Upon information and belief, the National Retail Pharmacies failed to
5 analyze: (a) the number of opioid prescriptions filled by individual pharmacies
6 relative to the population of the pharmacy's community; (b) the increase in opioid
7 sales relative to past years; (c) the number of opioid prescriptions filled relative to
8 other drugs; and (d) the increase in annual opioid sales relative to the increase in
9 annual sales of other drugs.

10 271. Upon information and belief, the National Retail Pharmacies also
11 failed to conduct adequate internal or external audits of their opioid sales to
12 identify patterns regarding prescriptions that should not have been filled and to
13 create policies accordingly, or if they conducted such audits, they failed to take
14 any meaningful action as a result.

15 272. Upon information and belief, the National Retail Pharmacies also
16 failed to effectively respond to concerns raised by their own employees regarding
17 inadequate policies and procedures regarding the filling of opioid prescriptions.

18 273. The National Retail Pharmacies were, or should have been, fully
19 aware that the quantity of opioids being distributed and dispensed by them was
20 untenable, and in many areas patently absurd; yet, they did not take meaningful
21 action to investigate or to ensure that they were complying with their duties and
22 obligations under the law with regard to controlled substances.

23 **b. Multiple Enforcement Actions against the National Retail**
24 **Pharmacies Confirm their Compliance Failures.**

25 274. The National Retail Pharmacies have long been on notice of their
26 failure to abide by state and federal law and regulations governing the distribution
27 and dispensing of prescription opioids. Indeed, several of the National Retail
28 Pharmacies have been repeatedly penalized for their illegal prescription opioid

1 practices. Upon information and belief, based upon the widespread nature of these
 2 violations, these enforcement actions are the product of, and confirm, national
 3 policies and practices of the National Retail Pharmacies.

4 **i. CVS**

5 275. CVS is one of the largest companies in the world, with annual
 6 revenue of more than \$150 billion. According to news reports, it manages
 7 medications for nearly 90 million customers at 9,700 retail locations. CVS could
 8 be a force for good in connection with the opioid crisis, but like other Defendants,
 9 CVS sought profits over people.

10 276. CVS is a repeat offender and recidivist: the company has paid fines
 11 totaling over \$40 million as the result of a series of investigations by the DEA and
 12 the United States Department of Justice (“DOJ”). It nonetheless treated these fines
 13 as the cost of doing business and has allowed its pharmacies to continue
 14 dispensing opioids in quantities significantly higher than any plausible medical
 15 need would require, and to continue violating its recordkeeping and dispensing
 16 obligations under the CSA.

17 277. As recently as July 2017, CVS entered into a \$5 million settlement
 18 with the U.S. Attorney’s Office for the Eastern District of California regarding
 19 allegations that its pharmacies failed to keep and maintain accurate records of
 20 Schedule II, III, IV, and V controlled substances.¹⁴⁹

21 278. This fine was preceded by numerous others throughout the country.

22 279. In February 2016, CVS paid \$8 million to settle allegations made by
 23 the DEA and the DOJ that from 2008-2012, CVS stores and pharmacists in
 24
 25
 26

27 ¹⁴⁹ Press Release, U.S. Attorney’s Office E. Dist. of Cal., *CVS Pharmacy Inc. Pays*
 28 *\$5M to Settle Alleged Violations of the Controlled Substance Act*, U.S. Dep’t of
 Just. (July 11, 2017), <https://www.justice.gov/usao-edca/pr/cvs-pharmacy-inc-pays-5m-settle-alleged-violations-controlled-substance-act>.

1 Maryland violated their duties under the CSA and filled prescriptions with no
2 legitimate medical purpose.¹⁵⁰

3 280. In October 2016, CVS paid \$600,000 to settle allegations by the DOJ
4 that stores in Connecticut failed to maintain proper records in accordance with the
5 CSA.¹⁵¹

6 281. In September 2016, CVS entered into a \$795,000 settlement with the
7 Massachusetts Attorney General wherein CVS agreed to require pharmacy staff to
8 access the state's prescription monitoring program website and review a patient's
9 prescription history before dispensing certain opioid drugs.¹⁵²

10 282. In June 2016, CVS agreed to pay the DOJ \$3.5 million to resolve
11 allegations that 50 of its stores violated the CSA by filling forged prescriptions for
12 controlled substances—mostly addictive painkillers—more than 500 times
13 between 2011 and 2014.¹⁵³

14 283. In August 2015, CVS entered into a \$450,000 settlement with the
15 U.S. Attorney's Office for the District of Rhode Island to resolve allegations that
16 several of its Rhode Island stores violated the CSA by filling invalid prescriptions
17 and maintaining deficient records. The United States alleged that CVS retail
18

19
20 ¹⁵⁰ Press Release, U.S. Attorney's Office Dist. of Md., *United States Reaches \$8*
21 *Million Settlement Agreement with CVS for Unlawful Distribution of Controlled*
22 *Substances*, U.S. Dep't of Just. (Feb. 12, 2016), [https://www.justice.gov/usao-](https://www.justice.gov/usao-md/pr/united-states-reaches-8-million-settlement-agreement-cvs-unlawful-distribution-controlled)
23 [md/pr/united-states-reaches-8-million-settlement-agreement-cvs-unlawful-](https://www.justice.gov/usao-md/pr/united-states-reaches-8-million-settlement-agreement-cvs-unlawful-distribution-controlled)
24 [distribution-controlled](https://www.justice.gov/usao-md/pr/united-states-reaches-8-million-settlement-agreement-cvs-unlawful-distribution-controlled).

25 ¹⁵¹ Press Release, U.S. Attorney's Office Dist. of Conn., *CVS Pharmacy Pays*
26 *\$600,000 to Settle Controlled Substances Act Allegations*, U.S. Dep't of Just. (Oct.
27 20, 2016), [https://www.justice.gov/usao-ct/pr/cvs-pharmacy-pays-600000-settle-](https://www.justice.gov/usao-ct/pr/cvs-pharmacy-pays-600000-settle-controlled-substances-act-allegations)
28 [controlled-substances-act-allegations](https://www.justice.gov/usao-ct/pr/cvs-pharmacy-pays-600000-settle-controlled-substances-act-allegations).

¹⁵² Dialynn Dwyer, *CVS will pay \$795,000, strengthen policies around dispensing*
opioids in agreement with state, Boston.com (Sept. 1, 2016),
[https://www.boston.com/news/local-news/2016/09/01/cvs-will-pay-795000-](https://www.boston.com/news/local-news/2016/09/01/cvs-will-pay-795000-strengthen-policies-around-dispensing-opioids-in-agreement-with-state)
[strengthen-policies-around-dispensing-opioids-in-agreement-with-state](https://www.boston.com/news/local-news/2016/09/01/cvs-will-pay-795000-strengthen-policies-around-dispensing-opioids-in-agreement-with-state).

¹⁵³ Press Release, U.S. Attorney's Office Dist. of Mass., *CVS to Pay \$3.5 Million*
to Resolve Allegations that Pharmacists Filled Fake Prescriptions, U.S. Dep't of
Just. (June 30, 2016), [https://www.justice.gov/usao-ma/pr/cvs-pay-35-million-](https://www.justice.gov/usao-ma/pr/cvs-pay-35-million-resolve-allegations-pharmacists-filled-fake-prescriptions)
[resolve-allegations-pharmacists-filled-fake-prescriptions](https://www.justice.gov/usao-ma/pr/cvs-pay-35-million-resolve-allegations-pharmacists-filled-fake-prescriptions).

1 pharmacies in Rhode Island filled a number of forged prescriptions with invalid
 2 DEA numbers, and filled multiple prescriptions written by psychiatric nurse
 3 practitioners for hydrocodone, despite the fact that these practitioners were not
 4 legally permitted to prescribe that drug. Additionally, the government alleged that
 5 CVS had recordkeeping deficiencies.¹⁵⁴

6 284. In May 2015, CVS agreed to pay a \$22 million penalty following a
 7 DEA investigation that found that employees at two pharmacies in Sanford,
 8 Florida, had dispensed prescription opioids, “based on prescriptions that had not
 9 been issued for legitimate medical purposes by a health care provider acting in the
 10 usual course of professional practice. CVS also acknowledged that its retail
 11 pharmacies had a responsibility to dispense only those prescriptions that were
 12 issued based on legitimate medical need.”¹⁵⁵

13 285. In September 2014, CVS agreed to pay \$1.9 million in civil penalties
 14 to resolve allegations it filled prescriptions written by a doctor whose controlled-
 15 substance registration had expired.¹⁵⁶

16 286. In August 2013, CVS was fined \$350,000 by the Oklahoma
 17 Pharmacy Board for improperly selling prescription narcotics in at least five
 18 locations in the Oklahoma City metropolitan area.¹⁵⁷

19
 20
 21 ¹⁵⁴ Press Release, U.S. Attorney’s Office Dist. of R.I., Drug Diversion Claims
 22 Against CVS Health Corp. Resolved With \$450,000 Civil Settlement, U.S. Dep’t
 23 of Just. (Aug. 10, 2015), <https://www.justice.gov/usao-ri/pr/drug-diversion-claims-against-cvs-health-corp-resolved-450000-civil-settlement>.

24 ¹⁵⁵ Press Release, U.S. Attorney’s Office M. Dist. of Fla., United States Reaches
 25 \$22 Million Settlement Agreement With CVS For Unlawful Distribution of
 26 Controlled Substances, U.S. Dep’t of Just. (May 13, 2015),
 27 <https://www.justice.gov/usao-mdfl/pr/united-states-reaches-22-million-settlement-agreement-cvs-unlawful-distribution>.

28 ¹⁵⁶ Patrick Danner, *H-E-B, CVS Fined Over Prescriptions*, San Antonio Express-
 News (Sept. 5, 2014), <http://www.expressnews.com/business/local/article/H-E-BCVS-fined-over-prescriptions-5736554.php>.

¹⁵⁷ Andrew Knittle, *Oklahoma pharmacy board stays busy, hands out massive fines at times*, NewsOK (May 3, 2015), <http://newsok.com/article/5415840>.

1 287. Dating back to 2006, CVS retail pharmacies in Oklahoma and
2 elsewhere intentionally violated the CSA by filling prescriptions signed by
3 prescribers with invalid DEA registration numbers.¹⁵⁸

4 **ii. Walgreens**

5 288. Walgreens is the second-largest pharmacy store chain in the United
6 States behind CVS, with annual revenue of more than \$118 billion. According to
7 its website, Walgreens operates more than 8,100 retail locations and filled 990
8 million prescriptions on a 30-day adjusted basis in fiscal 2017.

9 289. Walgreens also has been penalized for serious and flagrant violations
10 of the CSA. Indeed, Walgreens agreed to the largest settlement in DEA history—
11 \$80 million—to resolve allegations that it committed an unprecedented number of
12 recordkeeping and dispensing violations of the CSA, including negligently
13 allowing controlled substances such as oxycodone and other prescription
14 painkillers to be diverted for abuse and illegal black market sales.¹⁵⁹

15 290. The settlement resolved investigations into and allegations of CSA
16 violations in Florida, New York, Michigan, and Colorado that resulted in the
17 diversion of millions of opioids into illicit channels.

18 291. Walgreens' Florida operations at issue in this settlement highlight its
19 egregious conduct regarding diversion of prescription opioids. Walgreens' Florida
20
21
22

23
24 ¹⁵⁸ Press Release, U.S. Attorney's Office W. Dist. of Okla., CVS to Pay \$11
25 Million To Settle Civil Penalty Claims Involving Violations of Controlled
26 Substances Act, U.S. Dep't of Just. (Apr. 3, 2013), <https://www.justice.gov/usao-wdok/pr/cvs-pay-11-million-settle-civil-penalty-claims-involving-violations-controlled>.

27 ¹⁵⁹ Press Release, U.S. Attorney's Office S. Dist. of Fla., *Walgreens Agrees To Pay*
28 *A Record Settlement Of \$80 Million For Civil Penalties Under The Controlled*
Substances Act, U.S. Dep't of Just. (June 11, 2013), <https://www.justice.gov/usao-sdfl/pr/walgreens-agrees-pay-record-settlement-80-million-civil-penalties-under-controlled>.

1 pharmacies each allegedly ordered more than one million dosage units of
2 oxycodone in 2011—more than ten times the average amount.¹⁶⁰

3 292. They increased their orders over time, in some cases as much as
4 600% in the space of just two years, including, for example, supplying a town of
5 3,000 with 285,800 orders of oxycodone in a one-month period. Yet Walgreens
6 corporate officers turned a blind eye to these abuses. In fact, corporate attorneys
7 at Walgreens suggested, in reviewing the legitimacy of prescriptions coming from
8 pain clinics, that “if these are legitimate indicators of inappropriate prescriptions
9 perhaps we should consider not documenting our own potential noncompliance,”
10 underscoring Walgreens’ attitude that profit outweighed compliance with the CSA
11 or the health of communities.¹⁶¹

12 293. Defendant Walgreens’ settlement with the DEA stemmed from the
13 DEA’s investigation into Walgreens’ distribution center in Jupiter, Florida, which
14 was responsible for significant opioid diversion in Florida. According to the Order
15 to Show Cause, Defendant Walgreens’ corporate headquarters pushed to increase
16 the number of oxycodone sales to Walgreens’ Florida pharmacies, and provided
17 bonuses for pharmacy employees based on number of prescriptions filled at the
18 pharmacy in an effort to increase oxycodone sales. In July 2010, Defendant
19 Walgreens ranked all of its Florida stores by number of oxycodone prescriptions
20 dispensed in June of that year, and found that the highest-ranking store in
21 oxycodone sales sold almost 18 oxycodone prescriptions per day. All of these
22 prescriptions were filled by the Jupiter Center.¹⁶²

23
24
25
26 ¹⁶⁰ Order to Show Cause and Immediate Suspension of Registration, *In the Matter*
27 *of Walgreens Co.* (Drug Enf’t Admin. Sept. 13, 2012).

28 ¹⁶¹ *Id.*

¹⁶² *Id.*

294. Walgreens has also settled with a number of state attorneys general, including West Virginia (\$575,000) and Massachusetts (\$200,000).¹⁶³

295. The Massachusetts Attorney General's Medicaid Fraud Division found that, from 2010 through most of 2015, multiple Walgreens stores across the state failed to monitor the opioid use of some Medicaid patients who were considered high-risk.

296. In January 2017, an investigation by the Massachusetts Attorney General found that some Walgreens pharmacies failed to monitor patients' drug use patterns and didn't use sound professional judgment when dispensing opioids and other controlled substances—despite the context of soaring overdose deaths in Massachusetts. Walgreens agreed to pay \$200,000 and follow certain procedures for dispensing opioids.¹⁶⁴

iii. Rite Aid

297. With approximately 4,600 stores in 31 states and the District of Columbia, Rite Aid is the largest drugstore chain on the East Coast and the third-largest in the United States, with annual revenue of more than \$21 billion.

298. In 2009, as a result of a multi-jurisdictional investigation by the DOJ, Rite Aid and nine of its subsidiaries in eight states were fined \$5 million in civil penalties for its violations of the CSA.¹⁶⁵

299. The investigation revealed that from 2004 onwards, Rite Aid pharmacies across the country had a pattern of non-compliance with the requirements of the CSA and federal regulations that led to the diversion of

¹⁶³ *Walgreens to pay \$200,000 settlement for lapses with opioids*, APhA (Jan. 25, 2017), <https://www.pharmacist.com/article/walgreens-pay-200000-settlement-lapses-opioids>.

¹⁶⁴ *Id.*

¹⁶⁵ Press Release, Dep't of Just., *Rite Aid Corporation and Subsidiaries Agree to Pay \$5 Million in Civil Penalties to Resolve Violations in Eight States of the Controlled Substances Act*, U.S. Dep't of Just. (Jan. 12, 2009), <https://www.justice.gov/opa/pr/rite-aid-corporation-and-subsidiaries-agree-pay-5-million-civil-penalties-resolve-violations>.

1 prescription opioids in and around the communities of the Rite Aid pharmacies
2 investigated. Rite Aid also failed to notify the DEA of losses of controlled
3 substances in violation of 21 USC 842(a)(5) and 21 C.F.R 1301.76(b).¹⁶⁶

4 300. Numerous state and federal drug diversion prosecutions have
5 occurred in which prescription opioid pills were procured from National Retail
6 Pharmacies. The allegations in this Complaint do not attempt to identify all these
7 prosecutions, and the information above is merely by way of example.

8 301. The litany of state and federal actions against the National Retail
9 Pharmacies demonstrate that they routinely, and as a matter of standard operating
10 procedure, violated their legal obligations under the CSA and other laws and
11 regulations that govern the distribution and dispensing of prescription opioids.

12 302. Throughout the country and the State, the National Retail Pharmacies
13 were or should have been aware of numerous red flags of potential suspicious
14 activity and diversion.

15 303. On information and belief, from the catbird seat of their retail
16 pharmacy operations, the National Retail Pharmacies knew or reasonably should
17 have known about the disproportionate flow of opioids into California and the
18 operation of “pill mills” that generated opioid prescriptions that, by their quantity
19 or nature, were red flags for if not direct evidence of illicit supply and diversion.
20 Additional information was provided by news reports, and state and federal
21 regulatory actions, including prosecutions of pill mills in the area.

22 304. On information and belief, the National Retail Pharmacies knew or
23 reasonably should have known about the devastating consequences of the
24 oversupply and diversion of prescription opioids, including spiking opioid
25 overdose rates in the community.

26
27
28

¹⁶⁶ *Id.*

1 305. On information and belief, because of (among others sources of
 2 information) regulatory and other actions taken against the National Retail
 3 Pharmacies directly, actions taken against others pertaining to prescription opioids
 4 obtained from their retail stores, complaints and information from employees and
 5 other agents, and the massive volume of opioid prescription drug sale data that
 6 they developed and monitored, the National Retail Pharmacies were well aware
 7 that their distribution and dispensing activities fell far short of legal requirements.

8 306. The National Retail Pharmacies' actions and omission in failing to
 9 effectively prevent diversion and failing to monitor, report, and prevent suspicious
 10 orders have contributed significantly to the opioid crisis by enabling, and failing
 11 to prevent, the diversion of opioids.

12 **D. THE MANUFACTURER DEFENDANTS' UNLAWFUL FAILURE**
 13 **TO PREVENT DIVERSION AND MONITOR, REPORT, AND**
 14 **PREVENT SUSPICIOUS ORDERS.**

15 307. The same legal duties to prevent diversion, and to monitor, report,
 16 and prevent suspicious orders of prescription opioids that were incumbent upon
 17 the Distributor Defendants were also legally required of the Manufacturer
 18 Defendants under federal law.

19 308. Under federal law, the Manufacturing Defendants were required to
 20 comply with the same licensing requirements and with the same rules regarding
 21 prevention of diversion and reporting suspicious orders, as set out above.

22 309. Like the Distributor Defendants, the Manufacturer Defendants were
 23 required to register with the DEA to manufacture schedule II controlled
 24 substances, like prescription opioids. *See* 21 U.S.C. § 823(a). A requirement of
 25 such registration is the:

26 maintenance of effective controls against diversion of particular
 27 controlled substances and any controlled substance in schedule I or II
 28 compounded therefrom into other than legitimate medical, scientific,
 research, or industrial channels, by limiting the importation and bulk
 manufacture of such controlled substances to a number of
 establishments which can produce an adequate and uninterrupted

1 supply of these substances under adequately competitive conditions
2 for legitimate medical, scientific, research, and industrial purposes . . .

3 21 U.S.C. § 823(a)(1) (emphasis added).

4 310. Additionally, as “registrants” under Section 823, the Manufacturer
5 Defendants were also required to monitor, report, and prevent suspicious orders of
6 controlled substances:

7 The registrant shall design and operate a system to disclose to the
8 registrant suspicious orders of controlled substances. The registrant
9 shall inform the Field Division Office of the Administration in his
area of suspicious orders when discovered by the registrant.
Suspicious orders include orders of unusual size, orders deviating
substantially from a normal pattern, and orders of unusual frequency.

10 21 C.F.R. § 1301.74. *See also* 21 C.F.R. § 1301.02 (“Any term used in this part
11 shall have the definition set forth in section 102 of the Act (21 U.S.C. 802) or part
12 1300 of this chapter.”); 21 C.F.R. § 1300.01 (“Registrant means any person who is
13 registered pursuant to either section 303 or section 1008 of the Act (21 U.S.C. 823
14 or 958).” Like the Distributor Defendants, the Manufacture Defendants breached
15 these duties.

16 311. The Manufacturer Defendants had access to and possession of the
17 information necessary to monitor, report, and prevent suspicious orders and to
18 prevent diversion. The Manufacturer Defendants engaged in the practice of
19 paying “chargebacks” to opioid distributors. A chargeback is a payment made by
20 a manufacturer to a distributor after the distributor sells the manufacturer’s
21 product at a price below a specified rate. After a distributor sells a manufacturer’s
22 product to a pharmacy, for example, the distributor requests a chargeback from the
23 manufacturer and, in exchange for the payment, the distributor identifies to the
24 manufacturer the product, volume and the pharmacy to which it sold the product.
25 Thus, the Manufacturer Defendants knew – just as the Distributor Defendants
26 knew – the volume, frequency, and pattern of opioid orders being placed and
27 filled. The Manufacturer Defendants built receipt of this information into the
28 payment structure for the opioids provided to the opioid distributors.

1 312. Federal statutes and regulations are clear: just like opioid
2 distributors, opioid manufacturers are required to “design and operate a system to
3 disclose . . . suspicious orders of controlled substances” and to maintain “effective
4 controls against diversion.” 21 C.F.R. § 1301.74; 21 U.S.C. § 823(a)(1).

5 313. The Department of Justice has recently confirmed the suspicious
6 order obligations clearly imposed by federal law upon opioid manufacturers,
7 fining Mallinckrodt \$35 million for failure to report suspicious orders of
8 controlled substances, including opioids, and for violating recordkeeping
9 requirements.¹⁶⁷

10 314. In the press release accompanying the settlement, the Department of
11 Justice stated: Mallinckrodt “did not meet its obligations to detect and notify DEA
12 of suspicious orders of controlled substances such as oxycodone, the abuse of
13 which is part of the current opioid epidemic. These suspicious order monitoring
14 requirements exist to prevent excessive sales of controlled substances, like
15 oxycodone Mallinckrodt’s actions and omissions formed a link in the chain
16 of supply that resulted in millions of oxycodone pills being sold on the street. . . .
17 ‘Manufacturers and distributors have a crucial responsibility to ensure that
18 controlled substances do not get into the wrong hands. . . .’”¹⁶⁸

19 315. Among the allegations resolved by the settlement, the government
20 alleged “Mallinckrodt failed to design and implement an effective system to detect
21 and report ‘suspicious orders’ for controlled substances – orders that are unusual
22 in their frequency, size, or other patterns . . . [and] Mallinckrodt supplied
23 distributors, and the distributors then supplied various U.S. pharmacies and pain
24

25
26 ¹⁶⁷ See Press Release, U.S. Dep’t of Justice, Mallinckrodt Agrees to Pay Record
27 \$35 Million Settlement for Failure to Report Suspicious Orders of Pharmaceutical
28 Drugs and for Recordkeeping Violations (July 11, 2017),
<https://www.justice.gov/opa/pr/mallinckrodt-agrees-pay-record-35-million-settlement-failure-report-suspicious-orders>.

¹⁶⁸ *Id.* (quoting DEA Acting Administrator Chuck Rosenberg).

1 clinics, an increasingly excessive quantity of oxycodone pills without notifying
2 DEA of these suspicious orders.”¹⁶⁹

3 316. The Memorandum of Agreement entered into by Mallinckrodt
4 (“2017 Mallinckrodt MOA”) avers “[a]s a registrant under the CSA, Mallinckrodt
5 had a responsibility to maintain effective controls against diversion, including a
6 requirement that it review and monitor these sales and report suspicious orders to
7 DEA.”¹⁷⁰

8 317. The 2017 Mallinckrodt MOA further details the DEA’s allegations
9 regarding Mallinckrodt’s failures to fulfill its legal duties as an opioid
10 manufacturer:

11 With respect to its distribution of oxycodone and hydrocodone
12 products, Mallinckrodt’s alleged failure to distribute these controlled
13 substances in a manner authorized by its registration and
14 Mallinckrodt’s alleged failure to operate an effective suspicious order
15 monitoring system and to report suspicious orders to the DEA when
16 discovered as required by and in violation of 21 C.F.R. § 1301.74(b).
17 The above includes, but is not limited to Mallinckrodt’s alleged failure
18 to:

- 19 i. conduct adequate due diligence of its customers;
- 20 ii. detect and report to the DEA orders of unusual size and
21 frequency;
- 22 iii. detect and report to the DEA orders deviating substantially
23 from normal patterns including, but not limited to, those
24 identified in letters from the DEA Deputy Assistant
25 Administrator, Office of Diversion Control, to registrants dated
26 September 27, 2006 and December 27, 2007:
 - 27 1. orders that resulted in a disproportionate amount of a
28 substance which is most often abused going to a
particular geographic region where there was known
diversion,

26 ¹⁶⁹ *Id.*

27 ¹⁷⁰ Administrative Memorandum of Agreement between the United States
28 Department of Justice, the Drug Enforcement Agency, and Mallinckrodt, plc. and
its subsidiary Mallinckrodt, LLC (July 10, 2017), <https://www.justice.gov/usao-edmi/press-release/file/986026/download> (“2017 Mallinckrodt MOA”).

2. orders that purchased a disproportionate amount of a substance which is most often abused compared to other products, and
3. orders from downstream customers to distributors who were purchasing from multiple different distributors, of which Mallinckrodt was aware;
- iv. use "chargeback" information from its distributors to evaluate suspicious orders. Chargebacks include downstream purchasing information tied to certain discounts, providing Mallinckrodt with data on buying patterns for Mallinckrodt products; and
- v. take sufficient action to prevent recurrence of diversion by downstream customers after receiving concrete information of diversion of Mallinckrodt product by those downstream customers.¹⁷¹

318. Mallinckrodt agreed that its “system to monitor and detect suspicious orders did not meet the standards outlined in letters from the DEA Deputy Administrator, Office of Diversion Control, to registrants dated September 27, 2006 and December 27, 2007.” Mallinckrodt further agreed that it “recognizes the importance of the prevention of diversion of the controlled substances they manufacture” and would “design and operate a system that meets the requirements of 21 CFR 1301.74(b) . . . [such that it would] utilize all available transaction information to identify suspicious orders of any Mallinckrodt product. Further, Mallinckrodt agrees to notify DEA of any diversion and/or suspicious circumstances involving any Mallinckrodt controlled substances that Mallinckrodt discovers.”¹⁷²

319. Mallinckrodt acknowledged that “[a]s part of their business model Mallinckrodt collects transaction information, referred to as chargeback data, from their direct customers (distributors). The transaction information contains data relating to the direct customer sales of controlled substances to ‘downstream’

¹⁷¹ 2017 Mallinckrodt MOA at 2-3.

¹⁷² *Id.* at 3-4.

1 registrants.” Mallinckrodt agreed that, from this data, it would “report to the DEA
2 when Mallinckrodt concludes that the chargeback data or other information
3 indicates that a downstream registrant poses a risk of diversion.”¹⁷³

4 320. The same duties imposed by federal law on Mallinckrodt were
5 imposed upon all Manufacturer Defendants.

6 321. The same business practices utilized by Mallinckrodt regarding
7 “charge backs” and receipt and review of data from opioid distributors regarding
8 orders of opioids were utilized industry-wide among opioid manufacturers and
9 distributors, including, upon information and belief, the other Manufacturer
10 Defendants.

11 322. Through, *inter alia*, the charge back data, the Manufacturer
12 Defendants could monitor suspicious orders of opioids.

13 323. The Manufacturer Defendants failed to monitor, report, and halt
14 suspicious orders of opioids as required by federal and state law.

15 324. The Manufacturer Defendants’ failures to monitor, report, and halt
16 suspicious orders of opioids were intentional and unlawful.

17 325. The Manufacturer Defendants have misrepresented their compliance
18 with federal and state law.

19 326. The Manufacturer Defendants enabled the supply of prescription
20 opioids to obviously suspicious physicians and pharmacies, enabled the illegal
21 diversion of opioids, aided criminal activity, and disseminated massive quantities
22 of prescription opioids into the black market.

23 327. The wrongful actions and omissions of the Manufacturer Defendants
24 which have caused the diversion of opioids and which have been a substantial
25 contributing factor to and/or proximate cause of the opioid crisis are alleged in
26 greater detail in the racketeering allegations below.

27
28

¹⁷³ *Id.* at 5.

1 328. The Manufacturer Defendants’ actions and omissions in failing to
 2 effectively prevent diversion and failing to monitor, report, and prevent suspicious
 3 orders have enabled the unlawful diversion of opioids into Plaintiffs’ Community.

4 **E. DEFENDANTS’ UNLAWFUL CONDUCT AND BREACHES OF**
 5 **LEGAL DUTIES CAUSED THE HARM ALLEGED HEREIN AND**
 6 **SUBSTANTIAL DAMAGES.**

7 329. As the Manufacturer Defendants’ efforts to expand the market for
 8 opioids increased so have the rates of prescription and sale of their products —
 9 and the rates of opioid-related substance abuse, hospitalization, and death among
 10 the people of the State and the Plaintiffs’ Community. The Distributor Defendants
 11 have continued to unlawfully ship these massive quantities of opioids into
 12 communities like the Plaintiffs’ Community, fueling the epidemic.

13 330. There is a “parallel relationship between the availability of
 14 prescription opioid analgesics through legitimate pharmacy channels and the
 15 diversion and abuse of these drugs and associated adverse outcomes.”¹⁷⁴

16 331. Opioid analgesics are widely diverted and improperly used, and the
 17 widespread use of the drugs has resulted in a national epidemic of opioid overdose
 18 deaths and addictions.¹⁷⁵

19 332. The epidemic is “directly related to the increasingly widespread
 20 misuse of powerful opioid pain medications.”¹⁷⁶

21 333. The increased abuse of prescription painkillers along with growing
 22 sales has contributed to a large number of overdoses and deaths.¹⁷⁷

24 ¹⁷⁴ See Richard C. Dart et al., Trends in Opioid Analgesic Abuse and Mortality in
 25 the United States, 372 N. Eng. J. Med. 241 (2015).

26 ¹⁷⁵ See Nora D. Volkow & A. Thomas McLellan, *Opioid Abuse in Chronic Pain—*
Misconceptions and Mitigation Strategies, 374 N. Eng. J. Med. 1253 (2016).

27 ¹⁷⁶ See Robert M. Califf et al., *A Proactive Response to Prescription Opioid Abuse*,
 374 N. Eng. J. Med. 1480 (2016).

28 ¹⁷⁷ See Press Release, Ctrs. for Disease Control and Prevention, U.S. Dep’t of
 Health and Human Servs., Prescription Painkiller Overdoses at Epidemic Levels

1 334. As shown above, the opioid epidemic has escalated in Plaintiffs'
2 Community with devastating effects. Substantial opiate-related substance abuse,
3 hospitalization and death mirrors Defendants' increased distribution of opiates.

4 335. Because of the well-established relationship between the use of
5 prescription opiates and the use of non-prescription opioids, like heroin, the
6 massive distribution of opioids to Plaintiffs' Community and areas from which
7 such opioids are being diverted into Plaintiffs' Community, has caused the
8 Defendant-caused opioid epidemic to include heroin addiction, abuse, and death.

9 336. Prescription opioid abuse, addiction, morbidity, and mortality are
10 hazards to public health and safety in the State and in Plaintiffs' Community.

11 337. Heroin abuse, addiction, morbidity, and mortality are hazards to
12 public health and safety in the State and in Plaintiffs' Community.

13 338. Defendants repeatedly and purposefully breached their duties under
14 state and federal law, and such breaches are direct and proximate causes of, and/or
15 substantial factors leading to, the widespread diversion of prescription opioids for
16 nonmedical purposes into the Plaintiffs' Community.

17 339. The unlawful diversion of prescription opioids is a direct and
18 proximate cause of, and/or substantial factor leading to, the opioid epidemic,
19 prescription opioid abuse, addiction, morbidity and mortality in the State and
20 Plaintiffs' Community. This diversion and the epidemic are direct causes of
21 foreseeable harms incurred by the Plaintiffs and Plaintiffs' Community.

22 340. Defendants' intentional and/or unlawful conduct resulted in direct
23 and foreseeable, past and continuing, economic damages for which Plaintiffs seek
24 relief, as alleged herein. Plaintiffs also seek the means to abate the epidemic
25 created by Defendants' wrongful and/or unlawful conduct.

26
27
28 (Nov. 1, 2011),
https://www.cdc.gov/media/releases/2011/p1101_flu_pain_killer_overdose.html.

1 341. The County seeks economic damages from the Defendants as
2 reimbursement for the costs associated with damage to its property and past
3 efforts to eliminate the hazards to public health and safety.

4 342. Plaintiffs seek economic damages from the Defendants to pay for the
5 cost to permanently eliminate the hazards to public health and safety and abate the
6 temporary public nuisance.

7 343. To eliminate the hazard to public health and safety, and abate the
8 public nuisance, a “multifaceted, collaborative public health and law enforcement
9 approach is urgently needed.”¹⁷⁸

10 344. A comprehensive response to this crisis must focus on preventing
11 new cases of opioid addiction, identifying early opioid-addicted individuals, and
12 ensuring access to effective opioid addiction treatment while safely meeting the
13 needs of patients experiencing pain.¹⁷⁹

14 345. These community-based problems require community-based
15 solutions that have been limited by “budgetary constraints at the state and Federal
16 levels.”¹⁸⁰

17 346. Having profited enormously through the aggressive sale, misleading
18 promotion, and irresponsible distribution of opiates, Defendants should be
19 required to take responsibility for the financial burdens their conduct has inflicted
20 upon the Plaintiffs and Plaintiffs’ Community.

21
22
23 ¹⁷⁸ See Rose A. Rudd et al., *Increases in Drug and Opioid Overdose Deaths—*
24 *United States, 2000–2014*, 64 Morbidity & Mortality Wkly. Rep. 1378 (2016), at 1145.

25 ¹⁷⁹ See Johns Hopkins Bloomberg School of Public Health, *The Prescription*
26 *Opioid Epidemic: An Evidence-Based Approach* (G. Caleb Alexander et al. eds.,
27 2015), http://www.jhsph.edu/research/centers-and-institutes/center-for-drug-safety-and-effectiveness/research/prescription-opioids/JHSPH_OPIOID_EPIDEMIC_REPORT.pdf.

28 ¹⁸⁰ See Office of Nat’l Drug Control Policy, Exec. Office of the President, *Epidemic: Responding to America’s Prescription Drug Abuse Crisis* (2011), https://www.ncjrs.gov/pdffiles1/ondcp/rx_abuse_plan.pdf.

**F. DEFENDANTS' FRAUDULENT AND DECEPTIVE MARKETING
OF OPIOIDS DIRECTLY CAUSED HARM TO THE COUNTY.**

347. In the first instance, Plaintiff The County was damaged directly, through its payments of false claims for chronic opioid therapy by its workers' compensation program.

348. The Defendants' marketing of opioids caused health care providers to prescribe and Plaintiff, through its workers' compensation program, to pay for prescriptions of opioids to treat chronic pain. Because of the Defendants' unbranded marketing, health care providers wrote and the County paid for prescriptions opioids for chronic pain that were filled not only with their drugs, but with opioids sold by other manufacturers. All of these prescriptions were caused by Defendants' fraudulent marketing and therefore all of them constitute false claims. Because, as laid out below, The County is obligated to cover medically necessary and reasonably required care, it had no choice but to pay these false and fraudulent claims.

349. The fact that the County would pay for these ineligible prescriptions is both the foreseeable and intended consequence of the Defendants' fraudulent marketing scheme. The Defendants set out to change the medical and general consensus supporting chronic opioid therapy *so that* doctors would prescribe and government payors, such as the County, would pay for long-term prescriptions of opioids to treat chronic pain despite the absence of genuine evidence supporting chronic opioid therapy and the contrary evidence regarding the significant risks and limited benefits from long-term use of opioids.

1. Increase in Opioid Prescribing Nationally

350. Defendants' scheme to change the medical consensus regarding opioid therapy for chronic pain worked. During the year 2000, outpatient retail pharmacies filled 174 million prescriptions for opioids nationwide. During 2009, they provided 83 million more.

1 351. Opioid prescriptions increased even as the percentage of patients
2 visiting the doctor for pain remained constant.

3 352. A study of 7.8 million doctor visits between 2000 and 2010 found
4 that opioid prescriptions increased from 11.3% to 19.6% of visits, as NSAID and
5 acetaminophen prescriptions fell from 38% to 29%, driven primarily by the
6 decline in NSAID prescribing.¹⁸¹

7 353. Approximately 20% of the population between the ages of 30 and 44
8 and nearly 30% of the population over 45 have used opioids. Indeed, “[o]pioids
9 are the most common means of treatment for chronic pain.”¹⁸² From 1980 to 2000,
10 opioid prescriptions for chronic pain visits doubled. This is the result not of an
11 epidemic of pain, but an epidemic of prescribing. A study of 7.8 million doctor
12 visits found that prescribing for pain increased by 73% between 2000 and 2010 –
13 even though the number of office visits in which patients complained of pain did
14 not change and prescribing of non-opioid pain medications decreased. For back
15 pain alone – one of the most common chronic pain conditions – the percentage of
16 patients prescribed opioids increased from 19% to 29% between 1999 and 2010,
17 even as the use of NSAIDs, or acetaminophen declined and referrals to physical
18 therapy remained steady – and climbing.

19 354. This increase corresponds with, and was caused by, the Defendants’
20 massive marketing push. The industry’s spending nationwide on marketing of
21 opioids stood at more than \$20 million per quarter and \$91 million annually in
22 2000. By 2011, that figure hit its peak of more than \$70 million per quarter and
23 \$288 million annually, a more than three-fold increase. By 2014, the figures
24 dropped to roughly \$45 million per quarter and \$182 million annually, as the
25

26 ¹⁸¹ Matthew Daubress et al., *Ambulatory Diagnosis and Treatment of*
27 *Nonmalignant Pain in the United States, 2000-2010*, 51 (10) *Med. Care* 870
(2013).

28 ¹⁸² Deborah Grady et al., *Opioids for Chronic Pain*, 171 (16) *Arch. Intern. Med.*
1426 (2011).

1 Defendants confronted increased concern regarding opioid addiction, abuse, and
2 diversion. Even so, the Defendants still spend double what they spent in 2000 on
3 opioid marketing.

4 355. By far the largest component of this spending was opioid drug
5 makers' detailing visits to individual doctors, with total detailing expenditures
6 more than doubling between 2000 and 2014 and now standing at \$168 million
7 annually.

8 **2. The County's Increased Spending on Opioids through Self-Insured**
9 **Worker's Compensation Program.**

10 356. Commensurate with the Defendants' heavy promotion of opioids and
11 the resultant massive upswing in prescribing of opioids nationally, the County has
12 seen its own spending on opioids – through claims paid by its worker's
13 compensation program – increase.

14 **i. Workers' Compensation Programs**

15 357. Plaintiff The County, through a partially self-insured program,
16 provides workers' compensation, including prescription drug benefits, to eligible
17 employees injured in the course of their employment. When an employee is
18 injured on the job, he or she may file a claim for workers' compensation, and if
19 the injury is deemed work-related, The County is responsible for paying its share
20 of the employee's medical costs and lost wages.

21 358. The County uses a third party vendor to help manage medical
22 benefits under the workers' compensation program. Doctors submit claims to the
23 County's workers' compensation program for the costs associated with
24 prescribing opioids, including office visits and toxicology screens for patients
25 prescribed opioids.

26 359. Upon information and belief, the County's vendor uses a pharmacy
27 and drug utilization management program to manage prescriptions for the
28 County's workers' compensation program.

1 360. The County's workers' compensation program covers all costs
2 associated with opioids, including treatment related to any adverse outcomes from
3 chronic opioid therapy, such as addiction treatment.

4 361. The Defendants cause doctors and pharmacies to submit, and the
5 County to pay claims to its workers' compensation program that were false by: (a)
6 causing doctors to write prescriptions for chronic opioid therapy based on
7 deceptive representations regarding the risks, benefits, and superiority of those
8 drugs; (b) causing doctors to certify that these prescriptions and associated
9 services were medically necessary; (c) causing claims to be submitted for drugs
10 that were promoted for off-label uses and misbranded, and therefore not FDA-
11 approved; and (d) distorting the standard of care for treatment of chronic pain so
12 that doctors would feel not only that it was appropriate, but required, that they
13 prescribe and continue prescriptions for opioids long-term to treat chronic pain.
14 Each – or any – of these factors made claims to the County for chronic opioid
15 therapy false.

16 362. The California Workers' Compensation law requires employers or
17 their insurers to pay for, *inter alia*, medical and surgical services, hospital and
18 nursing services, and medicines that are reasonably required to cure or relieve the
19 injured worker from the effects of his or her injury. Cal. Lab. Code § 4600.

20 363. In prescribing opioids for chronic pain, doctors certify that the
21 treatment is medically necessary and reasonably required, and the workers'
22 compensation program authorizes payment from The County's funds.

23 364. The County's workers' compensation program is obligated to cover
24 all "medically necessary" and "reasonably required" treatment arising from a
25 compensable work-related injury.

26 365. As described above, however, the use of opioids to treat chronic pain
27 is not medically necessary or reasonably required in that their risks do not
28 materially exceed their benefits; they do not improve physiological function; and

1 their use is not consistent with guidelines that are *scientifically based* (as opposed
2 to marketing driven).

3 366. Nevertheless, the amount of such prescriptions paid by worker's
4 compensation programs is monumental. A study of the National Council on
5 Compensation Insurance ("NCCI") concluded that, in 2011, approximately 38%
6 of pharmacy costs in workers' compensation are for opioids and opioid
7 combinations, amounting to approximately \$1.4 billion.

8 367. Upon information and belief, those trends are reflected in the
9 County's experience with paying for opioids through its worker's compensation
10 plan.

11 368. The County incurred costs associated with the prescribing of opioids,
12 such as doctors' visits or toxicology screens, and the costs of treating the adverse
13 effects of prescribing opioids long-term such as overdose and addiction.

14 369. However, the costs of long-term opioid use are not limited to costs of
15 opioid prescriptions. Long-term opioid use is accompanied by a host of
16 consequential costs, including costs related to abuse, addiction, and death.

17 370. These claims – and their attendant and consequential costs – for
18 opioids prescribed for chronic pain, as opposed to acute and cancer or end-of-life
19 pain, were ineligible for payment and the result of the Defendant's fraudulent
20 scheme.

21
22 **ii. The County's Increased Costs Correlate with the Defendants' Promotion.**

23 371. Upon information and belief, a review of the County's costs related
24 to opioid prescriptions, and the costs associated with those prescriptions, will
25 show that as the Defendants spent more to promote their drugs, doctors began
26 prescribing them more often and as a result, the costs to the County went up.

27 372. It is also distressing (and a sign of further problems ahead) that the
28 drop in opioid prescribing beginning in 2014 has been accompanied by a

1 corresponding increase in the Defendants' promotional spending, which is headed
2 towards a new high, despite evidence of the grave toll that opioids are taking on
3 law enforcement, public health, and individual lives.

4 373. The County asserts that each Defendant made misrepresentations or
5 misrepresentation by omission of material facts by their employees, agents, or co-
6 conspirators to prescribing physicians who then wrote opioid prescriptions for
7 which the County paid. Furthermore, the County asserts that specific details about
8 the names of the employees, agents, or co-conspirators, the substance of the
9 misrepresentations or omissions, the time and date and location of said
10 misrepresentations or omissions, and the names of the prescribing physicians who
11 were exposed to each Defendants' misrepresentations or omissions were closely
12 tracked by the Defendants, are in the exclusive possession of the Defendants and
13 the County reasonably believes that such information will be disclosed in
14 discovery.

15 **G. STATUTES OF LIMITATIONS ARE TOLLED AND DEFENDANTS**
16 **ARE ESTOPPED FROM ASSERTING STATUTES OF**
17 **LIMITATIONS AS DEFENSES.**

18 **1. Enforcement of a Public Right.**

19 374. No statute of limitation can be pleaded against the Plaintiffs, which
20 seek to enforce strictly public rights.

21 **2. Continuing Conduct.**

22 375. Plaintiffs contend they continue to suffer harm from the unlawful
23 actions by the Defendants.

24 376. The continued tortious and unlawful conduct by the Defendants
25 causes a repeated or continuous injury. The damages have not occurred all at
26 once but have continued to occur and have increased as time progresses. The tort
27 is not completed nor have all the damages been incurred until the wrongdoing
28 ceases. The wrongdoing and unlawful activity by Defendants has not ceased. The

1 public nuisance remains unabated. The conduct causing the damages remains
2 unabated.

3 **3. Equitable Estoppel.**

4 377. To the extent any statute of limitations defense would apply,
5 Defendants are equitably estopped from relying upon a statute of limitations
6 defense because they undertook active efforts to deceive Plaintiffs and to
7 purposefully conceal their unlawful conduct and fraudulently assure the public,
8 including the State, the Plaintiffs, and Plaintiffs' Community, that they were
9 undertaking efforts to comply with their obligations under the state and federal
10 controlled substances laws, all with the goal of protecting their registered
11 manufacturer or distributor status in the State and to continue generating profits.
12 Notwithstanding the allegations set forth above, the Defendants affirmatively
13 assured the public, including the State, the Plaintiffs, and Plaintiffs' Community,
14 that they are working to curb the opioid epidemic.

15 378. For example, a Cardinal Health executive claimed that it uses
16 "advanced analytics" to monitor its supply chain, and assured the public it was
17 being "as effective and efficient as possible in constantly monitoring, identifying,
18 and eliminating any outside criminal activity."¹⁸³

19 379. Similarly, McKesson publicly stated that it has a "best-in-class
20 controlled substance monitoring program to help identify suspicious orders," and
21 claimed it is "deeply passionate about curbing the opioid epidemic in our
22 country."¹⁸⁴

23
24
25 ¹⁸³ Bernstein et al., *supra*.

26 ¹⁸⁴ Scott Higham et al., *Drug Industry Hired Dozens of Officials from the DEA as*
27 *the Agency Tried to Curb Opioid Abuse*, Wash. Post, Dec. 22, 2016,
28 https://www.washingtonpost.com/investigations/key-officials-switch-sides-from-dea-to-pharmaceutical-industry/2016/12/22/55d2e938-c07b-11e6-b527-949c5893595e_story.html.

1 380. Moreover, in furtherance of their effort to affirmatively conceal their
 2 conduct and avoid detection, the Distributor Defendants, through their trade
 3 associations, HDMA and NACDS, filed an *amicus* brief in *Masters*
 4 *Pharmaceuticals*, which made the following statements:¹⁸⁵

- 5 a. “HDMA and NACDS members not only have statutory and
 6 regulatory responsibilities to guard against diversion of controlled
 7 prescription drugs, but undertake such efforts as responsible
 8 members of society.”
- 9 b. “DEA regulations that have been in place for more than 40 years
 10 require distributors to *report* suspicious orders of controlled
 11 substances to DEA based on information readily available to them
 12 (e.g., a pharmacy’s placement of unusually frequent or large orders).”
- 13 c. “Distributors take seriously their duty to report suspicious orders,
 14 utilizing both computer algorithms and human review to detect
 15 suspicious orders based on the generalized information that *is*
 16 available to them in the ordering process.”
- 17 d. “A particular order or series of orders can raise red flags because of
 18 its unusual size, frequency, or departure from typical patterns with a
 19 given pharmacy.”
- 20 e. “Distributors also monitor for and report abnormal behavior by
 21 pharmacies placing orders, such as refusing to provide business
 22 contact information or insisting on paying in cash.”

23 Through the above statements made on their behalf by their trade associations,
 24 and other similar statements assuring their continued compliance with their legal
 25 obligations, the Distributor Defendants not only acknowledged that they
 26 understood their obligations under the law, but they further affirmed that their
 27 conduct was in compliance with those obligations.

28 381. The Distributor Defendants have also concealed and prevented
 discovery of information, including data from the ARCOS database that will
 confirm their identities and the extent of their wrongful and illegal activities.

 382. The Manufacturer Defendants distorted the meaning or import of
 studies they cited and offered them as evidence for propositions the studies did not
 support. The Manufacturer Defendants invented “pseudoaddiction” and promoted

¹⁸⁵ Brief for HDMA and NACDS, 2016 WL 1321983, at *3-4, *25.

1 it to an unsuspecting medical community. The Manufacturer Defendants provided
2 the medical community with false and misleading information about ineffectual
3 strategies to avoid or control opioid addiction. The Manufacturer Defendants
4 recommended to the medical community that dosages be increased, without
5 disclosing the risks. The Manufacturer Defendants spent millions of dollars over a
6 period of years on a misinformation campaign aimed at highlighting opioids'
7 alleged benefits, disguising the risks, and promoting sales. The medical
8 community, consumers, the State, and Plaintiffs' Community were duped by the
9 Manufacturer Defendants' campaign to misrepresent and conceal the truth about
10 the opioid drugs that they were aggressively pushing in the State and in Plaintiffs'
11 Community.

12 383. Defendants intended that their actions and omissions would be relied
13 upon, including by Plaintiffs and Plaintiffs' Community. Plaintiffs and Plaintiffs'
14 Community did not know, and did not have the means to know, the truth due to
15 Defendants' actions and omissions.

16 384. The Plaintiffs and Plaintiffs' Community reasonably relied on
17 Defendants' affirmative statements regarding their purported compliance with
18 their obligations under the law and consent orders. To the extent statutes of
19 limitations could apply to Plaintiffs' claims, Plaintiffs failed to commence an
20 action within the statutory periods because of reliance on Defendants' wrongful
21 conduct.

22 385. Defendants are estopped from asserting a statute of limitations
23 defense because their conduct and misrepresentations were so unfair and
24 misleading as to outweigh the public's interest in setting limitations on bringing
25 actions.

26 **4. Fraudulent Concealment**

27 386. To the extent any statute of limitations defense would apply,
28 Plaintiffs' claims are further subject to equitable tolling, stemming from

Defendants' knowing and fraudulent concealment of the facts alleged herein. As alleged herein, Defendants knew of the wrongful acts set forth above, had material information pertinent to their discovery, and concealed them from the Plaintiffs and Plaintiffs' Community. The Plaintiffs did not know, or could not have known through the exercise of reasonable diligence, of their causes of action, as a result of Defendants' conduct.

387. The purposes of the statutes of limitations period, if any, are satisfied because Defendants cannot claim prejudice due to a late filing where the Plaintiffs filed suit promptly upon discovering the facts essential to their claims, described herein, which Defendants knowingly concealed.

388. In light of their statements to the media, in legal filings and in settlements, it is clear that Defendants had actual or constructive knowledge that their conduct was deceptive, in that they consciously concealed the schemes set forth herein.

389. Defendants continually and secretly engaged in their scheme to avoid compliance with their legal obligations. Only Defendants and their agents knew or could have known about Defendants' unlawful actions because Defendants made deliberate efforts to conceal their conduct. As a result of the above, the Plaintiffs were unable to obtain vital information bearing on their claims absent any fault or lack of diligence on their part.

V. LEGAL CAUSES OF ACTION

COUNT I

PUBLIC NUISANCE

(Brought by The People Against all Defendants)

390. Plaintiff, The People, incorporate by reference all other paragraphs of this Complaint as if fully set forth here, and further allege as follows.

391. Each Defendant is liable for public nuisance because its conduct at issue has caused an unreasonable and substantial interference with a right

1 common to the general public. *See Cty. of Santa Clara v. Atl. Richfield Co.*, 137
 2 Cal. App. 4th 292, 305, 40 Cal. Rptr. 3d 313, 325 (2006) (cit. om.). The
 3 interference is substantial “if it causes significant harm and unreasonable if its
 4 social utility is outweighed by the gravity of the harm inflicted.” *Id.* The causation
 5 element of a public nuisance cause of action is satisfied if the defendant’s conduct
 6 is a substantial factor in bringing about the result. *People v. Conagra Grocery*
 7 *Prod. Co.*, 17 Cal. App. 5th 51, 101-02, 227 Cal. Rptr. 3d 499, 543 (Ct. App.
 8 2017), *reh’g denied* (Dec. 6, 2017), *review denied* (Feb. 14, 2018).

9 392. Under California law, a nuisance is “anything which is injurious to
 10 health, including but not limited to the illegal sale of controlled substances, or is
 11 indecent or offensive to the senses, or an obstruction to the free use of property, so
 12 as to interfere with the comfortable enjoyment of life or property.” Cal. Civ. Code
 13 § 3479.

14 393. California defines a “public nuisance” as “one which affects at the
 15 same time an entire community or neighborhood, or any considerable number of
 16 persons, although the extent of the annoyance or damage inflicted upon
 17 individuals may be unequal.” Cal. Civ. Code § 3480.

18 394. Defendants have created a public nuisance under California law.

19 395. The People have standing to bring this claim to abate the public
 20 nuisance due to the opioid epidemic which was created by Defendants and which
 21 is affecting and causing harm in Plaintiffs’ Community. *See* Cal. Civ. Proc. Code
 22 § 731.

23 396. By causing dangerously addictive drugs to flood the community, and
 24 to be diverted for illicit purposes, in contravention of federal and state law, each
 25 Defendant has injuriously affected rights common to the general public,
 26 specifically including the rights of the people of the Plaintiffs’ Community to
 27 public health, public safety, public peace, public comfort, and public convenience.
 28

1 The public nuisance caused by Defendants' diversion of dangerous drugs has
2 caused substantial annoyance, inconvenience, and injury to the public.

3 397. By selling dangerously addictive opioid drugs diverted from a
4 legitimate medical, scientific, or industrial purpose, Defendants have committed a
5 course of conduct that injuriously affects the safety, health, and morals of the
6 people of the Plaintiffs' Community.

7 398. By failing to maintain a closed system that guards against diversion
8 of dangerously addictive drugs for illicit purposes, Defendants injuriously affected
9 public rights, including the right to public health, public safety, public peace, and
10 public comfort of the people of the Plaintiffs' Community.

11 399. By affirmatively promoting opioids for use for chronic pain,
12 affirmatively promoting opioids as not addictive, affirmatively fostering a
13 misunderstanding of the signs of addiction and how to reliably identify and safely
14 prescribe opioids to patients predisposed to addiction, affirmatively exaggerating
15 the risks of competing medications like NSAIDs, affirmatively promoting their
16 so-called abuse-deterrent opioid formulations and affirmatively identifying and
17 targeting susceptible prescribers and vulnerable patient populations, Defendants
18 injuriously affected public rights, including the right to public health, public
19 safety, public peace, and public comfort of the people of the Plaintiffs'
20 Community. The public nuisance caused by Defendants' affirmative promotion
21 of opioids has caused substantial annoyance, inconvenience, and injury to the
22 public.

23 400. Defendants' interference with the comfortable enjoyment of life in
24 the Plaintiffs' Community is unreasonable because there is little social utility to
25 opioid diversion and abuse, and any potential value is outweighed by the gravity
26 of the harm inflicted by Defendants' actions.

27 401. The People allege that Defendants' wrongful and illegal actions have
28 created a public nuisance. Each Defendant is liable for public nuisance because its

1 conduct at issue has caused an unreasonable and substantial interference with a
2 right common to the general public.

3 402. The Defendants have intentionally and/or unlawfully created a
4 nuisance.

5 403. The residents of Plaintiffs' Community have a common right to be
6 free from conduct that creates an unreasonable jeopardy to the public health,
7 welfare and safety, and to be free from conduct that creates a disturbance and
8 reasonable apprehension of danger to person and property.

9 404. Defendants intentionally, unlawfully, and recklessly manufacture,
10 market, distribute, promote and sell prescription opioids that Defendants know, or
11 reasonably should know, will be diverted, causing widespread distribution of
12 prescription opioids in and/or to Plaintiffs' Community, resulting in addiction and
13 abuse, an elevated level of crime, death and injuries to the residents of Plaintiffs'
14 Community, a higher level of fear, discomfort and inconvenience to the residents
15 of Plaintiffs' Community, and direct costs to Plaintiffs' Community.

16 405. Defendants have unlawfully and/or intentionally caused and
17 permitted dangerous drugs under their control to be diverted such as to injure the
18 Plaintiffs' Community and its residents.

19 406. Defendants have unlawfully and/or intentionally promoted and
20 distributed opioids or caused opioids to be distributed without maintaining
21 effective controls against diversion. Such conduct was illegal. Defendants'
22 failures to maintain effective controls against diversion include Defendants'
23 failure to effectively monitor for suspicious orders, report suspicious orders,
24 and/or stop shipment of suspicious orders.

25 407. Defendants have caused a significant and unreasonable interference
26 with the public health, safety, welfare, peace, comfort and convenience, and
27 ability to be free from disturbance and reasonable apprehension of danger to
28 person or property.

1 408. Defendants' conduct in illegally distributing and selling prescription
2 opioids, or causing such opioids to be distributed and sold, where Defendants
3 know, or reasonably should know, such opioids will be diverted and possessed
4 and/or used illegally in Plaintiffs' Community is of a continuing nature.

5 409. Defendants' actions have been of a continuing nature and have
6 produced a significant effect upon the public's rights, including the public's right
7 to health and safety.

8 410. A violation of any rule or law controlling the distribution of a drug of
9 abuse in Plaintiffs' Community and the State is a public nuisance.

10 411. Defendants' distribution of opioids while failing to maintain effective
11 controls against diversion was proscribed by statute and regulation.

12 412. Defendants' ongoing conduct produces an ongoing nuisance, as the
13 prescription opioids that they allow and/or cause to be illegally distributed and
14 possessed in Plaintiffs' Community will be diverted, leading to abuse, addiction,
15 crime, and public health costs.

16 413. Because of the continued use and addiction caused by these illegally
17 distributed opioids, The People will continue to fear for their health, safety and
18 welfare, and will be subjected to conduct that creates a disturbance and reasonable
19 apprehension of danger to person and property.

20 414. Defendants know, or reasonably should know, that their conduct will
21 have an ongoing detrimental effect upon the public health, safety and welfare, and
22 the public's ability to be free from disturbance and reasonable apprehension of
23 danger to person and property.

24 415. Defendants know, or reasonably should know, that their conduct
25 causes an unreasonable and substantial invasion of the public right to health,
26 safety and welfare and the public's ability to be free from disturbance and
27 reasonable apprehension of danger to person and property.
28

1 416. Defendants are aware, and at a bare minimum certainly should be
2 aware, of the unreasonable interference that their conduct has caused in Plaintiffs'
3 Community. Defendants are in the business of manufacturing, marketing, selling,
4 and distributing prescription drugs, including opioids, which are specifically
5 known to Defendants to be dangerous because *inter alia* these drugs are defined
6 under federal and state law as substances posing a high potential for abuse and
7 severe addiction. *See, e.g.*, 21 U.S.C. § 812 (b)(2). Defendants created an
8 intentional nuisance. Defendants' actions created and expanded the abuse of
9 opioids, drugs specifically codified as constituting severely harmful substances.

10 417. Defendants' conduct in promoting, marketing, distributing, and
11 selling prescription opioids which the Defendants know, or reasonably should
12 know, will likely be diverted for non-legitimate, non-medical use, creates a strong
13 likelihood that these illegal distributions of opioids will cause death and injuries to
14 residents in Plaintiffs' Community and otherwise significantly and unreasonably
15 interfere with public health, safety and welfare, and with The People's right to be
16 free from disturbance and reasonable apprehension of danger to person and
17 property.

18 418. It is, or should be, reasonably foreseeable to defendants that their
19 conduct will cause deaths and injuries to residents in Plaintiffs' Community, and
20 will otherwise significantly and unreasonably interfere with public health, safety
21 and welfare, and with the public's right to be free from disturbance and reasonable
22 apprehension of danger to person and property.

23 419. The prevalence and availability of diverted prescription opioids in the
24 hands of irresponsible persons and persons with criminal purposes in Plaintiffs'
25 Community not only causes deaths and injuries, but also creates a palpable
26 climate of fear among residents in Plaintiffs' Community where opioid diversion,
27 abuse, addiction are prevalent and where diverted opioids tend to be used
28 frequently.

1 420. Defendants' conduct makes it easier for persons to divert prescription
2 opioids, constituting a dangerous threat to the public.

3 421. Defendants' actions were, at the least, a substantial factor in opioids
4 becoming widely available and widely used for non-medical purposes. Because of
5 Defendants' affirmative promotion of opioids and special positions within the
6 closed system of opioid distribution, without Defendants' actions, opioid use
7 would not have become so widespread, and the enormous public health hazard of
8 prescription opioid and heroin overuse, abuse, and addiction that now exists
9 would have been averted.

10 422. The presence of diverted prescription opioids in Plaintiffs'
11 Community, and the consequence of prescription opioids having been diverted in
12 Plaintiffs' Community, proximately results in and/or substantially contributes to
13 the creation of significant future costs to The People and to Plaintiffs' Community
14 in order to enforce the law, equip its police force and treat the victims of opioid
15 abuse and addiction.

16 423. Stemming the flow of illegally distributed prescription opioids, and
17 abating the nuisance caused by the illegal flow of opioids, will help to alleviate
18 this problem, save lives, prevent injuries and make Plaintiffs' Community a safer
19 place to live.

20 424. Defendants' conduct is a direct and proximate cause of and/or a
21 substantial contributing factor to opioid addiction and abuse in Plaintiffs'
22 Community, costs that will be borne by Plaintiffs' Community and The People,
23 and a significant and unreasonable interference with public health, safety and
24 welfare, and with the public's right to be free from disturbance and reasonable
25 apprehension of danger to person and property.

26 425. Defendants' conduct constitutes a public nuisance and, if unabated,
27 will continue to threaten the health, safety and welfare of the residents of
28 Plaintiffs' Community, creating an atmosphere of fear and addiction that tears at

1 the residents' sense of well-being and security. The People have a clearly
2 ascertainable right to prospectively abate conduct that perpetuates this nuisance.

3 426. Defendants created an intentional nuisance. Defendants' actions
4 created and expanded the abuse of opioids, which are dangerously addictive, and
5 the ensuing associated plague of prescription opioid and heroin addiction.
6 Defendants knew the dangers to public health and safety that diversion of opioids
7 would create in Plaintiffs' Community; however, Defendants intentionally and/or
8 unlawfully failed to maintain effective controls against diversion through proper
9 monitoring, reporting and refusal to fill suspicious orders of opioids. Defendants
10 intentionally and/or unlawfully distributed opioids or caused opioids to be
11 distributed without reporting or refusing to fill suspicious orders or taking other
12 measures to maintain effective controls against diversion. Defendants
13 intentionally and/or unlawfully continued to ship and failed to halt suspicious
14 orders of opioids, or caused such orders to be shipped. Defendants intentionally
15 and/or unlawfully promoted and marketed opioids in manners they knew to be
16 false and misleading. Such actions were inherently dangerous.

17 427. Defendants knew the prescription opioids have a high likelihood of
18 being diverted. It was foreseeable to Defendants that where Defendants distributed
19 prescription opioids or caused such opioids to be distributed without maintaining
20 effective controls against diversion, including monitoring, reporting, and refusing
21 shipment of suspicious orders, that the opioids would be diverted, and create an
22 opioid abuse nuisance in Plaintiffs' Community.

23 428. Defendants' actions also created a nuisance by acting recklessly,
24 negligently and/or carelessly, in breach of their duties to maintain effective
25 controls against diversion, thereby creating an unreasonable and substantial risk of
26 harm.

1 429. Defendants acted with actual malice because Defendants acted with a
2 conscious disregard for the rights and safety of other persons, and said actions
3 have a great probability of causing substantial harm.

4 430. The public nuisance created, perpetuated and maintained by
5 Defendants can be prospectively abated and further reoccurrence of such harm
6 and inconvenience can be prevented.

7 431. The People further seek to prospectively abate the nuisance created
8 by the Defendants' unreasonable, unlawful, intentional, ongoing, continuing,
9 substantial and persistent actions and omissions and interference with a right
10 common to the public.

11 432. Defendants' intentional and unlawful actions and omissions and
12 unreasonable interference with a right common to the public are of a continuing
13 nature.

14 433. The public nuisance created by Defendants' actions is substantial and
15 unreasonable – it has caused and continues to cause significant harm to the
16 community, and the harm inflicted outweighs any offsetting benefit. The
17 staggering rates of opioid and heroin use resulting from the Defendants'
18 abdication of their gate-keeping and diversion prevention duties, and the
19 Manufacturer Defendants' fraudulent marketing activities, have caused harm to
20 the entire community that includes, but is not limited to the following:

- 21 a. The high rates of use leading to unnecessary opioid abuse, addiction,
22 overdose, injuries, and deaths.
- 23 b. Even children have fallen victim to the opioid epidemic. Easy access
24 to prescription opioids made opioids a recreational drug of choice
25 among teenagers. Even infants have been born addicted to opioids
26 due to prenatal exposure, causing severe withdrawal symptoms and
27 lasting developmental impacts.
- 28 c. Even those residents of Plaintiffs' Community who have never taken
opioids have suffered from the public nuisance arising from
Defendants' abdication of their gate-keeper duties and fraudulent
promotions. Many residents have endured and will endure both the
emotional and financial costs of caring for loved ones addicted to or
injured by opioids, and the loss of companionship, wages, or other

support from family members who have used, abused, become addicted to, overdosed on, or been killed by opioids.

- d. The opioid epidemic has increased and will increase health care costs.
- e. Employers have lost and will continue to lose the value of productive and healthy employees.
- f. Defendants' conduct created and continues to create an abundance of drugs available for criminal use and fueled a new wave of addiction, abuse, and injury.
- g. Defendants' dereliction of duties and/or fraudulent misinformation campaign pushing dangerous drugs resulted in a diverted supply of narcotics to sell, and the ensuing demand of addicts to buy them. More prescription opioids sold by Defendants led to more addiction, with many addicts turning from prescription opioids to heroin. People addicted to opioids frequently require increasing levels of opioids, and many are turning to heroin as a foreseeable result.
- h. The diversion of opioids into the secondary, criminal market and the increased number of individuals who abuse or are addicted to opioids has increased and continues to increase the demands on health care services and law enforcement.
- i. The significant and unreasonable interference with the public rights caused by Defendants' conduct has taxed and continues to tax the human, medical, public health, law enforcement, and financial resources of the Plaintiffs' Community.

434. The People seek all legal and equitable relief as allowed by law, other than such damages disavowed herein, including *inter alia* injunctive relief and expenses to prospectively abate the nuisance.

435. Pursuant to California Code of Civil Procedure section 731, The People request an order from the Court on behalf of The People providing for abatement of Defendants' ongoing violations of California Civil Code Sections 3479 and 3480, and enjoining Defendants from future violations of California Civil Code Sections 3479 and 3480.

436. Each Defendant created or assisted in the creation of the epidemic of opioid use and injury and each Defendant is jointly and severally liable for abating it.

COUNT II

PUBLIC NUISANCE

(Brought by The County Against all Defendants)

437. Plaintiff, The County, incorporates by reference all other paragraphs of this Complaint as if fully set forth here, and further alleges as follows.

438. As set forth above, each Defendant is liable for public nuisance because its conduct at issue has caused an unreasonable and substantial interference with a right common to the general public. *See, e.g., Cty. of Santa Clara v. Atl. Richfield Co.*, 137 Cal. App. 4th 292, 305, 40 Cal. Rptr. 3d 313, 325 (2006); Cal. Civ. Code §§ 3479; 3480.

439. Defendants have created a public nuisance under California law.

440. The County has standing to bring this claim for damages incurred to its property by the public nuisance due to the opioid epidemic which was created by Defendants and which is affecting and causing harm to The County. An action can be “brought by any person whose property is injuriously affected, or whose personal enjoyment is lessened by a nuisance, as defined in Section 3479 of the Civil Code, and by the judgment in that action the nuisance may be enjoined or abated as well as damages recovered therefor.” Cal. Civ. Proc. Code § 731. “Where a public entity can show it has a property interest injuriously affected by the nuisance, then, like any other such property holder, it should be able to pursue the full panoply of tort remedies available to private persons.” *Selma Pressure Treating Co. v. Osmose Wood Preserving Co.*, 221 Cal. App. 3d 1601, 1616, 271 Cal. Rptr. 596, 604 (Ct. App. 1990).

441. The County has suffered harm to its property interests that is different from the type of harm suffered by the general public and has incurred substantial costs deriving from having to replace and retrofit its property that has been damaged and is being damaged by Defendants’ intentional, unlawful, and

1 reckless manufacturing, marketing, distribution, promotion and sale of
2 prescription opioids.

3 442. Defendants intentionally, unlawfully, and recklessly manufacture,
4 market, distribute, promote and sell prescription opioids that Defendants know, or
5 reasonably should know, will be diverted, causing widespread distribution of
6 prescription opioids in and/or to Plaintiffs' Community, resulting in The County
7 having to repair and remake its infrastructure, property and systems that have been
8 damaged by Defendants' action, including, *inter alia*, its property and systems to
9 treat addiction and abuse, to respond to and manage an elevated level of
10 emergencies and crime, and to respond to and treat injuries and process deaths in
11 Plaintiffs' Community.

12 443. The County owns property which has been injuriously affected by the
13 public nuisance caused by Defendants. These property interests, include, *inter*
14 *alia*, additional naloxone doses – The County owns these doses which have been
15 and are destroyed when The County has to administer them to persons who are
16 overdosing as a result of Defendants' intentional, unlawful, and reckless
17 manufacturing, marketing, distribution, promotion and sale of prescription
18 opioids. The County's emergency response system and medical services
19 equipment and other materials will similarly need to be improved and replaced
20 because this property has been and is being damaged due to persons who are
21 overdosing as a result of Defendants' intentional, unlawful, and reckless
22 manufacturing, marketing, distribution, promotion and sale of prescription
23 opioids. The County also has damage to its property related to evidence gathering
24 and testing for the prosecution of drug related crimes.

25 444. In addition, The County has suffered damages to its infrastructure,
26 which will need to be retrofitted and repaired as a result of Defendants'
27 intentional, unlawful, and reckless manufacturing, marketing, distribution,
28 promotion and sale of prescription opioids. This damage includes damage to its

1 law enforcement, medical and rehabilitation infrastructures and systems which are
 2 now inadequate to handle the new undue burden on these systems caused by
 3 Defendants' conduct. This includes, *inter alia*, repairing and upgrading jail
 4 facilities to add additional jail space and beds for opioid addicts who commit
 5 crimes as well as retrofitting the facilities to treat inmates' addictions. This also
 6 includes repairing and upgrading court systems for prosecution and defense of
 7 drug-related crimes. This also includes repairing and upgrading hospital and
 8 treatment facilities for members of Plaintiffs' Community addicted to opioids as
 9 well as property that is part of and used by The County's Department of the
 10 Sheriff-Coroner which must investigate deaths known or suspected to be due to
 11 drug intoxication.

12 445. The County owns, operates, manages, maintains, and otherwise has
 13 property interests in, all of which have been injured, damaged, or affected by
 14 Defendants, the following property:

- 15 a. County Jail system, including buildings, cells, beds, supplies,
 16 resources, materials, personnel, equipment, and other property.
- 17 b. County Probation system, including offices, personnel, supplies,
 18 resources, materials, equipment, and other property.
- 19 c. County District Attorney system, including offices, personnel,
 20 supplies, resources, materials, equipment, and other property.
- 21 d. County Health and Human Services system, including offices,
 22 personnel, supplies, resources, materials, equipment, and other
 23 property.
- 24 e. County Sheriff, Coroner and Law Enforcement systems, including
 25 Narcan, naloxone, offices, personnel, supplies, resources, materials,
 26 equipment, and other property.
- 27 f. County Emergency Responder system, including equipment, Narcan,
 28 naloxone, materials, supplies, personnel, offices, and other property.

1 g. County Public Health system, including offices, personnel, resources,
2 supplies, equipment, materials, and other property.

3 h. County Public Defender System, including personnel, offices,
4 supplies, equipment, materials, resources, and other property.

5 i. County Hospital System, including supplies, beds, medication,
6 equipment, personnel, devices, facilities, and other resources.

7 446. As set forth above in allegations specifically incorporated herein, by
8 selling dangerously addictive opioid drugs diverted from a legitimate medical,
9 scientific, or industrial purpose, Defendants have committed a course of conduct
10 that injuriously affects The County and its property.

11 447. The public nuisance caused by Defendants' affirmative promotion of
12 opioids has caused substantial annoyance, inconvenience, and injury to The
13 County and The County's property.

14 448. The acts by Defendants which have injured The County and its
15 property are unreasonable because there is little social utility to opioid diversion
16 and abuse, and any potential value is outweighed by the gravity of the harm
17 inflicted by Defendants' actions.

18 449. Defendants have unlawfully and/or intentionally caused and
19 permitted dangerous drugs under their control to be diverted such as to injure the
20 County's property.

21 450. Defendants' conduct in illegally distributing and selling prescription
22 opioids, or causing such opioids to be distributed and sold, where Defendants
23 know, or reasonably should know, such opioids will be diverted and possessed
24 and/or used illegally in Plaintiffs' Community is of a continuing nature and has
25 produced a significant injury to The County and its property.

26 451. Defendants' ongoing conduct produces an ongoing nuisance.

27 452. Defendants know, or reasonably should know, that their conduct will
28 have an ongoing detrimental effect upon The County and The County's property.

1 453. Defendants' actions were, at the least, a substantial factor causing the
2 harm to The County and its property.

3 454. The presence of diverted prescription opioids in Plaintiffs'
4 Community, and the consequence of prescription opioids having been diverted in
5 Plaintiffs' Community, proximately results in and/or substantially contributes to
6 the creation of significant past and future costs to The County as it must repair and
7 retrofit its property in order to enforce the law and treat the victims of opioid
8 abuse and addiction.

9 455. Defendants' conduct is a direct and proximate cause of and/or a
10 substantial contributing factor to opioid addiction and abuse in Plaintiffs'
11 Community, costs that will be borne by Plaintiffs' Community and The County.

12 456. As a direct and proximate result of Defendants' creation of a public
13 nuisance, The County has suffered and continues to suffer damages to its property
14 requiring investigation, repair, remediation, and other costs to be determined at
15 trial.

16 457. The damages available to The County include, *inter alia*, recoupment
17 of governmental costs, flowing from the damages to The County's property which
18 The County seeks to recover damages for. Defendants' conduct is ongoing and
19 persistent, and The County seeks all damages flowing from Defendants' conduct.

20 458. As a direct result of Defendants' conduct, The County and Plaintiffs'
21 Community have suffered actual injury and damages including, but not limited to,
22 significant expenses for repairing and retrofitting property related to police,
23 emergency, health, prosecution, corrections and other services. The County here
24 seeks recovery for its own harm.

25 459. The County has sustained specific and special injuries because its
26 damages include, *inter alia*, injury to the property and systems of its health
27 services, law enforcement, and Coroner, as well as property costs related to opioid
28 addiction treatment and overdose prevention, as described in this Complaint.

1 other ‘legal entities,’ and the second covering ‘any union or group of individuals
2 associated in fact although not a legal entity.’” *United State v. Turkette*, 452 U.S.
3 576, 577 (1981).

4 466. Beginning in the early 1990s, the RICO Marketing Defendants
5 aggressively sought to bolster their revenue, increase profit, and grow their share
6 of the prescription painkiller market by unlawfully increasing the volume of
7 opioids they sold. The RICO Marketing Defendants knew that they could not
8 increase their profits without misrepresenting that opioids were non-addictive and
9 safe for the long-term treatment of chronic pain.

10 467. The generally accepted standards of medical practice prior to the
11 1990s dictated that opioids should only be used in short durations to treat acute
12 pain, pain relating to recovery from surgery, or for cancer or palliative (end-of-
13 life) care. Due to the evidence of addiction and lack of evidence indicating that
14 opioids improved patients’ ability to overcome pain and function, the use of
15 opioids for chronic pain was discouraged or prohibited. As a result, doctors
16 generally did not prescribe opioids for chronic pain.

17 468. Knowing that their products were highly addictive, ineffective and
18 unsafe for the treatment of long-term chronic pain, non-acute and non-cancer pain,
19 the RICO Marketing Defendants formed an association-in-fact enterprise and
20 engaged in a scheme to unlawfully increase their profits and sales, and grow their
21 share of the prescription painkiller market, through repeated and systematic
22 misrepresentations about the safety and efficacy of opioids for treating long-term
23 chronic pain.

24 469. The RICO Marketing Defendants formed an association-in-fact
25 enterprise consisting of “advocacy groups and professional societies” (“Front
26 Groups”) and paid “physicians affiliated with these groups” (KOLs”) in order to
27 unlawfully increase the demand for opioids. Through their personal relationships,
28 the RICO Marketing Defendants and members of the Opioid Marketing Enterprise

1 had the opportunity to form and take actions in furtherance of the Opioid
 2 Marketing Enterprise's common purpose. The RICO Marketing Defendants'
 3 substantial financial contribution to the Opioid Marketing Enterprise, and the
 4 advancement of opioids-friendly messaging, fueled the U.S. opioids epidemic.¹⁸⁶

5 470. The RICO Marketing Defendants, through the Opioid Marketing
 6 Enterprise, made misleading statements and misrepresentations about opioids that
 7 downplayed the risk of addiction and exaggerated the benefits of opioid use,
 8 including: (1) downplaying the serious risk of addiction; (2) creating and
 9 promoting the concept of "pseudoaddiction" when signs of actual addiction began
 10 appearing and advocated that the signs of addiction should be treated with more
 11 opioids; (3) exaggerating the effectiveness of screening tools to prevent addiction;
 12 (4) claiming that opioid dependence and withdrawal are easily managed; (5)
 13 denying the risks of higher opioid dosages; and (6) exaggerating the effectiveness
 14 of "abuse-deterrent" opioid formulations to prevent abuse and addiction.

15 471. The RICO Marketing Defendants also falsely touted the benefits of
 16 long-term opioid use, including the supposed ability of opioids to improve
 17 function and quality of life, even though there was no scientifically reliable
 18 evidence to support the RICO Marketing Defendants' claims.

19 472. The RICO Marketing Defendants' scheme, and the common purpose
 20 of the Opioid Marketing Enterprise, has been wildly successful. Opioids are now
 21 the most prescribed class of drugs. Globally, opioid sales generated \$11 billion in
 22 revenue for drug companies in 2010 alone; sales in the United States have
 23 exceeded \$8 billion in revenue annually since 2009.¹⁸⁷ In an open letter to the
 24

25 ¹⁸⁶ *Fueling an Epidemic: Exposing the Financial Ties Between Opioid*
 26 *Manufacturers and Third Party Advocacy Groups*, U.S. Senate Homeland Security
 27 & Governmental Affairs Committee, Ranking Members' Office, February 12,
 28 2018 <https://www.hsdl.org/?abstract&did=808171> ("*Fueling an Epidemic*"), at 1.

¹⁸⁷ See Katherine Eban, *OxyContin: Purdue Pharma's Painful Medicine*, Fortune, Nov. 9, 2011, <http://fortune.com/2011/11/09/oxycontin-purdue-pharmas-painful-medicine/>; David Crow, *Drugmakers Hooked on \$10bn Opioid Habit*, Fin. Times,

1 nation's physicians in August 2016, the then-U.S. Surgeon General expressly
 2 connected this "urgent health crisis" to "heavy marketing of opioids to doctors . . .
 3 [m]any of [whom] were even taught – incorrectly – that opioids are not addictive
 4 when prescribed for legitimate pain."¹⁸⁸

5 473. The scheme devised and implemented by the RICO Marketing
 6 Defendants amounted to a common course of conduct designed to ensure that the
 7 RICO Marketing Defendants unlawfully increased their sales and profits through
 8 misrepresentations about the addictive nature and effective use of the RICO
 9 Marketing Defendants' drugs. As Senator McCaskill aptly recognized:

10 The opioid epidemic is the direct result of a calculated marketing and
 11 sales strategy developed in the 90's, which delivered three simple
 12 messages to physicians. First, that chronic pain was severely
 13 undertreated in the United States. Second, that opioids were the best
 tool to address that pain. And third, that opioids could treat pain
 without risk of serious addiction. As it turns out, these messages were
 exaggerations at best and outright lies at worst.¹⁸⁹

14 **A. THE OPIOID MARKETING ENTERPRISE**

15 474. The Opioid Marketing Enterprise consists of the RICO Marketing
 16 Defendants, the Front Groups, and the KOLs – each of whom is identified below:

- 17 • The RICO Defendants
 - 18 ○ Purdue
 - 19 ○ Cephalon
 - 20 ○ Janssen
 - 21 ○ Endo
- 22 • The Front Groups
 - 23 ○ American Pain Foundation ("APF")

24
 25 Aug. 10, 2016, <https://www.ft.com/content/f6e989a8-5dac-11e6-bb77-a121aa8abd95>.

26 ¹⁸⁸ Letter from Vivek H. Murthy, U.S. Surgeon General (Aug. 2016),
 27 <http://turnthetidex.org/>; *Fueling An Epidemic*, *supra* n.3, at 1.

28 ¹⁸⁹ See, *LIVESTREAM: Insys Opioid Sales and Marketing Practices Roundtable*,
 September 12, 2017, at 31:03-31:37,
https://www.youtube.com/watch?v=k9mrQa8_vAo (accessed on March 1, 2018).

- American Academy of Pain Medicine (“AAPM”)
- American Pain Society (“APS”)
- Federation of State Medical Boards (“FSMB”)
- U.S. Pain Foundation (“USPF”)
- American Geriatrics Society (“AGS”)
- The KOLs
 - Dr. Russell Portenoy (“Dr. Portenoy”)
 - Dr. Lynn Webster (“Dr. Webster”)
 - Dr. Perry Fine (“Dr. Fine”)
 - Dr. Scott M. Fishman (“Dr. Fishman”))

475. The Opioid Marketing Enterprise is an ongoing and continuing business organization that created and maintained systematic links, interpersonal relationships and engaged in a pattern of predicate acts (i.e. racketeering activity) in order to further the common purpose of the enterprise: unlawfully increasing profits and revenues from the continued prescription and use of opioids for long-term chronic pain. Each of the individuals and entities who formed the Opioid Marketing Enterprise is an entity or person within the meaning of 18 U.S.C. § 1961(3) and acted to enable the common purpose and fraudulent scheme of the Opioid Marketing Enterprise.

476. In order to accomplish the common purpose, members of the Opioid Marketing Enterprise repeatedly and systematically misrepresented – affirmatively, and through half-truths and omissions – that opioids are non-addictive and safe for the effective treatment of long-term, chronic, non-acute and non-cancer pain, and for other off-label uses not approved by the FDA. The Opioid Marketing Enterprise misrepresented and concealed the serious risks and lack of corresponding benefits of using opioids for long-term chronic pain. By

1 making these misrepresentations, the Opioid Marketing Enterprise ensured that a
2 large number of opioid prescriptions would be written and filled for chronic pain.

3 477. At all relevant times, the Opioid Marketing Enterprise: (a) had an
4 existence separate and distinct from each RICO Marketing Defendant and its
5 members; (b) was separate and distinct from the pattern of racketeering in which
6 the RICO Defendants engaged; (c) was an ongoing and continuing organization
7 consisting of individuals, persons, and legal entities, including each of the RICO
8 Marketing Defendants; (d) was characterized by interpersonal relationships
9 between and among each member of the Opioid Marketing Enterprise, including
10 between the RICO Marketing Defendants and each of the Front Groups and
11 KOLs; (e) had sufficient longevity for the enterprise to pursue its purpose; and (f)
12 functioned as a continuing unit.

13 478. The persons and entities engaged in the Opioid Marketing Enterprise
14 are systematically linked through contractual relationships, financial ties, personal
15 relationships, and continuing coordination of activities, as spearheaded by the
16 RICO Marketing Defendants.

17 479. Each of the RICO Marketing Defendants, and each member of the
18 Opioid Marketing Enterprise had systematic links to and personal relationships
19 with each other through joint participation in lobbying groups, trade industry
20 organizations, contractual relationships and continuing coordination of activities.
21 Each of the RICO Marketing Defendants coordinated their marketing efforts
22 through the same KOLs and Front Groups, based on their agreement and
23 understanding that the Front Groups and KOLs were industry friendly and would
24 work together with the RICO Marketing Defendants to advance the common
25 purpose of the Opioid Marketing Enterprise.

26 **1. The RICO Defendants**

27 480. In addition to their systematic links to and personal relationships with
28 the Front Groups and KOLS, described below, the RICO Marketing Defendants

1 had systematic links to and personal relationships with each other through their
 2 participation in lobbying groups, trade industry organizations, contractual
 3 relationships and continuing coordination of activities, including but not limited
 4 to, the Pain Care Forum (“PCF”) and the Healthcare Distribution Alliance
 5 (“HDA”).

6 481. The PCF has been described as a coalition of drug makers, trade
 7 groups and dozens of non-profit organizations supported by industry funding.
 8 Plaintiffs are informed and believe that the PCF was created with the stated goal
 9 of offering a “setting where multiple organizations can share information” and
 10 “promote and support taking collaborative action regarding federal pain policy
 11 issues.” Plaintiffs are informed and believe that past PCF President Will Rowe
 12 described the PCF as “a deliberate effort to positively merge the capacities of
 13 industry, professional associations, and patient organizations.”

14 482. The PCF recently became a national news story when it was
 15 discovered that lobbyists for members of the PCF, including the RICO Marketing
 16 Defendants, quietly shaped federal and state policies regarding the use of
 17 prescription opioids for more than a decade.

18 483. The Center for Public Integrity and The Associated Press obtained
 19 “internal documents shed[ding] new light on how drug makers and their allies
 20 shaped the national response to the ongoing wave of prescription opioid abuse.”¹⁹⁰
 21 Specifically, PCF members spent over \$740 million lobbying in the nation’s
 22 capital and in all 50 statehouses on an array of issues, including opioid-related
 23 measures.¹⁹¹

26 ¹⁹⁰ Matthew Perrone, Pro-Painkiller echo chamber shaped policy amid drug
 27 epidemic, The Center for Public Integrity (September 19, 2017, 12:01 a.m.),
 28 [https://www.publicintegrity.org/2016/09/19/20201/pro-painkiller-echo-chamber-](https://www.publicintegrity.org/2016/09/19/20201/pro-painkiller-echo-chamber-shaped-policy-amid-drug-epidemic)
[shaped-policy-amid-drug-epidemic](https://www.publicintegrity.org/2016/09/19/20201/pro-painkiller-echo-chamber-shaped-policy-amid-drug-epidemic) (emphasis added).

¹⁹¹ *Id.*

1 484. Not surprisingly, each of the RICO Marketing Defendants who stood
 2 to profit from lobbying in favor of prescription opioid use is a member of and/or
 3 participant in the PCF.¹⁹² In 2012, membership and participating organizations in
 4 the PCF included the HDA (of which all the RICO Defendants are members),
 5 Endo, Purdue, Johnson & Johnson (the parent company for Janssen
 6 Pharmaceuticals), and Teva (the parent company of Cephalon).¹⁹³ Each of the
 7 RICO Marketing Defendants worked together through the PCF to advance the
 8 interests of the Opioid Marketing Enterprise. But, the RICO Marketing
 9 Defendants were not alone, many of the RICO Marketing Defendants' Front
 10 Groups were also members of the PCF, including the American Academy of Pain
 11 Management, the American Pain Foundation, and the American Pain Society.
 12 Upon information and belief, the RICO Marketing Defendants' KOLs were also
 13 members of and participated in the PCF.

14 485. Through the Pain Care Forum, the RICO Marketing Defendants met
 15 regularly and in person to form and take action to further the common purpose of
 16 the Opioid Marketing Enterprise and shape the national response to the ongoing
 17 prescription opioid epidemic.

18 486. Through the HDA – or Healthcare Distribution Alliance – the RICO
 19 Marketing Defendants “strengthen[ed] . . . alliances”¹⁹⁴ and took actions to further
 20 the common purpose of the Opioid Marketing Enterprise.

21 487. Beyond strengthening alliances, the benefits of HDA membership
 22 included the ability to, among other things, “network one on one with
 23

24 ¹⁹² PAIN CARE FORUM 2012 Meetings Schedule, (last updated December 2011),
 25 [https://assets.documentcloud.org/documents/3108982/PAIN-CARE-FORUM-](https://assets.documentcloud.org/documents/3108982/PAIN-CARE-FORUM-Meetings-Schedule-amp.pdf)
[Meetings-Schedule-amp.pdf](https://assets.documentcloud.org/documents/3108982/PAIN-CARE-FORUM-Meetings-Schedule-amp.pdf) (last visited March 8, 2018).

26 ¹⁹³ *Id.* Upon information and belief, Mallinckrodt became an active member of the
 PCF sometime after 2012.

27 ¹⁹⁴ Manufacturer Membership Benefits, Healthcare Distribution Alliance, (accessed
 28 on September 14, 2017),
[https://www.healthcaredistribution.org/~media/pdfs/membership/manufacturing-](https://www.healthcaredistribution.org/~media/pdfs/membership/manufacturing-membership-benefits.ashx?la=en)
[membership-benefits.ashx?la=en](https://www.healthcaredistribution.org/~media/pdfs/membership/manufacturing-membership-benefits.ashx?la=en) (emphasis added).

1 manufacturer executives at HDA's members-only Business and Leadership
 2 Conference," "participate on HDA committees, task forces and working groups
 3 with peers and trading partners," and "make connections."¹⁹⁵ Clearly,
 4 membership in the HDA was an opportunity to create interpersonal and ongoing
 5 organizational relationships and "alliances" between the RICO Marketing
 6 Defendants.

7 488. The closed meetings of the HDA's councils, committees, task forces
 8 and working groups provided the RICO Marketing Defendants with the
 9 opportunity to work closely together, confidentially, to develop and further the
 10 common purpose and interests of the Opioid Marketing Enterprise.

11 489. The HDA also offered multiple conferences, including annual
 12 business and leadership conferences through which the RICO Marketing
 13 Defendants had an opportunity to "bring together high-level executives, thought
 14 leaders and influential managers . . . to hold strategic business discussions on the
 15 most pressing industry issues."¹⁹⁶ The HDA and its conferences were significant
 16 opportunities for the RICO Marketing Defendants to interact at the executive level
 17 and form and take actions in furtherance of the common purpose of the Opioid
 18 Marketing Enterprise. It is clear that the RICO Marketing Defendants embraced
 19 this opportunity by attending and sponsoring these events.¹⁹⁷

20 490. The systematic contacts and personal relationships developed by the
 21 RICO Marketing Defendants through the PCF and the HDA furthered the
 22 common purpose of the Opioid Marketing Enterprise because it allowed the RICO
 23

24 ¹⁹⁵ *Id.*

25 ¹⁹⁶ Business and Leadership Conference – Information for Manufacturers,
 26 Healthcare Distribution Alliance<https://www.healthcaredistribution.org/events/2015-business-and-leadership-conference/blc-for-manufacturers> (last accessed on September 14, 2017).

27 ¹⁹⁷ 2015 Distribution Management Conference and Expo, Healthcare Distribution
 28 Alliance, <https://www.healthcaredistribution.org/events/2015-distribution-management-conference> (last accessed on September 14, 2017).

Marketing Defendants to coordinate the conduct of the Opioid Marketing Enterprise by, including but not limited to, coordinating their interaction and development of relationships with the Front Groups and KOLs.

2. The Front Groups

491. Each of the RICO Marketing Defendants had systematic links to and personal relationships with Front Groups that operated as part of the Opioid Marketing Enterprise to further the common purpose of unlawfully increasing sales by misrepresenting the non-addictive and effective use of opioids for the treatment of long-term chronic pain. As recently reported by the U.S. Senate in *“Fueling an Epidemic”*:

The fact that these same manufacturers provided millions of dollars to the groups described below suggests, at the very least, a direct link between corporate donations and the advancement of opioids-friendly messaging. By aligning medical culture with industry goals in this way, many of the groups described in this report may have played a significant role in creating the necessary conditions for the U.S. opioids epidemic.¹⁹⁸

492. “Patient advocacy organizations and professional societies like the Front Groups ‘play a significant role in shaping health policy debates, setting national guidelines for patient treatment, raising disease awareness, and educating the public.’”¹⁹⁹ “Even small organizations— with ‘their large numbers and credibility with policymakers and the public’—have ‘extensive influence in specific disease areas.’ Larger organizations with extensive funding and outreach capabilities ‘likely have a substantial effect on policies relevant to their industry sponsors.’”²⁰⁰ Indeed, as reflected below, the U.S. Senate’s report found that the RICO Marketing Defendants made nearly \$9 million worth of contributions to various Front Groups, including members of the Opioid Marketing Enterprise.²⁰¹

¹⁹⁸ *Fueling an Epidemic*, at p. 1.

¹⁹⁹ *Id.* at p. 2

²⁰⁰ *Id.*

²⁰¹ *Id.* at p. 3.

FIGURE 1: Manufacturer Payments to Selected Groups, 2012-2017

	Purdue ²²	Janssen ²³	Depomed	Insys	Mylan	Total
Academy of Integrative Pain Management	\$1,091,024.86	\$128,000.00	\$43,491.95	\$3,050.00 ²⁴	\$0.00	\$1,265,566.81
American Academy of Pain Medicine	\$725,584.95	\$83,975.00	\$332,100.00	\$57,750.00	\$0.00	\$1,199,409.95
AAPM Foundation	\$0.00	\$0.00	\$304,605.00	\$0.00	\$0.00	\$304,605.00
ACS Cancer Action Network	\$168,500.00 ²⁵	\$0.00	\$0.00	\$0.00	\$0.00	\$168,500.00
American Chronic Pain Association	\$312,470.00	\$50,000.00	\$54,670.00	\$0.00	\$0.00	\$417,140.00
American Geriatrics Society	\$11,785.00 ²⁶	\$0.00	\$0.00	\$0.00	\$0.00	\$11,785.00
American Pain Foundation	\$25,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$25,000.00
American Pain Society	\$542,259.52	\$88,500.00	\$288,750.00	\$22,965.00	\$20,250.00	\$962,724.52
American Society of Pain Educators	\$30,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$30,000.00
American Society of Pain Management Nursing	\$242,535.00	\$55,177.85 ²⁷	\$25,500.00 ²⁸	\$0.00	\$0.00	\$323,212.85
The Center for Practical Bioethics	\$145,095.00	\$18,000.00	\$0.00	\$0.00	\$0.00	\$163,095.00
The National Pain Foundation ²⁹	\$0.00	\$0.00	\$0.00	\$562,500.00	\$0.00	\$562,500.00
U.S. Pain Foundation	\$359,300.00	\$41,500.00	\$22,000.00	\$2,500,000.00 ³⁰	\$0.00	\$2,922,800.00
Washington Legal Foundation	\$500,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$500,000.00
	\$4,153,554.33	\$465,152.85	\$1,071,116.95	\$3,146,265.00	\$20,250.00	\$8,856,339.13

493. The Front Groups included in the Opioid Marketing Enterprise “have promoted messages and policies favorable to opioid use while receiving millions of dollars in payments from opioid manufacturers. Through criticism of government prescribing guidelines, minimization of opioid addiction risk, and other efforts, ostensibly neutral advocacy organizations have often supported

industry interests at the expense of their own constituencies.²⁰² And, as reflected below, many of the RICO Marketing Defendants' Front Groups received the largest contributions:

FIGURE 5: Group Rankings by Manufacturer Payments, 2012-2017

U.S. Pain Foundation	\$2,922,800.00
Academy of Integrative Pain Management	\$1,265,566.81
American Academy of Pain Medicine	\$1,199,409.95
American Pain Society	\$962,724.52
The National Pain Foundation	\$562,500.00
Washington Legal Foundation	\$500,000.00
American Chronic Pain Association	\$417,140.00
American Society of Pain Management Nursing	\$323,212.85
AAPM Foundation	\$304,605.00
ACS Cancer Action Network	\$168,500.00
The Center for Practical Bioethics	\$163,095.00
American Society of Pain Educators	\$30,000.00
American Pain Foundation	\$25,000.00
American Geriatrics Society	\$11,785.00

494. But, the RICO Marketing Defendants connection with and control over the Front Groups did not end with financial contributions. Rather, the RICO Marketing Defendants made substantial contributions to physicians affiliated with the Front Groups totaling more than \$1.6 million.²⁰³ Moreover, the RICO Marketing Defendants "made substantial payments to individual group executives, staff members, board members, and advisory board members" affiliated with the Front Groups subject to the Senate Committee's study.²⁰⁴

²⁰² *Id.* at p. 3.

²⁰³ *Id.* at p. 3.

²⁰⁴ *Id.* at p. 10.

495. As described in more detail below²⁰⁵, the RICO Marketing Defendants “amplified or issued messages that reinforce industry efforts to promote opioid prescription and use, including guidelines and policies minimizing the risk of addiction and promoting opioids for chronic pain.”²⁰⁶ They also “lobbied to change laws directed at curbing opioid use, strongly criticized landmark CDC guidelines on opioid prescribing, and challenged legal efforts to hold physicians and industry executives responsible for overprescription and misbranding.”²⁰⁷

FIGURE 7: Purdue, Janssen, Insys, Depomed, and Mylan Payments to Groups and Group-Affiliated Individuals, 2012-Present⁴¹

	Payments to Group	Payments to Group-Affiliated Individuals	Total
U.S. Pain Foundation	\$2,922,800.00	\$126.20	\$2,922,926.20
The National Pain Foundation	\$562,500.00	\$839,848.84	\$1,402,348.84
Academy of Integrative Pain Management	\$1,265,566.81	\$30,223.42	\$1,295,790.23
American Academy of Pain Medicine	\$1,199,409.95	\$16,462.42	\$1,215,872.37
American Pain Society	\$962,724.52	\$95,474.56	\$1,058,199.08
AAPM Foundation	\$304,605.00	\$314,175.58	\$618,780.58
Washington Legal Foundation	\$500,000.00	N/A	\$500,000.00
American Chronic Pain Association	\$417,140.00	\$31,265.87	\$448,405.87
American Society of Pain Management Nursing	\$323,212.85	N/A	\$323,212.85
American Society of Pain Educators	\$30,000.00	\$280,765.92	\$310,765.92
The Center for Practical Bioethics	\$163,095.00	\$7,116.86	\$170,211.86
ACS Cancer Action Network	\$168,500.00	N/A	\$168,500.00
American Pain Foundation	\$25,000.00	N/A	\$25,000.00
American Geriatrics Society	\$11,785.00	\$194.13	\$11,979.13
Total	\$8,856,339.13	\$1,615,653.80	\$10,471,992.93

²⁰⁵ The activities that the Front Groups engaged in, and the misrepresentations that they made, in furtherance of the common purpose of the Opioid Marketing Enterprise are alleged more fully below, under the heading “Conduct of the Opioid Marketing Enterprise.”

²⁰⁶ *Id.* at 12-15.

²⁰⁷ *Id.* at 12.

1 496. The systematic contacts and interpersonal relationships of the RICO
2 Marketing Defendants, and the Front Groups are further described below:

3 497. The American Pain Foundation (“APF”) – The American Pain
4 Foundation was the most prominent member of the RICO Defendants’ Front
5 Groups and was funded almost exclusively by the RICO Marketing Defendants.
6 Plaintiffs are informed and believe that APF received more than \$10 million in
7 funding from the RICO Marketing Defendants between 2007 and the close of its
8 business in May 2012. The APF had multiple contacts and personal relationships
9 with the RICO Marketing Defendants through its many publishing and
10 educational programs, funded and supported by the RICO Marketing Defendants.
11 Plaintiffs are further informed and believe that between 2009 and 2010, APF
12 received more than eighty percent (80%) of its operating budget from
13 pharmaceutical industry sources. Including industry grants for specific projects,
14 APF received about \$2.3 million from industry sources out of total income of
15 about \$2.85 million in 2009; its budget for 2010 projected receipts of roughly \$2.9
16 million from drug companies, out of total income of about \$3.5 million. By 2011,
17 upon information and belief, APF was entirely dependent on incoming grants
18 from Defendants Purdue, Cephalon, Endo, and others.

19 498. On information and belief, APF was often called upon to provide
20 “patient representatives” for the RICO Marketing Defendants’ promotional
21 activities, including for Purdue’s “Partners Against Pain” and Janssen’s “Let’s
22 Talk Pain.” APF functioned largely as an advocate for the interests of the RICO
23 Marketing Defendants, not patients. Indeed, upon information and belief, as early
24 as 2001, Purdue told APF that the basis of a grant was Purdue’s desire to
25 “strategically align its investments in nonprofit organizations that share [its]
26 business interests.”

27 499. APF is also credited with creating the PCF in 2004. Plaintiffs are
28 informed and believe that the PCF was created with the stated goal of offering a

1 “setting where multiple organizations can share information” and “promote and
 2 support taking collaborative action regarding federal pain policy issues.”
 3 Plaintiffs are informed and believe that past APF President Will Rowe described
 4 the PCF as “a deliberate effort to positively merge the capacities of industry,
 5 professional associations, and patient organizations.”

6 500. Upon information and belief, representatives of the RICO Marketing
 7 Defendants, often at informal meetings at conferences, suggested activities and
 8 publications for APF to pursue. APF then submitted grant proposals seeking to
 9 fund these activities and publications, knowing that drug companies would
 10 support projects conceived as a result of these communications.

11 501. Furthermore, APF’s Board of Directors was largely comprised of
 12 doctors who were on Defendants’ payrolls, either as consultants or speakers at
 13 medical events.²⁰⁸ As described below, many of the KOLs involved in the Opioid
 14 Marketing Enterprise also served in leadership positions within the APF.

15 502. In December 2011, a ProPublica investigation found that in 2010,
 16 nearly 90% of APF’s funding came from the drug and medical device community,
 17 including RICO Marketing Defendants.²⁰⁹ More specifically, APF received
 18 approximately \$2.3 million from industry sources out of total income of \$2.85
 19 million in 2009. It’s budget for 2010 projected receipt of approximately \$2.9
 20 million from drug companies, out of total income of approximately \$3.5 million.
 21 In May 2012, the U.S. Senate Finance Committee began looking into APF to
 22 determine the links, financial and otherwise, between the organization and the
 23 manufacturers of opioid painkillers. Within days of being targeted by the Senate
 24

25 ²⁰⁸ Charles Ornstein and Tracy Weber, *The Champion of Painkillers*, ProPublica
 26 (Dec. 23, 2011), <https://www.propublica.org/article/the-champion-of-painkillers>.

27 ²⁰⁹ Charles Ornstein & Tracy Weber, *Patient advocacy group funded by success of*
 28 *painkiller drugs, probe finds*, Wash. Post (Dec. 23, 2011),
https://www.washingtonpost.com/national/healthscience/patient-advocacy-group-funded-by-success-of-painkiller-drugs-probefinds/2011/12/20/gIQAgvczDP_story.html?utm_term=.22049984c606.

1 investigation, APF's Board voted to dissolve the organization "due to irreparable
2 economic circumstances." APF "cease[d] to exist, effective immediately."²¹⁰

3 503. The American Academy of Pain Medicine ("AAPM") – The AAPM
4 was another Front Group that had systematic ties and personal relationships with
5 the RICO Defendants. AAPM received over \$2.2 million in funding since 2009
6 from opioid manufacturers. AAPM maintained a corporate relations council,
7 whose members paid \$25,000 per year (on top of other funding) to participate.
8 The benefits included allowing members to present educational programs at off-
9 site dinner symposia in connection with AAPM's marquee event – its annual
10 meeting held in Palm Springs, California, or other resort locations. AAPM
11 describes the annual event as an "exclusive venue" for offering education
12 programs to doctors. Membership in the corporate relations council also allowed
13 drug company executives and marketing staff to meet with AAPM executive
14 committee members in small settings. The RICO Marketing Defendants were all
15 members of the council and presented deceptive programs to doctors who
16 attended this annual event.²¹¹

17 504. The RICO Marketing Defendants internally viewed AAPM as
18 "industry friendly," with RICO Defendants' advisors and speakers among its
19 active members. The RICO Marketing Defendants attended AAPM conferences,
20 funded its CMEs and satellite symposia, and distributed its publications. AAPM
21 conferences heavily emphasized sessions on opioids. AAPM presidents have
22 included top industry-supported KOLs like Perry Fine and Lynn Webster.

23
24
25 ²¹⁰ Charles Ornstein & Tracy Weber, *Senate Panel Investigates Drug Companies'*
26 *Ties to Pain Groups*, Wash. Post, May 8, 2012,
27 [https://www.washingtonpost.com/national/health-science/senate-panel-](https://www.washingtonpost.com/national/health-science/senate-panel-investigates-drug-companies-ties-to-pain-groups/2012/05/08/gIQA2X4qBU_story.html)
28 [investigates-drug-companies-ties-to-pain-](https://www.washingtonpost.com/national/health-science/senate-panel-investigates-drug-companies-ties-to-pain-groups/2012/05/08/gIQA2X4qBU_story.html)
[groups/2012/05/08/gIQA2X4qBU_story.html](https://www.washingtonpost.com/national/health-science/senate-panel-investigates-drug-companies-ties-to-pain-groups/2012/05/08/gIQA2X4qBU_story.html).

²¹¹ The American Academy of Pain Medicine, *Pain Medicine DC The Governing*
Voices of Pain: Medicine, Science, and Government, March 24-27, 2011,
<http://www.painmed.org/files/2011-annual-meeting-program-book.pdf>.

1 505. Upon information and belief, representatives of the RICO Marketing
2 Defendants, often at informal meetings at conferences, suggested activities and
3 publications for AAPM to pursue. AAPM then submitted grant proposals seeking
4 to fund these activities and publications, knowing that drug companies would
5 support projects conceived as a result of these communications.

6 506. Plaintiffs are informed and believe that members of AAPM's Board
7 of Directors were doctors who were on the RICO Marketing Defendants' payrolls,
8 either as consultants or speakers at medical events. As described below, many of
9 the KOLs involved in the Opioid Marketing Enterprise also served in leadership
10 positions within the AAPM.

11 507. The American Pain Society ("APS") – The APS was another Front
12 Group with systematic connections and interpersonal relationships with the RICO
13 Marketing Defendants. APS was one of the Front Groups investigated by
14 Senators Grassley and Baucus, as evidenced by their May 8, 2012 letter arising
15 out of their investigation of "extensive ties between companies that manufacture
16 and market opioids and non-profit organizations" that "helped created a body of
17 dubious information favoring opioids."²¹²

18 508. Upon information and belief, representatives of the RICO Marketing
19 Defendants, often at informal meetings at conferences, suggested activities and
20 publications for APS to pursue. APS then submitted grant proposals seeking to
21 fund these activities and publications, knowing that drug companies would
22 support projects conceived as a result of these communications.

23 509. Plaintiffs are informed and believe that members of APS's Board of
24 Directors were doctors who were on the RICO Marketing Defendants' payrolls,
25

26
27 ²¹² Letter from U.S. Senators Charles E. Grassley and Max Baucus to Catherine
28 Underwood, Executive Director (May 8, 2012), American Pain Society,
<https://www.finance.senate.gov/imo/media/doc/05092012%20Baucus%20Grassley%20Opioid%20Investigation%20Letter%20to%20American%20Pain%20Society.pdf>.

1 either as consultants or speakers at medical events. As described below, many of
 2 the KOLs involved in the Opioid Marketing Enterprise also served in leadership
 3 positions within the APS.

4 510. The Federation of State Medical Boards (“FSMB”) – FSMB was
 5 another Front Group with systematic connections and interpersonal relationships
 6 with the RICO Marketing Defendants. In addition to the contributions reported in
 7 *Fueling an Epidemic*, a June 8, 2012 letter submitted by FSMB to the Senate
 8 Finance Committee disclosed substantial payments from the RICO Marketing
 9 Defendants beginning in 1997 and continuing through 2012.²¹³ Not surprisingly,
 10 the FSMB was another one of the Front Groups investigated by Senators Grassley
 11 and Baucus, as evidenced by their May 8, 2012 letter arising out of their
 12 investigation of “extensive ties between companies that manufacture and market
 13 opioids and non-profit organizations” that “helped created a body of dubious
 14 information favoring opioids.”²¹⁴

15 511. The U.S. Pain Foundation (“USPF”) – The USPF was another Front
 16 Group with systematic connections and interpersonal relationships with the RICO
 17 Marketing Defendants. The USPF was one of the largest recipients of
 18 contributions from the RICO Marketing Defendants, collection nearly \$3 million
 19 in payments between 2012 and 2015 alone.²¹⁵ The USPF was also a critical
 20 component of the Opioid Marketing Enterprise’s lobbying efforts to reduce the
 21 limits on over-prescription. The U.S. Pain Foundation advertises its ties to the
 22 RICO Marketing Defendants, listing opioid manufacturers like Pfizer, Teva,
 23

24 ²¹³ June 8, 2012 Letter from Federation of State Medical Boards to U.S. Senators
 25 Max Baucus and Charles Grassley.

26 ²¹⁴ Letter from U.S. Senators Charles E. Grassley and Max Baucus to Catherine
 27 Underwood, Executive Director (May 8, 2012), American Pain Society,
 28 <https://www.finance.senate.gov/imo/media/doc/05092012%20Baucus%20Grassley%20Opioid%20Investigation%20Letter%20to%20American%20Pain%20Society.pdf>.

²¹⁵ *Fueling an Epidemic*, at p. 4.

1 Depomed, Endo, Purdue, McNeil (i.e. Janssen), and Mallinckrodt as “Platinum,”
 2 “Gold,” and “Basic” corporate members.²¹⁶ Industry Front Groups like the
 3 American Academy of Pain Management, the American Academy of Pain
 4 Medicine, the American Pain Society, and PhRMA are also members of varying
 5 levels in the USPF.

6 512. American Geriatrics Society (“AGS”) – The AGS was another Front
 7 Group with systematic connections and interpersonal relationships with the RICO
 8 Defendants. The AGS was a large recipient of contributions from the RICO
 9 Marketing Defendants, including Endo, Purdue and Janssen. AGS contracted
 10 with the RICO Marketing Defendants to disseminate guidelines regarding the use
 11 of opioids for chronic pain in 2002 (The Management of Persistent Pain in Older
 12 Persons, hereinafter “2002 AGS Guidelines”) and 2009 (Pharmacological
 13 Management of Persistent Pain in Older Persons,²¹⁷ hereinafter “2009 AGS
 14 Guidelines”). According to news reports, AGS has received at least \$344,000 in
 15 funding from opioid manufacturers since 2009.²¹⁸ AGS’s complicity in the
 16 common purpose of the Opioid Marketing Enterprise is evidenced by the fact that
 17 AGS internal discussions in August 2009 reveal that it did not want to receive-up
 18 front funding from drug companies, which would suggest drug company
 19 influence, but would instead accept commercial support to disseminate pro-opioid
 20 publications.

21 513. Upon information and belief, representatives of the RICO Marketing
 22 Defendants, often at informal meetings at conferences, suggested activities,

24 ²¹⁶ *Id.* at 12; Transparency, U.S. Pain Foundation,
 25 <https://uspainfoundation.org/transparency/> (last accessed on March 9, 2018).

26 ²¹⁷ *Pharmacological Management of Persistent Pain in Older Persons*, 57 J. Am.
 27 Geriatrics Soc’y 1331, 1339, 1342 (2009), available at
 28 <https://www.nhqualitycampaign.org/files/AmericanGeriatricSociety-PainGuidelines2009.pdf> (last accessed on March 9, 2018).

²¹⁸ John Fauber & Ellen Gabler, *Narcotic Painkiller Use Booming Among Elderly*, Milwaukee J. Sentinel, May 30, 2012.

1 lobbying efforts and publications for AGS to pursue. AGS then submitted grant
2 proposals seeking to fund these activities and publications, knowing that drug
3 companies would support projects conceived as a result of these communications.

4 514. Plaintiffs are informed and believe that members of AGS Board of
5 Directors were doctors who were on the RICO Marketing Defendants' payrolls,
6 either as consultants or speakers at medical events. As described below, many of
7 the KOLs involved in the Opioid Marketing Enterprise also served in leadership
8 positions within the AGS.

9 515. There was regular communication between each of the RICO
10 Marketing Defendants, Front Groups and KOLs, in which information was shared,
11 misrepresentations were coordinated, and payments were exchanged. Typically,
12 the coordination, communication and payment occurred, and continues to occur,
13 through the use of the wires and mail in which the RICO Markets Defendants,
14 Front Groups, and KOLs share information necessary to overcome objections and
15 resistance to the use of opioids for chronic pain. The RICO Marketing
16 Defendants, Front Groups and KOLs functioned as a continuing unit for the
17 purpose of implementing the Opioid Marketing Enterprise's scheme and common
18 purpose, and each agreed to take actions to hide the scheme and continue its
19 existence.

20 516. At all relevant times, the Front Groups were aware of the RICO
21 Marketing Defendants' conduct, were knowing and willing participants in that
22 conduct, and reaped benefits from that conduct. Each Front Group also knew, but
23 did not disclose, that the other Front Groups were engaged in the same scheme, to
24 the detriment of consumers, prescribers, and The County. But for the Opioid
25 Marketing Enterprise's unlawful fraud, the Front Groups would have had
26 incentive to disclose the deceit by the RICO Marketing Defendants and the Opioid
27 Marketing Enterprise to their members and constituents. By failing to disclose
28

1 this information, Front Groups perpetuated the Opioid Marketing Enterprise's
2 scheme and common purpose, and reaped substantial benefits.

3 **3. The KOLs**

4 517. Similarly, each of the RICO Marketing Defendants financed,
5 supported, utilized and relied on the same KOLs by paying, financing, supporting,
6 managing, directing, or overseeing, and/or relying on their work. On Information
7 and belief, the RICO Marketing Defendants cultivated this small circle of doctors
8 solely because they favored the aggressive treatment of chronic pain with opioids.

9 518. The RICO Marketing Defendants and the Opioid Marketing
10 Enterprise relied on their KOLs to serve as part of their speakers bureaus and to
11 attend programs with speakers bureaus. The RICO Marketing Defendants graded
12 their KOLs on performance, post-program sales, and product usage. Furthermore,
13 the RICO Marketing Defendants expected their KOLs to stay "on message," and
14 obtained agreements from them, in writing, that "all slides must be presented in
15 their entirety and without alterations . . . and in sequence."

16 519. The RICO Marketing Defendants' KOLs have been at the center of
17 the Opioid Marketing Enterprise's marketing efforts, presenting the false
18 appearance of unbiased and reliable medical research supporting the broad use of
19 opioid therapy for chronic pain. As described in more detail below, the KOLs
20 have written, consulted, edited, and lent their names to books and articles, and
21 given speeches, and CMEs supporting chronic opioid therapy. They have served
22 on committees that developed treatment guidelines that strongly encourage the use
23 of opioids to treat chronic pain (even while acknowledging the lack of evidence in
24 support of that position) and on the boards of the pro-opioid Front Groups
25 identified above.

26 520. The RICO Marketing Defendants and KOLS all had systematic
27 connections and interpersonal relationships, as described below, through the
28 KOLs receipt of payments from the RICO Marketing Defendants and Front

1 Groups, the KOLs' authoring, publishing, speaking, and educating on behalf of
 2 the RICO Marketing Defendants, and their leadership roles and participation in
 3 the activities of the Front Groups, which were in turn financed by the RICO
 4 Marketing Defendants.

5 521. The systematic contacts and interpersonal relationships of the KOLs
 6 with the RICO Marketing Defendants and Front Groups are described below:

7 522. Dr. Russell Portenoy – Dr. Portenoy was one of the main KOLs that
 8 the RICO Marketing Defendants identified and promoted to further the common
 9 purpose of the Opioid Marketing Enterprise. Dr. Portenoy received research
 10 support, consulting fees, and honoraria from the RICO Defendants, and was a paid
 11 consultant to various RICO Marketing Defendants. Dr. Portenoy was
 12 instrumental in opening the door for the regular use of opioids to treat chronic
 13 pain. Dr. Portenoy is credited as one of the authors on a primary pillar of the
 14 RICO Marketing Defendants' misrepresentation regarding the risks and benefits
 15 of opioid use.²¹⁹ Dr. Portenoy had financial relationships with at least a dozen
 16 pharmaceutical companies, most of which produced prescription opioids.²²⁰

17
 18
 19 ²¹⁹ In 1986, the medical journal *Pain*, which would eventually become the official
 20 journal of the American Pain Society ("APS"), published an article by Portenoy
 21 and Foley summarizing the results of a "study" of 38 chronic non-cancer pain
 22 patients who had been treated with opioid painkillers. Portenoy and Foley
 23 concluded that, for non-cancer pain, opioids "can be safely and effectively
 24 prescribed to selected patients with relatively little risk of producing the
 25 maladaptive behaviors which define opioid abuse." However, their study was
 26 neither scientific nor did it meet the rigorous standards commonly used to evaluate
 the validity and strength of such studies in the medical community. For instance,
 there was no placebo control group, and the results were retroactive (asking
 patients to describe prior experiences with opioid treatment rather than less biased,
 in-the-moment reports). The authors themselves advised caution, stating that the
 drugs should be used as an "alternative therapy" and recognizing that longer term
 studies of patients on opioids would have to be performed. None were. See Russell
 K. Portenoy & Kathleen M. Foley, *Chronic use of opioid analgesics in non-
 malignant pain: report of 38 cases*, 25(2) *Pain* 171-86 (May 1986).

27 ²²⁰ Anna Lembke, *Drug Dealer, MD: How Doctors Were Duped, Patients Got*
 28 *Hooked, and Why It's So Hard to Stop*, (Johns Hopkins University Press 2016), at
 59 (citing Barry Meier, *Pain Killer: A "Wonder" Drug's Trail of Addiction and*
Death (St. Martin's Press, 1st Ed 2003).

523. In exchange for the payments he received from the RICO Marketing Defendants, Dr. Portenoy is credited as one of the authors on a primary pillar of the RICO Marketing Defendants' misrepresentation regarding the risks and benefits of opioids.²²¹ Dr. Portenoy, published, spoke, consulted, appeared in advertisements and on television broadcasts, and traveled the country to travel the country to promote more liberal prescribing for many types of pain and conduct continuing medical education ("CME") seminars sponsored by the RICO Marketing Defendants and Front Groups.

524. Dr. Portenoy was also a critical component of the RICO Marketing Defendants' control over their Front Groups, and the Front Groups support of the Opioid Marketing Enterprise's common purpose. Specifically, Dr. Portenoy sat as a Director on the board of the APF. He was also the President of the APS.

525. In a 2011 interview released by Physicians for Responsible Opioid Prescribing, Dr. Portenoy admitted that his earlier work relied on evidence that was not "real" and left real evidence behind, all in furtherance of the Opioid Marketing Enterprise's common purpose:

I gave so many lectures to primary care audiences in which the Porter and Jick article was just one piece of data that I would then cite, and I would cite six, seven, maybe ten different avenues of thought or avenues of evidence, none of which represented real evidence, and yet what I was trying to do was to create a narrative so that the primary

²²¹ In 1986, the medical journal *Pain*, which would eventually become the official journal of the American Pain Society ("APS"), published an article by Portenoy and Foley summarizing the results of a "study" of 38 chronic non-cancer pain patients who had been treated with opioid painkillers. Portenoy and Foley concluded that, for non-cancer pain, opioids "can be safely and effectively prescribed to selected patients with relatively little risk of producing the maladaptive behaviors which define opioid abuse." However, their study was neither scientific nor did it meet the rigorous standards commonly used to evaluate the validity and strength of such studies in the medical community. For instance, there was no placebo control group, and the results were retroactive (asking patients to describe prior experiences with opioid treatment rather than less biased, in-the-moment reports). The authors themselves advised caution, stating that the drugs should be used as an "alternative therapy" and recognizing that longer term studies of patients on opioids would have to be performed. None were. See Russell K. Portenoy & Kathleen M. Foley, *Chronic use of opioid analgesics in non-malignant pain: report of 38 cases*, 25(2) *Pain* 171-86 (May 1986).

1 care audience would look at this information in [total] and feel more
 2 comfortable about opioids in a way they hadn't before. In essence this
 was education to destigmatize [opioids], and because the primary goal
 was to destigmatize, we often left evidence behind.²²²

3 526. Dr. Lynn Webster – Dr. Webster was a critical component of the
 4 Opioid Marketing Enterprise, including advocating the RICO Marketing
 5 Defendants' fraudulent messages regarding prescription opioids and had
 6 systematic contacts and personal relationships with the RICO Marketing
 7 Defendants and the Front Groups.

8 527. Dr. Webster was the co-founder and Chief Medical Director of an
 9 otherwise unknown pain clinic in Salt Lake City, Utah (Lifetree Clinical
 10 Research), who went on to become one of the RICO Marketing Defendants' main
 11 KOLs. Dr. Webster was the President of American Academy of Pain Medicine
 12 ("AAPM") in 2013. He is a Senior Editor of Pain Medicine, the same journal that
 13 published Endo special advertising supplements touting Opana ER. Dr. Webster
 14 was the author of numerous CMEs sponsored by Cephalon, Endo, and Purdue. At
 15 the same time, Dr. Webster was receiving significant funding from the RICO
 16 Marketing Defendants (including nearly \$2 million from Cephalon alone).

17 528. During a portion of his time as a KOL, Dr. Webster was under
 18 investigation for overprescribing by the U.S. Department of Justice's Drug
 19 Enforcement Agency, which raided his clinic in 2010. Although the investigation
 20 was closed without charges in 2014, more than twenty (20) of Dr. Webster's
 21 former patients at the Lifetree Clinic have died of opioid overdoses.

22 529. Dr. Webster created and promoted the Opioid Risk Tool, a five
 23 question, one-minute screening tool relying on patient self-reports that purportedly
 24 allows doctors to manage the risk that their patients will become addicted to or
 25 abuse opioids. The claimed ability to pre-sort patients likely to become addicted is

26
 27
 28 ²²² Andrew Kolodny, *Opioids for Chronic Pain: Addiction is NOT Rare*, YouTube
 (Oct. 30, 2011),
<https://www.youtube.com/watch?v=DgyuBWN9D4w&feature=youtu.be>.

1 an important tool in giving doctors confidence to prescribe opioids long-term, and,
 2 for this reason, references to screening appear in various industry-supported
 3 guidelines. Versions of Dr. Webster's Opioid Risk Tool appear on, or are linked
 4 to, websites run by Endo, Janssen, and Purdue.

5 530. Dr. Webster is also credited as one of the leading proponents of
 6 "pseudoaddiction" that the RICO Marketing Defendants, Front Groups and KOLs
 7 disseminated as part of the common purpose of the Opioid Marketing Enterprise.

8 531. Plaintiff The County is informed and believes that in exchange for
 9 the payments he received from the RICO Marketing Defendants, Dr. Webster
 10 published, spoke, consulted, appeared in advertisements and on television
 11 broadcasts, and traveled the country to promote more liberal prescribing of
 12 opioids for many types of pain and conduct CME seminars sponsored by the
 13 RICO Marketing Defendants and Front Groups.

14 532. Like Dr. Portenoy, Dr. Webster later reversed his opinion and
 15 disavowed his previous work on and opinions regarding pseudoaddiction.
 16 Specifically, Dr. Webster acknowledged that "[pseudoaddiction] obviously
 17 became too much of an excuse to give patients more medication."²²³

18 533. Dr. Perry Fine – Dr. Webster was a critical component of the Opioid
 19 Marketing Enterprise, including advocating the RICO Marketing Defendants'
 20 fraudulent messages regarding prescription opioids and had systematic contacts
 21 and personal relationships with the RICO Marketing Defendants and the Front
 22 Groups.

23 534. Dr. Fine was originally a doctor practicing in Utah, who received
 24 support from the RICO Marketing Defendants, including Janssen, Cephalon,
 25 Endo, and Purdue. Dr. Fine's ties to the RICO Marketing Defendants have been
 26

27 ²²³ John Fauber, *Painkiller Boom Fueled by Networking*, Milwaukee Wisc. J.
 28 Sentinel, Feb. 18, 2012,
<http://archive.jsonline.com/watchdog/watchdogreports/painkiller-boom-fueled-by-networking-dp3p2rn-139609053.html>.

1 well documented.²²⁴ He has authored articles and testified in court cases and
 2 before state and federal committees, and he served as president of the AAPM, and
 3 argued against legislation restricting high-dose opioid prescription for non-cancer
 4 patients. Multiple videos featured Fine delivering educational talks about
 5 prescription opioids. He even testified in a trial that the 1,500 pills a month
 6 prescribed to celebrity Anna Nicole Smith for pain did not make her an addict
 7 before her death.²²⁵ He has also acknowledged having failed to disclose numerous
 8 conflicts of interest.

9 535. Dr. Fine was also a critical component of the RICO Marketing
 10 Defendants' control over their Front Groups, and the Front Groups support of the
 11 Opioid Marketing Enterprise's common purpose. Specifically, Dr. Fine served on
 12 the Board of Directors of APF and served as the President of the AAPM in 2011.

13 536. Plaintiff The County is informed and believes that in exchange for
 14 the payments he received from the RICO Marketing Defendants, Dr. Fine
 15 published, spoke, consulted, appeared in advertisements and on television
 16 broadcasts, and traveled the country to promote more liberal prescribing of
 17 opioids for many types of pain and conduct CME seminars sponsored by the
 18 RICO Marketing Defendants and Front Groups.

19 537. Dr. Scott M. Fishman – Dr. Fishman was a critical component of the
 20 Opioid Marketing Enterprise, including advocating the RICO Marketing
 21 Defendants' fraudulent messages regarding prescription opioids and had
 22
 23

24
 25 ²²⁴ Tracy Weber & Charles Ornstein, *Two Leaders in Pain Treatment Have Long*
 26 *Ties to Drug Industry*, ProPublica (Dec. 23, 2011, 2:14 PM),
[https://www.propublica.org/article/two-leaders-in-pain-treatment-have-long-ties-](https://www.propublica.org/article/two-leaders-in-pain-treatment-have-long-ties-to-drug-industry)
[to-drug-industry](https://www.propublica.org/article/two-leaders-in-pain-treatment-have-long-ties-to-drug-industry)

27 ²²⁵ Linda Deutsch, *Doctor: 1,500 pills don't prove Smith was addicted*, Seattle
 28 Times (Sept. 22, 2010, 5:16 PM),
[http://www.seattletimes.com/entertainment/doctor-1500-pills-dont-prove-](http://www.seattletimes.com/entertainment/doctor-1500-pills-dont-prove-smithwas-addicted/)
[smithwas-addicted/](http://www.seattletimes.com/entertainment/doctor-1500-pills-dont-prove-smithwas-addicted/).

1 systematic contacts and personal relationships with the RICO Marketing
2 Defendants and the Front Groups.

3 538. Although Dr. Fishman did not receive direct financial payments from
4 the RICO Marketing Defendants, his ties to the opioid drug industry are legion.²²⁶

5 539. As Dr. Fishman's personal biography indicates, he is critical
6 component of the RICO Marketing Defendants' control over their Front Groups,
7 and the Front Groups support of the Opioid Marketing Enterprise's common
8 purpose. Specifically, Dr. Fishman is an "internationally recognized expert on
9 pain and pain management" who has served in "numerous leadership roles with
10 the goal to alleviate pain."²²⁷ Dr. Fishman's roles in the pain industry include
11 "past president of the American Academy of Pain Medicine [AAPM], past
12 chairman of the board of directors of the American Pain Foundation [APF], and
13 past board member of the American Pain Society [APS]."²²⁸ Dr. Fishman is also
14 "the immediate past chair and current member of the Pain Care Coalition of the
15 American Society of Anesthesiologists, American Pain Society, and Academy of
16 Pain Medicine."²²⁹ Dr. Fishman's leadership positions within the central core of
17 the RICO Marketing Defendants' Front Groups was a direct result of his
18 participation in the Opioid Marketing Enterprise and agreement to cooperate with
19 the RICO Marketing Defendants' pattern of racketeering activity.

20 540. Plaintiff The County is informed and believes that in exchange for
21 the payments he received from the RICO Marketing Defendants, Dr. Fishman
22 published, spoke, consulted, appeared in advertisements and on television
23

24
25 ²²⁶ Scott M. Fishman, M.D., Professor, U.C. Davis Health, Center for Advancing
26 Pain Relief,
[https://www.ucdmc.ucdavis.edu/advancingpainrelief/our_team/Scott_Fishman.htm](https://www.ucdmc.ucdavis.edu/advancingpainrelief/our_team/Scott_Fishman.html)
l (accessed on February 28, 2018).

27 ²²⁷ *Id.*

28 ²²⁸ *Id.*

²²⁹ *Id.*

1 broadcasts, and traveled the country to promote more liberal prescribing of
2 opioids for many types of pain and conduct CME seminars sponsored by the
3 RICO Marketing Defendants and Front Groups.

4 541. There was regular communication between each of the RICO
5 Marketing Defendants, Front Groups and KOLs, in which information was shared,
6 misrepresentations are coordinated, and payments were exchanged. Typically, the
7 coordination, communication and payment occurred, and continues to occur,
8 through the use of the wires and mail in which the RICO Marketing Defendants,
9 Front Groups, and KOLs share information regarding overcoming objections and
10 resistance to the use of opioids for chronic pain. The RICO Marketing
11 Defendants, Front Groups and KOLs functioned as a continuing unit for the
12 purpose of implementing the Opioid Marketing Enterprise's scheme and common
13 purpose, and each agreed to take actions to hide the scheme and continue its
14 existence.

15 542. At all relevant times, the KOLs were aware of the RICO Marketing
16 Defendants' conduct, were knowing and willing participants in that conduct, and
17 reaped benefits from that conduct. The RICO Marketing Defendants selected
18 KOLs solely because they favored the aggressive treatment of chronic pain with
19 opioids. The RICO Marketing Defendants' support helped the KOLs become
20 respected industry experts. And, as they rose to prominence, the KOLs falsely
21 touted the benefits of using opioids to treat chronic pain, repaying the RICO
22 Marketing Defendants by advancing their marketing goals. The KOLs also knew,
23 but did not disclose, that the other KOLs and Front Groups were engaged in the
24 same scheme, to the detriment of consumers, prescribers, and The County. But
25 for the Opioid Marketing Enterprise's unlawful conduct, the KOLs would have
26 had incentive to disclose the deceit by the RICO Marketing Defendants and the
27 Opioid Marketing Enterprise, and to protect their patients and the patients of other
28 physicians. By failing to disclose this information, KOLs furthered the Opioid

1 Marketing Enterprise's scheme and common purpose, and reaped substantial
2 benefits.

3 543. As public scrutiny and media coverage focused on how opioids
4 ravaged communities in California and throughout the United States, the Front
5 Groups and KOLS did not challenge the RICO Marketing Defendants'
6 misrepresentations, seek to correct their previous misrepresentations, terminate
7 their role in the Opioid Marketing Enterprise, nor disclose publicly that the risks
8 of using opioids for chronic pain outweighed their benefits and were not supported
9 by medically acceptable evidence.

10 544. The RICO Marketing Defendants, Front Groups and KOLs engaged
11 in certain discrete categories of activities in furtherance of the common purpose of
12 the Opioid Marketing Enterprise. As reported in *Fueling an Epidemic*, the Opioid
13 Marketing Enterprise's conduct in furtherance of the common purpose of the
14 Opioid Marketing Enterprise involved: (1) misrepresentations regarding the risk
15 of addiction and safe use of prescription opioids for long-term chronic pain; (2)
16 lobbying to defeat measures to restrict over-prescription; (3) efforts to criticize or
17 undermine CDC guidelines; and (4) efforts to limit prescriber accountability. The
18 misrepresentations made in these publications are described in the following
19 section.

20 545. Efforts to Minimize the Risk of Addiction and Promote Opioid Use
21 As Safe for Long-Term Treatment of Chronic Pain – Members of the Opioid
22 Marketing Enterprise furthered the common purpose of the enterprise by
23 publishing and disseminating statements that minimized the risk of addiction and
24 misrepresented the safety of using prescription opioids for long-term treatment of
25 chronic, non-acute, and non-cancer pain. The categories of misrepresentations
26
27
28

made by the Opioid Marketing Enterprise and the RICO Defendants included the following:²³⁰

- The Use of Opioids for the Treatment of Chronic Pain: A Consensus Statement From the American Academy of Pain Medicine and the American Pain Society, 13 Clinical J. Pain 6 (1997). The “landmark consensus” was published by the AAPM and APS. Dr. Portenoy was the sole consultant. A member of Purdue’s speaker bureau authored the consensus.
- *Model Guidelines for the Use of Controlled Substances for the Treatment of Pain* (1998, 2004, 2007).²³¹ These guidelines, originally published by the FSMB in collaboration with RICO Defendants, advocated that opioids were “essential” and that “misunderstanding of addiction” contributed to undertreated pain.
- *Oxycontin: Balancing Risks and Benefits: Hearing of the S. Comm. on Health, Education, Labor and Pensions, Testimony by John D. Giglio, M.A., J.D., Executive Direction of the APF* (2002).²³²
- *The Management of Persistent Pain in Older Persons* (2002). These guidelines were published by AGS with substantial funding from Endo, Purdue and Janssen.
- *Overview of Management Options* (2003, 2007, 2010, and 2013).²³³ This CME was edited by Dr. Portenoy, sponsored by Purdue, and published by

²³⁰ As noted below, the earliest misrepresentations disseminated by the RICO Defendants and the Opioid Marketing Enterprise began in 1997 and has continued unabated since that time. Therefore, this list is alleged as fully and completely as possible.

²³¹ *Model Policy for the Use of Controlled Substances for the Treatment of Pain*, Federation of State Medical Boards of the United States, May 2004, https://www.ihs.gov/painmanagement/includes/themes/newihstheme/display_objects/documents/modelpolicytreatmentpain.pdf (last accessed on March 9, 2018).

²³² *Oxycontin: Balancing Risks and Benefits: Hearing of the S. Comm. on Health, Education, Labor and Pensions, Testimony by John D. Giglio, M.A., J.D., Executive Direction of the APF* (2002.)

1 the American Medical Association. It taught that opioids, unlike non-
2 prescription pain medication are safe at high doses.

- 3 • *Understanding Your Pain: Taking Oral Opioid Analgesics* (2004).²³⁴ This
4 article, published by Endo Pharmaceuticals advocated that withdrawal and
5 needing to take higher dosages are not signs of addiction.
- 6 • Interview by Paula Moyer with Scott M. Fishman, M.D. (2005). Dr.
7 Fishman advocated that “the risks of addiction are . . . small and can be
8 managed.”²³⁵
- 9 • Open-label study of fentanyl effervescent buccal tablets in patients with
10 chronic pain and breakthrough pain: interim safety and tolerability results
11 (2006).²³⁶ Dr. Webster gave this CME, sponsored by Cephalon, that
12 misrepresented that opioids were safe for the treatment of non-cancer pain.
- 13 • *Treatment Options: A Guide for People Living With Pain* (2007). This
14 document was published by the APF and sponsored by Cephalon and
15 Purdue.²³⁷

16
17
18 ²³³ Portenoy, et al., *Overview of Management Options*, [https://cme.ama-](https://cme.ama-assn.org/activity/1296783/detail.aspx)
19 [assn.org/activity/1296783/detail.aspx](https://cme.ama-assn.org/activity/1296783/detail.aspx). On information and belief, this CME was
published by the American Medical Association in 2003, 2007, 2010, and 2013.

20 ²³⁴ Margo McCaffery & Chris Pasero, *Understanding Your Pain: Taking Oral*
21 *Opioid Analgesics*, Endo Pharmaceuticals (2004),
[https://www.yumpu.com/en/document/view/35479278/understanding-your-pain-](https://www.yumpu.com/en/document/view/35479278/understanding-your-pain-taking-oral-opioid-analgesics)
taking-oral-opioid-analgesics (last accessed March 8, 2018).

22 ²³⁵ Interview by Paula Moyer with Scott M. Fishman, M.D., Professor of
23 Anesthesiology and Pain Medicine, Chief of the Division of Pain Medicine, Univ.
of Cal., Davis (2005), available at <http://www.medscape.org/viewarticle/500829>.

24 ²³⁶ Hale ME, Webster LR, Peppin JF, Messina J. Open-label study of fentanyl
25 effervescent buccal tablets in patients with chronic pain and breakthrough pain:
interim safety and tolerability results. Program and abstracts of the annual meeting
26 of the American Academy of Pain Medicine; February 22-25, 2006; San Diego,
California. Abstract 120. Published with permission of Lynn R. Webster, MD,
https://www.medscape.org/viewarticle/524538_2 (accessed on March 6, 2018).

27 ²³⁷ Am. Pain Found., *Treatment Options: A Guide for People Living in Pain* (2007)
[hereinafter APF, *Treatment Options*],
28 <https://assets.documentcloud.org/documents/277605/apf-treatmentoptions.pdf> (last
accessed on March 8, 2018).

- 1 • *Responsible Opioid Prescribing: A Physician's Guide* (2007).²³⁸ This book,
2 authored by Dr. Fishman was financed by the FSMB with funding from
3 Cephalon, Endo and Purdue.
- 4 • *Avoiding Opioid Abuse While Managing Pain* (2007).²³⁹ This book, co-
5 authored by Dr. Webster, misrepresented that for prescribers facing signs of
6 aberrant behavior, increasing the dose in "most cases . . . should be a
7 clinician's first response."
- 8 • *Screening and Opioid Assessment for Patients with Pain (SOAPP)® Version*
9 *1.0-SF* (2008).²⁴⁰ This screening tool was published by the National
10 Institutes of Health with support from Endo through an educational grant,
11 and advocated that most patients are able to successfully remain on long-
12 term opioid therapy without significant problems.
- 13 • *Case Challenges in Pain Management: Opioid Therapy for Chronic Pain*
14 (2007).²⁴¹ This article, sponsored by Endo, misrepresented that opioids are
15 a highly effective class of analgesic drugs.
- 16 • *Opioid-Based Management of Persistent and Breakthrough Pain* (2008).²⁴²
17 This document was written by Dr. Fine and sponsored by an educational

20 ²³⁸ Scott M. Fishman, *Responsible Opioid Prescribing: A Physician's Guide*, 8-9
21 (Waterford Life Sciences 2007).

22 ²³⁹ Lynn Webster & Beth Dove, *Avoiding Opioid Abuse While Managing Pain*
(2007).

23 ²⁴⁰ *Screening and Opioid Assessment for Patients with Pain (SOAPP)® Version 1.0-*
24 *SF*, PainEdu.org, 2008, [https://www.nhms.org/sites/default/files/Pdfs/SOAPP-](https://www.nhms.org/sites/default/files/Pdfs/SOAPP-5.pdf)
5.pdf (last accessed on March 8, 2018).

25 ²⁴¹ Charles E. Argoff, *Case Challenges in Pain Management: Opioid Therapy for*
26 *Chronic Pain*, Pain Med. News,
https://www.painmedicine.com/download/BtoB_Opana_WM.pdf (last visited
on March 8, 2018).

27 ²⁴² Perry G Fine, MD, et al. *Opioid-Based Management of Persistent and*
28 *Breakthrough Pain*, Pain Medicine News,
[https://www.yumpu.com/en/document/view/11409251/opioid-based-management-](https://www.yumpu.com/en/document/view/11409251/opioid-based-management-of-persistent-and-breakthrough-pain)
of-persistent-and-breakthrough-pain (accessed on February 27, 2018).

1 grant from Cephalon. Dr. Fine advocated for the prescription of rapid onset
2 opioids “in patients with non-cancer pain.”

- 3 • *Optimizing Opioid Treatment for Breakthrough Pain* (2008).²⁴³ Dr.
4 Webster presented an online seminar (webinar) sponsored by Cephalon, that
5 misrepresented that non-opioid analgesics and combination opioids
6 containing non-opioids are less effective because of dose limitations.
- 7 • *Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Non-*
8 *Cancer Pain* (2009).²⁴⁴ These guidelines were published by AAPM and
9 APS. Fourteen of the twenty-one panel members, including Dr. Portenoy
10 and Dr. Fine, received support from the RICO Defendants.
- 11 • *Pharmacological Management of Persistent Pain in Older Persons*
12 (2009).²⁴⁵ These guidelines were published by AGS, with substantial
13 funding from Endo, Purdue, and Janssen, updated the 2002 guidelines and
14 misrepresented that the risks of addiction are exceedingly low.
- 15 • *Iraq War Veteran Amputee, Pain Advocate and New Author Release Exit*
16 *Wounds: A Survival Guide to Pain Management for Returning Veterans*
17 *and Their Families*,²⁴⁶ American Pain Foundation, 2009. This article was
18 published in 2009 and sponsored by Purdue.

19
20
21 ²⁴³ Lynn Webster, *Optimizing Opioid Treatment for Breakthrough Pain*, Medscape,
http://www.medscape.org/viewarticle/563417_6 (last visited Dec. 11, 2017).

22 ²⁴⁴ Roger Chou et al., *Clinical Guidelines for the Use of Chronic Opioid Therapy in*
Chronic Non-Cancer Pain, 10 J. Pain 113 (2009).

23 ²⁴⁵ *Pharmacological Management of Persistent Pain in Older Persons*, 57 J. Am.
24 Geriatrics Soc’y 1331, 1339, 1342 (2009), available at
[https://www.nhqualitycampaign.org/files/AmericanGeriatricSociety-](https://www.nhqualitycampaign.org/files/AmericanGeriatricSociety-PainGuidelines2009.pdf)
25 [PainGuidelines2009.pdf](https://www.nhqualitycampaign.org/files/AmericanGeriatricSociety-PainGuidelines2009.pdf) (last accessed on March 9, 2018).

26 ²⁴⁶ *Iraq War Veteran Amputee, Pain Advocate and New Author Release Exit*
Wounds: A Survival Guide to Pain Management for Returning Veterans and Their
27 *Families*, Coalition for Iraq + Afghanistan Veterans,
[http://web.archive.org/web/20100308224011/http://coalitionforveterans.org:80/200](http://web.archive.org/web/20100308224011/http://coalitionforveterans.org:80/2009/10/iraq-war-veteran-amputee-pain-advocate-and-new-author-releases-exit-wounds-a-survival-guide-to-pain-management-for-returning-veterans-and-their-families)
28 [9/10/iraq-war-veteran-amputee-pain-advocate-and-new-author-releases-exit-](http://web.archive.org/web/20100308224011/http://coalitionforveterans.org:80/2009/10/iraq-war-veteran-amputee-pain-advocate-and-new-author-releases-exit-wounds-a-survival-guide-to-pain-management-for-returning-veterans-and-their-families)
[wounds-a-survival-guide-to-pain-management-for-returning-veterans-and-their-](http://web.archive.org/web/20100308224011/http://coalitionforveterans.org:80/2009/10/iraq-war-veteran-amputee-pain-advocate-and-new-author-releases-exit-wounds-a-survival-guide-to-pain-management-for-returning-veterans-and-their-families)
[families](http://web.archive.org/web/20100308224011/http://coalitionforveterans.org:80/2009/10/iraq-war-veteran-amputee-pain-advocate-and-new-author-releases-exit-wounds-a-survival-guide-to-pain-management-for-returning-veterans-and-their-families) (last visited March 1, 2018)

- 1 • *Finding Relief: Pain Management for Older Adults*, (2009).²⁴⁷ This article
2 was a collaboration between the American Geriatrics Society, AAPM and
3 Janssen.
- 4 • Good Morning America (2010). Dr. Portenoy appeared on Good Morning
5 America and stated that “Addiction, when treating pain, is distinctly
6 uncommon.”²⁴⁸
- 7 • *A Policymaker’s Guide to Understanding Pain & Its Management*,
8 *American Pain Foundation* (2011).²⁴⁹ APF published this document, that
9 was sponsored by Purdue, which argued that the notion of strong pain
10 leading to addiction is a common misconception.
- 11 • *Managing Patient’s Opioid Use: Balancing the Need and the Risk*
12 (2011).²⁵⁰ Dr. Webster presented a webinar, sponsored by Purdue, that
13 misrepresented the ability to use risk screen tools, urine samples and patient
14 agreements to prevent overuse and overdose death.
- 15 • *Safe and Effective Opioid Rotation* (2012).²⁵¹ This CME, delivered by Dr.
16 Fine, that is also available online, advocated for the safe and non-addictive
17 use of opioids to treat cancer and non-cancer patients over a person’s
18 “lifetime.”

21 ²⁴⁷ *Finding Relief, Pain Management for Older Adults*, (2009).

22 ²⁴⁸ Good Morning America (ABC television broadcast Aug. 30, 2010).

23 ²⁴⁹ *A Policymaker’s Guide to Understanding Pain & Its Management*, American
Pain Foundation (2011) at

24 5, <http://s3.documentcloud.org/documents/277603/apf-policymakers-guide.pdf>
(last visited March 6, 2018).

25 ²⁵⁰ *See, Managing Patient’s Opioid Use: Balancing the Need and the Risk*,
26 Emerging Solutions in Pain [http://www.emergingsolutionsinpain.com/ce-education/opioid-](http://www.emergingsolutionsinpain.com/ce-education/opioid-management?option=com_continued&view=frontmatter&Itemid=303&course=209)
27 management?option=com_continued&view=frontmatter&Itemid=303&course=20
9 (last visited Aug. 22, 2017).

28 ²⁵¹ Perry A. Fine, *Safe and Effective Opioid Rotation*, YouTube (Nov. 8, 2012),
https://www.youtube.com/watch?v=_G3II9yqgXI.

- 1 • *Pain: Opioid Facts* (2012).²⁵² This document was published online on
2 Endo’s website painknowledge.org and advocated for the use of opioids and
3 downplayed the risk of addiction, even for people with a history of
4 addiction and opioid use, and supported the concept of pseudoaddiction.

5 546. Efforts to Criticize or Undermine CDC Guidelines – Members of the
6 Opioid Marketing Enterprise criticized or undermined the CDC Guidelines which
7 represented “an important step – and perhaps the first major step from the federal
8 government – toward limiting opioid prescriptions for chronic pain.” The
9 following are examples of the actions taken by Opioid Marketing Enterprise
10 members to prevent restriction on over-prescription:

- 11 • Several Front Groups, including the U.S. Pain Foundation, and the AAPM
12 criticized the draft guidelines in 2015, arguing that the “CDC slides
13 presented on Wednesday were not transparent relative to process and failed
14 to disclose the names, affiliation, and conflicts of interest of the individuals
15 who participated in the construction of these guidelines.”²⁵³
16 • The AAPM criticized the prescribing guidelines in 2016, through its
17 immediate past president, stating “that the CDC guideline makes
18 disproportionately strong recommendations based upon a narrowly selected
19 portion of the available clinical evidence.”²⁵⁴

22 ²⁵² *Pain: Opioid Facts*,
23 http://web.archive.org/web/20120112051109/http://www.painknowledge.org/patient/pdf/Patient%20Education%20b380_b385%20%20pf%20opiod.pdf (last
24 visited March 6, 2018).

25 ²⁵³ Pat Anson, *Chronic Pain Group Blasts CDC for Opioid Guidelines*, Pain News
26 Networks, <https://www.painnewsnetwork.org/stories/2015/9/22/chronic-pain-groups-blast-cdc-for-opioid-guidelines> (last accessed on March 8, 2018).

27 ²⁵⁴ Practical Pain Management, Responses and Criticisms Over New CDC Opioid
28 Prescribing Guidelines
 (<https://www.practicalpainmanagement.com/resources/news-and-research/responses-criticisms-over-new-cdc-opioid-prescribing-guidelines>)
 (accessed Sept. 28, 2017).

1 547. In each of the actions performed by members of the Opioid
2 Marketing Enterprise, described above, the members of the Opioid Marketing
3 Enterprise made branded and unbranded marketing claims about prescription
4 opioids that misrepresented prescription opioids as non-addictive and safe for use
5 as identified in following section.

6 **4. Members of the Opioid Marketing Enterprise**
7 **Furthered the Common Purpose by Making**
8 **Misrepresentations.**

9 548. The RICO Marketing Defendants, Front Groups and KOLs
10 participated in the conduct of the Opioid Marketing Enterprise and shared in the
11 common purpose of marketing opioids for chronic pain through a pattern of
12 racketeering activity (including multiple instances of mail and wire fraud) by
13 knowingly making material misrepresentations or omissions to California
14 prescribers, consumers, the general public, regulators and The County. All of the
15 misrepresentations made by members of the Opioid Marketing Enterprise
16 furthered the common purpose of the Enterprise.

17 549. Members of the Opioid Marketing Enterprise, including the RICO
18 Marketing Defendants, Front Groups and KOLs made multiple unbranded
19 marketing misrepresentations about the benefits and risks of opioid use, in
20 furtherance of the Opioid Marketing Enterprise's common purpose, as follows:

21 550. Members of the Opioid Marketing Enterprise minimized the risks of
22 addiction and/or construed opioids as non-addictive:

- 23 • AAMP and APS endorsed the use of opioids to treat chronic pain and
24 claimed that the risk of a patients' addiction to opioids was low.²⁵⁵

25
26
27 ²⁵⁵ The Use of Opioids for the Treatment of Chronic Pain: A Consensus Statement
28 From the American Academy of Pain Medicine and the American Pain Society, 13
Clinical J. Pain 6 (1997).

1 • “[O]pioids are safe and effective, and only in rare cases lead to
2 addiction.”²⁵⁶

3 • “[T]he risks of addiction are . . . small and can be managed.”²⁵⁷

4 **Medscape: Controversy surrounds both the undertreatment and overtreatment**
5 **of pain. Overtreatment of pain obviously involves the fear of causing or**
6 **perpetuating opioid drug dependency. What recommendations can you give to**
7 **primary care physicians who are reluctant to prescribe opioids, either as**
8 **adjuncts or primary agents for pain control, because of these fears?**

9 **Dr. Fishman:** It used to be that when you had a patient with pain and you were
10 worried about giving him or her a drug that may be abusable or may cause
11 addiction, the safest thing to do was nothing, as though doing nothing would have
12 no risks in and of itself. We know that the risks of addiction are there, but they are
13 small and can be managed. The AAPM is going to be at the forefront, educating

14 • Represented that calling opioids “‘narcotics’ reinforces myths and
15 misunderstandings as it places emphasis on their potential abuse rather than
16 on the importance of their use as pain medicines.”²⁵⁸

17 • “Addiction, when treating pain, is distinctly uncommon. If a person does
18 not have a history, a personal history, of substance abuse, and does not have
19 a history in the family of substance abuse, and does not have a very major
20 psychiatric disorder, most doctors can feel very assured that that person is
21 not going to become addicted.”²⁵⁹

22 **OPIOID ANALGESICS (NARCOTICS)**

23 Opioid analgesics are another important class of medications that are very effective pain
24 relievers. As mentioned before, they may also be called “narcotics.” Unfortunately, this
25 term is used by law enforcement to refer to drugs that are abused. Cocaine and heroin
26 are called narcotics even though they are very different kinds of drugs. Calling opioid
27 analgesics “narcotics” reinforces myths and misunderstandings as it places emphasis on
28 their potential abuse rather than on the importance of their use as pain medicines. In
the pain treatment world, the word opioid is used when speaking about this class of
medications.

²⁵⁶ *Oxycontin: Balancing Risks and Benefits: Hearing of the S. Comm. on Health, Education, Labor and Pensions*, 107th Cong. 2 (Feb. 12, 2002) (testimony of John D. Giglio, M.A., J.D., Executive Director, American Pain Foundation), <https://www.help.senate.gov/imo/media/doc/Giglio.pdf>.

²⁵⁷ Interview by Paula Moyer with Scott M. Fishman, M.D., Professor of Anesthesiology and Pain Medicine, Chief of the Division of Pain Medicine, Univ. of Cal., Davis (2005), available at <http://www.medscape.org/viewarticle/500829>.

²⁵⁸ APF, *Treatment Options*, <https://assets.documentcloud.org/documents/277605/apf-treatmentoptions.pdf> (last accessed on March 8, 2018).

²⁵⁹ Good Morning America (ABC television broadcast Aug. 30, 2010).

- 1 • The risk of addiction is manageable for patients regardless of past abuse
2 histories.²⁶⁰
- 3 • “[T]he likelihood that the treatment of pain using an opioid drug which is
4 prescribed by a doctor will lead to addiction is extremely low.”²⁶¹
- 5 • Patients might experience withdrawal symptoms associated with physical
6 dependence as the decrease their dose, “[b]ut unlike actual addicts, such
7 individuals, if they resume their opioid use, will only take enough
8 medication to alleviate their pain.”²⁶²
- 9 • The notion that “strong pain medication leads to addiction” is a “common
10 misconception.”²⁶³

SOME COMMON MISCONCEPTIONS ABOUT PAIN

Use of strong pain medication leads to addiction. Many people living with pain, and even some health care practitioners, falsely believe that opioid pain medicines are universally addictive. As with any medication, there are risks, but these risks can be managed when these medicines are properly prescribed and taken as directed. For more information about safety issues related to opioids and other pain therapies, visit www.painsafe.org.

20
21 ²⁶⁰ Roger Chou et al., Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Non-Cancer Pain, 10 J. Pain 113 (2009).

22 ²⁶¹ Thomas Catan and Evan Perez, *A Pain-Drug Champion Has Second Thoughts*,
23 The Wall Street Journal (Dec. 17, 2012),
<https://www.wsj.com/articles/SB10001424127887324478304578173342657044604>.

24 ²⁶² Brief Amici Curiae of American Pain Foundation, National Foundation for the
25 Treatment of Pain, and The Ohio Pain Initiative, in Support of
26 Defendants/Appellants, *Howland v. Purdue Pharma, L.P., et al.*, Appeal No. CA
27 2002 09 0220 (Butler Co., Ohio 12th Court of Appeals, Dec. 23, 2002),
<https://ia801005.us.archive.org/23/items/279014-howland-apf-amicus/279014-howland-apf-amicus.pdf>.

28 ²⁶³ A Policymaker’s Guide to Understanding Pain & Its Management, American Pain Foundation (2011) at 5, <http://s3.documentcloud.org/documents/277603/apf-policymakers-guide.pdf> (last visited March 6, 2018).

- “Addiction to an opioid would mean that your pain has gone away but you still take the medicine regularly when you don’t need it for pain, maybe just to escape your problems.”²⁶⁴

How can I be sure I’m not addicted?

- ◆ Addiction to an opioid would mean that your pain has gone away but you still take the medicine regularly when you don’t need it for pain, maybe just to escape from your problems.
- ◆ Ask yourself: Would I want to take this medicine if my pain went away? If you answer no, you are taking opioids for the right reasons—to relieve your pain and improve your function. You are not addicted.

- Even for patients assessed to have a risk of abuse, “it does not mean that opioid use will become problematic or that opioids are contraindicated.”²⁶⁵

WILL I BECOME ADDICTED TO OPIOIDS?


This is a key issue for both you and your doctor to discuss. In general, people who have no history of drug abuse, including tobacco, and use their opioid medication as directed will probably not become addicted. However, patients who misuse or abuse opioids can become addicted to them, so openly discussing your concerns with your doctor is important. People who are addicted to opioids crave the “unusually happy” effect the drug has on them (a “buzz” or “high”) and will continue to use the drug even though it harms them.



²⁶⁴ Margo McCaffery & Chris Pasero, *Understanding Your Pain: Taking Oral Opioid Analgesics*, Endo Pharmaceuticals (2004), <https://www.yumpu.com/en/document/view/35479278/understanding-your-pain-taking-oral-opioid-analgesics> (last accessed March 8, 2018).

²⁶⁵ Scott M. Fishman, *Responsible Opioid Prescribing: A Physician’s Guide*, 8-9 (Waterford Life Sciences 2007).

- [P]eople who have no history of drug abuse, including tobacco, and use their opioid medication as directed will probably not become addicted.”²⁶⁶
- “A history of addiction would not rule out the use of opioid pain relievers.”²⁶⁷



- APF published exit wounds, wherein it represented that “[l]ong experience with opioids shows that people who are not predisposed to addiction are very unlikely to become addicted to opioid pain medications.”²⁶⁸

Iraq War Veteran Amputee, Pain Advocate and New Author Releases Exit Wounds: A Survival Guide to Pain Management for Returning Veterans and Their Families



"It's now four years since I lay in the dirt, near death, on the side of the road in Fallujah. I'm grateful for all the things I have, and proud of all I've accomplished. In the end though, I don't measure how far I've come by goals achieved, or academic degrees earned, or running trophies won. For me, what counts is that pain no longer rules my life." – Derek McGinnis

The American Pain Foundation (APF) announces the release of Iraq War Veteran and Pain Advocate Derek McGinnis' first book, *Exit Wounds: A Survival Guide to Pain Management for Returning Veterans and Their Families*. Written in collaboration with nationally renowned pain experts, the release date of September 21 for Exit Wounds coincided with September's designation as Pain Awareness Month.

- Patients rarely become addicted to prescribed opioids.²⁶⁹

²⁶⁶ *Pain: Opioid Facts*, http://web.archive.org/web/20120112051109/http://www.painknowledge.org/patient/pdf/Patient%20Education%20b380_b385%20%20pf%20opioid.pdf (last visited March 6, 2018).

²⁶⁷ *Id.*

²⁶⁸ Iraq War Veteran Amputee, Pain Advocate and New Author Release Exit Wounds: A Survival Guide to Pain Management for Returning Veterans and Their Families, Coalition for Iraq + Afghanistan Veterans, <http://web.archive.org/web/20100308224011/http://coalitionforveterans.org:80/2009/10/iraq-war-veteran-amputee-pain-advocate-and-new-author-releases-exit-wounds-a-survival-guide-to-pain-management-for-returning-veterans-and-their-families> (last visited March 1, 2018).

- 1 • Concern about patients becoming addicted reflects widespread failure to
2 appreciate the distinction between “(1) *tolerance* – the body’s tendency to
3 become accustomed to a substance so that, over time, a larger amount is
4 needed to produce the same physical effect (pain relief) and *physical*
5 *dependence* – the state defined by the experience of adverse symptoms if a
6 drug is abruptly withdrawn . . . each of which is common with pain
7 patients” . . . “and, on the other hand, (2) the psychological and behavioral
8 patterns – an unhealthy craving for, compulsive use of, and unhealthy
9 fixation – that characterize *addiction*.”²⁷⁰
- 10 • Evidence establishes that the risk of drug addiction (historically the
11 principal *medical* justification for withholding or limiting opioids) is far
12 *less* substantial than long and widely assumed.²⁷¹
- 13 • The “risks [of addiction] are exceedingly low in older patients with no
14 current or past history of substance abuse.”²⁷²

15 the addiction. Although the risks are exceedingly low in
16 older patients with no current or past history of substance
17 abuse, it is impossible to identify every patient who will
18 abuse or divert prescribed opioids.¹¹⁷ Therefore, many cli-
19 nicians have adopted a Universal Precautions approach to
20 pain management.¹¹⁸ This paradigm stresses that every pa-

21 ²⁶⁹ Brief of Amici the American Pain Foundation, the National Pain Foundation,
22 and the National Foundation for the Treatment of Pain, 2005 WL 2405247, *9
23 (citing Portenoy, Russell, et al., *Acute and Chronic Pain*, in *COMPREHENSIVE*
24 *TEXTBOOK OF SUBSTANCE ABUSE*, 863-903 (Lowinson et al. eds., 4th ed.
2005), *United States v. Hurowitz*, 459 F.3d 463 (2006) (citing Portenoy et. al,
Chronic Use of Opioid Analgesics in Non-Malignant Pain: Report of 38 Cases,
PAIN, Vol. 25, 171-186, (1986)).

25 ²⁷⁰ Brief of Amici Russel K. Portenoy, et al., 2005 WL 2405249, *United States v.*
26 *Hurwitz*, 459 F.3d 463 (2006) (emphasis in original).

²⁷¹ *Id.* and sources cited at note 9.

27 ²⁷² *Pharmacological Management of Persistent Pain in Older Persons*, 57 J. Am.
28 Geriatrics Soc’y 1331, 1339, 1342 (2009), available at
[https://www.nhqualitycampaign.org/files/AmericanGeriatricSociety-](https://www.nhqualitycampaign.org/files/AmericanGeriatricSociety-PainGuidelines2009.pdf)
[PainGuidelines2009.pdf](https://www.nhqualitycampaign.org/files/AmericanGeriatricSociety-PainGuidelines2009.pdf) (last accessed on March 9, 2018).

551. Members of the Opioid Marketing Enterprise advocated that opioids were safe and effective for long-term treatment of chronic, non-acute and non-cancer pain:

- “Opioids are an essential option for treating *moderate* to severe pain associated with surgery or trauma. They may also be an important part of the management of persistent pain unrelated to cancer.”²⁷³

Clinical uses

Opioids are an essential option for treating moderate to severe pain associated with surgery or trauma, and for pain related to cancer. They may also be an important part of the management of persistent pain unrelated to cancer. These medicines block pain

- Opioids were a safe and effective treatment for of pain as part of a physicians’ treatment guidelines.²⁷⁴
- The “small risk of abuse does not justify the withholding of these highly effective analgesics from chronic pain patients.”²⁷⁵
- Opioids, unlike some non-prescription pain medications, are safe at high doses.²⁷⁶
- Falsely representing “recent findings suggesting that most patients are able to successfully remain on long-term opioid therapy without significant problems.”²⁷⁷

²⁷³ APF, *Treatment Options*, <https://assets.documentcloud.org/documents/277605/apf-treatmentoptions.pdf>.

²⁷⁴ Roger Chou et al., *Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Non-Cancer Pain*, 10 J. Pain 113 (2009).

²⁷⁵ Brief Amici Curiae of American Pain Foundation, National Foundation for the Treatment of Pain, and The Ohio Pain Initiative, in Support of Defendants/Appellants, *Howland v. Purdue Pharma, L.P., et al.*, Appeal No. CA 2002 09 0220 (Butler Co., Ohio 12th Court of Appeals, Dec. 23, 2002), <https://ia801005.us.archive.org/23/items/279014-howland-apf-amicus/279014-howland-apf-amicus.pdf>.

²⁷⁶ Portenoy, et al., *Overview of Management Options*, <https://cme.ama-assn.org/activity/1296783/detail.aspx>. On information and belief, this CME was published in 2003, 2007, 2010, and 2013.

²⁷⁷ *Screener and Opioid Assessment for Patients with Pain (SOAPP)® Version 1.0-SF*, PainEdu.org, 2008, <https://www.nhms.org/sites/default/files/Pdfs/SOAPP-5.pdf> (last accessed on March 8, 2018).

- 1 • Opioid therapy is an appropriate treatment for chronic, non-cancer pain and
2 integral to good medical practice.²⁷⁸
 - 3 • Even for patients assessed to have a risk of abuse, “it does not mean that
4 opioid use will become problematic or that opioids are contraindicated.”²⁷⁹
 - 5 • Opioid therapy is an appropriate treatment for chronic, non-cancer pain and
6 integral to good medical practice.²⁸⁰
 - 7 • Broadly classifying pain syndromes as “either cancer- or non-cancer-related
8 has limited utility,” and recommended dispensing rapid onset opioids “in
9 patients with non-cancer pain.”²⁸¹
- 10 The data suggest that FEBT is safe and well tolerated in opioid-tolerant patients
11 with chronic noncancer pain. There was no respiratory depression, and a low
12 incidence of treatment-related adverse events was reported. Thirty-five patients
13 (37%) reported having at least 1 adverse event, the most common of which were
nausea (7%) and dizziness (5%).
- 14 • Opioids are safe and well-tolerated in patients with chronic pain and break
15 through pain.²⁸²
 - 16 • Non-opioid analgesics and combination opioids containing non-opioids
17 such as aspirin and acetaminophen are less effective than opioids because of
18 dose limitations on non-opioids.²⁸³

20 ²⁷⁸ Scott M. Fishman, *Responsible Opioid Prescribing: A Physician’s Guide*, 8-9
(Waterford Life Sciences 2007).

21 ²⁷⁹ *Id.*

22 ²⁸⁰ Scott M. Fishman, *Responsible Opioid Prescribing: A Physician’s Guide*, 8-9 (Waterford Life
23 Sciences 2007).

24 ²⁸¹ Perry G Fine, MD, et al. *Opioid-Based Management of Persistent and*
Breakthrough Pain, Pain Medicine News,
25 [https://www.yumpu.com/en/document/view/11409251/opioid-based-management-](https://www.yumpu.com/en/document/view/11409251/opioid-based-management-of-persistent-and-breakthrough-pain)
of-persistent-and-breakthrough-pain (accessed on February 27, 2018).

26 ²⁸² Hale ME, Webster LR, Peppin JF, Messina J. Open-label study of fentanyl
27 effervescent buccal tablets in patients with chronic pain and breakthrough pain:
interim safety and tolerability results. Program and abstracts of the annual meeting
28 of the American Academy of Pain Medicine; February 22-25, 2006; San Diego,
California. Abstract 120. Published with permission of Lynn R. Webster, MD,
https://www.medscape.org/viewarticle/524538_2 (accessed on March 6, 2018).

adverse events. Furthermore, although nonopioid analgesics, such as acetaminophen and NSAIDs/COX-2 inhibitors, are effective for nociceptive pain, their use in BTP is likewise restricted by dose-limiting toxicities, an onset of action that is delayed by 30 minutes or more, a long duration of action that could augment sedation and other side effects of the agent used for the baseline pain, and fears about renal and cardiovascular complications. Agents that combine an SAO, such as hydrocodone plus acetaminophen, aspirin, or ibuprofen, also are limited by potential adverse events and ceiling effects from the nonopioid component.

- Opioids can safely alleviate chronic pain unresponsive to other medication.²⁸⁴
- Medical organization and government-sponsored clinical guidelines support and encourage opioid treatment for chronic pain.²⁸⁵
- Respiratory depression, even at extremely high levels, does not occur in the context of appropriate clinical treatment.²⁸⁶
- There is no “ceiling dose” for opioids.²⁸⁷
- Opioid analgesics are the most effective way to treat pain of moderate to severe intensity and often the only treatment that provides significant relief.²⁸⁸
- “Opioid rotations” (switching from one opioid to another) not only for cancer patients, but also for non-cancer patients, may need to occur four or five times over a person’s “lifetime” to manage pain.²⁸⁹

²⁸³ Lynn Webster, *Optimizing Opioid Treatment for Breakthrough Pain*, Medscape, http://www.medscape.org/viewarticle/563417_6 (last visited Dec. 11, 2017).

²⁸⁴ Brief of Amici the American Pain Foundation, the National Pain Foundation, and the National Foundation for the Treatment of Pain, 2005 WL 2405247, *8, *United States v. Hurowitz*, 459 F.3d 463 (2006) (citing Portenoy et. al, *Chronic Use of Opioid Analgesics in Non-Malignant Pain: Report of 38 Cases*, PAIN, Vol. 25, 171-186, (1986)).

²⁸⁵ *Id.* at *8, and sources cited in note 11.

²⁸⁶ *Id.*

²⁸⁷ *Id.*

²⁸⁸ Brief of Amici Russel K. Portenoy, et al., 2005 WL 2405249, *United States v. Hurwitz*, 459 F.3d 463.

- Opioids represent a highly effective . . . class of analgesic medications for controlling both chronic and acute pain. The phenomenon of tolerance to opioids – the gradual waning of relief at a given dose – and fears of abuse, diversion, and misuse of these medications by patients have led many clinicians to be wary of prescribing these drugs, and/or to restrict dosages to levels that may be insufficient to provide meaningful relief.²⁹⁰

Opioids represent a highly effective but controversial and often misunderstood class of analgesic medications for controlling both chronic and acute pain. The phenomenon of tolerance to opioids—the gradual waning of relief at a given dose—and fears of abuse, diversion, and misuse of these medications by patients have led many clinicians to be wary of prescribing these drugs, and/or to restrict dosages to levels that may be insufficient to provide meaningful relief.³

552. Members of the Opioid Marketing Enterprise created and championed the concept of “pseudoaddiction,” advocating that signs of addiction were actually pseudoaddiction that required prescribing additional opioids:

²⁸⁹ Perry A. Fine, *Safe and Effective Opioid Rotation*, YouTube (Nov. 8, 2012), https://www.youtube.com/watch?v=_G3II9yqgXI.

²⁹⁰ Charles E. Argoff, *Case Challenges in Pain Management: Opioid Therapy for Chronic Pain*, Pain Med. News, 2007, https://www.painmedicineneeds.com/download/BtoB_Opana_WM.pdf (last visited on March 8, 2018).

WHAT SHOULD I KNOW ABOUT OPIOIDS AND ADDICTION?

You or your family may have questions about addiction. It is important to understand what addiction is. Addiction **IS** a chronic brain disease that can occur in some people exposed to certain substances such as alcohol, cocaine, and opioids. Taking opioids for pain relief is not addiction. People addicted to opioids crave the opioid and use it regularly for reasons other than pain relief.

Addiction **IS NOT** when a person develops "withdrawal" (such as abdominal cramping or sweating) after the medicine is stopped quickly or the dose is reduced by a large amount. Your doctor will avoid stopping your medication suddenly by slowly reducing the amount of opioid you take before the medicine is completely stopped. Addiction also **IS NOT** what happens when some people taking opioids need to take a higher dose after a period of time in order for it to continue to relieve their pain. This normal "tolerance" to opioid medications doesn't affect everyone who takes them and does not, by itself, imply addiction. If tolerance does occur, it does not mean you will "run out" of pain relief. Your dose can be adjusted or another medicine can be prescribed.

- Patients might experience withdrawal symptoms associated with physical dependence as they decrease their dose, "[b]ut unlike actual addicts, such individuals, if they resume their opioid use, will only take enough medication to alleviate their pain."²⁹¹

²⁹¹ Brief Amici Curiae of American Pain Foundation, National Foundation for the Treatment of Pain, and The Ohio Pain Initiative, in Support of Defendants/Appellants, Howland v. Purdue Pharma, L.P., et al., Appeal No. CA 2002 09 0220 (Butler Co., Ohio 12th Court of Appeals, Dec. 23, 2002), <https://ia801005.us.archive.org/23/items/279014-howland-apf-amicus/279014-howland-apf-amicus.pdf>.

- “Addiction **IS NOT** when a person develops ‘withdrawal’ (such as abdominal cramping or sweating) after the medicine is stopped or the dose is reduced by a large amount. . . . Addiction also **IS NOT** what happens when some people taking opioids need to take a higher dose after a period of time in order for it to continue to relieve their pain. This normal ‘tolerance’ to opioid medications doesn’t affect everyone who takes them and does not, by itself, imply addiction.”²⁹²
- “Addiction to an opioid would mean that your pain has gone away but you still take the medicine regularly when you don’t need it for pain, maybe just to escape your problems.”²⁹³

How can I be sure I’m not addicted?

- ◆ Addiction to an opioid would mean that your pain has gone away but you still take the medicine regularly when you don’t need it for pain, maybe just to escape from your problems.
- ◆ Ask yourself: Would I want to take this medicine if my pain went away? If you answer no, you are taking opioids for the right reasons—to relieve your pain and improve your function. You are not addicted.

- Behaviors such as “[r]equesting [drugs] by name,” “[d]emanding or manipulative behavior,” “[o]btaining drugs from more than one physician,” and “[h]oarding opioids,” are all really signs of pseudoaddiction, rather than genuine addiction.”²⁹⁴

²⁹² Margo McCaffery & Chris Pasero, *Understanding Your Pain: Taking Oral Opioid Analgesics*, Endo Pharmaceuticals (2004), http://www.thblack.com/links/RSD/Understand_Pain_Opioid_Analgesics.pdf (emphasis in original) (last accessed on March 9, 2018).

²⁹³ *Id.*

²⁹⁴ Scott M. Fishman, *Responsible Opioid Prescribing: A Physician’s Guide*, 8-9 (Waterford Life Sciences 2007).

- 1 • “Sometimes people behave as if they are addicted, when they are really in
2 need of more medication.”²⁹⁵

3
4 • **ADDICTION** - A craving that
5 drives a person to take an
6 opioid even though it causes
7 harm. This is a problem that
8 needs immediate treatment.
9 This happens to some patients
10 who use opioids.

11 Sometimes people behave as
12 if they are addicted, when they
13 are really in need of more
14 medication. This can be treated
15 with higher doses of medicine.

- 14 • For prescribers facing signs of aberrant behavior, increasing the does “in
15 most cases . . . should be the clinician’s first response.”²⁹⁶

16 553. Members of the Opioid Marketing Enterprise advocated that long-
17 term use of prescription opioids would improve function, including but not limited
18 to, psychological health, and health-related quality of life:
19
20
21
22
23
24

25
26 ²⁹⁵ *Pain: Opioid Facts*,
27 http://web.archive.org/web/20120112051109/http://www.painknowledge.org/patient/pdf/Patient%20Education%20b380_b385%20%20pf%20opiod.pdf (last
28 visited March 6, 2018).

29 ²⁹⁶ Lynn Webster & Beth Dove, *Avoiding Opioid Abuse While Managing Pain*
(2007).

Because of their long history of use, the clinical profile of opioids has been very well characterized. Multiple clinical studies have shown that long-acting opioids, in particular, are effective in improving:

- Daily function
- Psychological health
- Overall health-related quality of life for people with chronic pain¹²

- When opioids are managed, properly prescribed and taken as directed, they are effective in improving daily function, psychological health and health-related quality of life.²⁹⁷
- Opioid therapy to relieve pain and improve function is a legitimate medical practice for acute and chronic pain of both cancer and non-cancer origins.²⁹⁸
- “[Y]our level of function should improve, you may find you are now able to participate in activities of daily living, such as work and hobbies, that you were not able to enjoy when your pain was worse.”²⁹⁹
- “The goal of opioid therapy is to . . . improve your function.”³⁰⁰

The goal of opioid therapy is to control pain and improve your function.

²⁹⁷ A Policymaker’s Guide to Understanding Pain & Its Management, American Pain Foundation (2011) at

5, <http://s3.documentcloud.org/documents/277603/apf-policymakers-guide.pdf> (last visited March 6, 2018).

²⁹⁸ Scott M. Fishman, Responsible Opioid Prescribing: A Physician’s Guide, 8-9 (Waterford Life Sciences 2007); Scott M. Fishman, *Responsible Opioid Prescribing: A Clinician’s Guide*, 10-11 (2d ed. 2012).

²⁹⁹ Plaintiffs are informed and believe that this misrepresentation was made on the website [painknowledge.org](http://www.painknowledge.org).

³⁰⁰ *Pain: Opioid Facts*, http://web.archive.org/web/20120112051109/http://www.painknowledge.org/patient/pdf/Patient%20Education%20b380_b385%20%20pf%20opioid.pdf (last visited March 6, 2018).

- The “goal” for chronic pain patients is to “improve effectiveness which is different from efficacy and safety.”³⁰¹



554. Members of the Opioid Marketing Enterprise represented that screening questions and professional guidelines would help curb addiction and potential abuse:

- Screening questions and professional guidelines will “easily and efficiently” allow physicians to manage risk and “minimize the potential for abuse.”³⁰²
- Risk screening tools, urine testing, and patient agreements are a way to prevent “overuse of prescriptions” and “overdose deaths.”³⁰³

³⁰¹ Perry A. Fine, *Safe and Effective Opioid Rotation*, YouTube (Nov. 8, 2012), https://www.youtube.com/watch?v=_G3II9yqgXI.

³⁰² Scott M. Fishman, *Responsible Opioid Prescribing: A Physician’s Guide*, 8-9 (Waterford Life Sciences 2007).

³⁰³ See, *Managing Patient’s Opioid Use: Balancing the Need and the Risk*, Emerging Solutions in Pain http://www.emergingsolutionsinpain.com/ce-education/opioid-management?option=com_continued&view=frontmatter&Itemid=303&course=209 (last visited Aug. 22, 2017).

Program Overview

Compliance with regulatory and policy-driven authorities mandates improvement in the treatment of patients on chronic opioid therapy (COT) to ensure that the best possible care is provided to pain patients while minimizing potential risk of inappropriate use. Participants of this activity will be able to evaluate current issues in appropriate patient selection and management of chronic pain patients treated with COT including a review of the most current Risk Evaluation and Mitigation Strategies (REMS) requirements, updates in the development of novel delivery systems and the practical application of assessment tools to assist in their daily practice.

- The risks of addiction and abuse can be managed by doctors and evaluated with “tools.”³⁰⁴

555. In addition to the unbranded marketing misrepresentations made by members of the Opioid Marketing Enterprise, the RICO Marketing Defendants made misrepresentations in their branded marketing activities. The RICO Marketing Defendants’ branded marketing misrepresentations furthered the common purpose of the Opioid Marketing Enterprise because they advanced the common messages of the Opioid Marketing Enterprise. For example:

556. The RICO Marketing Defendants misrepresented that opioids were non-addictive or posed less risk of addiction or abuse:

- Purdue:
 - “Fear of addiction is exaggerated.”³⁰⁵

The fear of addiction is exaggerated.
One cause of patient resistance to appropriate pain treatment – the fear of addiction – is largely unfounded. According to Dr. Max, “Experts agree that most pain caused by surgery or cancer can be relieved, primarily by carefully adjusting the dose of opioid (narcotic) pain reliever to each patient’s need, and that there is very little risk of addiction from the proper uses of these drugs for pain relief.”

Paul D. Goldenheim, M.D., Vice President of **Purdue Pharma** L.P. in Norwalk, Connecticut, agrees with this assessment. “Proper use of medication is an essential weapon in the battle against persistent pain. But too often fear, misinformation and poor communication stand in the way of their legitimate use.”

³⁰⁴ Perry A. Fine, *Safe and Effective Opioid Rotation*, YouTube (Nov. 8, 2012), https://www.youtube.com/watch?v=_G3II9yqgXI.

³⁰⁵ Harriet Ryan, et al., “*You Want A Description of Hell?*” *OxyContin’s 12-Hour Problem*, L.A. Times (May 5, 2016), <http://documents.latimes.com/oxycontin-press-release-1996/> (hereinafter “Ryan, Description of Hell”).

- 1 ○ “[W]e’ve discovered that the simplicity and convenience of twice-
2 daily dosing also enhances patient compliance with their doctor’s
3 instructions.”³⁰⁶

4 taking tablets every four to six hours. Moreover, we’ve discovered that
5 the simplicity and convenience of twice-daily dosing also enhances

6 https://www.nexis.com/results/enhdocview.do?docLinkId=true&rsKey=23_T23962617276&format=GNBF



8 1/27/2016

9 patient compliance with their doctor’s instructions.”

- 10 ○ Long-acting, extended release formulations are safe and “less prone”
11 to abuse by patients and addiction.³⁰⁷
12 ○ OxyContin is safe and non-addictive when using extended release
13 formulations, and appropriate for use in non-cancer patients.³⁰⁸
14 ○ Consistently minimizing the risk of addiction in the use of opioids for
15 the treatment of chronic non-cancer-related pain.³⁰⁹
16 ○ OxyContin is virtually non-addicting.³¹⁰

17
18
19
20 ³⁰⁶ *Id.*

21 ³⁰⁷ Barry Meier, *In Guilty Plea, OxyContin Maker to Pay \$600 Million*, N.Y.
22 Times (May 10, 2007), [http://www.nytimes.com/2007/05/10/business/11drug-](http://www.nytimes.com/2007/05/10/business/11drug-web.html)
23 web.html (hereinafter “Meier, Guilty Plea”).

24 ³⁰⁸ Charles Ornstein & Tracy Weber, *American Pain Foundation Shuts Down as*
25 *Senators Launch Investigation of Prescription Narcotics*, ProPublica (May 8,
26 2012, 8:57 PM),
27 [http://www.opb.org/news/article/america_pain_foundation_shuts_down_as_senato](http://www.opb.org/news/article/america_pain_foundation_shuts_down_as_senators_launch_investigation_of_prescription_narcotics/)
28 rs_launch_investigation_of_prescription_narcotics/ (hereinafter “Ornstein,
 American Pain Foundation”).

³⁰⁹ Art Van Zee, *The Promotion and Marketing of OxyContin: Commercial*
 Triumph, Public Health Tragedy, 99(2) Am. J. Pub. Health 221-27 (Feb. 2009)
 (hereinafter, “Van Zee, Promotion and Marketing”).

³¹⁰ Patrick Keefe, *The Family that Built an Empire of Pain*, New Yorker (Oct. 30,
 2017), [https://www.newyorker.com/magazine/2017/10/30/the-family-that-built-an-](https://www.newyorker.com/magazine/2017/10/30/the-family-that-built-an-empire-of-pain)
 empire-of-pain

- “Assur[ing] doctors – repeatedly and without evidence – that ‘fewer than one percent’ of patients who took OxyContin became addicted.”³¹¹



- OxyContin was addiction resistant and had “abuse-deterrent properties.”³¹²
- Misrepresented the risk of addiction using misleading and inaccurate promotions of OxyContin that were unsupported by science.³¹³
- It was more difficult to extract the oxycodone from an OxyContin tablet for intravenous abuse.³¹⁴
- OxyContin created fewer chances for addiction than immediate-release opioids.³¹⁵

³¹¹ *Id.*; see also “I got my life back,” OxyContin Promotional Video, 1998, <https://www.youtube.com/watch?v=Er78Dj5hyeI> (last accessed on March 8, 2018).

³¹² *Id.*

³¹³ Press Release, U.S. Attorney for the Western District of Virginia, Statement of United States Attorney John Brownlee on the Guilty Plea of the Purdue Frederick Company and Its Executives for Illegally Misbranding OxyContin (May 10, 2007), <https://assets.documentcloud.org/documents/279028/purdue-guilty-plea.pdf>.

³¹⁴ *Id.*

- OxyContin had fewer “peak and trough” effects than immediate-release opioids resulting in less euphoria and less potential for abuse than short-acting opioids.³¹⁶
- Patients could abruptly stop opioid therapy without experiencing withdrawal symptoms, and patients who took OxyContin would not develop tolerance.³¹⁷
- OxyContin did not cause a “buzz,” caused less euphoria, had less addiction potential, had less abuse potential, was less likely to be diverted than immediate-release opioids, and could be used to “weed out” addicts and drug seekers.³¹⁸
- Purdue published a prescriber and law enforcement education pamphlet in 2011 entitled *Providing Relief, Preventing Abuse*, which under the heading, “Indications of Possible Drug Abuse,” shows pictures of the stigmata of injecting or snorting opioids—skin popping, track marks, and perforated nasal septa. In fact, opioid addicts who resort to these extremes are uncommon; the far more typical reality is patients who become dependent and addicted through oral use. Thus, these misrepresentations wrongly reassured doctors that as long as they do not observe those signs, they need not worry that their patients are abusing or addicted to opioids.
- Purdue sponsored APF’s *A Policymaker’s Guide to Understanding Pain & Its Management*, which inaccurately claimed that less than 1% of children prescribed opioids will become addicted. This

³¹⁵ *Id.*³¹⁶ *Id.*³¹⁷ *Id.*³¹⁸ *Id.*

publication is still available online. This publication also asserted that pain is undertreated due to “misconceptions about opioid addiction.”

- Purdue sponsored APF’s *Treatment Options: A Guide for People Living with Pain* (2007), which asserted that addiction is rare and limited to extreme cases of unauthorized dose escalations, obtaining opioids from multiple sources, or theft.
- A Purdue-funded study with a Purdue co-author claimed that “evidence that the risk of psychological dependence or addiction is low in the absence of a history of substance abuse.”³¹⁹ The study relied only on the 1980 Porter-Jick letter to the editor concerning a chart review of hospitalized patients, not patients taking Purdue’s long-acting, take-home opioid. Although the term “low” is not defined, the overall presentation suggests the risk is so low as not to be a worry.
- Purdue contracted with AGS to produce a CME promoting the 2009 guidelines for the *Pharmacological Management of Persistent Pain in Older Persons*. These guidelines falsely claim that “the risks [of addiction] are exceedingly low in older patients with no current or past history of substance abuse.” None of the references in the guidelines corroborates the claim that elderly patients are less likely to become addicted to opioids and the claim is, in fact, untrue. Purdue was aware of the AGS guidelines’ content when it agreed to provide this funding, and AGS drafted the guidelines with the expectation it would seek drug company funding to promote them after their completion.

³¹⁹ C. Peter N. Watson et al., Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial I painful diabetic neuropathy, 105 *Pain* 71 (2003).

- Purdue sponsored APF's *Exit Wounds* (2009), which counseled veterans that "[l]ong experience with opioids shows that people who are not predisposed to addiction are very unlikely to become addicted to opioid pain medications." Although the term "very unlikely" is not defined, the overall presentation suggests it is so low as not to be a worry.
- Purdue sales representatives told prescribers that its drugs were "steady state," the implication of which was that they did not produce a rush or euphoric effect, and therefore were less addictive and less likely to be abused.
- Purdue sales representatives told prescribers that Butrans has a lower abuse potential than other drugs because it was essentially tamperproof and, after a certain point, patients no longer experience a "buzz" from increased dosage.
- Advertisements that Purdue sent to prescribers stated that OxyContin ER was less likely to be favored by addicts, and, therefore, less likely to be abused or diverted, or result in addiction.
- In discussions with prescribers, Purdue sales representatives omitted discussion of addiction risks related to Purdue's drugs.
- Janssen:
 - **Myth:** Opioid medications are always addictive.
Fact: Many studies show that opioids are rarely addictive when used properly for the management of chronic pain.³²⁰
 - **Myth:** Opioid doses have to get bigger over time because the body gets used to them.

³²⁰ Finding Relief, Pain Management for Older Adults, (2009) (emphasis in original).

Fact: Unless the underlying cause of your pain gets worse (such as with cancer or arthritis), you will probably remain on the same dose or need only small increases over time.³²¹

- “[Q]uestions of addiction,” “are often overestimated” because, “[a]ccording to clinical opinion polls, true addiction occurs only in a small percentage of patients with chronic pain who receive chronic opioid analgesics.”³²²

Other Opioid Analgesic Concerns

Aside from medical issues related to opioid analgesics, there are nonmedical issues that may have an impact on prescribing patterns and patient use of these drugs. Practitioners are often concerned about prescribing opioid analgesics due to potential legal issues and questions of addiction.^{15,16} By the same token, patients report similar concerns about developing an addiction to opioid analgesics.¹⁷ While these concerns are not without some merit, it would appear that they are often overestimated. According to clinical opinion polls, true addiction occurs only in a small percentage of patients with chronic pain who receive chronic opioid analgesics analgesic therapy.¹⁸

- Janssen sponsored a patient education guide titled *Finding Relief: Pain Management for Older Adults* (2009), which its personnel reviewed and approved and which its sales force distributed. This guide described a “myth” that opioids are addictive, and asserts as fact that “[m]any studies show that opioids are rarely addictive when used properly for the management of chronic pain.” Although the term “rarely” is not defined, the overall presentation suggests the risk is so low as not to be a worry. The language also implies that as long as a prescription is given, opioid use is not a problem.

³²¹ Finding Relief, Pain Management for Older Adults, (2009) (emphasis in original).

³²² *Use of Opioid Analgesics in Pain Management*, Prescribe Responsibly, <http://www.prescriberesponsibly.com/articles/opioid-pain-management> (last visited Dec. 11, 2017).

- 1 ○ Janssen contracted with AGS to produce a CME promoting the 2009
2 guidelines for the *Pharmacological Management of Persistent Pain*
3 *in Older Persons*. These guidelines falsely claim that “the risks [of
4 addiction] are exceedingly low in older patients with no current or
5 past history of substance abuse.” The study supporting this assertion
6 does not analyze addiction rates by age and, as already noted,
7 addiction remains a significant risk for elderly patients. Janssen was
8 aware of the AGS guidelines’ content when it agreed to provide this
9 funding, and AGS drafted the guidelines with the expectation it
10 would seek drug company funding to promote them after their
11 completion.
- 12 ○ Janssen provided grants to APF to distribute *Exit Wounds* (2009) to
13 veterans, which taught that [l]ong experience with opioids shows that
14 people who are not predisposed to addiction are very unlikely to
15 become addicted to opioid pain medications.” Although the term
16 “very unlikely” is not defined, the overall presentation suggests the
17 risk is so low as not to be a worry.
- 18 ○ Janssen currently runs a website, Prescriberresponsibly.com (last
19 modified July 2, 2015), which claims that concerns about opioid
20 addiction are “overstated.”
- 21 ○ A June 2009 Nucynta Training module warns Janssen’s sales force
22 that physicians are reluctant to prescribe controlled substances like
23 Nucynta, but this reluctance is unfounded because “the risks . . . are
24 much smaller than commonly believed.”
- 25 ○ Janssen sales representatives told prescribers that its drugs were
26 “steady state,” the implication of which was that they did not produce
27 a rush or euphoric effect, and therefore were less addictive and less
28 likely to be abused.

- Janssen sales representatives told prescribers that Nucynta and Nucynta ER were “not opioids,” implying that the risks of addiction and other adverse outcomes associated with opioids were not applicable to Janssen’s drugs. In truth, however, as set out in Nucynta’s FDA-mandated label, Nucynta “contains tapentadol, an opioid agonist and Schedule II substance with abuse liability similar to other opioid agonists, legal or illicit.”
- Janssen’s sales representatives told prescribers that Nucynta’s unique properties eliminated the risk of addiction associated with the drug.
- In discussions with prescribers, Janssen sales representatives omitted discussion of addiction risks related to Janssen’s drugs.
- Cephalon:
 - Cephalon sponsored and facilitated the development of a guidebook, *Opioid Medications and REMS: A Patient’s Guide*, which claims, among other things, that “patients without a history of abuse or a family history of abuse do not commonly become addicted to opioids.”
 - Cephalon sponsored APF’s *Treatment Options: A Guide for People Living with Pain* (2007), which taught that addiction is rare and limited to extreme cases of unauthorized dose escalations, obtaining opioids from multiple sources, or theft.
 - In discussions with prescribers, Cephalon sales representatives omitted any discussion of addiction risks related to Cephalon’s drugs.
- Endo:
 - Opana ER was designed to be crush resistant

- 1 ○ Opana ER was crush and abuse resistant and not addictive.³²³
- 2 ○ “[T]he Reformulated Opana ER as ‘designed to be’ crush
- 3 resistant.”³²⁴
- 4 ○ “[P]atients treated with prolonged opioid medicines usually do not
- 5 become addicted.”³²⁵
- 6 ○ Endo trained its sales force in 2012 that use of long-acting opioids
- 7 resulted in increased patient compliance, without any supporting
- 8 evidence.
- 9 ○ Endo’s advertisements for the 2012 reformulation of Opana ER
- 10 claimed it was designed to be crush resistant, in a way that conveyed
- 11 that it was less likely to be abused. This claim was false; the FDA
- 12 warned in a May 10, 2013 letter that there was no evidence Endo’s
- 13 design “would provide a reduction in oral, intranasal or intravenous
- 14 abuse” and Endo’s “post-marketing data submitted are insufficient to
- 15 support any conclusion about the overall or route-specific rates of
- 16 abuse.” Further, Endo instructed its sales representatives to repeat
- 17 this claim about “design,” with the intention of conveying Opana ER
- 18 was less subject to abuse.
- 19 ○ Endo sponsored a website, painknowledge.com, through APF and
- 20 NIPC, which claimed in 2009 that: “[p]eople who take opioids as
- 21 prescribed usually do not become addicted.” Although the term
- 22
- 23

24 ³²³ *In the Matter of Endo Health Solutions Inc. and Endo Pharmaceuticals Inc.*,
 25 Assurance No. 15-228, Assurance of Discontinuance Under Executive Law
 26 Section 63, Subdivision 15, at 5 (Mar. 1, 2016),
 27 https://ag.ny.gov/pdfs/Endo_AOD_030116-Fully_Executed.pdf.

28 ³²⁴ *Id.* at 6.

29 ³²⁵ *In the Matter of Endo Health Solutions Inc. and Endo Pharmaceuticals Inc.*,
 30 Assurance No. 15-228, Assurance of Discontinuance Under Executive Law
 31 Section 63, Subdivision 15, at 5 (Mar. 1, 2016),
 32 https://ag.ny.gov/pdfs/Endo_AOD_030116-Fully_Executed.pdf.

1 “usually” is not defined, the overall presentation suggests the risk is
 2 so low as not to be a worry. The language also implies that as long as
 3 a prescription is given, opioid use will not become problematic. Endo
 4 continued to provide funding for this website through 2012, and
 5 closely tracked unique visitors to it.

- 6 ○ Endo sponsored a website, PainAction.com, which stated “Did you
 7 know? Most chronic pain patients do not become addicted to the
 8 opioid medications that are prescribed for them.”
- 9 ○ Endo sponsored CMEs published by APF’s NIPC, of which Endo
 10 was the sole funder, titled *Persistent Pain in the Older Adult and*
 11 *Persistent Pain in the Older Patient*. These CMEs claimed that
 12 opioids used by elderly patients present “possibly less potential for
 13 abuse than in younger patients[,]” which lacks evidentiary support
 14 and deceptively minimizes the risk of addiction for elderly patients.
- 15 ○ Endo distributed an education pamphlet with the Endo logo titled
 16 *Living with Someone with Chronic Pain*, which inaccurately
 17 minimized the risk of addiction: “Most health care providers who
 18 treat people with pain agree that most people do not develop an
 19 addiction problem.”
- 20 ○ Endo distributed a patient education pamphlet edited by key opinion
 21 leader Dr. Russell Portenoy titled *Understanding Your Pain: Taking*
 22 *Oral Opioid Analgesics*. It claimed that “[a]ddicts take opioids for
 23 other reasons [than pain relief], such as unbearable emotional
 24 problems.” This implies that pain patients prescribed opioids will not
 25 become addicted, which is unsupported and untrue.
- 26 ○ Endo contracted with AGS to produce a CME promoting the 2009
 27 guidelines for the *Pharmacological Management of Persistent Pain*
 28

1 *in Older Persons*. These guidelines falsely claim that “the risks [of
 2 addiction] are exceedingly low in older patients with no current or
 3 past history of substance abuse.” None of the references in the
 4 guidelines corroborates the claim that elderly patients are less likely
 5 to become addicted to opioids, and there is no such evidence. Endo
 6 was aware of the AGS guidelines’ content when it agreed to provide
 7 this funding, and AGS drafted the guidelines with the expectation it
 8 would seek drug company funding to promote them after their
 9 completion.

- 10 ○ Endo sales representatives told prescribers that its drugs were “steady
 11 state,” the implication of which was that they did not produce a rush
 12 or euphoric effect, and therefore were less addictive and less likely to
 13 be abused.
- 14 ○ Endo provided grants to APF to distribute *Exit Wounds* (2009) to
 15 veterans, which taught that “[l]ong experience with opioids shows
 16 that people who are not predisposed to addiction are very unlikely to
 17 become addicted to opioid pain medications.” Although the term
 18 “very unlikely” is not defined, the overall presentation suggests that
 19 the risk is so low as not to be a worry.
- 20 ○ In discussions with prescribers, Endo sales representatives omitted
 21 discussion of addiction risks related to Endo’s drugs.

22 557. The RICO Marketing Defendants misrepresented that opioids
 23 improved function and quality of life:

- 24 • Purdue:

- “[W]e’ve discovered that the simplicity and convenience of twice-daily dosing also enhances patient compliance with their doctor’s instructions.”³²⁶

taking tablets every four to six hours. Moreover, we’ve discovered that the simplicity and convenience of twice-daily dosing also enhances

https://www.nexis.com/results/enhdocview.do?docLinkInd=true&rsKey=23_T23962617276&format=GNBF



1/27/2016

patient compliance with their doctor’s instructions.”

- Purdue ran a series of advertisements for OxyContin in 2012 in medical journals titled “Pain vignettes,” which were case studies featuring patients, each with pain conditions persisting over several months, recommending OxyContin for each. One such patient, “Paul,” is described to be a “54-year-old writer with osteoarthritis of the hands,” and the vignettes imply that an OxyContin prescription will help him work more effectively.
- Purdue sponsored APF’s *A Policymaker’s Guide to Understanding Pain & Its Management*, which inaccurately claimed that “multiple clinical studies” have shown that opioids are effective in improving daily function, psychological health, and health-related quality of life for chronic pain patients.” The sole reference for the functional improvement claim noted the absence of long-term studies and actually stated: “For functional outcomes, the other analgesics were significantly more effective than were opioids.” *The Policymaker’s Guide* is still available online.

³²⁶ Ryan, *Description of Hell*, <http://documents.latimes.com/oxycontin-press-release-1996/>

- Purdue sponsored APF's Treatment Options: A Guide for People Living with Pain (2007), which counseled patients that opioids, when used properly, "give [pain patients] a quality of life we deserve." APF distributed 17,200 copies in one year alone, according to its 2007 annual report, and the guide currently is available online.
- Purdue sponsored APF's *Exit Wounds* (2009), which taught veterans that opioid medications "increase your level of functioning." *Exit Wounds* also omits warnings of the risk of interactions between opioids and benzodiazepines, which would increase fatality risk. Benzodiazepines are frequently prescribed to veterans diagnosed with post-traumatic stress disorder.
- Purdue sponsored the FSMB's Responsible Opioid Prescribing (2007), which taught that relief of pain itself improved patients' function. Responsible Opioid Prescribing explicitly describes functional improvement as the goal of a "long-term therapeutic treatment course." Purdue also spent over \$100,000 to support distribution of the book.
- Janssen:
 - Misrepresented that patients experienced "[s]ignificantly reduced nighttime awakenings."³²⁷
 - Misrepresented "[s]ignificant improvement in disability scores as measured by the Oswestry Disability Questionnaire and Pain Disability Index."³²⁸
 - Misrepresented "[s]ignificant improvement in social functioning."

³²⁷ NDA 19-813 Letter from Spencer Salis, U.S. Food & Drug Administration, to Cynthia Chianese, Janssen Pharmaceutica (Mar. 30, 2000) at 2.

³²⁸ *Id.*

- Misrepresented outcome claims that were misleading because they lacked substantial support, evidence or clinical experience and “impl[ied] that patients will experience improved social or physical functioning or improved work productivity when using Duragesic,” including: “1,360 loaves . . . and counting, [w]ork, uninterrupted, [l]ife, uninterrupted, [g]ame, uninterrupted, [c]hronic pain relief that supports functionality, [h]elps patients think less about their pain, and [i]mprove[s] . . . physical and social functioning.”³²⁹
- Misrepresented that “[o]pioid analgesics, for example, have no true ‘ceiling dose’ for analgesia and do not cause direct organ damage.”³³⁰

Use of Opioid Analgesics in Pain Management

Opioid analgesics are often the first line of treatment for many painful conditions and may offer advantages over nonsteroidal anti-inflammatory drugs (NSAIDs). Opioid analgesics, for example, have no true “ceiling dose” for analgesia and do not cause direct organ damage; however, they do have several possible side effects, including constipation, nausea, vomiting, a decrease in sexual interest, drowsiness, and respiratory depression. With the exception of constipation, many patients often develop tolerance to most of the opioid analgesic-related side effects.⁸

- **Myth:** Opioids make it harder to function normally.
Fact: When used correctly for appropriate conditions, opioids may make it easier for people to live normally.³³¹
- Janssen sponsored a patient education guide titled *Finding Relief: Pain Management for Older Adults* (2009), which its personnel reviewed and approved and its sales force distributed. This guide features a man playing golf on the cover and lists examples of

³²⁹ *Id.* at 3 (internal quotations omitted).

³³⁰ *Use of Opioid Analgesics in Pain Management*, Prescribe Responsibly, <http://www.prescriberesponsibly.com/articles/opioid-pain-management> (last visited Dec. 11, 2017).

³³¹ *Finding Relief, Pain Management for Older Adults*, (2009) (emphasis in original).

1 expected functional improvement from opioids, like sleeping through
 2 the night, returning to work, recreation, sex, walking, and climbing
 3 stairs. The guide states as a “fact” that “opioids may make it easier
 4 for people to live normally” (emphasis in the original). The myth/fact
 5 structure implies authoritative backing for the claim that does not
 6 exist. The targeting of older adults also ignored heightened opioid
 7 risks in this population.

- 8 ○ Janssen sponsored, developed, and approved content of a website,
 9 *Let’s Talk Pain* in 2009, acting in conjunction with the APF and
 10 AAPM whose participation in Let’s Talk Pain Janssen financed and
 11 orchestrated. This website featured an interview, which was edited by
 12 Janssen personnel, claiming that opioids were what allowed a patient
 13 to “continue to function,” inaccurately implying her experience
 14 would be representative. This video is still available today on
 15 youtube.com.
- 16 ○ Janssen provided grants to APF to distribute *Exit Wounds* to veterans,
 17 which taught that opioid medications “increase your level of
 18 functioning” (emphasis in the original). Exit Wounds also omits
 19 warnings of the risk of interactions between opioids and
 20 benzodiazepines, which would increase fatality risk. Benzodiazepines
 21 are frequently prescribed to veterans diagnosed with post-traumatic
 22 stress disorder.
- 23 • Cephalon:
- 24 ○ Cephalon sponsored the FSMB’s Responsible Opioid Prescribing
 25 (2007), which taught that relief of pain itself improved patients’
 26 function. Responsible Opioid Prescribing explicitly describes
 27 functional improvement as the goal of a “long-term therapeutic
 28

1 treatment course.” Cephalon also spent \$150,000 to purchase copies
 2 of the book in bulk and distributed the book through its pain sales
 3 force to 10,000 prescribers and 5,000 pharmacists.

4 ○ Cephalon sponsored the American Pain Foundation’s *Treatment*
 5 *Options: A Guide for People Living with Pain* (2007), which taught
 6 patients that opioids when used properly “give [pain patients] a
 7 quality of life we deserve.” The *Treatment Options* guide notes that
 8 non-steroidal anti-inflammatory drugs have greater risks with
 9 prolonged duration of use, but there was no similar warning for
 10 opioids. APF distributed 17,200 copies in one year alone, according
 11 to its 2007 annual report, and the publication is currently available
 12 online.

13 ○ Cephalon sponsored a CME written by Dr. Webster, titled
 14 Optimizing Opioid Treatment for Breakthrough Pain, which was
 15 offered online by Medscape, LLC from September 28, 2007, through
 16 December 15, 2008. The CME taught that Cephalon’s Actiq and
 17 Fentora improve patients’ quality of life and allow for more activities
 18 when taken in conjunction with long-acting opioids.

19 • Endo:

20 ○ Opana ER “will benefit patients, physicians and payers.”³³²

21 "Patient safety is our top concern and addressing appropriate use of opioids is a responsibility
 22 that we take very seriously. We firmly believe this new formulation of Opana ER, coupled with
 23 our long-term commitment to awareness and education around appropriate use of opioids will
 24 benefit patients, physicians and payers."

25
 26
 27 ³³² *FDA Approves Endo Pharmaceuticals’ Crush-Resistant Opana ER*, December
 28 12, 2011, <https://www.biospace.com/article/releases/fda-approves-endo-pharmaceuticals-crush-resistant-opana-er/>.

- 1 ○ “Endo distributed a pamphlet in New York and posted on its public
2 website, www.opana.com, photographs of purported Opana ER
3 patients that implied that patients can achieve higher function with
4 Opana ER.”³³³
- 5 ○ Endo sponsored a website, painknowledge.com, through APF and
6 NIPC, which claimed in 2009 that with opioids, “your level of
7 function should improve; you may find you are now able to
8 participate in activities of daily living, such as work and hobbies, that
9 you were not able to enjoy when your pain was worse.” Endo
10 continued to provide funding for this website through 2012, and
11 closely tracked unique visitors to it.
- 12 ○ A CME sponsored by Endo, titled *Persistent Pain in the Older*
13 *Patient*, taught that chronic opioid therapy has been “shown to reduce
14 pain and improve depressive symptoms and cognitive functioning.”
- 15 ○ Endo distributed handouts to prescribers that claimed that use of
16 Opana ER to treat chronic pain would allow patients to perform work
17 as a chef. This flyer also emphasized Opana ER’s indication without
18 including equally prominent disclosure of the “moderate to severe
19 pain” qualification.
- 20 ○ Endo’s sales force distributed FSMB’s *Responsible Opioid*
21 *Prescribing* (2007). This book taught that relief of pain itself
22 improved patients’ function. *Responsible Opioid Prescribing*
23 explicitly describes functional improvement as the goal of a “long-
24 term therapeutic treatment course.”
- 25 ○ Endo provided grants to APF to distribute *Exit Wounds* to veterans,
26 which taught that opioid medications “increase your level of
27

28 ³³³ *Id.* at 8.

functioning” (emphasis in the original). Exit Wounds also omits warnings of the risk of interactions between opioids and benzodiazepines, which would increase fatality risk. Benzodiazepines are frequently prescribed to veterans diagnosed with post-traumatic stress disorder.

558. The RICO Marketing Defendants misrepresented that addiction risks can be avoided or managed through screening tools and prescription guidelines:

- Purdue:
 - Purdue’s unbranded website, In the Face of Pain (inthefaceofpain.com) states that policies that “restrict[] access to patients with pain who also have a history of substance abuse” and “requiring special government-issued prescription forms for the only medications that are capable of relieving pain that is severe” are “at odds with” best medical practices.³³⁴
 - Purdue sponsored a 2012 CME program taught by a KOL titled *Chronic Pain Management and Opioid Use: Easing Fears, Managing Risks, and Improving Outcomes*. This presentation recommended that use of screening tools, more frequent refills, and switching opioids could treat a high-risk patient showing signs of potentially addictive behavior.
 - Purdue sponsored a 2011 webinar taught by Dr. Lynn Webster, titled *Managing Patient’s Opioid Use: Balancing the Need and Risk*. This publication taught prescribers that screening tools, urine tests, and

³³⁴ See In the Face of Pain Fact Sheet: Protecting Access to Pain Treatment, Purdue Pharma L.P. (Resources verified Mar. 2012), www.inthefaceofpain.com/content/uploads/2011/12/factsheet_ProtectingAccess.pdf.

1 patient agreements have the effect of preventing “overuse of
2 prescriptions” and “overdose deaths.”

- 3 ○ Purdue sales representatives told prescribers that screening tools can
4 be used to select patients appropriate for opioid therapy and to
5 manage the risks of addiction.

- 6 • Cephalon:

- 7 ○ Cephalon sponsored APF’s *Treatment Options: A Guide for People*
8 *Living with Pain* (2007), which taught patients that “opioid
9 agreements” between doctors and patients can “ensure that you take
10 the opioid as prescribed.”

- 11 • Endo:

- 12 ○ Endo paid for a 2007 supplement³³⁵ available for continuing
13 education credit in the Journal of Family Practice and written by a
14 doctor who later became a member of Endo’s speakers bureau. This
15 publication, titled *Pain Management Dilemmas in Primary Care:*
16 *Use of Opioids*, recommended screening patients using tools like the
17 Opioid Risk Tool or the Screener and Opioid Assessment for Patients
18 with Pain, and advised that patients at high risk of addiction could
19 safely (e.g., without becoming addicted) receive chronic opioid
20 therapy using a “maximally structured approach” involving
21 toxicology screens and pill counts.

22 559. The RICO Marketing Defendants misrepresented that signs of opioid
23 addiction were not addiction, withdrawal could be simply managed, and promoted
24 the concept of pseudoaddiction:

- 25 • Purdue:

26
27 ³³⁵ The Medical Journal, The Lancet found that all of the supplement papers it
28 received failed peer-review. Editorial, “*The Perils of Journal and Supplement*
Publishing,” 375 The Lancet 9712 (347) 2010.

- Purdue published a prescriber and law enforcement education pamphlet in 2011 entitled *Providing Relief, Preventing Abuse*, which described pseudoaddiction as a concept that “emerged in the literature to describe the inaccurate interpretation of [drug-seeking behaviors] in patients who have pain that has not been effectively treated.”
- Purdue distributed to physicians, at least as of November 2006 and posted on its unbranded website, Partners Against Pain, a pamphlet copyrighted 2005 and titled *Clinical Issues in Opioid Prescribing*. This pamphlet included a list of conduct including “illicit drug use and deception” it defined as indicative of pseudoaddiction or untreated pain. It also states: “Pseudoaddiction is a term which has been used to describe patient behaviors that may occur when pain is undertreated. . . . Even such behaviors as illicit drug use and deception can occur in the patient’s efforts to obtain relief. Pseudoaddiction can be distinguished from true addiction in that the behaviors resolve when the pain is effectively treated.”
- Purdue sponsored FSMB’s *Responsible Opioid Prescribing* (2007), which taught that behaviors such as “requesting drugs by name, “demanding or manipulative behavior,” seeing more than one doctor to obtain opioids, and hoarding, are all signs of pseudoaddiction. Purdue also spent over \$100,000 to support distribution of the book.
- Purdue sponsored APF’s *A Policymaker’s Guide to Understanding Pain & Its Management*, which states: “Pseudo-addiction describes patient behaviors that may occur when pain is undertreated. . . . Pseudo-addiction can be distinguished from true addiction in that this behavior ceases when pain is effectively treated.”

- *A Policymaker's Guide to Understanding Pain & Its Management* also taught that “Symptoms of physical dependence can often be ameliorated by gradually decreasing the dose of medication during discontinuation,” but did not disclose the significant hardships that often accompany cessation of use.
- Purdue sales representatives told prescribers that the effects of withdrawal from opioid use can be successfully managed.
- Purdue sales representatives told prescribers that the potential for withdrawal on Butrans was low due to Butrans’ low potency and its extended release mechanism.
- Janssen:
 - Janssen’s website, Let’s Talk Pain, stated from 2009 through 2011 that “pseudoaddiction . . . refers to patient behaviors that may occur when pain is under-treated” and “[p]seudoaddiction is different from true addiction because such behaviors can be resolved with effective pain management.”
 - A Janssen PowerPoint presentation used for training its sales representatives titled “*Selling Nucynta ER*” indicates that the “low incidence of withdrawal symptoms” is a “core message” for its sales force. This message is repeated in numerous Janssen training materials between 2009 and 2011. The studies supporting this claim did not describe withdrawal symptoms in patients taking Nucynta ER beyond 90 days or at high doses and would therefore not be representative of withdrawal symptoms in the chronic pain population. Patients on opioid therapy long-term and at high doses will have a harder time discontinuing the drugs and are more likely to experience withdrawal symptoms. In addition, in claiming a low rate

1 of withdrawal symptoms, Janssen relied upon a study that only began
 2 tracking withdrawal symptoms in patients two to four days after
 3 discontinuing opioid use, when Janssen knew or should have known
 4 that these symptoms peak earlier than that for most patients. Relying
 5 on data after that initial window painted a misleading picture of the
 6 likelihood and severity of withdrawal associated with chronic opioid
 7 therapy. Janssen also knew or should have known that the patients
 8 involved in the study were not on the drug long enough to develop
 9 rates of withdrawal symptoms comparable to rates of withdrawal
 10 suffered by patients who use opioids for chronic pain—the use for
 11 which Janssen promoted Nucynta ER.

- 12 ○ Janssen sales representatives told prescribers that patients on
 13 Janssen’s drugs were less susceptible to withdrawal than those on
 14 other opioids.
- 15 ● Cephalon:
 - 16 ○ Cephalon sponsored FSMB’s Responsible Opioid Prescribing (2007),
 17 which taught that behaviors such as “requesting drugs by name,”
 18 “demanding or manipulative behavior,” seeing more than one doctor
 19 to obtain opioids, and hoarding are all signs of pseudoaddiction.
 20 Cephalon also spent \$150,000 to purchase copies of the book in bulk
 21 and distributed it through its pain sales force to 10,000 prescribers
 22 and 5,000 pharmacists.
- 23 ● Endo:
 - 24 ○ Endo distributed copies of a book by KOL Dr. Lynn Webster entitled
 25 *Avoiding Opioid Abuse While Managing Pain* (2007). Endo’s internal
 26 planning documents describe the purpose of distributing this book as
 27 to “[i]ncrease the breadth and depth of the Opana ER prescriber
 28

base.” The book claims that when faced with signs of aberrant behavior, the doctor should regard it as pseudoaddiction and thus, increasing the dose in most cases . . . should be the clinician’s first response.”

- Endo spent \$246,620 to buy copies of FSMB’s *Responsible Opioid Prescribing* (2007), which was distributed by Endo’s sales force. This book asserted that behaviors such as “requesting drugs by name,” “demanding or manipulative behavior,” seeing more than one doctor to obtain opioids, and hoarding, are all signs of “pseudoaddiction.”
- A CME sponsored by Endo, titled *Persistent Pain in the Older Adult*, taught that withdrawal symptoms can be avoided entirely by tapering the dose by 10-20% per day for ten days.
- Endo misrepresented that “symptoms of withdrawal do not indicate addiction.”³³⁶
- “Endo also trained its sales representatives to distinguish addiction from ‘pseudoaddiction.’”³³⁷

560. The RICO Defendants misrepresented that opioids were safe for the long-term treatment of chronic, non-acute, and non-cancer pain:

- Purdue:

- “[W]e do not want to niche OxyContin just for cancer pain.”³³⁸

three tablet strengths were passed around. OxyContin will be indicated for the relief of pain with the convenience of q12h dosing. OxyContin’s primary market positioning will be for cancer pain and the secondary market will be for non-malignant pain (musculoskeletal, injury and trauma). It was reinforced that we do not want to niche OxyContin just for cancer pain. OxyContin will be positioned into Step 2 of the

³³⁶ *In the Matter of Endo Health Solutions Inc. and Endo Pharmaceuticals Inc.*, Assurance No. 15-228, Assurance of Discontinuance Under Executive Law Section 63, Subdivision 15, at 7 (Mar. 1, 2016), https://ag.ny.gov/pdfs/Endo_AOD_030116-Fully_Executed.pdf.

³³⁷ *Id.*

³³⁸ Ryan, *Description of Hell*, <http://documents.latimes.com/oxycontin-launch-1995/> (emphasis in the L.A. Times document).

- OxyContin was safe and non-addictive when using extended release formulations, and appropriate for use in non-cancer patients.³³⁹
- OxyContin should be prescribed not merely for severe short-term pain associated with surgery or cancer, but also for less acute, longer-lasting pain like arthritis, back pain, sports injuries, fibromyalgia with almost limitless treatment potential.³⁴⁰
- Janssen:
 - Duragesic was “more useful in a broader range of conditions or patients than has been demonstrated by substantial evidence.”³⁴¹
 - Duragesic was “not just for end stage cancer anymore” when the FDA only approved Duragesic for “the management of chronic pain in patients who require continuous opioid analgesia for pain that cannot be managed by lesser means.”³⁴²
 - Misrepresented that “Duragesic can be used for any type of pain management” despite the fact that the FDA approved warning stated that “BECAUSE SERIOUS OR LIFE-THREATENING HYPOVENTILATION COULD OCCUR, DURAGESIC® (FENTANYL TRANSDERMAL SYSTEM) IS

³³⁹ Charles Ornstein & Tracy Weber, *American Pain Foundation Shuts Down as Senators Launch Investigation of Prescription Narcotics*, ProPublica (May 8, 2012, 8:57 PM), http://www.opb.org/news/article/america_pain_foundation_shuts_down_as_senators_launch_investigation_of_prescription_narcotics/ (hereinafter “Ornstein, *American Pain Foundation*”).

³⁴⁰ Patrick Keefe, *The Family that Built an Empire of Pain*, New Yorker (Oct. 30, 2017), <https://www.newyorker.com/magazine/2017/10/30/the-family-that-built-an-empire-of-pain>

³⁴¹ NDA 19-813 Letter from Spencer Salis, U.S. Food & Drug Administration, to Cynthia Chianese, Janssen Pharmaceutica (Mar. 30, 2000) at 2.

³⁴² *Id.*

1 CONTRAINDICATED: In the management of acute or post-
 2 operative pain, including use in outpatient surgeries”³⁴³

3 ○ Misrepresented “numerous claims for the efficacy and safety of
 4 Duragesic,” but failed to “present[] any risk information concerning
 5 the boxed warnings, contraindications, warnings, or side effects
 6 associated with Duragesic’s use . . . [and] . . . fail[ed] to address
 7 important risks and restrictions associated with Duragesic
 8 therapy.”³⁴⁴

9 ○ Misrepresented “[d]emonstrated effectiveness in chronic back pain
 10 with additional patient benefits, . . . 86% of patients experienced
 11 overall benefit in a clinical study based on: pain control, disability in
 12 ADLs, quality of sleep.”³⁴⁵

13 • Cephalon:

14 ○ “[P]romoting [Actiq] for non-cancer patients to use for such maladies
 15 as migraines, sickle-cell pain crises, injuries, and in anticipation of
 16 changing wound dressings or radiation therapy.”³⁴⁶

17 ○ “[P]romot[ing] Actiq for use in patients who were not yet opioid
 18 tolerant, and for whom it could have life-threatening results.”³⁴⁷

19 ○ In 2011, Cephalon wrote an article titled “2011 Special Report: An
 20 Integrated Risk Evaluation and Risk Mitigation Strategy for Fentanyl
 21 Buccal Tablet (FENTORA®) AND Oral Transmucosal Fentanyl
 22 Citrate (Actiq®), published in Pain Medicine News. Plaintiffs are
 23

24 ³⁴³ *Id.*

25 ³⁴⁴ *Id.*

26 ³⁴⁵ *Id.* at 2-3.

27 ³⁴⁶ Press Release, U.S. Department of Justice, Pharmaceutical Company Cephalon
 To Pay \$425 Million For Off-Label Drug Marketing (Sept. 29, 2008),
<https://www.justice.gov/archive/usao/pae/News/2008/sep/cephalonrelease.pdf>.

28 ³⁴⁷ *Id.*

1 informed and believe that Cephalon misrepresented that its drugs
 2 were “shown to be effective in treatment of [break through pain]
 3 associated with multiple causes of pain,” not just cancer.

4 561. The RICO Defendants also misrepresented that opioids were safer
 5 that non-opioid analgesics because there is no ceiling dose for opioid treatment.

6 • Purdue:

- 7 ○ Purdue’s In the Face of Pain website, along with initiatives of APF,
 8 promoted the notion that if a patient’s doctor does not prescribe them
 9 what—in their view—is a sufficient dose of opioids, they should find
 10 another doctor who will. In so doing, Purdue exerted undue, unfair,
 11 and improper influence over prescribers who face pressure to accede
 12 to the resulting demands.
- 13 ○ Purdue sponsored APF’s *A Policymaker’s Guide to Understanding*
 14 *Pain & Its Management*, which taught that dose escalations are
 15 “sometimes necessary,” even indefinitely high ones, which suggested
 16 that high dose opioids are safe and appropriate and did not disclose
 17 the risks from high dose opioids. This publication is still available
 18 online.
- 19 ○ Purdue sponsored APF’s *Treatment Options: A Guide for People*
 20 *Living with Pain* (2007), which taught patients that opioids have “no
 21 ceiling dose” and are therefore the most appropriate treatment for
 22 severe pain. The guide also claimed that some patients “need” a
 23 larger dose of the drug, regardless of the dose currently prescribed.
 24 This language fails to disclose heightened risks at elevated doses.
- 25 ○ *Treatment Options*, also taught that opioids differ from NSAIDs in
 26 that they have “no ceiling dose” and are therefore the most
 27 appropriate treatment for severe pain. *Treatment Options* continued,
 28

1 warning that risks of NSAIDs increase if “taken for more than a
 2 period of months,” with no corresponding warning about opioids.
 3 The publication attributed 10,000 to 20,000 deaths annually to
 4 NSAID overdose.

- 5 ○ Purdue sponsored a CME issued by the American Medical
 6 Association in 2003, 2007, 2010, and 2013. The CME, *Overview of*
 7 *Management Options*, was edited by KOL Dr. Russell Portenoy,
 8 among others, and taught that other drugs, but not opioids, are unsafe
 9 at high doses. The 2013 version is still available for CME credit.
- 10 ○ *Overview of Management Options* also taught NSAIDs and other
 11 drugs, but not opioids, are unsafe at high doses.
- 12 ○ Purdue sponsored APF’s *Exit Wounds* (2009), which omits warnings
 13 of the risk of interactions between opioids and benzodiazepines,
 14 which would increase fatality risk. *Exit Wounds* also contained a
 15 lengthy discussion of the dangers of using alcohol to treat chronic
 16 pain but did not disclose dangers of mixing
- 17 ○ Purdue sales representatives told prescribers that opioids were just as
 18 effective for treating patients long-term and omitted any discussion
 19 that increased tolerance would require increasing, and increasingly
 20 dangerous, doses.
- 21 ○ Purdue sales representatives told prescribers that NSAIDs were more
 22 toxic than opioids.

- 23 • Janssen:

- 24 ○ Janssen sponsored a patient education guide entitled *Finding Relief:*
 25 *Pain Management for Older Adults* (2009), which its personnel
 26 reviewed and approved and its sales force distributed. This guide
 27 listed dose limitations as “disadvantages” of other pain medicines but
 28

omitted any discussion of risks of increased doses from opioids. The publication also falsely claimed that it is a “myth” that “opioid doses have to be bigger over time.”

- *Finding Relief: Pain Management for Older Adults* also described the advantages and disadvantages of NSAIDs on one page, and the “myths/facts” of opioids on the facing page. The disadvantages of NSAIDs are described as involving “stomach upset or bleeding,” “kidney or liver damage if taken at high doses or for a long time,” “adverse reactions in people with asthma,” and “can increase the risk of heart attack and stroke.” The only adverse effects of opioids listed are “upset stomach or sleepiness,” which the brochure claims will go away, and constipation.
- Janssen sponsored APF’s *Exit Wounds* (2009), which omits warnings of the risk of interactions between opioids and benzodiazepines. Janssen’s label for Duragesic, however, states that use with benzodiazepines “may cause respiratory depression, [low blood pressure], and profound sedation or potentially result in coma. *Exit Wounds* also contained a lengthy discussion of the dangers of using alcohol to treat chronic pain but did not disclose dangers of mixing alcohol and opioids.
- Janssen sales representatives told prescribers that Nucynta was not an opioid, making it a good choice for chronic pain patients who previously were unable to continue opioid therapy due to excessive side effects. This statement was misleading because Nucynta is an opioid and has the same effects as other opioids.
- Cephalon:

- Cephalon sponsored APF's *Treatment Options: A Guide for People Living with Pain* (2007), which claims that some patients "need" a larger dose of their opioid, regardless of the dose currently prescribed.
- *Treatment Options*, also taught patients that opioids differ from NSAIDs in that they have "no ceiling dose" and are therefore the most appropriate treatment for severe pain. *Treatment Options* continued, warning that risks of NSAIDs increase if "taken more than a period of months." With no corresponding warning about opioids. The publication attributed 10,000 to 20,000 deaths annually to NSAID overdose.
- Cephalon sponsored a CME written by KOL Dr. Lynn Webster, *Optimizing Opioid Treatment for Breakthrough Pain*, which was offered online by Medscape, LLC from September 28, 2007 through December 15, 2008. The CME taught that non-opioid analgesics and combination opioids that include aspirin and acetaminophen are less effective to treat breakthrough pain because of dose limitations.
- Cephalon sales representatives assured prescribers that opioids were safe, even at high doses.
- Cephalon sales representatives told prescribers that NSAIDs were more toxic than opioids.
- "[P]romot[ing] Actiq for use in patients who were not yet opioid tolerant, and for whom it could have life-threatening results."³⁴⁸
- Endo:
 - Endo sponsored a website, painknowledge.com, through APF and NIPC, which claimed in 2009 that opioids may be increased until

³⁴⁸ *Id.*

1 “you are on the right dose of medication for your pain,” and once that
 2 occurs, further dose increases would not occur. Endo funded the site,
 3 which was a part of Endo’s marketing plan, and tracked visitors to it.

- 4 ○ Through painknowledge.com Endo distributed a flyer called “Pain:
 5 Opioid Therapy.” This publication included a list of adverse effects
 6 from opioids that omitted significant adverse effects like
 7 hyperalgesia, immune and hormone dysfunction, cognitive
 8 impairment, tolerance, dependence, addiction, and death. Endo
 9 continued to provide funding for this website through 2012, and
 10 closely tracked unique visitors to it.
- 11 ○ Endo provided grants to APF to distribute Exit Wounds (2009),
 12 which omitted warnings of the risk of interactions between opioids
 13 and benzodiazepines, which would increase fatality risk. Exit
 14 Wounds also contained a lengthy discussion of the dangers of using
 15 alcohol to treat chronic pain but did not disclose dangers of mixing
 16 alcohol and opioids.
- 17 ○ Endo sales representatives told prescribers that NSAIDs were more
 18 toxic than opioids.
- 19 ○ Endo distributed a patient education pamphlet edited by KOL Dr.
 20 Russell Portenoy titled *Understanding Your Pain: Taking Oral*
 21 *Opioid Analgesics*. In Q&A format, it asked: “If I take the opioid
 22 now, will it work later when I really need it?” The response was:
 23 “The dose can be increased You won’t ‘run out’ of pain relief.”
- 24 ○ Endo distributed a “case study” to prescribers titled *Case Challenges*
 25 *in Pain Management: Opioid Therapy for Chronic Pain*. The study
 26 cites an example, meant to be representative, of a patient “with a
 27 massive upper gastrointestinal bleed believed to be related to his
 28

1 protracted use of NSAIDs” (over eight years), and recommends
2 treating with opioids instead.

3 562. These misrepresentations, and the legion of other representations
4 made by the RICO Defendants and members of Opioid Marketing Enterprise all
5 furthered the common purpose and fraudulent scheme of the Opioid Marketing
6 Enterprise. But they were demonstrably false, as confirmed by investigations and
7 enforcement actions against the RICO Marketing Defendants.

8 563. In May 2007, Purdue and three of its executives pled guilty to federal
9 charges of misbranding OxyContin in what the company acknowledged was an
10 attempt to mislead doctors about the risk of addiction. Purdue was ordered to pay
11 \$600 million in fines and fees. In its plea, Purdue admitted that its promotion of
12 OxyContin was misleading and inaccurate, misrepresented the risk of addiction
13 and was unsupported by science. The Order adopting the guilty pleas provide:

14
15 effects than immediate-release opioids resulting in less
16 euphoria and less potential for abuse than short-acting
 opioids;

17 d. Told certain health care providers that patients could stop
18 therapy abruptly without experiencing withdrawal
19 symptoms and that patients who took OxyContin would not
 develop tolerance to the drug; and

20 e. Told certain health care providers that OxyContin did not
21 cause a “buzz” or euphoria, caused less euphoria, had less
22 addiction potential, had less abuse potential, was less likely
 to be diverted than immediate-release opioids, and could be
 used to “weed out” addicts and drug seekers.

23 (Information ¶ 19.) Purdue has agreed that these facts are true, and the individual
24 defendants, while they do not agree that they had knowledge of these things, have
25 agreed that the court may accept these facts in support of their guilty pleas. (Agreed
26 Statement of Facts ¶ 46.)

27 564. Additionally, Michael Friedman (“Friedman”), the company’s
28 president, pled guilty to a misbranding charge and agreed to pay \$19 million in

1 fines; Howard R. Udell (“Udell”), Purdue’s top lawyer, also pled guilty and
 2 agreed to pay \$8 million in fines; and Paul D. Goldenheim (“Goldenheim”), its
 3 former medical director, pled guilty as well and agreed to pay \$7.5 million in
 4 fines.³⁴⁹

5 565. In a statement announcing the guilty plea, John Brownlee
 6 (“Brownlee”), the U.S. Attorney for the Western District of Virginia, stated:

7 Purdue claimed it had created the miracle drug – a low risk drug that
 8 could provide long acting pain relief but was less addictive and less
 9 subject to abuse. Purdue’s marketing campaign worked, and sales for
 OxyContin skyrocketed – making billions for Purdue and millions for
 its top executives.

10 But OxyContin offered no miracles to those suffering in pain.
 11 Purdue’s claims that OxyContin was less addictive and less subject to
 12 abuse and diversion were false – and Purdue knew its claims were
 13 false. The result of their misrepresentations and crimes sparked one of
 our nation’s greatest prescription drug failures. . . . OxyContin was the
 child of marketers and bottom line financial decision making.³⁵⁰

14 566. Brownlee characterized Purdue’s criminal activity as follows:

15 First, Purdue trained its sales representatives to falsely inform
 16 health care providers that it was more difficult to extract the
 17 oxycodone from an OxyContin tablet for the purpose of intravenous
 18 abuse. Purdue ordered this training even though its own study showed
 that a drug abuser could extract approximately 68% of the oxycodone
 from a single 10 mg OxyContin tablet by simply crushing the tablet,
 stirring it in water, and drawing the solution through cotton into a
 syringe.

19 Second, Purdue falsely instructed its sales representatives to
 20 inform health care providers that OxyContin could create fewer
 chances for addiction than immediate-release opioids.

21 Third, Purdue sponsored training that falsely taught Purdue
 22 sales supervisors that OxyContin had fewer “peak and trough” blood
 23 level effects than immediate-release opioids resulting in less euphoria
 and less potential for abuse than short-acting opioids.

24 Fourth, Purdue falsely told certain health care providers that
 25 patients could stop therapy abruptly without experiencing withdrawal

26 ³⁴⁹ *Id.*

27 ³⁵⁰ Press Release, U.S. Attorney for the Western District of Virginia, Statement of
 28 United States Attorney John Brownlee on the Guilty Plea of the Purdue Frederick
 Company and Its Executives for Illegally Misbranding OxyContin (May 10, 2007),
<https://assets.documentcloud.org/documents/279028/purdue-guilty-plea.pdf>.

1 symptoms and that patients who took OxyContin would not develop
2 tolerance to the drug.

3 And fifth, Purdue falsely told health care providers that
4 OxyContin did not cause a “buzz” or euphoria, caused less euphoria,
5 had less addiction potential, had less abuse potential, was less likely to
6 be diverted than immediate-release opioids, and could be used to
7 “weed out” addicts and drug seekers.³⁵¹

8 567. Purdue pled guilty to illegally misbranding OxyContin in an effort to
9 mislead and defraud physicians and consumers, while Friedman, Udell and
10 Goldenheim pled guilty to the misdemeanor charge of misbranding OxyContin for
11 introducing misbranded drugs into interstate commerce in violation of 21 U.S.C.
12 §§ 331(a), 333(a)(1)-(2) and 352(a).

13 568. Similarly, Endo’s marketing of Purdue was criticized and punished
14 by the FDA and New York Attorney General.

15 569. On February 18, 2017, the State of New York announced a
16 settlement with Endo requiring it “to cease all misrepresentations regarding the
17 properties of Opana ER [and] to describe accurately the risk of addiction to Opana
18 ER.”³⁵² In the Assurance of Discontinuance that effectuated the settlement, the
19 State of New York stated that Endo knew about the risks arising from the
20 reformulated Opana ER even before it received FDA approval. Among other
21 things, the investigation concluded that:

- 22 • Endo improperly marketed Opana ER as designed to be crush resistant,
23 when Endo’s own studies dating from 2009 and 2010 showed that the pill
24 could be crushed and ground;

25 ³⁵¹ *Id.*

26 ³⁵² Press Release, Attorney General Eric T. Schneiderman, A.G. Schneiderman
27 Announces Settlement With Endo Health Solutions Inc. & Endo Pharmaceuticals
28 Inc. Over Marketing Of Prescription Opioid Drugs (Mar. 3, 2016),
<https://ag.ny.gov/press-release/ag-schneiderman-announces-settlement-endo-health-solutions-inc-endo-pharmaceuticals> (last accessed on March 9, 2018).

- 1 • Endo improperly instructed its sales representatives to diminish and distort
- 2 the risks associated with Opana ER, including the serious danger of
- 3 addiction; and
- 4 • Endo made unsupported claims comparing Opana ER to other opioids and
- 5 failed to disclose accurate information regarding studies addressing the
- 6 negative effects of Opana ER.³⁵³

7 570. The 2017 settlement also identified and discussed a February 2013
 8 communication from a consultant hired by Endo to the company, in which the
 9 consultant concluded that “[t]he initial data presented do not necessarily establish
 10 that the reformulated Opana ER is tamper resistant.” The same consultant also
 11 reported that the distribution of the reformulated Opana ER had already led to
 12 higher levels of abuse of the drug via injection.³⁵⁴

13 571. The Office of the Attorney General of New York also revealed that
 14 the “managed care dossier” Endo provided to formulary committees of healthcare
 15 plans and pharmacy benefit managers misrepresented the studies that had been
 16 conducted on Opana ER. According to Endo’s vice president for
 17 pharmacovigilance and risk management, the dossier was presented as a complete
 18 compendium of all research on the drug. However, it omitted certain studies:
 19 Study 108 (completed in 2009) and Study 109 (completed in 2010), which showed
 20 that reformulated Opana ER could be ground and chewed.

21 572. The settlement also detailed Endo’s false and misleading
 22 representations about the non-addictiveness of opioids and Opana. For example,
 23 until April 2012, Endo’s website for the drug, www.opana.com, contained the
 24 following representation: “Most healthcare providers who treat patients with pain
 25 agree that patients treated with prolonged opioid medicines usually do not become

27 ³⁵³ *Id.*

28 ³⁵⁴ *Id.* at 6.

1 addicted.”³⁵⁵ However, Endo neither conducted nor possessed a survey
2 demonstrating that most healthcare providers who treat patients with pain agree
3 with that representation.

4 573. The Office of the Attorney General of New York also disclosed the
5 following facts that it determined to violate Opana’s obligations to truthfully
6 market its products:

7 a. Training materials provided by Endo to sales
8 representatives stated: “Symptoms of withdrawal do not
9 indicate addiction.”³⁵⁶ This representation is inconsistent with
10 the diagnosis of opioid-use disorder as provided in the
11 Diagnostic and Statistical Manual of Mental Disorders by the
12 American Psychiatric Association (Fifth Edition).

13 b. Endo trained its sales representatives to falsely
14 distinguish addiction from “pseudoaddiction,” which it defined
15 as a condition in which patients exhibit drug-seeking behavior
16 that resembles but is not the same as addiction. Endo’s vice
17 president for pharmacovigilance and risk management testified
18 that he was not aware of any research validating the concept of
19 pseudoaddiction.

20 574. On June 9, 2017, the FDA asked Endo to voluntarily cease sales of
21 Opana ER after determining that the risks associated with its abuse outweighed
22 the benefits. According to Dr. Janet Woodcock, director of the FDA’s Center for
23 Drug Evaluation and Research, the risks include “several serious problems,”
24 including “outbreaks of HIV and Hepatitis C from sharing the drug after it was
25
26
27

28 ³⁵⁵ *Id.*

³⁵⁶ *Id.* at 7.

1 extracted by abusers” and “”a serious disease outbreak.”³⁵⁷ If Endo did not
 2 comply, the FDA stated that it “intends to take steps to formally require its
 3 removal by withdrawing approval.”³⁵⁸

4 575. Like Purdue and Endo, Janssen was the subject of an FDA
 5 enforcement action that identified its marketing statements as misrepresentations.
 6 For example:

7 576. On February 15, 2000, the FDA sent Janssen a letter concerning the
 8 alleged dissemination of “homemade” promotional pieces that promoted
 9 Duragesic in violation of the Federal Food, Drug, and Cosmetic Act. In a
 10 subsequent letter, dated March 30, 2000, the FDA explained that the “homemade”
 11 promotional pieces were “false or misleading because they contain
 12 misrepresentations of safety information, broaden Duragesic’s indication, contain
 13 unsubstantiated claims, and lack fair balance.”³⁵⁹

14 577. The March 30, 2000 letter identified specific violations, including
 15 misrepresentations that Duragesic had a low potential for abuse:

16 You present the claim, “Low abuse potential!” This claim suggests
 17 that Duragesic has less potential for abuse than other currently
 18 available opioids. However, this claim has not been demonstrated by
 19 substantial evidence. Furthermore, this claim is contradictory to
 20 information in the approved product labeling (PI) that states,
 “Fentanyl is a Schedule II controlled substance and can produce drug
 dependence similar to that produced by morphine.” Therefore, this
 claim is false or misleading.³⁶⁰

21 578. The March 30, 2000 letter also stated that the promotional materials
 22 represented that Duragesic was “more useful in a broader range of conditions or
 23

24
 25 ³⁵⁷ *FDA requests removal of Opana ER for risks related to abuse*, June 8, 2017,
[https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562401.ht](https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562401.htm)
 26 [m](https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562401.htm).

27 ³⁵⁸ *Id.*

28 ³⁵⁹ NDA 19-813 Letter from Spencer Salis, U.S. Food & Drug Administration, to
 Cynthia Chianese, Janssen Pharmaceutica (Mar. 30, 2000) at 2.

³⁶⁰ *Id.*

1 patients than has been demonstrated by substantial evidence.”³⁶¹ Specifically, the
 2 FDA stated that Janssen was marketing Duragesic for indications other than the
 3 treatment of chronic pain that cannot otherwise be managed, for which it was
 4 approved:

5 You present the claim, “It’s not just for end stage cancer anymore!”
 6 This claim suggests that Duragesic can be used for any type of pain
 7 management. However, the PI for Duragesic states, “Duragesic
 8 (fentanyl transdermal system) is indicated in the management of
 9 chronic pain in patients who require continuous opioid analgesia for
 10 pain that cannot be managed by lesser means” Therefore, the
 11 suggestion that Duragesic can be used for any type of pain
 12 management promotes Duragesic[] for a much broader use than is
 13 recommended in the PI, and thus, is misleading. In addition, the
 14 suggestion that Duragesic can be used to treat any kind of pain is
 15 contradictory to the boxed warning in the PI. Specifically, the PI
 16 states,

17 **BECAUSE SERIOUS OR LIFE-THREATENING**
 18 **HYPOVENTILATION COULD OCCUR, DURAGESIC®**
 19 **(FENTANYL TRANSDERMAL SYSTEM) IS**
 20 **CONTRAINDICATED:**

21 In the management of acute or post-operative pain, including use in
 22 outpatient surgeries³⁶²

23 579. The March 30, 2000 letter also stated Janssen failed to adequately
 24 present “contraindications, warnings, precautions, and side effects with a
 25 prominence and readability reasonably comparable to the presentation of
 26 information relating to the effectiveness of the product.”³⁶³

27 580. On February 15, 2000, the FDA sent Janssen a letter concerning the
 28 alleged dissemination of “homemade” promotional pieces that promoted
 Duragesic in violation of the Federal Food, Drug, and Cosmetic Act. In a
 subsequent letter, dated March 30, 2000, the FDA explained that the “homemade”
 promotional pieces were “false or misleading because they contain

³⁶¹ *Id.*

³⁶² *Id.* at 2-3.

³⁶³ *Id.* at 3 (emphasis in original).

misrepresentations of safety information, broaden Duragesic's indication, contain unsubstantiated claims, and lack fair balance."³⁶⁴

581. The March 30, 2000 letter identified specific violations, including misrepresentations that Duragesic had a low potential for abuse:

You present the claim, "Low abuse potential!" This claim suggests that Duragesic has less potential for abuse than other currently available opioids. However, this claim has not been demonstrated by substantial evidence. Furthermore, this claim is contradictory to information in the approved product labeling (PI) that states, "Fentanyl is a Schedule II controlled substance and can produce drug dependence similar to that produced by morphine." Therefore, this claim is false or misleading.³⁶⁵

582. The March 30, 2000 letter also stated that the promotional materials represented that Duragesic was "more useful in a broader range of conditions or patients than has been demonstrated by substantial evidence."³⁶⁶ Specifically, the FDA stated that Janssen was marketing Duragesic for indications other than the treatment of chronic pain that cannot otherwise be managed, for which it was approved:

You present the claim, "It's not just for end stage cancer anymore!" This claim suggests that Duragesic can be used for any type of pain management. However, the PI for Duragesic states, "Duragesic (fentanyl transdermal system) is indicated in the management of chronic pain in patients who require continuous opioid analgesia for pain that cannot be managed by lesser means" Therefore, the suggestion that Duragesic can be used for any type of pain management promotes Duragesic[] for a much broader use than is recommended in the PI, and thus, is misleading. In addition, the suggestion that Duragesic can be used to treat any kind of pain is contradictory to the boxed warning in the PI. Specifically, the PI states,

**BECAUSE SERIOUS OR LIFE-THREATENING
HYPOVENTILATION COULD OCCUR, DURAGESIC®
(FENTANYL TRANSDERMAL SYSTEM) IS
CONTRAINDICATED:**

³⁶⁴ NDA 19-813 Letter from Spencer Salis, U.S. Food & Drug Administration, to Cynthia Chianese, Janssen Pharmaceutica (Mar. 30, 2000) at 2.

³⁶⁵ *Id.*

³⁶⁶ *Id.*

1 In the management of acute or post-operative pain, including use in
outpatient surgeries³⁶⁷

2 583. The March 30, 2000 letter also stated Janssen failed to adequately
3 present “contraindications, warnings, precautions, and side effects with a
4 prominence and readability reasonably comparable to the presentation of
5 information relating to the effectiveness of the product”:

6 Although this piece contains numerous claims for the efficacy and
7 safety of Duragesic, you have not presented any risk information
8 concerning the boxed warnings, contraindications, warnings,
9 precautions, or side effects associated with Duragesic’s use
Therefore, this promotional piece is lacking in fair balance, or
otherwise misleading, because it fails to address important risks and
restrictions associated with Duragesic therapy.³⁶⁸

10 584. On September 2, 2004, the U.S. Department of Health and Human
11 Services (“HHS”) sent Janssen a warning letter concerning Duragesic due to
12 “false or misleading claims about the abuse potential and other risks of the drug,
13 and . . . unsubstantiated effectiveness claims for Duragesic,” including,
14 specifically, “suggesting that Duragesic has a lower potential for abuse compared
15 to other opioid products.”

16 585. The September 2, 2004 letter warned Janssen regarding its claims
17 that Duragesic had a low reported rate of mentions in the Drug Abuse Warning
18 Network (“DAWN”) as compared to other opioids. The letter stated that the claim
19 was false or misleading because the claim was not based on substantial data and
20 because the lower rate of mentions was likely attributable to Duragesic’s lower
21 frequency of use compared to other opioids listed in DAWN:

22 The file card presents the prominent claim, “Low reported rate
23 of mentions in DAWN data,” along with Drug Abuse Warning
24 Network (DAWN) data comparing the number of mentions for
Fentanyl/combinations (710 mentions) to other listed opioid products,
25 including Hydrocodone/combinations (21,567 mentions),
Oxycodone/combinations (18,409 mentions), and Methadone (10,725
26 mentions). The file card thus suggests that Duragesic is less abused
than other opioid drugs.

27
28 ³⁶⁷ *Id.* at 2-3.

³⁶⁸ *Id.* at 3 (emphasis in original).

1 This is false or misleading for two reasons. First, we are not
 2 aware of substantial evidence or substantial clinical experience to
 3 support this comparative claim. The DAWN data cannot provide the
 4 basis for a valid comparison among these products. As you know,
 DAWN is not a clinical trial database. Instead, it is a national public
 health surveillance system that monitors drug-related emergency
 department visits and deaths. If you have other data demonstrating
 that Duragesic is less abused, please submit them.

5 Second, Duragesic is not as widely prescribed as other opioid
 6 products. As a result, the relatively lower number of mentions could
 be attributed to the lower frequency of use, and not to a lower
 incidence of abuse. The file card fails to disclose this information.³⁶⁹

7 586. The September 2, 2004 letter also detailed a series of unsubstantiated
 8 false or misleading claims regarding Duragesic's effectiveness. The letter
 9 concluded that various claims made by Janssen were insufficiently supported,
 10 including:

- 11 • “Demonstrated effectiveness in chronic back pain with additional patient
 12 benefits, . . . 86% of patients experienced overall benefit in a clinical study
 13 based on: pain control, disability in ADLs, quality of sleep.”
- 14 • “All patients who experienced overall benefit from DURAGESIC would
 15 recommend it to others with chronic low back pain.”
- 16 • “Significantly reduced nighttime awakenings.”
- 17 • “Significant improvement in disability scores as measured by the Oswestry
 18 Disability Questionnaire and Pain Disability Index.”
- 19 • “Significant improvement in physical functioning summary score.”
- 20 • “Significant improvement in social functioning.”³⁷⁰

21 587. In addition, the September 2, 2004 letter identified “outcome claims
 22 [that] are misleading because they imply that patients will experience improved
 23 social or physical functioning or improved work productivity when using
 24

25
 26 ³⁶⁹ Warning Letter from Thomas W. Abrams, U.S. Department of Health and
 27 Human Services, to Ajit Shetty, Janssen Pharmaceutica, Inc. (Sept. 2, 2004),
[https://www.pharmamedtechbi.com/~media/Images/Publications/Archive/The%20](https://www.pharmamedtechbi.com/~media/Images/Publications/Archive/The%20Pink%20Sheet/66/038/00660380018/040920_duragesic_letter.pdf)
 28 [Pink%20Sheet/66/038/00660380018/040920_duragesic_letter.pdf](https://www.pharmamedtechbi.com/~media/Images/Publications/Archive/The%20Pink%20Sheet/66/038/00660380018/040920_duragesic_letter.pdf) at 2.

³⁷⁰ *Id.* at 2-3.

1 Duragesic.” The claims include “‘1,360 loaves . . . and counting,’ ‘[w]ork,
 2 uninterrupted,’ ‘[l]ife, uninterrupted,’ ‘[g]ame, uninterrupted,’ ‘[c]hronic pain
 3 relief that supports functionality,’ ‘[h]elps patients think less about their pain,’ and
 4 ‘[i]mprove[s] . . . physical and social functioning.’” The September 2, 2004 letter
 5 stated: “Janssen has not provided references to support these outcome claims. We
 6 are not aware of substantial evidence or substantial clinical experience to support
 7 these claims.”³⁷¹

8 588. On July 15, 2005, the FDA issued a public health advisory warning
 9 doctors of deaths resulting from the use of Duragesic and its generic competitor,
 10 manufactured by Mylan N.V. Plaintiffs are informed and believe that the advisory
 11 noted that the FDA had been “‘examining the circumstances of product use to
 12 determine if the reported adverse events may be related to inappropriate use of the
 13 patch’” and noted the possibility “that patients and physicians might be unaware
 14 of the risks” of using the fentanyl transdermal patch, which is a potent opioid
 15 analgesic meant to treat chronic pain that does not respond to other painkillers.³⁷²

16 589. Finally, Cephalon has been the subject of investigations and
 17 enforcement actions for is misrepresentations concerning Actiq. For example:

18 590. In October 2000, Cephalon acquired the worldwide product rights to
 19 Actiq and began marketing and selling Actiq in the United States. The FDA
 20 explicitly stated that Actiq “***must not*** be used in opioid non-tolerant patients,” was
 21 contraindicated for the management of acute or postoperative pain, could be
 22 deadly to children, and was “intended to be used only in the care of opioid-
 23 tolerant cancer patients and only by oncologists and pain specialists who are
 24 knowledgeable of and skilled in the use of Schedule II opioids to treat cancer
 25

26
 27 ³⁷¹ *Id.* at 3.

28 ³⁷² *New Fentanyl Warnings: More Needed to Protect Patients*, Institute for Safe
 Medication Practices, August 11, 2005,
<https://www.ismp.org/newsletters/acute/articles/20050811.asp>

1 pain.”³⁷³ The FDA also required that Actiq be provided only in compliance with a
2 strict risk management program that explicitly limited the drug’s direct marketing
3 to the approved target audiences, defined as oncologists, pain specialists, their
4 nurses and office staff.³⁷⁴

5 591. Cephalon purchased the rights to Fentora, an even faster-acting tablet
6 formulation of fentanyl, from Cima Labs, and submitted a new drug application to
7 the FDA in August 2005. In September 2006, Cephalon received FDA approval to
8 sell this faster-acting version of Actiq; but once again, concerned about the power
9 and risks inherent to fentanyl, the FDA limited Fentora’s approval to the treatment
10 of BTP in cancer patients who were already tolerant to around-the-clock opioid
11 therapy for their underlying persistent cancer pain. Cephalon began marketing and
12 selling Fentora in October 2006.

13 592. Due to the FDA’s restrictions, Actiq’s consumer base was limited, as
14 was its potential for growing revenue. In order to increase its revenue and market
15 share, Cephalon needed to find a broader audience and thus began marketing its
16 lollipop to treat headaches, back pain, sports injuries and other chronic non-cancer
17 pain, targeting non-oncology practices, including, but not limited to, pain doctors,
18 general practitioners, migraine clinics, anesthesiologists and sports clinics. It did
19 so in violation of applicable regulations prohibiting the marketing of medications
20 for off-label use and indirect contravention of the FDA’s strict instructions that
21 Actiq be prescribed only to terminal cancer patients and by oncologists and pain
22 management doctors experienced in treating cancer pain.

23 593. Beginning in or about 2003, former Cephalon employees filed four
24 whistleblower lawsuits claiming the company had wrongfully marketed Actiq for
25

26 ³⁷³ *Id.*

27 ³⁷⁴ See John Carreyrou, *Narcotic “Lollipop” Becomes Big Seller Despite FDA*
28 *Curbs*, Wall St. J. (Nov. 3, 2006), <https://www.opiates.com/media/narcotic-lollipop-becomes-big-seller-despite-fdacurbs/>.

1 unapproved off-label uses. On September 29, 2008, Cephalon finalized and
 2 entered into a corporate integrity agreement with the Office of the Inspector
 3 General of HHS and agreed to pay \$425 million in civil and criminal penalties for
 4 its off-label marketing of Actiq and two other drugs (Gabitril and Provigil).

5 According to a DOJ press release, Cephalon trained sales representatives to
 6 disregard restrictions of the FDA-approved label, employed sales representatives
 7 and healthcare professionals to speak to physicians about off-label uses of the
 8 three drugs and funded CME to promote off-label uses. Specifically, the DOJ
 9 stated:

10 From 2001 through at least 2006, Cephalon was allegedly promoting
 11 [Actiq] for non-cancer patients to use for such maladies as migraines,
 12 sickle-cell pain crises, injuries, and in anticipation of changing wound
 13 dressings or radiation therapy. Cephalon also promoted Actiq for use
 in patients who were not yet opioid-tolerant, and for whom it could
 have life-threatening results.³⁷⁵

14 594. Then-acting U.S. Attorney Laurie Magid commented on the dangers
 15 of Cephalon's unlawful practices:

16 "This company subverted the very process put in place to protect the public
 17 from harm, and put patients' health at risk for nothing more than boosting
 18 its bottom line. People have an absolute right to their doctors' best medical
 19 judgment. They need to know the recommendations a doctor makes are not
 20 influenced by sales tactics designed to convince the doctor that the drug
 21 being prescribed is safe for uses beyond what the FDA has approved."³⁷⁶

22 595. Upon information and belief, documents uncovered in the
 23 government's investigations confirm that Cephalon directly targeted non-
 24 oncology practices and pushed its sales representatives to market Actiq for off-
 25 label use. For instance, the government's investigations confirmed:

26 _____
 27 ³⁷⁵ Press Release, U.S. Department of Justice, Pharmaceutical Company Cephalon
 To Pay \$425 Million For Off-Label Drug Marketing (Sept. 29, 2008),
 28 <https://www.justice.gov/archive/usao/pae/News/2008/sep/cephalonrelease.pdf>.

³⁷⁶ *Id.*

- 1 a. Cephalon instructed its sales representatives to ask non-cancer doctors
2 whether they have the potential to treat cancer pain. Even if the doctor
3 answered “no,” a decision tree provided by Cephalon instructed the sales
4 representatives to give these physicians free Actiq coupons;
- 5 b. Cephalon targeted neurologists in order to encourage them to prescribe
6 Actiq to patients with migraine headaches;
- 7 c. Cephalon sales representatives utilized the assistance of outside pain
8 management specialists when visiting non-cancer physicians to pitch Actiq. The
9 pain management specialist would falsely inform the physician that Actiq does not
10 cause patients to experience a “high” and carries a low risk of diversion toward
11 recreational use;
- 12 d. Cephalon set sales quotas for its sales and marketing representatives that
13 could not possibly have been met solely by promoting Actiq for its FDA-approved
14 indication;
- 15 e. Cephalon promoted the use of higher doses of Actiq than patients required
16 by encouraging prescriptions of the drug to include larger-than-necessary numbers
17 of lozenges with unnecessarily high doses of fentanyl; and
- 18 f. Cephalon promoted Actiq for off-label use by funding and controlling
19 CME seminars that promoted and misrepresented the efficacy of the
20 drug for off-label uses such as treating migraine headaches and for
21 patients not already opioid-tolerant.³⁷⁷

22 596. The FDA’s letters and safety alerts, the DOJ and state investigations,
23 and the massive settlement seemed to have had little impact on Cephalon as it
24 continued its deceptive marketing strategy for both Actiq and Fentora.

25
26
27
28 ³⁷⁷ John Carreyrou, Cephalon Used Improper Tactics to Sell Drug, Probe Finds, Wall St. J., Nov. 21, 2006, at B1 (hereinafter “Carreyrou, Cephalon Used Improper Tactics”).

1 597. On September 27, 2007, the FDA issued a public health advisory to
2 address numerous reports that patients who did not have cancer or were not
3 opioid-tolerant had been prescribed Fentora, and death or life-threatening side
4 effects had resulted. The FDA warned: “Fentora should not be used to treat any
5 type of short-term pain.”³⁷⁸

6 598. Nevertheless, in 2008, Cephalon pushed forward to expand the target
7 base for Fentora and filed a supplemental drug application requesting FDA
8 approval of Fentora for the treatment of non-cancer BTP. In the application and
9 supporting presentations to the FDA, Cephalon admitted both that it knew the
10 drug was heavily prescribed for off-label use and that the drug’s safety for such
11 use had never been clinically evaluated.³⁷⁹ An FDA advisory committee noted that
12 Fentora’s existing risk management program was ineffective and stated that
13 Cephalon would have to institute a risk evaluation and mitigation strategy for the
14 drug before the FDA would consider broader label indications. In response,
15 Cephalon revised Fentora’s label and medication guide to add strengthened
16 warnings.

17 599. But in 2009, the FDA once again informed Cephalon that the risk
18 management program was not sufficient to ensure the safe use of Fentora for
19 already approved indications.

20 600. On March 26, 2009, the FDA warned Cephalon against its
21 misleading advertising of Fentora (“Warning Letter”). The Warning Letter
22

23 ³⁷⁸ Press Release, U.S. Food & Drug Administration, Public Health Advisory:
24 Important Information for the Safe Use of Fentora (fentanyl buccal tablets) (Sept.
25 26, 2007), <https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm051273.htm>.

26 ³⁷⁹ FENTORA (fentanyl buccal tablet) CII, Joint Meeting of Anesthetic and Life
27 Support Drugs and
28 Drug Safety and Risk Management Advisory Committee, U.S. Food & Drug
Administration (May 6, 2008), <https://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4356s2-03-Cephalon.pdf>.

1 described a Fentora Internet advertisement as misleading because it purported to
 2 broaden “the indication for Fentora by implying that any patient with cancer who
 3 requires treatment for breakthrough pain is a candidate for Fentora . . . when this
 4 is not the case.”³⁸⁰ Rather, Fentora was only indicated for those who were already
 5 opioid tolerant. It further criticized Cephalon’s other direct Fentora advertisements
 6 because they did not disclose the risks associated with the drug.

7 601. Flagrantly disregarding the FDA’s refusal to approve Fentora for
 8 non-cancer BTP and its warning against marketing the drug for the same,
 9 Cephalon continued to use the same sales tactics to push Fentora as it did with
 10 Actiq.

11 602. The misrepresentations disseminated by members of the Opioid
 12 Marketing Enterprise, and the RICO Marketing Defendants, caused The County
 13 and California consumers to pay for excessive opioid prescriptions, suffer injuries
 14 and losses, and to incur costs associated with the opioid epidemic caused by the
 15 Opioid Marketing Enterprise.

16 603. The RICO Marketing Defendants alone could not have accomplished
 17 the purpose of the Opioid Marketing Enterprise without the assistance of the Front
 18 Groups and KOLs, who were perceived as “neutral” and more “scientific” than
 19 the RICO Defendants themselves. Without these misrepresentations, the Opioid
 20 Marketing Enterprise could not have achieved its common purpose.

21 604. The impact of the Opioid Marketing Enterprise’s scheme is still in
 22 place – i.e., the opioids continue to be prescribed and used for chronic pain
 23 throughout the State of California, and the epidemic continues to injure The
 24 County, and consume the resources of The County’s and California’s health care
 25 and law enforcement systems.

26
 27
 28 ³⁸⁰ Letter from Michael Sauers, Regulatory Review Officer, Division of Drug
 Marketing, Advertising and Communications, to Carole S. Marchione, Senior
 Director and Group Leader, Regulatory Affairs (March 26, 2009)

1 605. The foregoing evidences that the RICO Marketing Defendants, the
 2 Front Groups, and the KOLs were each willing participants in the Opioid
 3 Marketing Enterprise, had a common purpose and interest in the object of the
 4 scheme, and functioned within a structure designed to effectuate the Enterprise's
 5 purpose.

6 **B. CONDUCT OF THE OPIOID MARKETING ENTERPRISE.**

7 606. During time period described in this Complaint, from approximately
 8 the late 1990s to the present, the RICO Marketing Defendants exerted control over
 9 the Opioid Marketing Enterprise and participated in the operation or management
 10 of the affairs of the Opioid Marketing Enterprise, directly or indirectly, in the
 11 following ways:

- 12 a. Creating a body of deceptive, misleading and unsupported medical and
 13 popular literature about opioids that (a) understated the risks and
 14 overstated the benefits of long-term use; (b) appeared to be the result of
 15 independent, objective research; and (c) was thus more likely to be
 16 relied upon by physicians, patients, and payors;
- 17 b. Creating a body of deceptive, misleading and unsupported electronic and
 18 print advertisements about opioids that (a) understated the risks and
 19 overstated the benefits of long-term use; (b) appeared to be the result of
 20 independent, objective research; and (c) was thus more likely to be
 21 relied upon by physicians, patients, and payors;
- 22 c. Creating a body of deceptive, misleading and unsupported sales and
 23 promotional training materials about opioids that (a) understated the
 24 risks and overstated the benefits of long-term use; (b) appeared to be the
 25 result of independent, objective research; and (c) was thus more likely to
 26 be relied upon by physicians, patients, and payors;
- 27 d. Creating a body of deceptive, misleading and unsupported CMEs and
 28 speaker presentations about opioids that (a) understated the risks and

1 overstated the benefits of long-term use; (b) appeared to be the result of
2 independent, objective research; and (c) was thus more likely to be
3 relied upon by physicians, patients, and payors;

4 e. Selecting, cultivating, promoting and paying KOLs based solely on their
5 willingness to communicate and distribute the RICO Defendants' messages about
6 the use of opioids for chronic pain;

7 f. Providing substantial opportunities for KOLs to participate in research
8 studies on topics the RICO Defendants suggested or chose, with the predictable
9 effect of ensuring that many favorable studies appeared in the academic literature;

10 g. Paying KOLs to serve as consultants or on the RICO Defendants' advisory
11 boards, on the advisory boards and in leadership positions on Front Groups, and to
12 give talks or present CMEs, typically over meals or at conferences;

13 h. Selecting, cultivating, promoting, creating and paying Front Groups based
14 solely on their willingness to communicate and distribute the RICO Defendants'
15 messages about the use of opioids for chronic pain;

16 i. Providing substantial opportunities for Front Groups to participate in and/or
17 publish research studies on topics the RICO Defendants suggested or chose (and
18 paid for), with the predictable effect of ensuring that many favorable studies
19 appeared in the academic literature;

20 j. Paying significant amounts of money to the leaders and individuals
21 associated with Front Groups;

22 k. Donating to Front Groups to support talks or CMEs, that were typically
23 presented over meals or at conferences;

24 l. Disseminating many of their false, misleading, imbalanced, and
25 unsupported statements through unbranded materials that appeared to be
26 independent publications from Front Groups;

1 m. Sponsoring CME programs put on by Front Groups that focused
2 exclusively on the use of opioids for chronic pain;

3 n. Developing and disseminating pro-opioid treatment guidelines with the help
4 of the KOLs as authors and promoters, and the help of the Front Groups as
5 publishers, and supporters;

6 o. Encouraging Front Groups to disseminate their pro-opioid messages to
7 groups targeted by the RICO Defendants, such as veterans and the elderly, and
8 then funded that distribution;

9 p. Concealing their relationship to and control of Front Groups and KOLs
10 from the The County and the public at large; and

11 q. Intending that Front Groups and KOLs would distribute through the U.S.
12 mail and interstate wire facilities, promotional and other materials that claimed
13 opioids could be safely used for chronic pain.

14 607. The Front Groups also participated in the conduct of the Opioid
15 Marketing Enterprise, directly or indirectly, in the following ways:

16 a. The Front Groups promised to, and did, make representations regarding
17 opioids and the RICO Marketing Defendants' drugs that were consistent
18 with the RICO Marketing Defendants' messages;

19 b. The Front Groups distributed, through the U.S. Mail and interstate wire
20 facilities, promotional and other materials which claimed that opioids
21 could be safely used for chronic pain without addiction, and
22 misrepresented the benefits of using opioids for chronic pain outweighed
23 the risks;

24 c. The Front Groups echoed and amplified messages favorable to increased
25 opioid use—and ultimately, the financial interests of the RICO
26 Marketing Defendants;

27 d. The Front Groups issued guidelines and policies minimizing the risk of
28 opioid addiction and promoting opioids for chronic pain;

e. The Front Groups strongly criticized the 2016 guidelines from the Center for Disease Control and Prevention (CDC) that recommended limits on opioid prescriptions for chronic pain; and

f. The Front Groups concealed their connections to the KOLs and the RICO Marketing Defendants.

608. The RICO Marketing Defendants' Front Groups, "with their large numbers and credibility with policymakers and the public—have 'extensive influence in specific disease areas.'" The RICO Marketing Defendants' larger Front Groups "likely have a substantial effect on policies relevant to their industry sponsors."³⁸¹ "By aligning medical culture with industry goals in this way, many of the groups described in this report may have played a significant role in creating the necessary conditions for the U.S. opioid epidemic."³⁸²

609. The KOLs also participated, on information and belief, in the conduct of the affairs of the Opioid Marketing Enterprise, directly or indirectly, in the following ways:

a. The KOLs promised to, and did, make representations regarding opioids and the RICO Marketing Defendants' drugs that were consistent with the RICO Marketing Defendants' messages themselves;

b. The KOLs distributed, through the U.S. Mail and interstate wire facilities, promotional and other materials which claimed that opioids could be safely used for chronic pain without addiction, and misrepresented the benefits of using opioids for chronic pain outweighed the risks;

c. The KOLs echoed and amplified messages favorable to increased opioid use—and ultimately, the financial interests of the RICO Marketing Defendants;

³⁸¹ *Fueling an Epidemic: Exposing the Financial Ties Between Opioid Manufacturers and Third Party Advocacy Groups*, U.S. Senate Homeland Security & Governmental Affairs Committee, Ranking Members' Office, February 12, 2018 <https://www.hsd.org/?abstract&did=808171> ("*Fueling an Epidemic*"), at 1.

³⁸² *Id.* 2.

1 d. The KOLs issued guidelines and policies minimizing the risk of opioid
2 addiction and promoting opioids for chronic pain;

3 e. The KOLs strongly criticized the 2016 guidelines from the Center for
4 Disease Control and Prevention (CDC) that recommended limits on opioid
5 prescriptions for chronic pain; and

6 f. The KOLs concealed their connections to the Front Groups and the RICO
7 Defendants, and their sponsorship by the RICO Marketing Defendants.

8 610. The scheme devised and implemented by the RICO Marketing
9 Defendants and members of the Opioid Marketing Enterprise, amounted to a
10 common course of conduct intended to increase the RICO Marketing Defendants
11 sales from prescription opioids by encouraging the prescribing and use of opioids
12 for long-term chronic pain. The scheme was a continuing course of conduct, and
13 many aspects of it continue through to the present.

14 **C. PATTERN OF RACKETEERING ACTIVITY**

15 611. The RICO Marketing Defendants conducted and participated in the
16 conduct of the Opioid Marketing Enterprise through a pattern of racketeering
17 activity within the meaning of 18 U.S.C. § 1961(1) that employed the use of mail
18 and wire facilities, in violation of 18 U.S.C. § 1341 (mail fraud) and § 1343 (wire
19 fraud).

20 612. The RICO Marketing Defendants committed, conspired to commit,
21 and/or aided and abetted in the commission of at least two predicate acts of
22 racketeering activity (*i.e.* violations of 18 U.S.C. §§ 1341 and 1343) within the
23 past ten years. The multiple acts of racketeering activity that the RICO Marketing
24 Defendants committed, or aided and abetted in the commission of, were related to
25 each other, posed a threat of continued racketeering activity, and therefore
26 constitute a “pattern of racketeering activity.” The racketeering activity was made
27 possible by the RICO Marketing Defendants’ regular use of the facilities, services,
28 distribution channels, and employees of the Opioid Marketing Enterprise, the U.S.

1 Mail and interstate wire facilities. The RICO Marketing Defendants participated
2 in the scheme to defraud by using mail, telephones and the Internet to transmit
3 mailings and wires in interstate or foreign commerce.

4 613. The pattern of racketeering activity described herein used by the
5 RICO Marketing Defendants and the Opioid Marketing Enterprise likely involved
6 thousands of separate instances of the use of the U.S. Mail or interstate wire
7 facilities in furtherance of the unlawful Opioid Marketing Enterprise, including
8 virtually uniform misrepresentations, concealments and material omissions
9 regarding the beneficial uses and non-addictive qualities for the long-term
10 treatment of chronic, non-acute and non-cancer pain, with the goal of profiting
11 from increased sales of the RICO Marketing Defendants' drugs induced by
12 consumers, prescribers, regulators and the County's reliance on the RICO
13 Marketing Defendants' misrepresentations.

14 614. Each of these fraudulent mailings and interstate wire transmissions
15 constitutes racketeering activity and collectively, these violations constitute a
16 pattern of racketeering activity, through which Defendants, the Front Groups and
17 the KOLs defrauded and intended to defraud California consumers, the State, and
18 other intended victims.

19 615. In devising and executing the illegal scheme, the RICO Marketing
20 Defendants devised and knowingly carried out a material scheme and/or artifice to
21 defraud by means of materially false or fraudulent pretenses, representations,
22 promises, or omissions of material facts regarding the safe, non-addictive and
23 effective use of opioids for long-term chronic, non-acute and non-cancer pain.
24 The RICO Marketing Defendants and members of the Opioid Marketing
25 Enterprise knew that these representations violated the FDA approved use these
26 drugs, and were not supported by actual evidence. For the purpose of executing
27 the illegal scheme, the RICO Marketing Defendants intended that that their
28 common purpose and scheme to defraud would, and did, use the U.S. Mail and

1 interstate wire facilities, intentionally and knowingly with the specific intent to
2 advance their illegal scheme.

3 616. The RICO Marketing Defendants' predicate acts of racketeering (18
4 U.S.C. § 1961(1)) include, but are not limited to:

5 a. Mail Fraud: The RICO Marketing Defendants violated 18 U.S.C. § 1341
6 by sending or receiving, or by causing to be sent and/or received,
7 materials via U.S. mail or commercial interstate carriers for the purpose
8 of executing the unlawful scheme to design, manufacture, market, and
9 sell the prescription opioids by means of false pretenses,
10 misrepresentations, promises, and omissions.

11 b. Wire Fraud: The RICO Marketing Defendants violated 18 U.S.C. § 1343
12 by transmitting and/or receiving, or by causing to be transmitted and/or
13 received, materials by wire for the purpose of executing the unlawful
14 scheme to design, manufacture, market, and sell the prescription opioids
15 by means of false pretenses, misrepresentations, promises, and
16 omissions.

17 617. Each instance of racketeering activity alleged herein was related, had
18 similar purposes, involved the same or similar participants and methods of
19 commission, and had similar results affecting similar victims, including California
20 consumers, prescribers, regulators and The County. The RICO Marketing
21 Defendants, Front Groups and KOLs calculated and intentionally crafted the
22 scheme and common purpose of the Opioid Marketing Enterprise to ensure their
23 own profits remained high. In designing and implementing the scheme, the RICO
24 Marketing Defendants understood and intended that those in the distribution chain
25 rely on the integrity of the pharmaceutical companies and ostensibly neutral third
26 parties to provide objective and scientific evidence regarding the RICO Marketing
27 Defendants' products.
28

1 618. By intentionally misrepresenting the risks and benefits of using
2 opioids for chronic pain, and then subsequently failing to disclose such practices
3 to California consumers, prescribers, regulators and The County. Defendants, the
4 Front Groups and the KOLs engaged in a fraudulent and unlawful course of
5 conduct constituting a pattern of racketeering activity.

6 619. The racketeering activities conducted by the RICO Marketing
7 Defendants, Front Groups and KOLs amounted to a common course of conduct,
8 with a similar pattern and purpose, intended to deceive California consumers,
9 prescribers, regulators and The County. Each separate use of the U.S. Mail and/or
10 interstate wire facilities employed by Defendants was related, had similar intended
11 purposes, involved similar participants and methods of execution, and had the
12 same results affecting the same victims, including California consumers,
13 prescribers, regulators and The County. The RICO Marketing Defendants have
14 engaged in the pattern of racketeering activity for the purpose of conducting the
15 ongoing business affairs of the Opioid Marketing Enterprise.

16 620. The RICO Marketing Defendants' pattern of racketeering activity
17 alleged herein and the Opioid Marketing Enterprise are separate and distinct from
18 each other. Likewise, the RICO Marketing Defendants are distinct from the
19 Opioid Marketing Enterprise.

20 621. The pattern of racketeering activity alleged herein is continuing as of
21 the date of this complaint, and, upon information and belief, will continue into the
22 future unless enjoined by this Court.

23 622. Many of the precise dates of the Opioid Marketing Enterprise's uses
24 of the U.S. Mail and interstate wire facilities (and corresponding predicate acts of
25 mail and wire fraud) have been hidden and cannot be alleged without access to the
26 books and records maintained by the RICO Marketing Defendants, Front Groups,
27 and KOLs. Indeed, an essential part of the successful operation of the Opioid
28 Marketing Enterprise alleged herein depended upon secrecy. However, Plaintiffs

1 have described the occasions on which the RICO Marketing Defendants, Front
2 Groups, and KOLs disseminated misrepresentations and false statements to
3 California consumers, prescribers, regulators and The County, and how those acts
4 were in furtherance of the scheme, and do so further below.

5 623. The RICO Marketing Defendants' use of the U.S. Mail and interstate
6 wire facilities to perpetrate the opioids marketing scheme involved thousands of
7 communications, publications, representations, statements, electronic
8 transmissions, payments, including, *inter alia*:

- 9 a. Marketing materials about opioids, and their risks and benefits, which
10 the RICO Marketing Defendants sent to health care providers,
11 transmitted through the internet and television, published, and
12 transmitted to Front Groups and KOLs located across the country and
13 the State;
- 14 b. Written representations and telephone calls between the RICO
15 Marketing Defendants and Front Groups regarding the
16 misrepresentations, marketing statements and claims about opioids,
17 including the non-addictive, safe use of chronic long-term pain
18 generally;
- 19 c. Written representations and telephone calls between the RICO
20 Marketing Defendants and KOLs regarding the misrepresentations,
21 marketing statements and claims about opioids, including the non-
22 addictive, safe use of chronic long-term pain generally;
- 23 d. E-mails, telephone and written communications between the RICO
24 Marketing Defendants and the Front Groups agreeing to or
25 implementing the opioids marketing scheme;
- 26 e. E-mails, telephone and written communications between the RICO
27 Marketing Defendants and the KOLs agreeing to or implementing the
28 opioids marketing scheme;

- 1 f. Communications between the RICO Marketing Defendants, Front
2 Groups and the media regarding publication, drafting of treatment
3 guidelines, and the dissemination of the same as part of the Opioid
4 Marketing Enterprise;
- 5 g. Communications between the RICO Marketing Defendants, KOLs and
6 the media regarding publication, drafting of treatment guidelines, and
7 the dissemination of the same as part of the Opioid Marketing
8 Enterprise;
- 9 h. Written and oral communications directed to State agencies, federal and
10 state courts, and private insurers throughout the State that fraudulently
11 misrepresented the risks and benefits of using opioids for chronic pain;
12 and
- 13 i. Receipts of increased profits sent through the U.S. Mail and interstate
14 wire facilities – the wrongful proceeds of the scheme.

15 624. In addition to the above-referenced predicate acts, it was foreseeable
16 to the RICO Marketing Defendants that the Front Groups and the KOLs would
17 distribute publications through the U.S. Mail and by interstate wire facilities, and,
18 in those publications, claim that the benefits of using opioids for chronic pain
19 outweighed the risks of doing so.

20 625. The RICO Marketing Defendants aided and abetted others in the
21 violations of the above laws, thereby rendering them indictable as principals in the
22 18 U.S.C. §§ 1341 and 1343 offenses.

23 626. To achieve the common goal and purpose of the Opioid Marketing
24 Enterprise, the RICO Marketing Defendants and members of the Opioid
25 Marketing Enterprise hid from the consumers, prescribers, regulators and The
26 County: (1) the fraudulent nature of the RICO Marketing Defendants' marketing
27 scheme; (2) the fraudulent nature of statements made by the RICO Marketing
28 Defendants and by their KOLs, Front Groups and other third parties regarding the

1 safety and efficacy of prescription opioids; and (3) the true nature of the
2 relationship between the members of the Opioid Marketing Enterprise.

3 627. The RICO Marketing Defendants, and each member of the Opioid
4 Marketing Enterprise agreed, with knowledge and intent, to the overall objective
5 of the RICO Marketing Defendants' fraudulent scheme and participated in the
6 common course of conduct to commit acts of fraud and indecency in marketing
7 prescription opioids.

8 628. Indeed, for the RICO Marketing Defendants' fraudulent scheme to
9 work, each of the RICO Marketing Defendants had to agree to implement similar
10 tactics regarding fraudulent marketing of prescription opioids. This conclusion is
11 supported by the fact that the RICO Marketing Defendants each financed,
12 supported, and worked through the same KOLs and Front Groups, and often
13 collaborated on and mutually supported the same publications, CMEs,
14 presentations, and prescription guidelines.

15 629. As described herein, the RICO Marketing Defendants engaged in a
16 pattern of related and continuous predicate acts for years. The predicate acts
17 constituted a variety of unlawful activities, each conducted with the common
18 purpose of obtaining significant money and revenue from the marketing and sale
19 of their highly addictive and dangerous drugs. The predicate acts also had the
20 same or similar results, participants, victims, and methods of commission. The
21 predicate acts were related and not isolated events.

22 630. The RICO Marketing Defendants predicate acts all had the purpose
23 of creating the opioid epidemic that substantially injured The County's business
24 and property, while simultaneously generating billion-dollar revenue and profits
25 for the RICO Marketing Defendants. The predicate acts were committed or caused
26 to be committed by the RICO Marketing Defendants through their participation in
27 the Opioid Marketing Enterprise and in furtherance of its fraudulent scheme.
28

631. The RICO Marketing Defendants' predicate acts and pattern of racketeering activity were a substantial and foreseeable cause of The County's injury and the relationship between the RICO Marketing Defendants' conduct and The County's injury is logical and not speculative. It was foreseeable to the RICO Marketing Defendants that when they fraudulently marketed highly-addictive and dangerous drugs, that were approved for very limited and specific uses by the FDA, as non-addictive and safe for off-label uses such as moderate pain, non-cancer pain, and long-term chronic pain, that the RICO Marketing Defendants would create an opioid-addiction epidemic that logically, substantially and foreseeably harmed The County.

632. The pattern of racketeering activity alleged herein is continuing as of the date of this Complaint and, upon information and belief, will continue into the future unless enjoined by this Court. The last racketeering incident occurred within five years of the commission of a prior incident of racketeering.

D. DAMAGES.

1. Impact of the Opioid Marketing Enterprise.

633. California has been especially ravaged by the national opioid crisis.

634. More people die each year from drug overdoses in California than in any other state.³⁸³ The State's death rate has continued to climb, increasing by 30 percent from 1999 to 2015, according to the Center for Disease Control (CDC).³⁸⁴

635. In 2016, 1,925 Californians died due to prescription opioids.³⁸⁵ This number is on par with other recent years: in 2015, 1,966 deaths in California were due just to prescription opioids (not including heroin); in 2014 that number was

³⁸³ Davis, *supra*.

³⁸⁴ Karlamangla, *supra*.

³⁸⁵ Davis, *supra*.

1 even higher at 2,024 prescription opioid deaths; and in 2013, 1,934 Californians
 2 died from a prescription opioid overdose.³⁸⁶

3 636. Of the 1,925 opioid-related deaths in California in 2016, fentanyl was
 4 a factor in at least 234 of them.³⁸⁷ This is an increase of 47 percent for 2016.³⁸⁸
 5 Heroin-related deaths have risen by 67 percent in California since 2006.³⁸⁹

6 637. The high number of deaths are due in part to the extraordinary
 7 number of opioids prescribed in the State. Over 23.6 million prescriptions for
 8 opioids were written in California in just 2016.³⁹⁰

9 638. The California Department of Public Health tracks the number of
 10 reported hospitalizations and emergency department visits due to prescription
 11 opioids.³⁹¹ In 2015, the last year for which information is currently available,
 12 California had 3,935 emergency department visits and 4,095 hospitalizations
 13 related to prescription opioid overdoses (excluding heroin).³⁹² The numbers were
 14 even higher in 2014, when 4,106 people visited the emergency department and
 15 4,482 people were hospitalized due to prescription opioid abuse.³⁹³ In 2013, there
 16 were 3,964 emergency department visits and 4,344 hospitalizations for
 17
 18
 19

20 ³⁸⁶California Department of Public Health, *California Opioid Overdose*
Surveillance Dashboard, *supra*.

21 ³⁸⁷ Davis, *supra*.

22 ³⁸⁸ Karlamangla, *supra*.

23 ³⁸⁹ California Department of Public Health, *State of California Strategies to*
Address Prescription Drug (Opioid) Misuse, Abuse, and Overdose Epidemic in
California at 3 (June 2016), available at
 24 <https://www.cdph.ca.gov/Programs/CCDCPHP/DCDIC/SACB/CDPH%20Documents/Library/Prescription%20Drug%20Overdose%20Program/CAOpioidPreventionStrategies4.17.pdf> (last visited March 2, 2018).
 25

26 ³⁹⁰ California Department of Public Health, *California Opioid Overdose*
Surveillance Dashboard, *supra*.

27 ³⁹¹ *Id.*

28 ³⁹² *Id.*


³⁹³ *Id.*

prescription opioid overdoses.³⁹⁴ When emergency visits and hospitalizations include heroin, the numbers are even higher.³⁹⁵

639. Neonatal Abstinence Syndrome (NAS) has increased dramatically in California, with the rate of infants born with NAS more than tripling from 2008 to 2013.³⁹⁶ While the number of affected newborns rose from 1,862 in 2008 to 3,007 in 2014, that number jumped by another 21 percent in 2015.³⁹⁷ This is despite a steady decline in the overall number of births in California during that same time.³⁹⁸

OSHPD
Office of Statewide Health
Planning and Development

Newborns Affected by Drugs* Transmitted Via Placenta or Breast Milk



*Includes cocaine, hallucinogenic agents, other narcotics, other drugs of addiction, or noxious substances, or those that displayed withdrawal symptoms of the same.

Source: Inpatient Discharge Data, 2006 – 2015; Office of Statewide Health Planning and Development

³⁹⁴ *Id.*

³⁹⁵ *Id.*

³⁹⁶ California Child Welfare Co-Investment Partnership, *supra* at 5.

³⁹⁷ Clark, *supra*.

³⁹⁸ *Id.*

640. Reports from California's Office of Statewide Health Planning, which collects data from licensed health care facilities, have shown a 95 percent increase between 2008 and 2015 of newborns affected by drugs transmitted via placenta or breast milk.³⁹⁹

641. The opioid epidemic has also had an impact on crime in California. Pharmacy robberies have gone up by 163 percent in California over the last two years, according to the DEA. The DEA recorded 90 incidents in 2015, 154 in 2016 and, through mid-November of 2017, that number had climbed to 237.⁴⁰⁰ Most perpetrators were after prescription opioids.⁴⁰¹ In addition, fentanyl seizures at California ports increased 266 percent in fiscal year 2017.⁴⁰²

642. The opioid epidemic is particularly devastating in Plaintiffs' Community.

643. In 2016, 12 people died from opioid overdoses in the County.⁴⁰³ The County also had 13 deaths from opioid overdoses in 2015 and 14 in 2014.⁴⁰⁴ These numbers are down from prior years. In 2013, the County suffered 26 fatalities due to opioids.⁴⁰⁵ There were 25 deaths in 2012 and 31 in 2011.⁴⁰⁶

³⁹⁹ California Child Welfare Co-Investment Partnership, *supra*.

⁴⁰⁰ Ed Fletcher, "What's behind the spike in drug store robberies?" *The Sacramento Bee*, Dec. 8, 2017 (available at <http://www.sacbee.com/news/local/crime/article188636384.html> (last visited March 2, 2018)).

⁴⁰¹ *Id.*

⁴⁰² United State Department of Justice, The United States Attorney's Office, Southern District of California, *U.S. Attorney Appoints Opioid Coordinators* (Feb. 8, 2018) available at <https://www.justice.gov/usao-sdca/pr/us-attorney-appoints-opioid-coordinators> (last visited March 2, 2018).

⁴⁰³ California Department of Public Health, *California Opioid Overdose Surveillance Dashboard*, available at https://pdop.shinyapps.io/ODdash_v1/ (last visited May 1, 2018) (Monterey County specific page).

⁴⁰⁴ *Id.* at Table on California Deaths by County for 2015, 2014.

⁴⁰⁵ *Id.* at Table on California Deaths by County for 2013.

⁴⁰⁶ *Id.* at Table on California Deaths by County for 2012, 2011.

1 Monterey County has a higher rate of opioid overdose deaths than Los Angeles
2 County.⁴⁰⁷

3 644. From 2012 to 2014, the County suffered 146 deaths due to drug
4 overdoses, which is a drug overdose mortality rate of 11 deaths per 100,000
5 people.⁴⁰⁸

6 645. Prescription opioids have also been responsible for increased
7 emergency department visits and hospitalizations in the County. In 2016,
8 Monterey County had 40 emergency department visits due to opioid overdoses
9 (excluding heroin) for a rate of 8.9, and 30 opioid overdose hospitalizations for a
10 rate of 6.7 per 100,000 residents.⁴⁰⁹

11 646. In 2016, an estimated 5.8 percent of the population aged 12 and up in
12 Monterey County misused opioids (almost 4,000 people) and about one percent
13 had an opioid use disorder.⁴¹⁰

14 647. Law enforcement in the County has been equipped with naloxone – a
15 drug that can reverse opioid overdoses – and all of the ambulances in Monterey
16 County are carrying it.⁴¹¹

17 648. One reason for these high numbers is the high number of
18 prescriptions being written for opioids in Monterey County. According to the
19

20 ⁴⁰⁷ Brynne Whittaker, “Opioid overdoses rising in Santa Cruz, Monterey counties,”
21 *KSBW*8, Jan. 23, 2017, available at <http://www.ksbw.com/article/california-sees-increase-in-opioid-overdose-deaths/3311493> (last visited May 1, 2018).

22 ⁴⁰⁸ County Health Rankings & Roadmaps, Drug overdose deaths, available at
23 <http://www.countyhealthrankings.org/app/california/2016/measure/factors/138/data>
24 a (last visited April 20, 2018).

25 ⁴⁰⁹ California Department of Public Health, *California Opioid Overdose*
26 *Surveillance Dashboard*, *supra*, (Monterey County specific page).

27 ⁴¹⁰ Lisa Clemans-Cope, Marni Epstein, and Doug Wissoker, “County-Level
28 Estimates of Opioid Use Disorder and Treatment Needs in California,” *The Urban Institute*, March 19, 2018, available at
<https://www.urban.org/sites/default/files/monterey.pdf> (last visited May 1, 2018).

⁴¹¹ Tom Wright, “Pacific Grove, Carmel police equip officers with opioid overdose
antidote,” *Monterey Herald*, (September 1, 2017), available at
<http://www.montereyherald.com/article/NF/20170901/NEWS/170909972> (last
visited May 1, 2018).

1 California Department of Public Health, over 237,300 prescriptions were written
2 in 2016 in Monterey County alone.⁴¹²

3 **2. Relief Sought.**

4 649. The RICO Marketing Defendants' violations of law and their pattern
5 of racketeering activity directly and proximately caused The County injury in its
6 business and property. The RICO Marketing Defendants' pattern of racketeering
7 activity logically, substantially and foreseeably caused an opioid epidemic. The
8 County's injuries, as described below, were not unexpected, unforeseen or
9 independent.⁴¹³ Rather, as Plaintiffs allege, the RICO Marketing Defendants
10 knew that the opioids were unsuited to treatment of long-term chronic, non-acute,
11 and non-cancer pain, or for any other use not approved by the FDA, and knew that
12 opioids were highly addictive and subject to abuse.⁴¹⁴ Nevertheless, the RICO
13 Marketing Defendants engaged in a scheme of deception, that utilized the mail
14 and wires as part of their fraud, in order to increase sales of their opioid products.

15 650. It was foreseeable and expected that a massive marketing campaign
16 utilized by the RICO Marketing Defendants that misrepresented the non-addictive
17 and effective use of prescription opioids for purposes for which they are not suited
18 and not approved by the FDA would lead to a nationwide opioid epidemic.⁴¹⁵ It
19 was also foreseeable and expected that the RICO Marketing Defendants'
20 marketing campaign would lead to increased opioid addiction and overdose.⁴¹⁶
21 The County's injuries were logically, foreseeable, and substantially caused by the
22 opioid epidemic that the RICO Marketing Defendants created.

24 ⁴¹² California Department of Public Health, *California Opioid Overdose*
25 *Surveillance Dashboard*, *supra*, (Monterey County specific page).

26 ⁴¹³ *Traveler's Property Casualty Company of America v. Actavis, Inc.*, 22 Cal.
Rptr. 3d 5, 19 (Cal. Ct. App. 2017).

27 ⁴¹⁴ *Id.*

28 ⁴¹⁵ *Id.*

⁴¹⁶ *Id.*

1 651. Specifically, the RICO Marketing Defendants' predicate acts and
2 pattern of racketeering activity caused the opioid epidemic which has injured The
3 County in the form of substantial losses of money and property that logically,
4 directly and foreseeably arise from the opioid-addiction epidemic. The County's
5 injuries, as alleged throughout this complaint, and expressly incorporated herein
6 by reference, include:

- 7 a. Losses caused by purchasing and/or paying reimbursements for the
8 RICO Marketing Defendants' prescription opioids, that The County
9 would not have paid for or purchased but for the RICO Marketing
10 Defendants' conduct;
- 11 b. Losses caused by the decrease in funding available for The County's
12 public services for which funding was lost because it was diverted to
13 other public services designed to address the opioid epidemic;
- 14 c. Costs for providing healthcare and medical care, additional therapeutic,
15 and prescription drug purchases, and other treatments for patients
16 suffering from opioid-related addiction or disease, including overdoses
17 and deaths;
- 18 d. Costs of training emergency and/or first responders in the proper
19 treatment of drug overdoses;
- 20 e. Costs associated with providing police officers, firefighters, and
21 emergency and/or first responders with Naloxone – an opioid antagonist
22 used to block the deadly effects of opioids in the context of overdose;
- 23 f. Costs associated with emergency responses by police officers,
24 firefighters, and emergency and/or first responders to opioid overdoses;
- 25 g. Costs for providing mental-health services, treatment, counseling,
26 rehabilitation services, and social services to victims of the opioid
27 epidemic and their families;
- 28

- h. Costs for providing treatment of infants born with opioid-related medical conditions, or born addicted to opioids due to drug use by mother during pregnancy;
- i. Costs associated with law enforcement and public safety relating to the opioid epidemic, including but not limited to attempts to stop the flow of opioids into local communities, to arrest and prosecute street-level dealers, to prevent the current opioid epidemic from spreading and worsening, and to deal with the increased levels of crimes that have directly resulted from the increased homeless and drug-addicted population;
- j. Costs associated with increased burden on the County's judicial system, including increased security, increased staff, and the increased cost of adjudicating criminal matters due to the increase in crime directly resulting from opioid addiction;
- k. Costs associated with providing care for children whose parents suffer from opioid-related disability or incapacitation;
- l. Loss of tax revenue due to the decreased efficiency and size of the working population in Plaintiffs' Community;
- m. Losses caused by diminished property values in neighborhoods where the opioid epidemic has taken root; and
- n. Losses caused by diminished property values in the form of decreased business investment and tax revenue.

652. The County's injuries were proximately caused by the RICO Marketing Defendants' racketeering activities because they were the logical, substantial and foreseeable cause of The County's injuries. But for the opioid-addiction epidemic created by the RICO Marketing Defendants' conduct, The County would not have lost money or property.

1 Healthcare Distribution Alliance (the “HDA”)⁴¹⁷ which is a distinct legal entity
 2 that satisfies the definition of a RICO enterprise because it is a non-profit
 3 corporation and, therefore, and “enterprise” within the definition set out in 18
 4 U.S.C. § 1961(4). On information and belief, each of the RICO Diversion
 5 Defendants is a member, participant, and/or sponsor of the HDA and utilized the
 6 HDA to conduct the Opioid Diversion Enterprise and to engage in the pattern of
 7 racketeering activity that gives rise to this cause of action. The legal and
 8 association-in-fact enterprises alleged in the previous and subsequent paragraphs
 9 are pleaded in the alternative and are collectively referred to as the “Opioid
 10 Diversion Enterprise.”

11 659. For over a decade, the RICO Diversion Defendants aggressively
 12 sought to bolster their revenue, increase profit, and grow their share of the
 13 prescription painkiller market by unlawfully and surreptitiously increasing the
 14 volume of opioids they sold. However, the RICO Diversion Defendants are not
 15 permitted to engage in a limitless expansion of their sales through the unlawful
 16 sales of regulated painkillers. As “registrants” under the Controlled Substances
 17 Act, 21 U.S.C. § 821, *et seq.* (the “CSA”), the RICO Diversion Defendants
 18 operated and continue to operate within a “closed-system.” The CSA restricts the
 19 RICO Diversion Defendants’ ability to manufacture or distribute Schedule II
 20 substances like opioids by: (1) requiring them to make sales within a limited quota
 21 set by the DEA for the overall production of Schedule II substances like opioids;
 22 (2) register to manufacture or distribute opioids; (3) maintain effective controls
 23 against diversion of the controlled substances that they manufacturer or distribute;
 24 and (4) design and operate a system to identify suspicious orders of controlled
 25 substances, halt such unlawful sales, and report them to the DEA.

26
 27
 28 ⁴¹⁷ Health Distribution Alliance, History, Health Distribution Alliance, (last
 accessed on September 15, 2017),
<https://www.healthcaredistribution.org/about/hda-history>.

1 660. The closed-system created by the CSA, and the establishment of
 2 quotas, was specifically intended to reduce or eliminate the diversion of Schedule
 3 II substances like opioids from “legitimate channels of trade” to the illicit market
 4 by controlling the “quantities of the basic ingredients needed for the manufacture
 5 of [controlled substances].”⁴¹⁸

6 661. Finding it impossible to legally achieve their ever increasing sales
 7 ambitions, members of the Opioid Diversion Enterprise (defined below) engaged
 8 in the common purpose of fraudulently increasing the quotas that governed the
 9 manufacture and distribution of their prescription opioids. The RICO Diversion
 10 Defendants formed and pursued their common purpose through the many personal
 11 interactions that they had, confidentially, in organizations like the Pain Care
 12 Forum and the Healthcare Distribution Alliance.

13 662. The RICO Diversion Defendants’ common purpose and fraudulent
 14 scheme to unlawfully increase the DEA quotas violated the RICO Act in two
 15 ways. First, the RICO Diversion Defendants violated the RICO Act because they
 16 engaged in the felonious manufacture, buying selling, or otherwise dealing in
 17 controlled substances that are punishable by law in the United States.
 18 Specifically, the RICO Diversion Defendants “furnish[ed] false or fraudulent
 19 material information in, or omit[ted] material information from, applications,
 20 reports, records, and other document required to be made, kept, and filed under 21
 21 U.S.C. §§ 801, et seq.”, in violation of 21 U.S.C. § 843(b), which is a felony.
 22 Second, the RICO Diversion Defendants violated the RICO Act by engaging in
 23 mail and wire fraud. The RICO Diversion Defendants common purpose and
 24 fraudulent scheme was intended to, and did, utilize interstate mail and wire
 25

26
 27 ⁴¹⁸ 1970 U.S.C.C.A.N. 4566 at 5490; *see also* Testimony of Joseph T. Rannazzisi
 28 before the Caucus on International Narcotics Control, United States Senate, May 5,
 2015 (available at https://www.drugcaucus.senate.gov/sites/default/files/Rannazzisi%20Testimony_0.pdf).

1 facilities for the commission of their fraud in violation 18 U.S.C. §§ 1341 (mail
2 fraud) and 1343 (wire fraud).

3 663. The RICO Diversion Defendants' fraudulent scheme arises at the
4 intersection between the quotas governing the RICO Diversion Defendants'
5 prescription opioids and the RICO Diversion Defendants' duty to identify, report,
6 and halt suspicious orders of controlled substances. The RICO Diversion
7 Defendants' formed an enterprise with the intent to fraudulently increase the
8 quotas for prescription opioids by refusing to identify, report and halt suspicious
9 orders, thereby omitting both the fact and the RICO Diversion Defendants'
10 knowledge of widespread diversion of prescription opioids into illegitimate
11 channels.

12 664. The RICO Diversion Defendants engaged in systematic and
13 fraudulent acts as part of the Opioid Diversion Enterprise, that furnished false or
14 fraudulent material information in, and omitted material information from their
15 applications, reports, records and other documents that the RICO Defendants were
16 required to make, keep and/or file. Furthermore, the RICO Diversion Defendants
17 engaged in systematic and fraudulent acts as part of the Opioid Diversion
18 Enterprise that were intended to and actually did utilize the mail and wire facilities
19 of the United States and California, including refusing to maintain effective
20 controls against diversion of their drugs, to design and operate a system to identify
21 suspicious orders of their drugs, to halt unlawful sales of suspicious orders, and to
22 notify the DEA of suspicious orders.⁴¹⁹

23 665. Through the RICO Diversion Defendants' scheme, members of the
24 Opioid Diversion Enterprise repeatedly requested increases of the quotas
25 governing the manufacture, sale and distribution of prescription opioids,
26 misrepresented that they were complying with their duties under the CSA,
27

28 ⁴¹⁹ 21 U.S.C. § 823(a)(1), (b)(1); 21 C.F.R. § 1301.74(b)-(c).

1 furnished false or fraudulent material information in, and omitted material
2 information from their applications, reports, records and other documents,
3 engaged in unlawful sales of painkillers that resulted in diversion of controlled
4 substances through suspicious orders, and refused to identify or report suspicious
5 orders of controlled substances sales to the DEA.⁴²⁰ Defendants' refusal to report
6 suspicious orders resulted in artificial and illegal increases in the annual
7 production quotas for opioids allowed by the DEA. The end result of the RICO
8 Diversion Defendants' fraudulent scheme and common purpose was continually
9 increasing quotas that generated obscene profits and, in turn, fueled an opioid
10 epidemic.

11 666. The RICO Diversion Defendants' illegal scheme was hatched by an
12 enterprise between the Manufacturer Defendants and the Distributor Defendants,
13 and executed in perfect harmony by each of them. In particular, each of the RICO
14 Diversion Defendants were associated with, and conducted or participated in, the
15 affairs of the Opioid Diversion Enterprise, whose common purpose was
16 fraudulently increase the quotas governing the manufacture and sale of
17 prescription opioids.

18 667. The success of the RICO Diversion Defendants' scheme allowed
19 them to unlawfully increase and/or maintain high production quotas and, as a
20 direct result, allowed them to make billions from the unlawful sale and diversion
21 of opioids.

22 668. Simultaneously, the opioid epidemic created by the RICO Diversion
23 Defendants' actions caused The County's multi-million dollar injuries. The
24 County's injuries were and is a reasonably foreseeable consequence of the
25 prescription opioid addiction epidemic that the RICO Diversion Defendants
26 created by fraudulently increasing quotas, misrepresenting their compliance with
27

28 ⁴²⁰ 21 C.F.R. § 1303.11(b); 21 C.F.R. § 1303.23.

1 their duties under the CSA, and allowing the widespread diversion of legally
 2 produced prescription opioids into the illicit market. As explained in detail below,
 3 the RICO Diversion Defendants' misconduct violated Section 1962(c) and the
 4 County is entitled to treble damages for their injuries under 18 U.S.C. § 1964(c).

5 **A. THE OPIOID DIVERSION ENTERPRISE.**

6 669. Recognizing that there is a need for greater scrutiny over controlled
 7 substances due to their potential for abuse and danger to public health and safety,
 8 the United States Congress enacted the Controlled Substances Act in 1970.⁴²¹ The
 9 CSA and its implementing regulations created a closed-system of distribution for
 10 all controlled substances and listed chemicals.⁴²² Congress specifically designed
 11 the closed chain of distribution to prevent the diversion of legally produced
 12 controlled substances into the illicit market.⁴²³ Congress was concerned with the
 13 diversion of drugs out of legitimate channels of distribution and acted to halt the
 14 "widespread diversion of [controlled substances] out of legitimate channels into
 15 the illegal market."⁴²⁴ Moreover, the closed-system was specifically designed to
 16 ensure that there are multiple ways of identifying and preventing diversion
 17 through active participation by registrants within the drug delivery chain.⁴²⁵ All
 18 registrants -- manufacturers and distributors alike -- must adhere to the specific
 19

20 ⁴²¹ Joseph T. Rannazzisi Decl. ¶ 4, *Cardinal Health, Inc. v. Eric Holder, Jr.,*
 21 *Attorney General*, D.D.C. Case No. 12-cv-185 (Document 14-2 February 10,
 22 2012).

⁴²² See H.R. Rep. No. 91-1444, 1970 U.S.C.C.A.N. at 4566.

23 ⁴²³ *Gonzalez v. Raich*, 545 U.S. 1, 12-14 (2005); 21 U.S.C. § 801(20; 21 U.S.C. §§
 24 821-824, 827, 880; H.R. Rep. No. 91-1444, 1970 U.S.C.C.A.N. 4566, 4572 (Sept.
 10, 1970).

25 ⁴²⁴ See Testimony of Joseph T. Rannazzisi before the Caucus on International
 26 Narcotics Control, United States Senate, May 5, 2015 (available at
https://www.drugcaucus.senate.gov/sites/default/files/Rannazzisi%20Testimony_0.pdf).

27 ⁴²⁵ See Statement of Joseph T. Rannazzisi before the Caucus on International
 28 Narcotics Control United States Senate, July 18, 2012 (available at
<https://www.justice.gov/sites/default/files/testimonies/witnesses/attachments/07/18/12/07-18-12-dea-rannazzisi.pdf>).

1 security, recordkeeping, monitoring and reporting requirements that are designed
 2 to identify or prevent diversion.⁴²⁶ When registrants at any level fail to fulfill their
 3 obligations, the necessary checks and balances collapse.⁴²⁷ The result is the
 4 scourge of addiction that has occurred

5 670. Central to the closed-system created by the CSA was the directive
 6 that the DEA determine quotas of each basic class of Schedule I and II controlled
 7 substances each year. The quota system was intended to reduce or eliminate
 8 diversion from “legitimate channels of trade” by controlling the “quantities of the
 9 basic ingredients needed for the manufacture of [controlled substances], and the
 10 requirement of order forms for all transfers of these drugs.”⁴²⁸ When evaluating
 11 production quotas, the DEA was instructed to consider the following information:

- 12 a. Information provided by the Department of Health and Human Services;
- 13 b. Total net disposal of the basic class by all manufacturers;
- 14 c. Trends in the national rate of disposal of the basic class;
- 15 d. An applicant’s production cycle and current inventory position;
- 16 e. Total actual or estimated inventories of the class and of all substances
 17 manufactured from the class and trends in inventory accumulation; and
- 18 g. Other factors such as: changes in the currently accepted medical use of
 19 substances manufactured for a basic class; the economic and physical
 20 availability of raw materials; yield and sustainability issues; potential
 21 disruptions to production; and unforeseen emergencies.⁴²⁹

22
 23 ⁴²⁶ Id.

24 ⁴²⁷ Joseph T. Rannazzisi Decl. ¶ 10, *Cardinal Health, Inc. v. Eric Holder, Jr.,*
Attorney General, D.D.C. Case No. 12-cv-185 (Document 14-2 February 10,
 25 2012).

26 ⁴²⁸ 1970 U.S.C.C.A.N. 4566 at 5490; *see also* Testimony of Joseph T. Rannazzisi
 before the Caucus on International Narcotics Control, United States Senate, May 5,
 2015 (available at
 27 https://www.drugcaucus.senate.gov/sites/default/files/Rannazzisi%20Testimony_0.pdf).

28 ⁴²⁹ See Testimony of Joseph T. Rannazzisi before the Caucus on International
 Narcotics Control, United State Senate, May 5, 2015 (available at

1 671. It is unlawful for a registrant to manufacture a controlled substance in
2 Schedule II, like prescription opioids, that is (1) not expressly authorized by its
3 registration and by a quota assigned to it by DEA, or (2) in excess of a quota
4 assigned to it by the DEA.⁴³⁰

5 672. At all relevant times, the RICO Diversion Defendants operated as an
6 association-in-fact enterprise formed for the purpose of unlawfully increasing
7 sales, revenues and profits by fraudulently increasing the quotas set by the DEA
8 that would allow them to collectively benefit from a greater pool of prescription
9 opioids to manufacture and distribute. In support of this common purpose and
10 fraudulent scheme, the RICO Diversion Defendants jointly agreed to disregard
11 their statutory duties to identify, investigate, halt and report suspicious orders of
12 opioids and diversion of their drugs into the illicit market so that those orders
13 would not result in a decrease, or prevent an increase in, the necessary quotas.
14 The RICO Diversion Defendants conducted their pattern of racketeering activity
15 in this jurisdiction and throughout the United States through this enterprise.

16 673. The opioid epidemic has its origins in the mid-1990s when, between
17 1997 and 2007, per capita purchase of methadone, hydrocodone, and oxycodone
18 increased 13-fold, 4-fold, and 9-fold, respectively. By 2010, enough prescription
19 opioids were sold in the United States to medicate every adult in the country with
20 a dose of 5 milligrams of hydrocodone every 4 hours for 1 month.⁴³¹ On
21 information and belief, the Opioid Diversion Enterprise has been ongoing for at
22 least the last decade.⁴³²

23
24 https://www.drugcaucus.senate.gov/sites/default/files/Rannazzisi%20Testimony_0.pdf.

25 ⁴³⁰ *Id.* (citing 21 U.S.C. 842(b)).

26 ⁴³¹ Keyes KM, Cerdá M, Brady JE, Havens JR, Galea S. Understanding the rural-
27 urban differences in nonmedical prescription opioid use and abuse in the United
States. *Am J Public Health.* 2014;104(2):e52-9.

28 ⁴³² Matthew Perrone, Pro-Painkiller echo chamber shaped policy amid drug epidemic, The Center for Public Integrity (September 19, 2017, 12:01 a.m.),

674. The Opioid Diversion Enterprise was and is a shockingly successful endeavor. The Opioid Diversion Enterprise has been conducting business uninterrupted since its genesis. However, it was not until recently that federal and state regulators finally began to unravel the extent of the enterprise and the toll that it exacted on the American public.

675. At all relevant times, the Opioid Diversion Enterprise: (a) had an existence separate and distinct from each RICO Diversion Defendant; (b) was separate and distinct from the pattern of racketeering in which the RICO Diversion Defendants engaged; (c) was an ongoing and continuing organization consisting of legal entities, including each of the RICO Diversion Defendants; (d) was characterized by interpersonal relationships among the RICO Diversion Defendants; (e) had sufficient longevity for the enterprise to pursue its purpose; and (f) functioned as a continuing unit.. Each member of the Opioid Diversion Enterprise participated in the conduct of the enterprise, including patterns of racketeering activity, and shared in the astounding growth of profits supplied by fraudulently inflating opioid quotas and resulting sales.

676. The Opioid Diversion Enterprise also engaged in efforts to constrain the DEA's authority to hold the RICO Diversion Defendants liable for disregarding their duty to prevent diversion. Members of the Pain Care Forum (described in greater detail below) and the Healthcare Distribution Alliance lobbied for the passage of legislation to weaken the DEA's enforcement authority. To this end, the Ensuring Patient Access and Effective Drug Enforcement Act significantly reduced the DEA's ability to issue orders to show cause and to suspend and/or revoke registrations.⁴³³ The HDA and other members of the Pain

<https://www.publicintegrity.org/2016/09/19/20201/pro-painkiller-echo-chamber-shaped-policy-amid-drug-epidemic>.

⁴³³ See HDMA is now the Healthcare Distribution Alliance, Pharmaceutical Commerce, (June 13, 2016, updated July 6, 2016), <http://pharmaceuticalcommerce.com/business-and-finance/hdma-now-healthcare-distribution-alliance/>; Lenny Bernstein & Scott Higham, *Investigation: The DEA*

Care Forum contributed substantial amounts of money to political campaigns for federal candidates, state candidates, political action committees and political parties. Upon information and belief, the Pain Care Forum and its members and HDA, poured millions into such efforts.

677. The RICO Diversion Defendants, through their illegal enterprise, engaged in a pattern of racketeering activity that involves a fraudulent scheme to profit from the unlawful sale of prescription opioids by increasing the quotas governing the manufacture and sale of these controlled substances. In order to achieve that goal, the RICO Diversion Defendants knowingly allowed suspicious orders of controlled substances to occur unhindered while millions of opioid doses diverted into illegal markets. The end result of this strategy was exactly as the RICO Diversion Defendants intended – artificially increased quotas for the manufacture and distribution of opioids, all of which resulted in a National opioid epidemic.

678. The Opioid Diversion Enterprise engaged in, and its activities affected, interstate and foreign commerce because the enterprise involved commercial activities across states lines, such as manufacture, sale, distribution, and shipment of prescription opioids throughout the United States, and the corresponding payment and/or receipt of money from such interstate sales.

679. Within the Opioid Diversion Enterprise, there were interpersonal relationships and common communication by which the RICO Diversion

Slowed Enforcement While the Opioid Epidemic Grew Out of Control, Wash. Post, Oct. 22, 2016, https://www.washingtonpost.com/investigations/the-dea-slowed-enforcement-while-the-opioid-epidemic-grew-out-of-control/2016/10/22/aea2bf8e-7f71-11e6-8d13-d7c704ef9fd9_story.html; Lenny Bernstein & Scott Higham, *Investigation: U.S. Senator Calls for Investigation of DEA Enforcement Slowdown Amid Opioid Crisis*, Wash. Post, Mar. 6, 2017, https://www.washingtonpost.com/investigations/us-senator-calls-for-investigation-of-dea-enforcement-slowdown/2017/03/06/5846ee60-028b-11e7-b1e9-a05d3c21f7cf_story.html; Eric Eyre, *DEA Agent: "We Had no Leadership" in WV Amid Flood of Pain Pills*, Charleston Gazette-Mail, Feb. 18, 2017, <http://www.wvgazettemail.com/news/20170218/dea-agent-we-had-no-leadership-in-wv-amid-flood-of-pain-pills->.

1 Defendants shared information on a regular basis. These interpersonal
2 relationships also formed the organization of the Opioid Diversion Enterprise.
3 The Opioid Diversion Enterprise used their interpersonal relationships and
4 communication network for the purpose of conducting the enterprise through a
5 pattern of racketeering activity.

6 680. Each of the RICO Diversion Defendants had systematic links to each
7 other through joint participation in trade industry organizations, contractual
8 relationships and continuing coordination of activities. The RICO Diversion
9 Defendants participated in the operation and management of the Opioid Diversion
10 Enterprise by directing its affairs, as described herein. While the RICO Diversion
11 Defendants participated in, and are members of, the enterprise, they each have a
12 separate existence from the enterprise, including distinct legal statuses, different
13 offices and roles, bank accounts, officers, directors, employees, individual
14 personhood, reporting requirements, and financial statements.

15 681. The RICO Diversion Defendants exerted substantial control over the
16 Opioid Diversion Enterprise through their membership in the Pain Care Forum,
17 the HDA, and through their contractual relationships.

18 682. The Pain Care Forum (“PCF”) has been described as a coalition of
19 drug makers, trade groups and dozens of non-profit organizations supported by
20 industry funding. The PCF recently became a national news story when it was
21 discovered that lobbyists for members of the PCF quietly shaped federal and state
22 policies regarding the use of prescription opioids for more than a decade.

23 683. The Center for Public Integrity and The Associated Press obtained
24 “internal documents shed[ding] new light on how drug makers and their allies
25 shaped the national response to the ongoing wave of prescription opioid abuse.”⁴³⁴

26
27 ⁴³⁴ Matthew Perrone, Pro-Painkiller echo chamber shaped policy amid drug
28 epidemic, The Center for Public Integrity (September 19, 2017, 12:01 a.m.),
[https://www.publicintegrity.org/2016/09/19/20201/pro-painkiller-echo-chamber-](https://www.publicintegrity.org/2016/09/19/20201/pro-painkiller-echo-chamber-shaped-policy-amid-drug-epidemic)
[shaped-policy-amid-drug-epidemic](https://www.publicintegrity.org/2016/09/19/20201/pro-painkiller-echo-chamber-shaped-policy-amid-drug-epidemic) (emphasis added).

Specifically, PCF members spent over \$740 million lobbying in the nation's capital and in all 50 statehouses on an array of issues, including opioid-related measures.⁴³⁵

684. Not surprisingly, each of the RICO Diversion Defendants who stood to profit from expanded prescription opioid use is a member of and/or participant in the PCF.⁴³⁶ In 2012, membership and participating organizations included the HDA (of which all RICO Defendants are members), Endo, Purdue, Actavis (i.e., Allergan), and Teva (the parent company of Cephalon).⁴³⁷ Each of the Manufacturer Defendants worked together through the PCF to advance the interests of the enterprise. But, the Manufacturer Defendants were not alone. The Distributor Defendants actively participated, and continue to participate in the PCF, at a minimum, through their trade organization, the HDA.⁴³⁸ Upon information and belief, the Distributor Defendants participated directly in the PCF as well.

685. Additionally, the HDA – or Healthcare Distribution Alliance – led to the formation of interpersonal relationships and an organization between the RICO Diversion Defendants. Although the entire HDA membership directory is private, the HDA website confirms that each of the Distributor Defendants and the Manufacturer Defendants named in the Complaint, including Actavis (i.e.,

⁴³⁵ *Id.*

⁴³⁶ PAIN CARE FORUM 2012 Meetings Schedule, (last updated December 2011), <https://assets.documentcloud.org/documents/3108982/PAIN-CARE-FORUM-Meetings-Schedule-amp.pdf>

⁴³⁷ *Id.* Upon information and belief, Mallinckrodt became an active member of the PCF sometime after 2012.

⁴³⁸ *Id.* The Executive Committee of the HDA (formerly the HDMA) currently includes the Chief Executive Officer, Pharmaceutical Segment for Cardinal Health, Inc., the Group President, Pharmaceutical Distribution and Strategic Global Source for AmerisourceBergen Corporation, and the President, U.S. Pharmaceutical for McKesson Corporation. Executive Committee, Healthcare Distribution Alliance (accessed on September 14, 2017), <https://www.healthcaredistribution.org/about/executive-committee>.

Allergan), Endo, Purdue, Mallinckrodt and Cephalon were members of the HDA.⁴³⁹ Additionally, the HDA and each of the Distributor Defendants, eagerly sought the active membership and participation of the Manufacturer Defendants by advocating for the many benefits of members, including “**strengthening . . . alliances**.”⁴⁴⁰

686. Beyond strengthening alliances, the benefits of HDA membership included the ability to, among other things, “network one on one with manufacturer executives at HDA’s members-only Business and Leadership Conference,” “networking with HDA wholesale distributor members,” “opportunities to host and sponsor HDA Board of Directors events,” “participate on HDA committees, task forces and working groups with peers and trading partners,” and “make connections.”⁴⁴¹ Clearly, the HDA and the Distributor Defendants believed that membership in the HDA was an opportunity to create interpersonal and ongoing organizational relationships and “alliances” between the Manufacturers and Defendants.

687. The application for manufacturer membership in the HDA further indicates the level of connection between the RICO Defendants and the level of insight that they had into each other’s businesses.⁴⁴² For example, the manufacturer membership application must be signed by a “senior company

⁴³⁹ Manufacturer Membership, Healthcare Distribution Alliance, (accessed on September 14, 2017), <https://www.healthcaredistribution.org/about/membership/manufacturer>.

⁴⁴⁰ Manufacturer Membership Benefits, Healthcare Distribution Alliance, (accessed on September 14, 2017), <https://www.healthcaredistribution.org/~media/pdfs/membership/manufacturer-membership-benefits.ashx?la=en>.

⁴⁴¹ *Id.*

⁴⁴² Manufacturer Membership Application, Healthcare Distribution Alliance, (accessed on September 14, 2017), <https://www.healthcaredistribution.org/~media/pdfs/membership/manufacturer-membership-application.ashx?la=en>.

1 executive,” and it requests that the manufacturer applicant identify a key contact
2 and any additional contacts from within its company.

3 688. The HDA application also requests that the manufacturer identify its
4 current distribution information, including the facility name and contact
5 information.

6 689. And, Manufacturer Members were asked to identify their “most
7 recent year end net sales” through wholesale distributors, including the Distributor
8 Defendants AmerisourceBergen, Cardinal Health, and McKesson and their
9 subsidiaries.

10 690. The closed meetings of the HDA’s councils, committees, task forces
11 and working groups provided the Manufacturer and Distributor Defendants with
12 the opportunity to work closely together, confidentially, to develop and further the
13 common purpose and interests of the enterprise.

14 691. The HDA also offers a multitude of conferences, including annual
15 business and leadership conferences. The HDA, and the Distributor Defendants
16 advertise these conferences to the Manufacturer Defendants as an opportunity to
17 “bring together high-level executives, thought leaders and influential managers . .
18 . to hold strategic business discussions on the most pressing industry issues.”⁴⁴³
19 The conferences also gave the Manufacturer and Distributor Defendants
20 “unmatched opportunities to network with [their] peers and trading partners at all
21 levels of the healthcare distribution industry.”⁴⁴⁴ The HDA and its conferences
22 were significant opportunities for the Manufacturer and Distributor Defendants to
23
24

25
26 ⁴⁴³ Business and Leadership Conference – Information for Manufacturers,
27 Healthcare Distribution Alliance[https://www.healthcaredistribution.org/events/2015-business-and-](https://www.healthcaredistribution.org/events/2015-business-and-leadership-conference/blc-for-manufacturers)
28 [leadership-conference/blc-for-manufacturers](https://www.healthcaredistribution.org/events/2015-business-and-leadership-conference/blc-for-manufacturers) (last accessed on September 14,
2017).

⁴⁴⁴ *Id.*

1 interact at a high-level of leadership. It is clear that the Manufacturer Defendants
2 embraced this opportunity by attending and sponsoring these events.⁴⁴⁵

3 692. Third, the RICO Diversion Defendants maintained their interpersonal
4 relationships by working together, through contractual chargeback arrangements,
5 to exchanging sales information and drive the unlawful sales of their opioids. To
6 this end, the Manufacturer Defendants engaged in an industry-wide practice of
7 paying rebates to the Distributor Defendants for sales of prescription opioids.⁴⁴⁶

8 693. For example, the *Washington Post* reported that “[o]n Aug. 23, 2011,
9 DEA supervisors met with Mallinckrodt executives at the agency’s headquarters
10 in Arlington, Va., the day a rare 5.8-magnitude earthquake hit the Washington
11 region. People involved in the case still call the gathering ‘the earthquake
12 meeting.’ DEA officials showed the company the remarkable amounts of its
13 oxycodone going to distributors and the number of arrests being made for
14 oxycodone possession and distribution on the street, according to one participant
15 in the meeting who also spoke on the condition of anonymity because the case is
16 pending.”⁴⁴⁷

17
18
19 ⁴⁴⁵ 2015 Distribution Management Conference and Expo, Healthcare Distribution
20 Alliance, [https://www.healthcaredistribution.org/events/2015-distribution-](https://www.healthcaredistribution.org/events/2015-distribution-management-conference)
management-conference (last accessed on September 14, 2017).

21 ⁴⁴⁶ Lenny Bernstein & Scott Higham, The government’s struggle to hold opioid
22 manufacturers accountable, The Washington Post, (April 2, 2017),
[https://www.washingtonpost.com/graphics/investigations/dea-](https://www.washingtonpost.com/graphics/investigations/dea-mallinckrodt/?utm_term=.b24cc81cc356)
23 [mallinckrodt/?utm_term=.b24cc81cc356](https://www.washingtonpost.com/graphics/investigations/dea-mallinckrodt/?utm_term=.b24cc81cc356); *see also*, Letter from Sen. Claire
24 McCaskill, (July 27, 2017),
[https://www.mccaskill.senate.gov/imo/media/image/july-opioid-investigation-](https://www.mccaskill.senate.gov/imo/media/image/july-opioid-investigation-letter-manufacturers.png)
25 [letter-manufacturers.png](https://www.mccaskill.senate.gov/imo/media/image/july-opioid-investigation-letter-manufacturers.png); Letter from Sen. Claire McCaskill, (July 27, 2017),
[https://www.mccaskill.senate.gov/imo/media/image/july-opioid-investigation-](https://www.mccaskill.senate.gov/imo/media/image/july-opioid-investigation-letter-manufacturers.png)
26 [letter-manufacturers.png](https://www.mccaskill.senate.gov/imo/media/image/july-opioid-investigation-letter-manufacturers.png); Letters From Sen. Claire McCaskill, (March 28, 2017),
<https://www.mccaskill.senate.gov/opioid-investigation>; Purdue Managed Markets,
Purdue Pharma, (accessed on September 14, 2017),
<http://www.purduepharma.com/payers/managed-markets/>.

27 ⁴⁴⁷ [https://www.washingtonpost.com/graphics/investigations/dea-](https://www.washingtonpost.com/graphics/investigations/dea-mallinckrodt/?utm_term=.f336835fd5da)
28 [mallinckrodt/?utm_term=.f336835fd5da](https://www.washingtonpost.com/graphics/investigations/dea-mallinckrodt/?utm_term=.f336835fd5da)

1 694. “Three weeks after the Aug. 23 meeting, Mallinckrodt notified 43 of
2 its distributors that they would no longer receive rebates from the company if they
3 continued to supply certain pharmacies whose orders appeared to be
4 suspicious.”⁴⁴⁸

5 695. “On Nov. 30, 2011, the DEA served a subpoena on Mallinckrodt,
6 demanding documents related to its suspicious-order-monitoring program,
7 according to the company’s filings with the Securities and Exchange Commission.
8 The subpoena brought a windfall of information. The DEA gained access to data
9 from Mallinckrodt’s rebate or ‘chargeback’ program, an industry-wide practice
10 that provides reimbursements to wholesale distributors. That information and
11 other records showed where Mallinckrodt’s oxycodone was going — from the
12 company to its network of distributors to retailers down the chain.”⁴⁴⁹

13 696. In addition, the Distributor Defendants and Manufacturer Defendants
14 participated, through the HDA, in Webinars and other meetings designed to
15 exchange detailed information regarding their prescription opioid sales, including
16 purchase orders, acknowledgements, ship notices, and invoices.⁴⁵⁰ For example,
17 on April 27, 2011, the HDA offered a Webinar to “accurately and effectively
18 exchange business transactions between distributors and manufacturers...”:
19
20
21
22
23
24
25

26 ⁴⁴⁸ Id.

27 ⁴⁴⁹ Id.

28 ⁴⁵⁰ Webinars, Healthcare Distribution Alliance, (accessed on September 14, 2017),
<https://www.healthcaredistribution.org/resources/webinar-leveraging-edi>.

Webinar Leveraging EDI: Order-to-Cash Transactions CD Box Set



(Webinar held: April 27, 2011) Using EDI to accurately and efficiently exchange business transactions (i.e., purchase orders, acknowledgements, ship notices, invoices, etc.) between distributors and manufacturers in the healthcare supply chain is critical. The development and use of voluntary guidelines for specific EDI standards provide industry

trading partners with a means to effectively convey the necessary information.

Hear updates on HDMA's Order-to-Cash Guidelines for Electronic Data Interchange (EDI) in the Healthcare Product Supply Chain, including the 810 Invoice; 850 Purchase Order; 855 Purchase Order Acknowledgement; and the 856 Ship Notice/Manifest.

697. On information and belief, the Manufacturer Defendants used this information to gather high-level data regarding overall distribution and direct the Distributor Defendants on how to most effectively sell the prescription opioids.

698. And, through the HDA, Manufacturer Members were asked to identify their “most recent year end net sales” through wholesale distributors, including the Distributor Defendants as follows:

Company	Most Recent Year End Net Sales
Henry Schein, Inc.	
Henry Schein Distribution Centers (7)	
Hospital Pharmaceutical Consulting (1)	
KeySource Medical, Inc. (1)	
Louisiana Wholesale Drug Co. Inc. (1)	
McKesson Corporation (71)	
McKesson Supply Solutions (25)	
McKesson Canada (12)	
McKesson Corporation (4)	
McKesson Specialty Health (1)	
McKesson Strategic Redistribution Center (1)	
McKesson Medical Surgical (1)	
Physician Sales & Service (PSS) (25)	
US Oncology (1)	
DeVetoria Healthcare, Inc. PR (1)	
Miami-Luken, Inc. (1)	
Morris & Dickson Co., LLC (1)	
Mutual Wholesale Drug Co. (1)	
PBA Health (1)	
Prescription Supply, Inc. (1)	
Prodigy Health Supplier Corporation (1)	
Quality Care Products, LLC (1)	
RDC (3)	
R&S Northeast LLC (2)	
Richie Pharmacal Co., LLC (1)	
Seacoast Medical LLC (1)	
Smith Drug Company, Div. JM Smith Corporation (4)	
Burlington Drug Company, Inc. (1)	
Smith Drug Company, Div. JM Smith Corporation (3)	
Top Rx (4)	
Value Drug Company (1)	
VaxServe (1)	
TOTAL SALES (millions)	\$ 0

1 699. The contractual relationships among the RICO Defendants also
2 include vault security programs. The RICO Diversion Defendants are required to
3 maintain certain security protocols and storage facilities for the manufacture and
4 distribution of their opiates. Upon information and belief, the manufacturers
5 negotiated agreements whereby the Manufacturers installed security vaults for
6 Distributors in exchange for agreements to maintain minimum sales performance
7 thresholds. Upon information and belief, these agreements were used by the
8 RICO Diversion Defendants as a tool to violate their reporting and diversion
9 duties in order to reach the required sales requirements.

10 700. Taken together, the interaction and length of the relationships
11 between and among the Manufacturer and Distributor Defendants reflects a deep
12 level of interaction and cooperation between two groups in a tightly knit industry.
13 The Manufacturer and Distributor Defendants were not two separate groups
14 operating in isolation or two groups forced to work together in a closed system.
15 The RICO Diversion Defendants operated together as a united entity, working
16 together on multiple fronts, to engage in the unlawful sale of prescription opioids.
17 The HDA and the Pain Care Forum are but two examples of the overlapping
18 relationships, and concerted joint efforts to accomplish common goals and
19 demonstrates that the leaders of each of the RICO Diversion Defendants were in
20 communication and cooperation.

21 701. Alternatively, the RICO Diversion Defendants were members of a
22 legal entity enterprise within the meaning of 18 U.S.C. § 1961(4), through which
23 the RICO Diversion Defendants conducted their pattern of racketeering activity in
24 this jurisdiction and throughout the United States. As alleged, the Healthcare
25 Distribution Alliance (the “HDA”)⁴⁵¹ is a distinct legal entity that satisfies the
26

27 ⁴⁵¹ Health Distribution Alliance, History, Health Distribution Alliance, (last
28 accessed on September 15, 2017),
<https://www.healthcaredistribution.org/about/hda-history>.

1 definition of a RICO enterprise because it is a corporation formed under the laws
2 of the District of Columbia, doing business in Virginia. As such, the HDA
3 qualifies as an “enterprise” within the definition set out in 18 U.S.C. § 1961(4).

4 702. On information and belief, each of the RICO Diversion Defendants is
5 a member, participant, and/or sponsor of the HDA, and has been since at least
6 2006, and utilized the HDA to conduct the Opioid Diversion Enterprise and to
7 engage in the pattern of racketeering activity that gives rise to the Count.

8 703. Each of the RICO Diversion Defendants is a legal entity separate and
9 distinct from the HDA. Additionally, the HDA serves the interests of distributors
10 and manufacturers beyond the RICO Diversion Defendants. Therefore, the HDA
11 exists separately from the Opioid Diversion Enterprise, and each of the RICO
12 Diversion Defendants exists separately from the HDA. Therefore, the HDA may
13 serve as a RICO enterprise.

14 **B. CONDUCT OF THE OPIOID DIVERSION ENTERPRISE.**

15 704. During the time period alleged in this Complaint, the RICO
16 Diversion Defendants exerted control over, conducted and/or participated in the
17 Opioid Diversion Enterprise by fraudulently claiming that they were complying
18 with their duties under the CSA to identify, investigate and report suspicious
19 orders of opioids in order to prevent diversion of those highly addictive substances
20 into the illicit market, and to halt such unlawful sales, so as to increase production
21 quotas and generate unlawful profits, as follows:

22 705. Defendants disseminated false and misleading statements to state and
23 federal regulators claiming that (1) the quotas for prescription opioids should be
24 increased, (2) they were complying with their obligations to maintain effective
25 controls against diversion of their prescription opioids, (3) they were complying
26 with their obligations to design and operate a system to disclose to the registrant
27 suspicious orders of their prescription opioids, (4) they were complying with their
28 obligation to notify the DEA of any suspicious orders or diversion of their

1 prescription opioids and (5) they did not have the capability to identify suspicious
 2 orders of controlled substances despite their possession of national, regional, state,
 3 and local prescriber- and patient-level data that allowed them to track prescribing
 4 patterns over time, which the Defendants obtained from data companies, including
 5 but not limited to: IMS Health, QuintilesIMS, Iqvia, Pharmaceutical Data
 6 Services, Source Healthcare Analytics, NDS Health Information Services,
 7 Verispan, Quintiles, SDI Health, ArcLight, Scriptline, Wolters Kluwer, and/or
 8 PRA Health Science, and all of their predecessors or successors in interest (the
 9 “Data Vendors”).

10 706. The RICO Diversion Defendants applied political and other pressure
 11 on the DOJ and DEA to halt prosecutions for failure to report suspicious orders of
 12 prescription opioids and lobbied Congress to strip the DEA of its ability to
 13 immediately suspend registrations pending investigation by passing the “Ensuring
 14 Patient Access and Effective Drug Enforcement Act.”⁴⁵²

15 707. The Distributor Defendants developed “know your customer”
 16 questionnaires and files. This information, compiled pursuant to comments from
 17 the DEA in 2006 and 2007 was intended to help the RICO Diversion Defendants
 18 identify suspicious orders or customers who were likely to divert prescription
 19

20
 21 ⁴⁵² See HDMA is now the Healthcare Distribution Alliance, Pharmaceutical
 22 Commerce, (June 13, 2016, updated July 6, 2016),
 23 [http://pharmaceuticalcommerce.com/business-and-finance/hdma-now-healthcare-](http://pharmaceuticalcommerce.com/business-and-finance/hdma-now-healthcare-distribution-alliance/)
 24 [distribution-alliance/](http://pharmaceuticalcommerce.com/business-and-finance/hdma-now-healthcare-distribution-alliance/); Lenny Bernstein & Scott Higham, *Investigation: The DEA*
 25 *Slowed Enforcement While the Opioid Epidemic Grew Out of Control*, Wash. Post,
 26 Oct. 22, 2016, [https://www.washingtonpost.com/investigations/the-dea-slowed-](https://www.washingtonpost.com/investigations/the-dea-slowed-enforcement-while-the-opioid-epidemic-grew-out-of-control/2016/10/22/aea2bf8e-7f71-11e6-8d13-d7c704ef9fd9_story.html)
 27 [enforcement-while-the-opioid-epidemic-grew-out-of-control/2016/10/22/aea2bf8e-](https://www.washingtonpost.com/investigations/the-dea-slowed-enforcement-while-the-opioid-epidemic-grew-out-of-control/2016/10/22/aea2bf8e-7f71-11e6-8d13-d7c704ef9fd9_story.html)
 28 [7f71-11e6-8d13-d7c704ef9fd9_story.html](https://www.washingtonpost.com/investigations/the-dea-slowed-enforcement-while-the-opioid-epidemic-grew-out-of-control/2016/10/22/aea2bf8e-7f71-11e6-8d13-d7c704ef9fd9_story.html); Lenny Bernstein & Scott Higham,
Investigation: U.S. Senator Calls for Investigation of DEA Enforcement Slowdown
Amid Opioid Crisis, Wash. Post, Mar. 6, 2017,
[https://www.washingtonpost.com/investigations/us-senator-calls-for-investigation-](https://www.washingtonpost.com/investigations/us-senator-calls-for-investigation-of-dea-enforcement-slowdown/2017/03/06/5846ee60-028b-11e7-b1e9-a05d3c21f7cf_story.html)
[of-dea-enforcement-slowdown/2017/03/06/5846ee60-028b-11e7-b1e9-](https://www.washingtonpost.com/investigations/us-senator-calls-for-investigation-of-dea-enforcement-slowdown/2017/03/06/5846ee60-028b-11e7-b1e9-a05d3c21f7cf_story.html)
[a05d3c21f7cf_story.html](https://www.washingtonpost.com/investigations/us-senator-calls-for-investigation-of-dea-enforcement-slowdown/2017/03/06/5846ee60-028b-11e7-b1e9-a05d3c21f7cf_story.html); Eric Eyre, *DEA Agent: “We Had no Leadership” in WV*
Amid Flood of Pain Pills, Charleston Gazette-Mail, Feb. 18, 2017,
[http://www.wvgazettemail.com/news/20170218/dea-agent-we-had-no-leadership-](http://www.wvgazettemail.com/news/20170218/dea-agent-we-had-no-leadership-in-wv-amid-flood-of-pain-pills-)
[in-wv-amid-flood-of-pain-pills-.](http://www.wvgazettemail.com/news/20170218/dea-agent-we-had-no-leadership-in-wv-amid-flood-of-pain-pills-)

1 opioids.⁴⁵³ On information and belief, the “know your customer” questionnaires
 2 informed the RICO Diversion Defendants of the number of pills that the
 3 pharmacies sold, how many non-controlled substances are sold compared to
 4 controlled substances, whether the pharmacy buys from other distributors, the
 5 types of medical providers in the area, including pain clinics, general practitioners,
 6 hospice facilities, cancer treatment facilities, among others, and these
 7 questionnaires put the recipients on notice of suspicious orders.

8 708. The RICO Diversion Defendants purchased nationwide, regional,
 9 state, and local prescriber- and patient-level data from the Data Vendors that
 10 allowed them to track prescribing trends, identify suspicious orders, identify
 11 patients who were doctor shopping, identify pill mills, etc. The Data Vendors’
 12 information purchased by the RICO Diversion Defendants allowed them to view,
 13 analyze, compute, and track their competitors sales, and to compare and analyze
 14 market share information.⁴⁵⁴


15 709. IMS, for example, IMS provided the RICO Diversion Defendants
 16 with reports detailing prescriber behavior and the number of prescriptions written
 17 between competing products.⁴⁵⁵

21 ⁴⁵³ Suggested Questions a Distributor should ask prior to shipping controlled
 22 substances, Drug Enforcement Administration (available at
 23 https://www.dea.gov/diversion/mtgs/pharm_industry/14th_pharm/levinl_ques.pdf); Richard Widup, Jr., Kathleen H. Dooley, Esq. Pharmaceutical Production
 24 Diversion: Beyond the PDMA, Purdue Pharma and McGuireWoods LLC, (available at https://www.mcguirewoods.com/news-resources/publications/lifesciences/product_diversion_beyond_pdma.pdf).

25 ⁴⁵⁴ A Verispan representative testified that the RICO Defendants use the
 26 prescribing information to “drive market share.” *Sorrell v. IMS Health Inc.*, 2011
 27 WL 661712, *9-10 (Feb. 22, 2011).

28 ⁴⁵⁵ Paul Kallukaran & Jerry Kagan, *Data Mining at IMS HEALTH: How we Turned*
 27 *a Mountain of Data into a Few Information-rich Molehills*, (accessed on February
 15, 2018),
<http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.198.349&rep=rep1&type=pdf>, Figure 2 at p.3.

Figure 2:



710. Similarly, Wolters Kluwer, an entity that eventually owned data mining companies that were created by McKesson (Source) and Cardinal Health (ArcLight), provided the RICO Defendants with charts analyzing the weekly prescribing patterns of multiple physicians, organized by territory, regarding competing drugs, and analyzed the market share of those drugs.⁴⁵⁶

⁴⁵⁶ *Sorrell v. IMS Health Inc.*, 2011 WL 705207, *467-471 (Feb. 22, 2011).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

1. The Prescriber Roster shows Prescriber demographics, prescribing information and indicator arrows

Territory : 1102 Prescriber				Weekly Prescriber TR			
	Trend	Specialty	Product	WEEK Feb-03-06	WEEK Jan-27-06	WEEK Jan-20-06	WEEK Jan-13-06
Territory : 1102 – TOTAL			PRODUCT A	46	64	58	88
			PRODUCT B	292	253	247	278
			PRODUCT C	55	56	56	58
			PRODUCT D	36	28	34	33
			PRODUCT E	7	9	2	9
			PRODUCT F	1	3	5	0
Doctor A		IM	PRODUCT A	4	1	1	1
			PRODUCT B	2	2	2	3
			PRODUCT C	0	2	0	0
			PRODUCT D	0	0	0	0
			PRODUCT E	0	0	0	0
			PRODUCT F	0	0	0	0
Doctor B		GE	PRODUCT A	3	1	1	2
			PRODUCT B	5	4	7	2
			PRODUCT C	0	1	0	0
			PRODUCT D	0	0	0	0
			PRODUCT E	0	1	0	1
			PRODUCT F	0	0	0	0
Doctor C		GE	PRODUCT A	3	1	2	0
			PRODUCT B	4	5	0	3
			PRODUCT C	0	1	1	0
			PRODUCT D	0	1	0	2
			PRODUCT E	0	0	0	0
			PRODUCT F	0	0	0	0

* * *

3. Territory Summary Report shows Prescriber Roster information aggregated at a territory level

Territory Summary

Name	Spec	Zip	Product A NRX	Product A MM Share	Product A Rank	Market NRX	Market Rank
ABNEY, RAY C.	P	05302	6	10.7%	43	56	38
ALLISTER, ROBERT	P	03820	6	18.8%	43	32	63
ALTMAN, LEE S.	P	01655	34	14.0%	3	247	3
BALLARD, HARLOW	P	05801	0	0.0%	93	8	96
BARNEY, CHRISTINE A.	P	03766	6	26.1%	43	23	85
BARTON, GAIL	P	03755	13	32.5%	18	40	50
BERNSTEIN, RICHARD A.	P	05401	0	0.0%	93	14	94
BOHNERI, MICHAEL	P	03060	3	4.5%	73	66	29
BOSTIC, JEFFERY O.	CHP	03079	5	10.9%	55	45	44
BREITHOLTZ, TIMOTHY	P	03870	13	34.2%	18	38	52
BROWN, KENNETH	P	03941	4	10.0%	61	40	50
BUCHANAN, KEVIN	P	05701	5	16.1%	55	31	70
CARMAN, MEGAN W.	P	03246	10	12.3%	28	81	18
CARSEN, MARJORIA	P	05701	6	18.2%	43	33	59
CATPANO-FRIEDMAN, LISA	P	05201	5	8.6%	43	70	25
CLARKE-RUBIN, LORNA	P	12901	8	24.2%	32	33	59
COHEN, DEVRA H.	CHP	03060	3	6.5%	73	46	44
COLE, STEPHEN A.	P	05101	5	13.2%	55	38	52
COTTON, PAUL G.	P	05401	13	28.3%	18	46	44
CUSI, PRISCILLA M.	P	03104	17	7.9%	14	215	5
DAVISON, MARTHA F.	P	03110	14	11.3%	16	124	8
DEJONG, JACOB	P	03067	0	0.0%	93	21	87
DELFAUSSE, PETER O.	P	03301	6	35.3%	43	17	90
DENNETT, DOUGLAS E.	CHP	05401	0	0.0%	93	33	59
DEPPE, SUSAN L.	P	05401	1	0.3%	87	300	2
DEVENDERRAO, T.	P	03060	7	9.6%	37	73	21

711. This information allowed the RICO Diversion Defendants to track and identify instances of, overprescribing.⁴⁵⁷ In fact, one of the Data Venders' experts testified that a manufacturer of "narcotic analgesics" used the Data Venders' information to track, identify, report and halt suspicious orders of controlled substances.⁴⁵⁸

⁴⁵⁷ See *Sorrell v. IMS Health Inc.*, 2011 WL 1449043, *37-38 (March 24, 2011) (arguing that data had been used to "identify overuse of antibiotics in children," and "whether there is a wide use of anthrax prophylactic medicines after the scares happened in 2001."). The Data Vender Respondents also cited evidence from the trial court proving that "because analysis of PI data makes it possible to 'identify overuse of a pharmaceutical in specific conditions, the government employs the data to monitor usage of controlled substances.'" *Id.*

⁴⁵⁸ *Id.* at *38. Eugene "Mick" Kolassa testified as an expert on behalf of the Data Vender stating that "a firm that sells narcotic analgesics was able to use prescriber-identifiable information to identify physicians that seemed to be prescribing an

1 [455] Q. Besides marketing and promotion, are
2 there any other uses for prescriber-identifiable data?

3 A. There's a number of other uses.

4 Q. And what are those?

5 A. The one that I was most impressed with
6 was a firm that used it to identify – a firm that
7 sells narcotic analgesics was able to use prescriber-
8 identifiable information to identify physicians that
9 seemed to be prescribing an inordinately high num-
10 ber of prescriptions for their product and they would
11 use that to notify the DEA and other authorities of
12 potential problems.

13
14 712. The RICO Diversion Defendants were, therefore, collectively aware
15 of the suspicious orders that flowed daily from their manufacturing and
16 distribution facilities.

17 713. The RICO Diversion Defendants refused to identify, investigate and
18 report suspicious orders to the DEA when they became aware of the same despite
19 their actual knowledge of drug diversion rings. The RICO Diversion Defendants
20 refused to identify suspicious orders and diverted drugs despite the DEA issuing
21 final decisions against the Distributor Defendants in 178 registrant actions
22 between 2008 and 2012⁴⁵⁹ and 117 recommended decision in registrant actions
23 from The Office of Administrative Law Judges. These numbers include seventy-
24 six (76) actions involving orders to show cause and forty-one (41) actions

25
26 inordinately high number of prescriptions for their product.” *Id*; see also Joint
27 Appendix in *Sorrell v. IMS Health*, 2011 WL 687134, at *204 (Feb. 22, 2011).

28 ⁴⁵⁹ Evaluation and Inspections Div., Office of the Inspector Gen., U.S. Dep’t of
Justice, *The Drug Enforcement Administration’s Adjudication of Registrant
Actions* 6 (2014), <https://oig.justice.gov/reports/2014/e1403.pdf>.

1 involving immediate suspension orders – all for failure to report suspicious
2 orders.⁴⁶⁰

3 714. Defendants' scheme had a decision-making structure driven by the
4 Manufacturer Defendants and corroborated by the Distributor Defendants. The
5 Manufacturer Defendants worked together to control the State and Federal
6 Government's response to the manufacture and distribution of prescription opioids
7 by increasing production quotas through a systematic refusal to maintain effective
8 controls against diversion, and identify suspicious orders and report them to the
9 DEA.

10 715. The RICO Diversion Defendants worked together to control the flow
11 of information and influence state and federal governments and political
12 candidates to pass legislation that was pro-opioid. The Manufacturer and
13 Distributor Defendants did this through their participation in the PCF and HDA.

14 716. The RICO Diversion Defendants also worked together to ensure that
15 the Aggregate Production Quotas, Individual Quotas and Procurement Quotas
16 allowed by the DEA remained artificially high and ensured that suspicious orders
17 were not reported to the DEA in order to ensure that the DEA had no basis for
18 refusing to increase or decrease production quotas due to diversion. The RICO
19 Diversion Defendants influenced the DEA production quotas in the following
20 ways:

21 717. The scheme devised and implemented by the RICO Diversion
22 Defendants amounted to a common course of conduct characterized by a refusal to
23 maintain effective controls against diversion, and all designed and operated to
24 ensure the continued unlawful sale of controlled substances.

25
26
27
28

⁴⁶⁰ Id.

1 **C. PATTERN OF RACKETEERING ACTIVITY.**

2 718. The RICO Diversion Defendants conducted and participated in the
3 conduct of the Opioid Diversion Enterprise through a pattern of racketeering
4 activity as defined in 18 U.S.C. § 1961(1)(D), including ; the felonious
5 manufacture, importation, receiving, concealment buying selling, or otherwise
6 dealing in a controlled substance or listed chemical (as defined in section 102 of
7 the Controlled Substance Act), punishable under any law of the United States; and
8 18 U.S.C. 1961(1)(B), including mail fraud (18 U.S.C. § 1341) and wire fraud (18
9 U.S.C. § 1343).

10 **1. The RICO Defendants Manufactured, Sold and/or Dealt**
11 **in Controlled Substances and Their Actions Constitute**
12 **Crimes Punishable as Felonies.**

13 719. The RICO Diversion Defendants conducted and participated in the
14 conduct of the affairs of the Opioid Diversion Enterprise through a pattern of
15 racketeering activity as defined in 18 U.S.C. § 1961(1)(D) by the felonious
16 manufacture, importation, receiving, concealment, buying, selling, or otherwise
17 dealing in a controlled substance or listed chemical (as defined in section 102 of
18 the Controlled Substance Act), punishable under any law of the United States.

19 720. The RICO Diversion Defendants committed crimes that are
20 punishable as felonies under the laws of the United States. Specifically, 21 U.S.C.
21 § 843(a)(4) makes it unlawful for any person to knowingly or intentionally furnish
22 false or fraudulent information in, or omit any material information from, any
23 application, report, record or other document required to be made, kept or filed
24 under this subchapter. A violation of section 843(a)(4) is punishable by up to four
25 years in jail, making it a felony. 21 U.S.C. § 843(d)(1).

26 721. Each of the RICO Diversion Defendants qualifies as a registrant
27 under the CSA. Their status as registrants under the CSA requires that they
28 maintain effective controls against diversion of controlled substances in schedule I

1 or II, design and operate a system to disclose to the registrant suspicious orders of
 2 controlled substances and inform the DEA of suspicious orders when discovered
 3 by the registrant. 21 U.S.C. § 823; 21 C.F.R. § 1301.74(b).

4 722. The CSA and the Code of Federal Regulations, require the RICO
 5 Diversion Defendants to make reports to the DEA of any suspicious orders
 6 identified through the design and operation of their system to disclose suspicious
 7 orders. The failure to make reports as required by the CSA and Code of Federal
 8 Regulations amounts to a criminal violation of the statute.

9 723. The RICO Diversion Defendants knowingly and intentionally
 10 furnished false or fraudulent information in their reports to the DEA about
 11 suspicious orders, and/or omitted material information from reports, records and
 12 other document required to be filed with the DEA including the Manufacturer
 13 Defendants' applications for production quotas. Specifically, the RICO Diversion
 14 Defendants were aware of suspicious orders of prescription opioids and the
 15 diversion of their prescription opioids into the illicit market, and failed to report
 16 this information to the DEA in their mandatory reports and their applications for
 17 production quotas.

18 724. Upon information and belief, the foregoing examples reflect the
 19 RICO Diversion Defendants' pattern and practice of willfully and intentionally
 20 omitting information from their mandatory reports to the DEA as required by 21
 21 C.F.R. § 1301.74. The sheer volume of enforcement actions available in the
 22 public record against the Distributor Defendants supports this conclusion.⁴⁶¹ For
 23 example:

24 725. On April 24, 2007, the DEA issued an *Order to Show Cause and*
 25 *Immediate Suspension Order* against the AmerisourceBergen Orlando, Florida
 26

27 ⁴⁶¹ Evaluation and Inspections Div., Office of the Inspector Gen., U.S. Dep't of
 28 Justice, *The Drug Enforcement Administration's Adjudication of Registrant*
Actions 6 (2014), <https://oig.justice.gov/reports/2014/e1403.pdf>.

1 distribution center (“Orlando Facility”) alleging failure to maintain effective
2 controls against diversion of controlled substances. On June 22, 2007,
3 AmerisourceBergen entered into a settlement that resulted in the suspension of its
4 DEA registration.

5 726. On November 28, 2007, the DEA issued an *Order to Show Cause*
6 *and Immediate Suspension Order* against the Cardinal Health Auburn,
7 Washington Distribution Center (“Auburn Facility”) for failure to maintain
8 effective controls against diversion of hydrocodone.

9 727. On December 5, 2007, the DEA issued an *Order to Show Cause and*
10 *Immediate Suspension Order* against the Cardinal Health Lakeland, Florida
11 Distribution Center (“Lakeland Facility”) for failure to maintain effective controls
12 against diversion of hydrocodone.

13 728. On December 7, 2007, the DEA issued an *Order to Show Cause and*
14 *Immediate Suspension Order* against the Cardinal Health Swedesboro, New Jersey
15 Distribution Center (“Swedesboro Facility”) for failure to maintain effective
16 controls against diversion of hydrocodone.

17 729. On January 30, 2008, the DEA issued an *Order to Show Cause and*
18 *Immediate Suspension Order* against the Cardinal Health Stafford, Texas
19 Distribution Center (“Stafford Facility”) for failure to maintain effective controls
20 against diversion of hydrocodone.

21 730. On May 2, 2008, McKesson Corporation entered into an
22 *Administrative Memorandum of Agreement* (“2008 MOA”) with the DEA which
23 provided that McKesson would “maintain a compliance program designed to
24 detect and prevent the diversion of controlled substances, inform DEA of
25 suspicious orders required by 21 C.F.R. § 1301.74(b), and follow the procedures
26 established by its Controlled Substance Monitoring Program.”

27 731. On September 30, 2008, Cardinal Health entered into a *Settlement*
28 *and Release Agreement and Administrative Memorandum of Agreement* with the

1 DEA related to its Auburn Facility, Lakeland Facility, Swedesboro Facility and
2 Stafford Facility. The document also referenced allegations by the DEA that
3 Cardinal failed to maintain effective controls against the diversion of controlled
4 substances at its distribution facilities located in McDonough, Georgia
5 (“McDonough Facility”), Valencia, California (“Valencia Facility”) and Denver,
6 Colorado (“Denver Facility”).

7 732. On February 2, 2012, the DEA issued an *Order to Show Cause and*
8 *Immediate Suspension Order* against the Cardinal Health Lakeland, Florida
9 Distribution Center (“Lakeland Facility”) for failure to maintain effective controls
10 against diversion of oxycodone.

11 733. On May, 14, 2012, Cardinal Health entered into an Administrative
12 Memorandum of Agreement with the DEA in which, among other things,
13 Cardinal Health “admits that its due diligence efforts for some pharmacy
14 customers and its compliance with the 2008 MOA, in certain respects, were
15 inadequate.”

16 734. Thereafter, on December 23, 2016, Cardinal Health agreed to pay a
17 \$44 million fine to the DEA to resolve the civil penalty portion of the
18 administrative action taken against its Lakeland, Florida Distribution Center.

19 735. On January 5, 2017, McKesson Corporation entered into an
20 *Administrative Memorandum Agreement* with the DEA wherein it agreed to pay a
21 \$150,000,000 civil penalty for violation of the 2008 MOA as well as failure to
22 identify and report suspicious orders at its facilities in Aurora CO, Aurora IL,
23 Delran NJ, LaCrosse WI, Lakeland FL, Landover MD, La Vista NE, Livonia MI,
24 Methuen MA, Santa Fe Springs CA, Washington Courthouse OH and West
25 Sacramento CA.

1 736. In its Administrative Memorandum Agreement, McKesson
2 acknowledged its wrongdoing and failure to comply with the obligations imposed
3 by the CSA:

4 2. Acceptance of Responsibility. On or about September 27, 2006, February 7, 2007 and
5 December 27, 2007, DEA's Deputy Assistant Administrator, Office of Diversion Control, sent
6 letters to every entity in the United States that was registered with DEA to manufacture or
7 distribute controlled substances, including McKesson (the "DEA Letters"). The DEA Letters
8 contained, among other things, guidance for the identification and reporting of suspicious orders
9 to DEA, as required by 21 C.F.R. § 1301.74(b). McKesson acknowledges that, at various times
10 during the period from January 1, 2009 up through and including the Effective Date of this
11 Agreement (the "Covered Time Period"), it did not identify or report to DEA certain orders
12 placed by certain pharmacies which should have been detected by McKesson as suspicious based
13 on the guidance contained in the DEA Letters about the requirements set forth in 21 C.F.R. §
14 1301.74(b) and 21 U.S.C. § 842(a)(5). McKesson has taken steps to prevent such conduct from
15 occurring in the future, including the measures delineated in the Compliance Addendum.

16 On or about May 2, 2008, DEA and McKesson entered into an Administrative
17 Memorandum of Agreement (the "2008 MOA"). The 2008 MOA provided among other things,
18 that McKesson maintain a compliance program designed to detect and prevent the diversion of
19 controlled substances, inform DEA of suspicious orders as required by 21 C.F.R. § 1301.74(b),
20 and follow procedures established by its Controlled Substance Monitoring Program ("CSMP").
21 McKesson acknowledges that, at various times during the Covered Time Period, it did not
22 identify or report to DEA certain orders placed by certain pharmacies, which should have been
23 detected by McKesson as suspicious, in a manner fully consistent with the requirements set forth
24 in the 2008 MOA. McKesson has taken steps to prevent such conduct from occurring in the
25 future, including the measures delineated in the Compliance Addendum.

26 737. On April 23, 2015, McKesson filed a Form-8-K announcing a
27 settlement with the DEA and DOJ wherein it admitted to violating the CSA and
28 agreed to pay \$150 million and have some of its DEA registrations suspended on a
staggered basis.

 738. In 2016, the Los Angeles Times reported that Purdue was aware of a
pill mill operating out of Los Angeles yet failed to alert the DEA. The LA Times
uncovered that Purdue began tracking a surge in prescriptions in Los Angeles,
including one prescriber in particular. Documents published by the L.A. Times
reveal that a Purdue sales manager spoke with company officials, asking:

 739. Purdue was clearly aware of diversion. As a registrant, Purdue has
the same obligation to report suspicious orders as a wholesale distributor.
Although Purdue claimed that it was considering making a report to the DEA, it

1 shirked its responsibility, claimed that it was the wholesaler's responsibility and
2 then reserved the right to make the report:

3 740. Despite its knowledge of obvious diversion, "Purdue did not shut off
4 the supply of highly addictive OxyContin and did not tell authorities what it knew
5 about [a pill mill] until several years later when the clinic was out of business and
6 its leaders indicted. By that time, 1.1 million pills had spilled into the hands of
7 Armenian mobsters, the Crips gang and other criminals."

8 741. Finally, Mallinckrodt was recently the subject of a DEA and Senate
9 investigation for its opioid practices. Specifically, in 2011, the DEA targeted
10 Mallinckrodt arguing that it ignored its responsibility to report suspicious orders
11 as 500 million of its pills ended up in Florida between 2008 and 2012. After six
12 years of DEA investigation, Mallinckrodt agreed to a settlement involving a \$35
13 million fine. Federal prosecutors summarized the case by saying that
14 Mallinckrodt's response was that everyone knew what was going on in Florida but
15 they had no duty to report it.

16 742. These actions against the Distributor Defendants confirm that the
17 Distributor Defendants knew they had a duty to maintain effective controls against
18 diversion, design and operate a system to disclose suspicious orders, and to report
19 suspicious orders to the DEA. These actions also demonstrate, on information and
20 belief, that the Manufacturer Defendants were aware of the enforcement against
21 their Distributors and the diversion of the prescription opioids and a
22 corresponding duty to report suspicious orders.

23 743. The pattern of racketeering activity alleged herein is continuing as of
24 the date of this Complaint and, upon information and belief, will continue into the
25 future unless enjoined by this Court.

26 744. Many of the precise dates of the RICO Diversion Defendants'
27 criminal actions at issue herein were hidden and cannot be alleged without access
28 to their books and records. Indeed, an essential part of the successful operation of

1 the Opioid Diversion Enterprise depended upon the secrecy of the participants in
2 that enterprise.

3 745. Each instance of racketeering activity alleged herein was related, had
4 similar purposes, involved the same or similar participants and methods of
5 commission, and had similar results affecting similar victims, Plaintiffs'
6 Community and the County. Defendants calculated and intentionally crafted the
7 diversion scheme to increase and maintain profits from unlawful sales of opioids,
8 without regard to the effect such behavior would have on this jurisdiction, its
9 citizens or the County. The Defendants were aware that the County and the
10 citizens of this jurisdiction rely on the Defendants to maintain a closed system of
11 manufacturing and distribution to protect against the non-medical diversion and
12 use of their dangerously addictive opioid drugs.

13 746. By intentionally refusing to report and halt suspicious orders of their
14 prescription opioids, Defendants engaged in a fraudulent scheme and unlawful
15 course of conduct constituting a pattern of racketeering activity.

16 747. The RICO Diversion Defendants' predicate acts and pattern of
17 racketeering activity were a substantial and foreseeable cause of the County's
18 injury and the relationship between the RICO Diversion Defendants' conduct and
19 the County's injury are logical and not speculative. It was foreseeable to the
20 RICO Diversion Defendants that when they refused to identify, report and halt
21 suspicious orders as required by the CSA and Code of Federal Regulations, it
22 would allow the wide-spread diversion of prescriptions opioids into the illicit
23 market and create an opioid-addiction epidemic that logically, substantially, and
24 foreseeably harmed the County.

25 748. The RICO Diversion Defendants' predicate acts and pattern of
26 racketeering activity were a substantial and foreseeable cause of the County's
27 injury and the relationship between the RICO Diversion Defendants' conduct and
28 the County's injury is logical and not speculative. It was foreseeable to the RICO

1 Diversion Defendants that when they fraudulently marketed highly-addictive and
2 dangerous drugs, that were approved for very limited and specific uses by the
3 FDA, as non-addictive and safe for off-label uses such as moderate pain, non-
4 cancer pain, and long-term chronic pain, that the RICO Diversion Defendants
5 would create an opioid-addiction epidemic that logically, substantially and
6 foreseeably harmed the County.

7 749. The last racketeering incident occurred within five years of the
8 commission of a prior incident of racketeering.

9 **2. The RICO Diversion Defendants Engaged in Mail and**
10 **Wire Fraud.**

11 750. The RICO Diversion Defendants carried out, or attempted to carry
12 out, a scheme to defraud federal and state regulators, and the American public by
13 knowingly conducting or participating in the conduct of the Opioid Diversion
14 Enterprise through a pattern of racketeering activity within the meaning of 18
15 U.S.C. § 1961(1) that employed the use of mail and wire facilities, in violation of
16 18 U.S.C. § 1341 (mail fraud) and § 1343 (wire fraud).

17 751. The RICO Diversion Defendants committed, conspired to commit,
18 and/or aided and abetted in the commission of at least two predicate acts of
19 racketeering activity (*i.e.* violations of 18 U.S.C. §§ 1341 and 1343) within the
20 past ten years. The multiple acts of racketeering activity that the RICO Diversion
21 Defendants committed, or aided and abetted in the commission of, were related to
22 each other, posed a threat of continued racketeering activity, and therefore
23 constitute a “pattern of racketeering activity.” The racketeering activity was made
24 possible by the RICO Diversion Defendants’ regular use of the facilities, services,
25 distribution channels, and employees of the Opioid Diversion Enterprise. The
26 RICO Diversion Defendants participated in the scheme to defraud by using mail,
27 telephone and the Internet to transmit mailings and wires in interstate or foreign
28 commerce.

1 752. The RICO Diversion Defendants used, directed the use of, and/or
2 caused to be used, thousands of interstate mail and wire communications in
3 service of their scheme through virtually uniform misrepresentations,
4 concealments and material omissions regarding their compliance with their
5 mandatory reporting requirements and the actions necessary to carry out their
6 unlawful goal of selling prescription opioids without reporting suspicious orders
7 or the diversion of opioids into the illicit market.

8 753. In devising and executing the illegal scheme, the RICO Diversion
9 Defendants devised and knowingly carried out a material scheme and/or artifice to
10 defraud by means of materially false or fraudulent pretenses, representations,
11 promises, or omissions of material facts. For the purpose of executing the illegal
12 scheme, the RICO Diversion Defendants committed these racketeering acts,
13 which number in the thousands, intentionally and knowingly with the specific
14 intent to advance the illegal scheme.

15 754. The RICO Diversion Defendants' predicate acts of racketeering (18
16 U.S.C. § 1961(1)) include, but are not limited to:

17 a. Mail Fraud: The RICO Defendants violated 18 U.S.C. § 1341 by
18 sending or receiving, or by causing to be sent and/or received, materials
19 via U.S. mail or commercial interstate carriers for the purpose of
20 executing the unlawful scheme to design, manufacture, market, and sell
21 the prescription opioids by means of false pretenses, misrepresentations,
22 promises, and omissions.

23 b. Wire Fraud: The RICO Defendants violated 18 U.S.C. § 1343 by
24 transmitting and/or receiving, or by causing to be transmitted and/or
25 received, materials by wire for the purpose of executing the unlawful
26 scheme to design, manufacture, market, and sell the prescription opioids
27 by means of false pretenses, misrepresentations, promises, and
28 omissions.

1 755. The RICO Diversion Defendants' use of the mail and wires includes,
2 but is not limited to, the transmission, delivery, or shipment of the following by
3 the Manufacturers, Distributors, or third parties that were foreseeably caused to be
4 sent as a result of the RICO Diversion Defendants' illegal scheme, including but
5 not limited to:

- 6 a. The prescription opioids themselves;
- 7 b. Documents and communications that supported and/or facilitated the
8 Defendants' request for higher aggregate production quotas, individual
9 production quotas, and procurement quotas;
- 10 c. Documents and communications that facilitated the manufacture,
11 purchase and sale of prescription opioids;
- 12 d. Defendants' DEA registrations;
- 13 e. Documents and communications that supported and/or facilitated
14 Defendants' DEA registrations;
- 15 f. Defendants' records and reports that were required to be submitted to the
16 DEA pursuant to 21 U.S.C. § 827;
- 17 g. Documents and communications related to the Defendants' mandatory
18 DEA reports pursuant to 21 U.S.C. § 823 and 21 C.F.R. § 1301.74;
- 19 h. Documents intended to facilitate the manufacture and distribution of
20 Defendants' prescription opioids, including bills of lading, invoices,
21 shipping records, reports and correspondence;
- 22 i. Documents for processing and receiving payment for prescription
23 opioids;
- 24 j. Payments from the Distributors to the Manufacturers;
- 25 k. Rebates and chargebacks from the Manufacturers to the Distributors;
- 26 l. Payments to Defendants' lobbyists through the PCF;
- 27 m. Payments to Defendants' trade organizations, like the HDA, for
28 memberships and/or sponsorships;

n. Deposits of proceeds from Defendants' manufacture and distribution of prescription opioids; and

o. Other documents and things, including electronic communications.

756. On information and belief, the RICO Diversion Defendants (and/or their agents), for the purpose of executing the illegal scheme, sent and/or received (or caused to be sent and/or received) by mail or by private or interstate carrier, shipments of prescription opioids and related documents by mail or by private carrier affecting interstate commerce, including the following:

Defendant Group Name	Company Names	Drugs		
		Drug Name	Chemical Name	CSA Schedule
Purdue	(1) Purdue Pharma, LP, (2) Purdue Pharma, Inc., (3) The Purdue Frederick Company	OxyContin	Oxycodone hydrochloride extended release	Schedule II
		MS Contin	Morphine sulfate extended release	Schedule II
		Dilaudid	Hydromorphone hydrochloride	Schedule II
		Dilaudid-HP	Hydromorphone hydrochloride	Schedule II
		Butrans	Buprenorphine	Schedule II
		Hysinga ER	Hydrocodone bitrate	Schedule II
		Targiniq ER	Oxycodone hydrochloride	Schedule II
Cephalon	(1) Cephalon, Inc., (2) Teva Pharmaceutical Industries, Ltd., (3) Teva Pharmaceuticals USA, Inc.	Actiq	Fentanyl citrate	Schedule II
		Fentora	Fentanyl citrate	Schedule II
		Generic oxycontin	Oxycodone hydrochloride	Schedule II
Endo	(1) Endo Health Solutions, Inc., (2) Endo Pharmaceuticals Inc., (3) Qualitest Pharmaceuticals, Inc. (wholly-owned subsidiary of Endo)	Opana ER	Oxymorphone hydrochloride extended release	Schedule II
		Opana	Oxymorphone hydrochloride	Schedule II
		Percodan	Oxymorphone hydrochloride and aspirin	Schedule II
		Percocet	Oxymorphone hydrochloride and acetaminophen	Schedule II
		Generic oxycodone		Schedule II
		Generic oxymorphone		Schedule II

Defendant Group Name	Company Names	Drugs		
		Drug Name	Chemical Name	CSA Schedule
		Generic hydromorphone		Schedule II
		Generic hydrocodone		Schedule II
Mallinckrodt	(1) Mallinckrodt PLC, (2) Mallinckrodt LLC (wholly-owned subsidiary of Mallinckrodt PLC)	Exalgo	Hydromorphone hydrochloride	Schedule II
		Roxicodone	Oxycodone hydrochloride	Schedule II
Allergan	(1) Allergan Plc, (2) Actavis LLC, (3) Actavis Pharma, Inc., (4) Actavis Plc, (5) Actavis, Inc., (6) Watson Pharmaceuticals, Inc., (7) Watson Pharma, Inc.	Kadian	Morphine Sulfate	Schedule II
		Norco (Generic of Kadian)	Hydrocodone and acetaminophen	Schedule II
		Generic Duragesic	Fentanyl	Schedule II
		Generic Opana	Oxymorphone hydrochloride	Schedule II

757. Each of the RICO Diversion Defendants identified manufactured, shipped, paid for and received payment for the drugs identified above, throughout the United States.

758. The RICO Diversion Defendants also used the internet and other electronic facilities to carry out their scheme and conceal the ongoing fraudulent activities. Specifically, the RICO Diversion Defendants made misrepresentations about their compliance with Federal and State laws requiring them to identify, investigate and report suspicious orders of prescription opioids and/or diversion of the same into the illicit market.

759. At the same time, the RICO Diversion Defendants misrepresented the superior safety features of their order monitoring programs, ability to detect suspicious orders, commitment to preventing diversion of prescription opioids, and their compliance with all state and federal regulations regarding the identification and reporting of suspicious orders of prescription opioids.

760. Upon information and belief, the RICO Diversion Defendants utilized the internet and other electronic resources to exchange communications,

1 to exchange information regarding prescription opioid sales, and to transmit
2 payments and rebates/chargebacks.

3 761. The RICO Diversion Defendants also communicated by U.S. Mail,
4 by interstate facsimile, and by interstate electronic mail with each other and with
5 various other affiliates, regional offices, regulators, distributors, and other third-
6 party entities in furtherance of the scheme.

7 762. The mail and wire transmissions described herein were made in
8 furtherance of Defendants' scheme and common course of conduct to deceive
9 regulators, the public and The County that Defendants were complying with their
10 state and federal obligations to identify and report suspicious orders of
11 prescription opioids all while Defendants were knowingly allowing millions of
12 doses of prescription opioids to divert into the illicit drug market. The RICO
13 Diversion Defendants' scheme and common course of conduct was to increase or
14 maintain high production quotas for their prescription opioids from which they
15 could profit.

16 763. Many of the precise dates of the fraudulent uses of the U.S. mail and
17 interstate wire facilities have been deliberately hidden by Defendants and cannot
18 be alleged without access to Defendants' books and records. However, Plaintiffs
19 have described the types of, and in some instances, occasions on which the
20 predicate acts of mail and/or wire fraud occurred. They include thousands of
21 communications to perpetuate and maintain the scheme, including the things and
22 documents described in the preceding paragraphs.

23 764. The RICO Diversion Defendants did not undertake the practices
24 described herein in isolation, but as part of a common scheme. Various other
25 persons, firms, and corporations, including third-party entities and individuals not
26 named as defendants in this Complaint, may have contributed to and/or
27 participated in the scheme with the RICO Diversion Defendants in these offenses
28 and have performed acts in furtherance of the scheme to increase revenues,

1 increase market share, and /or minimize the losses for the RICO Diversion
2 Defendants.

3 765. The RICO Diversion Defendants aided and abetted others in the
4 violations of the above laws, thereby rendering them indictable as principals in the
5 18 U.S.C. §§ 1341 and 1343 offenses.

6 766. The RICO Diversion Defendants hid from the general public and
7 suppressed and/or ignored warnings from third parties, whistleblowers and
8 governmental entities about the reality of the suspicious orders that the RICO
9 Diversion Defendants were filling on a daily basis – leading to the diversion of
10 hundreds of millions of doses of prescriptions opioids into the illicit market.

11 767. The RICO Diversion Defendants, with knowledge and intent, agreed
12 to the overall objective of their fraudulent scheme and participated in the common
13 course of conduct to commit acts of fraud and indecency in manufacturing and
14 distributing prescription opioids.

15 768. Indeed, for the Defendants' fraudulent scheme to work, each of the
16 Defendants had to agree to implement similar tactics regarding manufacturing
17 prescription opioids and refusing to report suspicious orders.

18 769. As described herein, the RICO Diversion Defendants engaged in a
19 pattern of related and continuous predicate acts for years. The predicate acts
20 constituted a variety of unlawful activities, each conducted with the common
21 purpose of obtaining significant monies and revenues from the sale of their highly
22 addictive and dangerous drugs. The predicate acts also had the same or similar
23 results, participants, victims, and methods of commission. The predicate acts were
24 related and not isolated events.

25 770. The predicate acts all had the purpose of creating the opioid epidemic
26 that substantially injured the County's business and property, while
27 simultaneously generating billion-dollar revenue and profits for the RICO
28 Diversion Defendants. The predicate acts were committed or caused to be

1 committed by the RICO Diversion Defendants through their participation in the
2 Opioid Diversion Enterprise and in furtherance of its fraudulent scheme.

3 771. The pattern of racketeering activity alleged herein and the Opioid
4 Diversion Enterprise are separate and distinct from each other. Likewise,
5 Defendants are distinct from the enterprise.

6 772. The pattern of racketeering activity alleged herein is continuing as of
7 the date of this Complaint and, upon information and belief, will continue into the
8 future unless enjoined by this Court.

9 773. Many of the precise dates of the RICO Diversion Defendants'
10 criminal actions at issue here have been hidden by Defendants and cannot be
11 alleged without access to Defendants' books and records. Indeed, an essential part
12 of the successful operation of the Opioid Diversion Enterprise alleged herein
13 depended upon secrecy.

14 774. Each instance of racketeering activity alleged herein was related, had
15 similar purposes, involved the same or similar participants and methods of
16 commission, and had similar results affecting similar victims, including Plaintiffs'
17 Community and the County. Defendants calculated and intentionally crafted the
18 Opioid Diversion Enterprise and their scheme to increase and maintain their
19 increased profits, without regard to the effect such behavior would have on
20 Plaintiffs' Community, its citizens or the County. In designing and implementing
21 the scheme, at all times Defendants were cognizant of the fact that those in the
22 manufacturing and distribution chain rely on the integrity of the pharmaceutical
23 companies and ostensibly neutral third parties to provide objective and reliable
24 information regarding Defendants' products and their manufacture and
25 distribution of those products. The Defendants were also aware that The County
26 and the citizens of this jurisdiction rely on the Defendants to maintain a closed
27 system and to protect against the non-medical diversion and use of their
28 dangerously addictive opioid drugs.

1 775. By intentionally refusing to report and halt suspicious orders of their
2 prescription opioids, Defendants engaged in a fraudulent scheme and unlawful
3 course of conduct constituting a pattern of racketeering activity.

4 776. It was foreseeable to Defendants that The County would be harmed
5 when they refused to report and halt suspicious orders, because their violation of
6 the duties imposed by the CSA and Code of Federal Regulations allowed the
7 widespread diversion of prescription opioids out of appropriate medical channels
8 and into the illicit drug market – causing the opioid epidemic that the CSA
9 intended to prevent.

10 777. The last racketeering incident occurred within five years of the
11 commission of a prior incident of racketeering.

12 **D. DAMAGES.**

13 **1. Impact of the Opioid Diversion Enterprise.**

14 778. California has been especially ravaged by the national opioid crisis.

15 779. More people die each year from drug overdoses in California than in
16 any other state.⁴⁶² The State's death rate has continued to climb, increasing by 30
17 percent from 1999 to 2015, according to the Center for Disease Control (CDC).⁴⁶³

18 780. In 2016, 1,925 Californians died due to prescription opioids.⁴⁶⁴ This
19 number is on par with other recent years: in 2015, 1,966 deaths in California were
20 due just to prescription opioids (not including heroin); in 2014 that number was
21 even higher at 2,024 prescription opioid deaths; and in 2013, 1,934 Californians
22 died from a prescription opioid overdose.⁴⁶⁵

25 ⁴⁶² Davis, *supra*.

26 ⁴⁶³ Karlamangla, *supra*.

27 ⁴⁶⁴ Davis, *supra*.

28 ⁴⁶⁵ California Department of Public Health, *California Opioid Overdose Surveillance Dashboard*, available at https://pdop.shinyapps.io/ODdash_v1/ (last visited March 2, 2018).

1 781. Of the 1,925 opioid-related deaths in California in 2016, fentanyl was
 2 a factor in at least 234 of them.⁴⁶⁶ This is an increase of 47 percent for 2016.⁴⁶⁷
 3 Heroin-related deaths have risen by 67 percent in California since 2006.⁴⁶⁸

4 782. The high number of deaths are due in part to the extraordinary
 5 number of opioids prescribed in the State. Over 23.6 million prescriptions for
 6 opioids were written in California in just 2016.⁴⁶⁹

7 783. The California Department of Public Health tracks the number of
 8 reported hospitalizations and emergency department visits due to prescription
 9 opioids.⁴⁷⁰ In 2015, the last year for which information is currently available,
 10 California had 3,935 emergency department visits and 4,095 hospitalizations
 11 related to prescription opioid overdoses (excluding heroin).⁴⁷¹ The numbers were
 12 even higher in 2014, when 4,106 people visited the emergency department and
 13 4,482 people were hospitalized due to prescription opioid abuse.⁴⁷² In 2013, there
 14 were 3,964 emergency department visits and 4,344 hospitalizations for
 15 prescription opioid overdoses.⁴⁷³ When emergency visits and hospitalizations
 16 include heroin, the numbers are even higher.⁴⁷⁴

19 ⁴⁶⁶ Davis, *supra*.

20 ⁴⁶⁷ Karlamangla, *supra*.

21 ⁴⁶⁸ California Department of Public Health, *State of California Strategies to*
 22 *Address Prescription Drug (Opioid) Misuse, Abuse, and Overdose Epidemic in*
 23 *California* at 3 (June 2016), available at
<https://www.cdph.ca.gov/Programs/CCDC/DCDC/SACB/CDPH%20Documents/20Library/Prescription%20Drug%20Overdose%20Program/CAOpioidPreventionStrategies4.17.pdf> (last visited March 2, 2018).

24 ⁴⁶⁹ California Department of Public Health, *California Opioid Overdose*
 25 *Surveillance Dashboard*, *supra*.

26 ⁴⁷⁰ *Id.*

27 ⁴⁷¹ *Id.*

28 ⁴⁷² *Id.*

⁴⁷³ *Id.*

⁴⁷⁴ *Id.*

1 784. NAS has increased dramatically in California, with the rate of infants
2 born with NAS more than tripling from 2008 to 2013.⁴⁷⁵ While the number of
3 affected newborns rose from 1,862 in 2008 to 3,007 in 2014, that number jumped
4 by another 21 percent in 2015.⁴⁷⁶ This is despite a steady decline in the overall
5 number of birth in California during that same time.⁴⁷⁷

6 785. Reports from California's Office of Statewide Health Planning,
7 which collects data from licensed health care facilities, have shown a 95 percent
8 increase between 2008 and 2015 of newborns affected by drugs transmitted via
9 placenta or breast milk.⁴⁷⁸

10 786. The opioid epidemic has also had an impact on crime in California.
11 Pharmacy robberies have gone up by 163 percent in California over the last two
12 years, according to the DEA. The DEA recorded 90 incidents in 2015, 154 in
13 2016 and, through mid-November of 2017, that number had climbed to 237.⁴⁷⁹
14 Most perpetrators were after prescription opioids.⁴⁸⁰ In addition, fentanyl seizures
15 at California ports increased 266 percent in fiscal year 2017.⁴⁸¹

16 787. The opioid epidemic is particularly devastating in Plaintiffs'
17 Community.

18
19
20
21 ⁴⁷⁵ California Child Welfare Co-Investment Partnership, *supra* at 5.

22 ⁴⁷⁶ Clark, *supra*.

23 ⁴⁷⁷ *Id.*

24 ⁴⁷⁸ California Child Welfare Co-Investment Partnership, *supra*.

25 ⁴⁷⁹ Ed Fletcher, "What's behind the spike in drug store robberies?" *The Sacramento Bee*, Dec. 8, 2017 (available at <http://www.sacbee.com/news/local/crime/article188636384.html> (last visited March 2, 2018)).

26 ⁴⁸⁰ *Id.*

27 ⁴⁸¹ United State Department of Justice, The United States Attorney's Office,
28 Southern District of California, *U.S. Attorney Appoints Opioid Coordinators* (Feb. 8, 2018) available at <https://www.justice.gov/usao-sdca/pr/us-attorney-appoints-opioid-coordinators> (last visited March 2, 2018).

788. In 2016, 12 people died from opioid overdoses in the County.⁴⁸² The County also had 13 deaths from opioid overdoses in 2015 and 14 in 2014.⁴⁸³ These numbers are down from prior years. In 2013, the County suffered 26 fatalities due to opioids.⁴⁸⁴ There were 25 deaths in 2012 and 31 in 2011.⁴⁸⁵ Monterey County has a higher rate of opioid overdose deaths than Los Angeles County.⁴⁸⁶

789. From 2012 to 2014, the County suffered 146 deaths due to drug overdoses, which is a drug overdose mortality rate of 11 deaths per 100,000 people.⁴⁸⁷

790. Prescription opioids have also been responsible for increased emergency department visits and hospitalizations in the County. In 2016, Monterey County had 40 emergency department visits due to opioid overdoses (excluding heroin) for a rate of 8.9, and 30 opioid overdose hospitalizations for a rate of 6.7 per 100,000 residents.⁴⁸⁸

791. In 2016, an estimated 5.8 percent of the population aged 12 and up in Monterey County misused opioids (almost 4,000 people) and about one percent had an opioid use disorder.⁴⁸⁹

⁴⁸² California Department of Public Health, *California Opioid Overdose Surveillance Dashboard*, available at https://pdop.shinyapps.io/ODdash_v1/ (last visited May 1, 2018) (Monterey County specific page).

⁴⁸³ *Id.* at Table on California Deaths by County for 2015, 2014.

⁴⁸⁴ *Id.* at Table on California Deaths by County for 2013.

⁴⁸⁵ *Id.* at Table on California Deaths by County for 2012, 2011.

⁴⁸⁶ Brynne Whittaker, “Opioid overdoses rising in Santa Cruz, Monterey counties,” *KSBW8*, Jan. 23, 2017, available at <http://www.ksbw.com/article/california-sees-increase-in-opioid-overdose-deaths/3311493> (last visited May 1, 2018).

⁴⁸⁷ County Health Rankings & Roadmaps, Drug overdose deaths, available at <http://www.countyhealthrankings.org/app/california/2016/measure/factors/138/data> (last visited April 20, 2018).

⁴⁸⁸ California Department of Public Health, *California Opioid Overdose Surveillance Dashboard*, *supra*, (Monterey County specific page).

⁴⁸⁹ Lisa Clemans-Cope, Marni Epstein, and Doug Wissoker, “County-Level Estimates of Opioid Use Disorder and Treatment Needs in California,” *The Urban*

1 792. Law enforcement in the County has been equipped with naloxone – a
2 drug that can reverse opioid overdoses – and all of the ambulances in Monterey
3 County are carrying it.⁴⁹⁰

4 793. One reason for these high numbers is the high number of
5 prescriptions being written for opioids in Monterey County. According to the
6 California Department of Public Health, over 237,300 prescriptions were written
7 in 2016 in Monterey County alone.⁴⁹¹

8 **2. The Relief Sought.**

9 794. The RICO Diversion Defendants’ violations of law and their pattern
10 of racketeering activity directly and proximately caused the County injury in its
11 business and property. The RICO Diversion Defendants’ pattern of racketeering
12 activity, including their refusal to identify, report and halt suspicious orders of
13 controlled substances, logically, substantially and foreseeably cause an opioid
14 epidemic. The County was injured by the RICO Diversion Defendants’ pattern of
15 racketeering activity and the opioid epidemic that they created.

16 795. As the County alleges, the RICO Diversion Defendants knew that the
17 opioids they manufactured and supplied were unsuited to treatment of long-term,
18 chronic, non-acute, and non-cancer pain, or for any other use not approved by the
19 FDA, and knew that opioids were highly addictive and subject to abuse. ⁴⁹²
20 Nevertheless, the RICO Diversion Defendants engaged in a scheme of deception,
21 that utilized the mail and wires as part of their fraud, in order to increase sales of
22

23 *Institute*, March 19, 2018, available at
24 <https://www.urban.org/sites/default/files/monterey.pdf> (last visited May 1, 2018).

25 ⁴⁹⁰ Tom Wright, “Pacific Grove, Carmel police equip officers with opioid overdose
26 antidote,” *Monterey Herald*, (September 1, 2017), available at
<http://www.montereyherald.com/article/NF/20170901/NEWS/170909972> (last
visited May 1, 2018).

27 ⁴⁹¹ California Department of Public Health, *California Opioid Overdose
Surveillance Dashboard*, *supra*, (Monterey County specific page).

28 ⁴⁹² *Traveler’s Property Casualty Company of America v. Actavis, Inc.*, 22 Cal.
Rptr. 3d 5, 19 (Cal. Ct. App. 2017).

1 their opioid products by refusing to identify, report suspicious orders of
 2 prescription opioids that they knew were highly addictive, subject to abuse, and
 3 were actually being diverted into the illegal market.⁴⁹³

4 796. Here, as the County alleges, the link of causation generally breaks
 5 down into three very short steps: (1) the RICO Diversion Defendants' affirmative
 6 action to continue supplying prescription opioids through legal channels with
 7 knowledge that they were being diverted into the illicit market; (2) an opioid
 8 epidemic in the form of criminal drug trafficking, misuse and abuse; and (3)
 9 injuries to the County.⁴⁹⁴ Although not as direct as a car accident or a slip-and-fall
 10 case, this causal chain is still a "direct sequence" and a logical, substantial and
 11 foreseeable cause of the County's injury.⁴⁹⁵

12 797. Specifically, the RICO Diversion Defendants' predicate acts and
 13 pattern of racketeering activity caused the opioid epidemic which has injured the
 14 County in the form of substantial losses of money and property that logically,
 15 directly and foreseeably arise from the opioid-addiction epidemic. The County's
 16 injuries, as alleged throughout this complaint, and expressly incorporated herein
 17 by reference, include:

- 18 a. Losses caused by purchasing and/or paying reimbursements for the
- 19 RICO Defendants' prescription opioids, that The County would not have
- 20 paid for or purchased but for the RICO Diversion Defendants' conduct;
- 21 b. Losses caused by the decrease in funding available for The County's
- 22 public services for which funding was lost because it was diverted to
- 23 other public services designed to address the opioid epidemic;
- 24
- 25

26 ⁴⁹³ *City of Everett v. Purdue Pharma L.P.*, 2017 WL 4236062, *6 (W.D. Wash.
 27 Sept. 25, 2017).

28 ⁴⁹⁴ *Id.*

⁴⁹⁵ *Id.*

- c. Costs for providing healthcare and medical care, additional therapeutic, and prescription drug purchases, and other treatments for patients suffering from opioid-related addiction or disease, including overdoses and deaths;
- d. Costs of training emergency and/or first responders in the proper treatment of drug overdoses;
- e. Costs associated with providing police officers, firefighters, and emergency and/or first responders with Naloxone – an opioid antagonist used to block the deadly effects of opioids in the context of overdose;
- f. Costs associated with emergency responses by police officers, firefighters, and emergency and/or first responders to opioid overdoses;
- g. Costs for providing mental-health services, treatment, counseling, rehabilitation services, and social services to victims of the opioid epidemic and their families;
- h. Costs for providing treatment of infants born with opioid-related medical conditions, or born addicted to opioids due to drug use by mother during pregnancy;
- i. Costs associated with law enforcement and public safety relating to the opioid epidemic, including but not limited to attempts to stop the flow of opioids into local communities, to arrest and prosecute street-level dealers, to prevent the current opioid epidemic from spreading and worsening, and to deal with the increased levels of crimes that have directly resulted from the increased homeless and drug-addicted population;
- j. Costs associated with increased burden on the County’s judicial system, including increased security, increased staff, and the increased cost of adjudicating criminal matters due to the increase in crime directly resulting from opioid addiction;

- 1 k. Costs associated with providing care for children whose parents suffer
2 from opioid-related disability or incapacitation;
3 l. Loss of tax revenue due to the decreased efficiency and size of the
4 working population in Plaintiffs' Community;
5 m. Losses caused by diminished property values in neighborhoods where
6 the opioid epidemic has taken root; and
7 n. Losses caused by diminished property values in the form of decreased
8 business investment and tax revenue.

9 798. The County's injuries were proximately caused by Defendants'
10 racketeering activities because they were the logical, substantial and foreseeable
11 cause of The County's injuries. But for the opioid-addiction epidemic created by
12 Defendants' conduct, The County would not have lost money or property.

13 799. The County's injuries were directly caused by the RICO Diversion
14 Defendants' pattern of racketeering activities.

15 800. The County is most directly harmed and there is no other Plaintiff
16 better suited to seek a remedy for the economic harms at issue here.

17 801. Plaintiff seeks all legal and equitable relief as allowed by law,
18 including *inter alia* actual damages, treble damages, equitable relief, forfeiture as
19 deemed proper by the Court, attorney's fees and all costs and expenses of suit and
20 pre- and post-judgment interest

21 **COUNT V**

22 **FALSE ADVERTISING**

23 **Violations of California Business and Professions Code section 17500, et seq.**
24 **(Against All Defendants)**

25 802. Plaintiff, The People, incorporate by reference all other paragraphs of
26 this Complaint as if fully set forth here, and further alleges as follows.
27
28

1 803. This Count is brought by the People of the State. This Count is
2 brought pursuant to Sections 17535 and 17536 of the California Business and
3 Professions Code for injunctive relief, restitution and civil penalties.

4 804. Section 17500 of the California Business and Professions Code
5 makes it “unlawful for any person, . . . corporation . . . with intent directly or
6 indirectly to dispose of real or personal property . . . or to induce the public to
7 enter into any obligation relating thereto, to make or disseminate or cause to be
8 made or disseminated before the public in this state, . . . in any . . . manner or
9 means whatever . . . any statement, concerning that real or personal property . . .
10 which is untrue or misleading, and which is known, or which by the exercise of
11 reasonable care should be known, to be untrue or misleading.” Cal. Bus. & Prof.
12 Code § 17500.

13 805. As described above in allegations expressly incorporated herein, at
14 all times relevant to this Complaint, Defendants directly and indirectly violated
15 Section 17500 by making and disseminating untrue, false and misleading
16 statements about, *inter alia*, the use of opioids for chronic pain, about the risks of
17 addiction related to opioids, about the signs of addiction and how to reliably
18 identify and safely prescribe opioids to patients predisposed to addiction, and
19 about their so-called abuse-deterrent opioid formulations. Defendants also
20 repeatedly failed to disclose material facts about the risks of opioids.

21 806. The Manufacturer Defendants also made untrue, false, and
22 misleading statements that included, but were not limited to:

23 807. Claiming or implying that opioids would improve patients’ function
24 and quality of life;

25 808. Claiming that opioids should be used to treat chronic pain and that
26 there was a significant upside to long-term opioid use;

27 809. Mischaracterizing the risk of opioid addiction and abuse, including
28 by stating or implying the opioids were rarely addictive, that “steady state” and

1 abuse-resistant properties meant the drugs were less likely to be addictive or
2 abused, and that specific opioid drugs were less addictive or less likely to be
3 abused than other opioids;

4 810. Claiming or implying that addiction can be avoided or successfully
5 managed through the use of screening and other tools and exaggerating the
6 effectiveness of screening tools to prevent addiction;

7 811. Promoting the misleading concept of pseudoaddiction, thus
8 concealing the true risk of addiction, and advocating that the signs of addiction
9 should be treated with more opioids;

10 812. Mischaracterizing the difficulty of discontinuing opioid therapy,
11 including by mischaracterizing the prevalence and severity of withdrawal
12 symptoms, and claiming that opioid dependence and withdrawal are easily
13 managed;

14 813. Claiming of implying that increased doses of opioids pose no
15 significant additional risk;

16 814. Misleadingly depicting the safety profile of opioids prescribed by
17 minimizing their risks and adverse effects while emphasizing or exaggerating the
18 risks of competing products, including NSAIDs; and

19 815. In the case of Purdue, mischaracterizing OxyContin's onset of action
20 and duration of efficacy to imply that the drug provided a full 12 hours of pain
21 relief.

22 816. The Manufacturer Defendants made deceptive representations to the
23 public about the use of opioids to treat chronic non-cancer pain. Each
24 Manufacturer Defendant also omitted or concealed material facts and failed to
25 correct prior misrepresentations and omissions to the public about the risks and
26 benefits of opioids. Each Defendant's omissions rendered even their seemingly
27 truthful statements about opioids deceptive.
28

1 817. Defendants' conduct was likely to mislead or deceive The People and
2 Plaintiffs' Community, including Californians who purchased or covered or paid
3 for the purchase of opioids for chronic pain.

4 818. Each Manufacturer Defendant has conducted, and has continued to
5 conduct, a widespread marketing scheme designed to promote opioids and
6 persuade doctors and patients that opioids can and should be used for chronic
7 pain, resulting in opioid treatment for a far broader group of patients who are
8 much more likely to become addicted and suffer other adverse effects from the
9 long-term use of opioids. In connection with this scheme, each Manufacturer
10 Defendant spent, and continues to spend, millions of dollars on promotional
11 activities and materials that falsely deny or trivialize the risks of opioids while
12 overstating the benefits of using them for chronic pain. This conduct tends to
13 mislead or deceive, and has misled and deceived, The People and Plaintiffs'
14 Community.

15 819. The Manufacturer Defendants have disseminated these common
16 messages to reverse the popular and medical understanding of opioids and risks of
17 opioid use. They disseminated these messages directly, through their sales
18 representatives, in speaker groups led by physicians the Manufacturer Defendants
19 recruited for their support of their marketing messages, and through unbranded
20 marketing and industry-funded front groups.

21 820. Pursuant to Section 17535 of the California Business and Professions
22 Code, The People request an order from this Court enjoining Defendants from any
23 further violations of the California False Advertising law, California Business and
24 Professions Code §§ 17500 *et seq.*

25 821. Pursuant to Section 17535 of the California Business and Professions
26 Code, the People request restitution of any money acquired by Defendants'
27 violations of the California False Advertising law, California Business and
28 Professions Code §§ 17500 *et seq.*

1 827. As described elsewhere in this Complaint in allegations expressly
2 incorporated herein, Distributor Defendants misrepresented their compliance with
3 their duties under the law and concealed their noncompliance and shipments of
4 suspicious orders of opioids to Plaintiffs' Community and destinations from
5 which they knew opioids were likely to be diverted into Plaintiffs' Community, in
6 addition to other misrepresentations alleged and incorporated herein.

7 828. As described elsewhere in the Complaint in allegations expressly
8 incorporated herein, Manufacturer Defendants breached their duties to exercise
9 due care in the business of pharmaceutical manufacturers of dangerous opioids,
10 which are Schedule II Controlled Substances, by misrepresenting the nature of the
11 drugs and aggressively promoting them for chronic pain for which they knew the
12 drug were not safe or suitable.

13 829. The Manufacturer Defendants misrepresented and concealed the
14 addictive nature of prescription opioids and their lack of suitability for chronic
15 pain, in addition to other misrepresentations alleged and incorporated herein.

16 830. All Defendants breached their duties to prevent diversion and report
17 and halt suspicious orders, and they misrepresented their compliance with their
18 legal duties. Defendants knew or should have known that the representations they
19 were making were untrue because they did not have reasonable grounds for
20 believing their statements to be true.

21 831. Defendants made these false representations and concealed facts with
22 knowledge of the falsity of their representations, or without reasonable grounds
23 for believing them to be true, and did so with the intent of inducing reliance by
24 The County, Plaintiffs' Community, the public, and persons on whom The County
25 relied.

26 832. These false representations and concealments were reasonably
27 calculated to deceive The County, Plaintiffs' Community, and the physicians who
28 prescribed opioids for persons in Plaintiffs' Community, were made with the

1 intent of inducing reliance, and did in fact deceive these persons, The County, and
2 Plaintiffs' Community.

3 833. The County, Plaintiffs' Community, and the physicians who
4 prescribed opioids reasonably relied on these false representations and
5 concealments of material fact

6 834. The County justifiably relied on Defendants' representations and/or
7 concealments, both directly and indirectly. This reliance proximately caused The
8 County's injuries.

9 835. The causal connection between the Defendants' breaches of their
10 duties and misrepresentations and the ensuing harm was entirely foreseeable.

11 836. As described above in allegations expressly incorporated herein,
12 Defendants' breaches of duty and misrepresentations caused, bear a causal
13 connection with and/or proximately resulted in the damages sought herein.

14 837. The Defendants' breaches of their duties and misrepresentations were
15 the cause-in-fact of The County's injuries.

16 838. The risk of harm to The County and Plaintiffs' Community and the
17 harm caused should have been reasonably foreseen by Defendants. The
18 Defendants' conduct was substantial factor in causing The County's injuries.

19 839. The Defendants were selling dangerous drugs statutorily categorized
20 as posing a high potential for abuse and severe dependence. The Defendants
21 knowingly traded in drugs that presented a high degree of danger if prescribed
22 incorrectly or diverted to other than medical, scientific, or industrial channels.
23 However, the Defendants misrepresented what their duties were and their
24 compliance with their legal duties.

25 840. The Defendants failed to disclose the material facts that *inter alia*
26 they were not in compliance with laws and regulations requiring that they
27 maintain a system to prevent diversion, protect against addiction and severe harm,
28 and specifically monitor, investigate, report, and refuse suspicious orders. But for

1 these material factual omissions, the Defendants would not have been able to sell
2 opioids.

3 841. As alleged herein, each Manufacturer Defendant wrongfully
4 represented that the opioid prescription medications they manufactured, marketed
5 and sold had characteristics, uses or benefits that they do not have. The
6 Manufacturer Defendants also wrongfully misrepresented that the opioids were
7 safe and effective when the Manufacturer Defendants knew, or should have
8 known, such representations were untrue, false and misleading.

9 842. Because of the dangerously addictive nature of these drugs, which the
10 Manufacturer Defendants concealed and misrepresented, they lacked medical
11 value and in fact caused addiction and overdose deaths.

12 843. The Manufacturer Defendants made deceptive representations about
13 the use of opioids to treat chronic non-cancer pain. Each Manufacturer Defendant
14 also omitted or concealed material facts and failed to correct prior
15 misrepresentations and omissions about the risks and benefits of opioids. Each
16 Defendant's omissions rendered even their seemingly truthful statements about
17 opioids deceptive.

18 844. The Defendants' unlawful and/or intentional actions create a
19 rebuttable presumption of negligent misrepresentation under State law.

20 845. The County seeks economic losses (direct, incidental, or
21 consequential pecuniary losses) resulting from the Defendants' actions and
22 omissions.

23 846. The County seeks all legal and equitable relief as allowed by law,
24 other than such damages disavowed herein, including *inter alia* injunctive relief,
25 restitution, disgorgement of profits, compensatory and punitive damages, and all
26 damages allowed by law to be paid by the Defendants, attorney fees and costs, and
27 pre- and post-judgment interest.
28

COUNT VII

FRAUD AND FRAUDULENT MISREPRESENTATION

(Against All Defendants)

847. Plaintiff, The County, incorporates by reference all other paragraphs of this Complaint as if fully set forth here, and further alleges as follows.

848. In California, the tort of fraud or intentional misrepresentation has five elements: “The elements of fraud, which gives rise to the tort action for deceit, are (a) misrepresentation (false representation, concealment, or nondisclosure); (b) knowledge of falsity (or ‘scienter’); (c) intent to defraud, i.e., to induce reliance; (d) justifiable reliance; and (e) resulting damage.” *Small v. Fritz Companies, Inc.*, 30 Cal. 4th 167, 173–74, 65 P.3d 1255, 1258 (2003) (citing *Lazar v. Superior Court*, 12 Cal. 4th 631, 638, 49 Cal. Rptr. 2d 377, 909 P.2d 981 (1996)).

849. Section 1709 of the California Civil Code provides: “Fraudulent deceit. One who willfully deceives another with intent to induce him to alter his position to his injury or risk, is liable for any damage which he thereby suffers.” Cal. Civ. Code. § 1709.

850. Section 1710 of the California Civil Code provides: “Deceit, what. A deceit, within the meaning of the last section, is either: 1. The suggestion, as a fact, of that which is not true, by one who does not believe it to be true; . . . 3.

The suppression of a fact, by one who is bound to disclose it, or who gives information of other facts which are likely to mislead for want of communication of that fact.” Cal. Civ. Code. §§ 1710(1) & (3). “In California, the elements of the misrepresentation torts (which are also denominated forms of “deceit”) are prescribed by statute . . . and our common law tradition.” *Bily v. Arthur Young & Co.*, 3 Cal. 4th 370, 414, 834 P.2d 745 (1992) (citing Cal. Civ. Code § 1710).

851. Defendants violated their general duty not to actively deceive, have made knowingly false statements and have omitted and/or concealed information

1 which made statements Defendants did make knowingly false. Defendants acted
2 intentionally and/or unlawfully.

3 852. As alleged herein, Defendants made false statements regarding their
4 compliance with state and federal law regarding their duties to prevent diversion,
5 their duties to monitor, report and halt suspicious orders, and/or concealed their
6 noncompliance with these requirements.

7 853. As alleged herein, the Manufacturer Defendants engaged in false
8 representations and concealments of material fact regarding the use of opioids to
9 treat chronic, non-cancer pain.

10 854. As alleged herein, the Defendants knowingly and/or intentionally
11 made representations that were false. Defendants had a duty to disclose material
12 facts and concealed them. These false representations and concealed facts were
13 material to the conduct and actions at issue. Defendants made these false
14 representations and concealed facts with knowledge of the falsity of their
15 representations, and did so with the intent of misleading The County, Plaintiffs'
16 Community, the public, and persons on whom The County relied.

17 855. These false representations and concealments were reasonably
18 calculated to deceive The County, Plaintiffs' Community, and the physicians who
19 prescribed opioids for persons in Plaintiffs' Community, were made with the
20 intent to deceive and induce reliance, and did in fact deceive these persons, The
21 County, and Plaintiffs' Community.

22 856. The County, Plaintiffs' Community, and the physicians who
23 prescribed opioids reasonably relied on these false representations and
24 concealments of material fact.

25 857. The County justifiably relied on Defendants' representations and/or
26 concealments, both directly and indirectly. The County's injuries were
27 proximately caused by this reliance.
28

1 865. The County has expended substantial amounts of money in an effort
2 to remedy or mitigate the societal harms caused by Defendants' conduct.

3 866. These expenditures include the provision of healthcare services and
4 treatment services to people who use opioids.

5 867. These expenditures have helped sustain Defendants' businesses.

6 868. The County has conferred a benefit upon Defendants by paying for
7 Defendants' externalities: the cost of the harms caused by Defendants' improper
8 distribution practices.

9 869. Defendants were aware of these obvious benefits, and their retention
10 of the benefit is unjust.

11 870. The County has paid for the cost of Defendants' externalities and
12 Defendants have benefited from those payments because they allowed them to
13 continue providing customers with a high volume of opioid products. Because of
14 their deceptive marketing of prescription opioids, Manufacturer Defendants
15 obtained enrichment they would not otherwise have obtained. Because of their
16 conscious failure to exercise due diligence in preventing diversion, Defendants
17 obtained enrichment they would not otherwise have obtained. The enrichment
18 was without justification and the County lacks a remedy provided by law.

19 871. Defendants have unjustly retained benefits to the detriment of the
20 County, and Defendants' retention of such benefits violates the fundamental
21 principles of justice, equity, and good conscience.

22 872. Defendants' misconduct alleged in this case is ongoing and
23 persistent.

24 873. Defendants' misconduct alleged in this case does not concern a
25 discrete event or discrete emergency of the sort a political subdivision would
26 reasonably expect to occur, and is not part of the normal and expected costs of a
27 local government's existence. The County alleges wrongful acts which are neither
28 discrete nor of the sort a local government can reasonably expect.

880. Defendants also committed fraud by knowingly and intentionally making representations that were false. Defendants had a duty to disclose material facts and concealed them. These false representations and concealed facts were material to the conduct and actions at issue.

881. Defendants were selling and/or manufacturing dangerous drugs statutorily categorized as posing a high potential for abuse and severe dependence. Thus, Defendants knowingly traded in drugs that presented a high degree of danger if prescribed incorrectly or diverted to other than legitimate medical, scientific or industrial channels. Because of the severe level of danger posed by, and indeed visited upon the State and Plaintiffs' Community by, these dangerous drugs, Defendants owed a high duty of care to ensure that these drugs were only used for proper medical purposes. Defendants chose profit over prudence and the safety of the community, and an award of punitive damages is appropriate as punishment and a deterrence. Punitive damages should be awarded pursuant to the common law and Cal. Civ. Code § 3294.

882. By engaging in the above-described wrongful conduct, Defendants also engaged in willful misconduct and gross negligence and exhibited an entire want of care that would raise the presumption of a conscious indifference to consequences.

RELIEF

WHEREFORE, Plaintiffs respectfully pray that this Court grant the following relief:

883. Entering Judgment in favor of The County in a final order against each of the Defendants;

884. Declare that Defendants have created a public nuisance in violation of California Civil Code Sections 3479 and 3480;

885. Enjoin the Defendants from performing any further acts in violation of California Civil Code Sections 3479 and 3480;

1 886. Order Defendants to fund an “abatement fund” on behalf of The
2 People for the purposes of prospectively abating the ongoing opioid nuisance;

3 887. Order that Defendants compensate The County for damages to its
4 property due to the ongoing public nuisance caused by the opioid epidemic;

5 888. Awarding actual damages, treble damages, injunctive and equitable
6 relief, and forfeiture as deemed proper by the Court, and attorney fees and all
7 costs and expenses of suit pursuant to The County’s racketeering claims;

8 889. Declare that Defendants have made, disseminated as part of a plan or
9 scheme, or aided and abetted in the dissemination of false and misleading
10 statements in violation of the California False Advertising Act;

11 890. Enjoining the Defendants and their employees, officers, directors,
12 agents, successors, assignees, merged or acquired predecessors, parent or
13 controlling entities, subsidiaries, and all other persons acting in concert or
14 participation with it, from engaging in false advertising in violation of the
15 California False Advertising Act and ordering a temporary, preliminary or
16 permanent injunction;

17 891. Order Defendants to pay restitution to The People of any money
18 acquired by Defendants’ false and misleading advertising, pursuant to the
19 California False Advertising Act;

20 892. Order Defendants to pay civil penalties to The People of two
21 thousand five hundred dollars (\$2,500) for each act of false and misleading
22 advertising, pursuant to Section 17536 of the California False Advertising Act;

23 893. Awarding The County the damages caused by the opioid epidemic,
24 and their negligent misrepresentations, fraud and deceit, including (A) costs for
25 providing medical care, additional therapeutic and prescription drug purchases,
26 and other treatments for patients suffering from opioid-related addiction or
27 disease, including overdoses and deaths; (B) costs for providing treatment,
28 counseling, and rehabilitation services; (C) costs for providing treatment of infants

1 born with opioid-related medical conditions; (D) costs for providing care for
2 children whose parents suffer from opioid-related disability or incapacitation; and
3 (E) costs associated with law enforcement and public safety relating to the opioid
4 epidemic;

5 894. Enter a judgment against the Defendants requiring Defendants to pay
6 punitive damages to Plaintiffs;

7 895. Granting The County:

- 8 1. The cost of investigation, reasonable attorneys' fees, and all costs and
9 expenses;
10 2. Pre-judgment and post-judgment interest; and,
11 3. All other relief as provided by law and/or as the Court deems
12 appropriate and just.

13 Dated: May 8, 2018

RESPECTFULLY SUBMITTED:

14 THE PEOPLE OF THE STATE OF
15 CALIFORNIA, COUNTY OF
16 MONTEREY, By Charles J. McKee,
17 OFFICE OF THE COUNTY
18 COUNSEL,
19 MONTEREY COUNTY,
20 CALIFORNIA, Plaintiffs

21 /s/ William Litt

22 Charles J. McKee (SBN 152458)
23 **MONTEREY COUNTY COUNSEL**
24 William Litt (SBN 166614)
25 Deputy County Counsel
26 168 West Alisal Street, 3rd Floor
27 Salinas, CA 93901
28 Tel: 831-755-5045
mckeecj@co.monterey.ca.us
Litt WM@co.monterey.ca.us

///

///

///

/s/ John P. Fiske

John P. Fiske (SBN 249256)
BARON & BUDD, P.C.
603 North Coast Highway, Suite G
Solana Beach, CA 92075
Tel.: 858-633-8337
jfiske@baronbudd.com

1
2 Peter J. Mougey
3 Archie C. Lamb, Jr.
4 **LEVIN, PAPANTONIO, THOMAS,**
5 **MITCHELL,**
6 **RAFFERTY & PROCTOR, P.A.**
7 316 S. Baylen Street, Suite 600
8 Pensacola, FL 32502-5996
9 Tel.: 850-435-7068
10 Fax: 850-436-6068
11 pmougey@levinlaw.com

12 Michael J. Fuller, Jr.
13 Amy Quezon
14 **McHUGH FULLER LAW GROUP,**
15 **PLLC**
16 97 Elias Whiddon Rd.
17 Hattiesburg, MS 39402
18 Tel.: 601-261-2220
19 Fax: 601-261-2481
20 mike@mchughfuller.com
21 amy@mchughfuller.com

22 James C. Peterson
23 **HILL, PETERSON, CARPER,**
24 **BEE & DEITZLER, PLLC**
25 NorthGate Business Park
26 500 Tracy Way
27 Charleston, WV 25311
28 Tel.: 304-345-5667
Fax: 304-345-1519
jcpeterson@hpcbd.com

Russell W. Budd
Laura J. Baughman (SBN 263944)
J. Burton LeBlanc, IV
S. Ann Saucer
Christine C. Mansour
BARON & BUDD, P.C.
3102 Oak Lawn Avenue, Suite 1100
Dallas, TX 75219
Tel.: 214-521-3605
Fax: 214-520-1181
rbudd@baronbudd.com
lbaughman@baronbudd.com
bleblanc@baronbudd.com
asaucer@baronbudd.com
cmansour@baronbudd.com

Paul T. Farrell, Jr.
GREENE, KETCHUM, FARRELL,
BAILEY & TWEEL, LLP
419 - 11th Street (25701)/ P.O. Box
2389
Huntington, West Virginia 25724-2389
Tel.: 800-479-0053 or 304-525-9115
Fax: 304-529-3284
paul@greeneketchum.com

Anthony J. Majestro
POWELL & MAJESTRO, PLLC
405 Capitol Street, Suite P-1200
Charleston, WV 25301
Tel.: 304-346-2889
Fax: 304-346-2895
amajestro@powellmajestro.com